

APPROVED DRUG PRODUCTS


With Therapeutic Equivalence Evaluations



The "Orange Book"

FDA data supplied by [DrugPatentWatch.com](https://www.drugpatentwatch.com)

**CUMULATIVE
SUPPLEMENT 10
OCTOBER 2012**



**APPROVED
DRUG PRODUCTS**

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

Department of Health and Human Services

**Food and Drug Administration
Center for Drug Evaluation and Research
Office of Generic Drugs**

2012

Prepared By
Office of Generic Drugs
Center for Drug Evaluation and Research
Food and Drug Administration

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

Cumulative Supplement 10

October 2012

CONTENTS

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to use the Cumulative Supplement	iii
1.2 Cumulative Supplement Content.....	iv
1.3 Applicant Name Changes.....	v
1.4 Levothyroxine Sodium.....	vi
1.5 Availability of the Edition	vii
1.6 Report of Counts for the Prescription Drug Product List	viii
1.7 Cumulative Supplement Legend	ix
 DRUG PRODUCT LISTS	
Prescription Drug Product List	1-1
OTC Drug Product List	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists	A-1
B. Patent and Exclusivity Terms	B-1

**APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS**

32nd EDITION

**CUMULATIVE SUPPLEMENT 10
October 2012**

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 30th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 32nd Edition List will then be added to the "Discontinued Drug Product List" appearing in the 33rd Edition. The current Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
 - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
 - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals (20,000 and 50,000 series) appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at drugproducts@fda.hhs.gov. Send Changes by FAX: 240-276-8974; mail to:

FDA/CDER Orange Book Staff
Office of Generic Drugs, HFD-610
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
ABBOTT LABORATORIES (ABBOTT LABS) (ABBOTT)	ABBVIE INC (ABBVIE) (ABBVIE)
ABBOTT LABORATORIES HOSP PRODUCTS DIV (ABBOTT)	ABBVIE INC (ABBVIE)
ABBOTT LABORATORIES PHARMACEUTICAL (ABBOTT)	ABBVIE INC (ABBVIE)
ABBOTT PRODUCTS (ABBOTT)	ABBVIE INC (ABBVIE)
ABRAXIX PHARMACEUTICAL PRODUCTS (ABRAXIS PHARM)	FRESENIUS KABI USA LLC (FRESENIUS KABI USA)
ALCON UNIVERSAL LTD (ALCON UNIVERSAL)	ALCON PHARMACEUTICALS LTD (ALCON PHARMS LTD)

APP PHARMACEUTICALS (APP PHARMS)	FRESENIUS KABI USA LLC (FRESENIUS KABI USA)
APP PHARMACEUTICALS LLC (APP PHARMS)	FRESENIUS KABI USA LLC (FRESENIUS KABI USA)
NEXUS PHARMACEUTICALS (NEXUS PHARMS)	FRESENIUS KABI USA LLC (FRESENIUS KABI USA)
OVATION PHARMACEUTICALS INC (OVATION PHARMS)	OAK PHARMACEUTICALS INC (OAK PHARMS)
ROSS LABORATORIES DIV ABBOTT LABORATORIES (ROSS LABS)	ABBVIE INC (ABBVIE)
SOLVAY PHARMACEUTICALS (SOLVAY)	ABBVIE INC (ABBVIE)
UNIMED PHARMACEUTICALS INC (UNIMED PHARMS)	ABBVIE INC (ABBVIE)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001

SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB2	76752	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHYROXINE SODIUM	MERCK KGAA	0.025MG	AB3	76752	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2011) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2011</u>	<u>MAR 2012</u>	<u>JUN 2012</u>	<u>SEPT 2012</u>	<u>DEC 2012</u>
DRUG PRODUCTS LISTED	14480	14711	14834	15160	
SINGLE SOURCE	2451	2446	2428	2429	
	(16.9%)	(16.6%)	(16.4%)	(16.0%)	
MULTISOURCE	11953	12187	12328	12653	
	(82.5%)	(82.8%)	(83.1%)	(83.5%)	
THERAPEUTICALLY EQUIVALENT	11792	12037	12187	12509	
	(81.4%)	(81.8%)	(82.2%)	(82.5%)	
NOT THERAPEUTICALLY EQUIVALENT	161	150	141	144	
	(1.1%)	(1.0%)	(1.0%)	(0.9%)	
EXCEPTIONS ¹	76	78	78	78	
	(0.5%)	(0.5%)	(0.5%)	(0.5%)	
NEW MOLECULAR ENTITIES APPROVED	6	8	7	9	
NUMBER OF APPLICANTS	810	826	826	836	

¹Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

PRESCRIPTION DRUG PRODUCT LIST - 32ND EDITION

RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

1-1

ABACAVIR SULFATE

TABLET; ORAL						
ABACAVIR SULFATE						
AB	MYLAN PHARMS INC	EQ 300MG BASE	A091294 001	Jun 18, 2012	Jun	NEWA
ZIAGEN						
AB	+ VIIV HLTHCARE	EQ 300MG BASE	N020977 001	Dec 17, 1998	Jun	CFTG

ACARBOSE

TABLET; ORAL						
ACARBOSE						
AB	EMCURE PHARMS LTD	25MG	A202271 001	Feb 07, 2012	Jan	NEWA
AB		50MG	A202271 002	Feb 07, 2012	Jan	NEWA
AB		100MG	A202271 003	Feb 07, 2012	Jan	NEWA

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL						
BUTAPAP						
+	MIKART	325MG;50MG	A089987 001	Oct 26, 1992	Jun	CRLD
PHRENILIN						
	@ VALEANT	325MG;50MG	A087811 001	Jun 19, 1985	Jun	DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

TABLET; ORAL						
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE						
AA	LANNETT HOLDINGS INC	325MG;50MG;40MG	A200243 001	Sep 13, 2012	Aug	NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL						
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE						
	NEXGEN PHARMA INC	300MG;50MG;40MG;30MG	A076560 002	Jul 19, 2012	Jul	NEWA

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION; ORAL						
ACETAMINOPHEN AND CODEINE PHOSPHATE						
AA	+ PHARM ASSOC	120MG/5ML;12MG/5ML	A087508 001		Jan	CRLD
SUSPENSION; ORAL						
CAPITAL AND CODEINE						
+	VALEANT	120MG/5ML;12MG/5ML	A086024 001		Jan	CTEC
+	VALEANT PHARMS LLC	120MG/5ML;12MG/5ML	A086024 001		Jun	CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL						
HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
	@ NESHER PHARMS	500MG/15ML;7.5MG/15ML	A040366 001	Jan 23, 2002	Jun	DISC
AA	VISTAPHARM	325MG/15ML;7.5MG/15ML	A200343 001	Jan 25, 2012	Jan	NEWA
TABLET; ORAL						
HYDROCODONE BITARTRATE AND ACETAMINOPHEN						
AA	AUROLIFE PHARMA LLC	325MG;5MG	A201013 001	Apr 11, 2012	Mar	NEWA
AA		325MG;7.5MG	A201013 002	Apr 11, 2012	Mar	NEWA
AA		325MG;10MG	A201013 003	Apr 11, 2012	Mar	NEWA
	@ VINTAGE PHARMS LLC	500MG;5MG	A040281 001	Sep 30, 1998	Sep	CAHN
	@	500MG;7.5MG	A040280 001	Sep 30, 1998	Sep	CAHN
	@	650MG;7.5MG	A040280 002	Sep 30, 1998	Sep	CAHN

TABLET; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ VINTAGE PHARMS LLC 650MG;10MG

A040280 003 Sep 30, 1998 Sep CAHN

@ 750MG;7.5MG

A040281 002 Sep 30, 1998 Sep CAHN

VICODIN

AA + ABBVIE 500MG;5MG

A088058 001 Jan 07, 1983 Sep CAHN

VICODIN ES

AA + ABBVIE 750MG;7.5MG

A089736 001 Dec 09, 1988 Sep CAHN

VICODIN HP

AA ABBVIE 660MG;10MG

A040117 001 Sep 23, 1996 Sep CAHN

ZYDONE

+ VINTAGE PHARMS LLC 400MG;5MG

A040288 001 Nov 27, 1998 Sep CAHN

+ 400MG;7.5MG

A040288 002 Nov 27, 1998 Sep CAHN

+ 400MG;10MG

A040288 003 Nov 27, 1998 Sep CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE AND ACETAMINOPHEN

@ VINTAGE PHARMS LLC 500MG;5MG

A040303 001 Dec 30, 1999 Sep CAHN

TABLET; ORAL

OXYCODONE AND ACETAMINOPHEN

AA ACTAVIS TOTOWA 325MG;7.5MG

A040800 001 Apr 03, 2012 Mar NEWA

AA 325MG;10MG

A040800 002 Apr 03, 2012 Mar NEWA

AA ALVOGEN INC 325MG;7.5MG

A202677 001 Jul 26, 2012 Jul NEWA

AA 325MG;10MG

A202677 002 Jul 26, 2012 Jul NEWA

PERCOCET

AA + VINTAGE PHARMS LLC 325MG;2.5MG

A040330 001 Jun 25, 1999 Sep CAHN

AA + 325MG;5MG

A040330 002 Jun 25, 1999 Sep CAHN

@ 325MG;5MG

A085106 002 Sep CAHN

AA + 325MG;7.5MG

A040434 001 Nov 23, 2001 Sep CAHN

AA + 325MG;10MG

A040434 002 Nov 23, 2001 Sep CAHN

AA + 500MG;7.5MG

A040341 001 Jul 26, 1999 Sep CAHN

AA + 650MG;10MG

A040341 002 Jul 26, 1999 Sep CAHN

ACETAMINOPHEN; PROPOXYPHENE HYDROCHLORIDE

TABLET; ORAL

WYGESIC

>A> @ CARACO 650MG;65MG

A084999 001 Oct CAHN

>D> @ LEITNER PHARMS 650MG;65MG

A084999 001 Oct CAHN

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN

AB ALVOGEN INC 325MG;37.5MG

A202076 001 Mar 30, 2012 Mar NEWA

AB ZYDUS PHARMS USA INC 325MG;37.5MG

A090460 001 Sep 06, 2012 Aug NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

ACETAZOLAMIDE SODIUM

AP SAGENT STRIDES EQ 500MG BASE/VIAL

A200880 001 May 09, 2012 Apr NEWA

AP + X GEN PHARMS EQ 500MG BASE/VIAL

A040784 001 Dec 10, 2008 Apr CRLD

DIAMOX

@ TEVA WOMENS EQ 500MG BASE/VIAL

N009388 001 Dec 05, 1990 Apr DISC

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS

ACETADOTE

>D>	+	CUMBERLAND PHARMS	6GM/30ML (200MG/ML)	N021539 001	Jan 23, 2004	Oct	CFTG
>A>	AP	+	6GM/30ML (200MG/ML)	N021539 001	Jan 23, 2004	Oct	CFTG
>A>		ACETYLCYSTEINE					
>A>	AP	INNOPHARMA INC	6GM/30ML (200MG/ML)	A200644 001	Nov 07, 2012	Oct	NEWA
		SOLUTION; INHALATION, ORAL					
		ACETYLCYSTEINE					
AN		INNOPHARMA INC	20%	A203853 001	Jun 21, 2012	Jun	NEWA

ACLIDINIUM BROMIDE

POWDER, METERED; INHALATION

TUDORZA PRESSAIR

+	FOREST LABS INC	0.375MG/INH	N202450 001	Jul 23, 2012	Jul	NEWA
---	-----------------	-------------	-------------	--------------	-----	------

ACYCLOVIR

CAPSULE; ORAL

ACYCLOVIR

@	HERITAGE PHARMS INC	200MG	A074889 001	Oct 31, 1997	May	CAHN
---	---------------------	-------	-------------	--------------	-----	------

TABLET; ORAL

ACYCLOVIR

@	HERITAGE PHARMS INC	400MG	A074891 001	Oct 31, 1997	May	CAHN
---	---------------------	-------	-------------	--------------	-----	------

@		800MG	A074891 002	Oct 31, 1997	May	CAHN
---	--	-------	-------------	--------------	-----	------

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE

>D>	+	BAXTER HLTHCARE	EQ 500MG BASE/VIAL	A074885 001	Dec 19, 1997	Oct	CAHN
>D>			EQ 1GM BASE/VIAL	A074885 002	Dec 19, 1997	Oct	CAHN
>A>	+	HIKMA MAPLE	EQ 500MG BASE/VIAL	A074885 001	Dec 19, 1997	Oct	CAHN
>A>			EQ 1GM BASE/VIAL	A074885 002	Dec 19, 1997	Oct	CAHN
		ACYCLOVIR SODIUM					
>D>	AP	BAXTER HLTHCARE	EQ 500MG BASE/VIAL	A074913 001	Oct 15, 1997	Oct	CAHN
>D>	AP		EQ 1GM BASE/VIAL	A074913 002	Oct 15, 1997	Oct	CAHN
>A>	AP	HIKMA MAPLE	EQ 500MG BASE/VIAL	A074913 001	Oct 15, 1997	Oct	CAHN
>A>	AP		EQ 1GM BASE/VIAL	A074913 002	Oct 15, 1997	Oct	CAHN

ADAPALENE

CREAM; TOPICAL

ADAPALENE

AB		FOUGERA PHARMS	0.1%	A090824 001	Jun 30, 2010	Jan	CAHN
----	--	----------------	------	-------------	--------------	-----	------

GEL; TOPICAL

ADAPALENE

AB		TOLMAR	0.3%	A200298 001	Jun 14, 2012	Jun	NEWA
----	--	--------	------	-------------	--------------	-----	------

DIFFERIN

AB	+	GALDERMA LABS LP	0.3%	N021753 001	Jun 19, 2007	Jun	CFTG
----	---	------------------	------	-------------	--------------	-----	------

LOTION; TOPICAL

DIFFERIN

+	GALDERMA LABS LP	0.1%	N022502 001	Mar 17, 2010	Apr	CAHN
---	------------------	------	-------------	--------------	-----	------

ADENOSINE

INJECTABLE; INJECTION

ADENOSINE

>D>	@	BAXTER HLTHCARE	3MG/ML	A076501 001	Jun 16, 2004	Oct	CAHN
-----	---	-----------------	--------	-------------	--------------	-----	------

INJECTABLE; INJECTIONADENOSINE

>D>	AP	BAXTER HLTHCARE	3MG/ML	A076500	001	Jun 16, 2004	Oct	CAHN
>A>		@ HIKMA MAPLE	3MG/ML	A076501	001	Jun 16, 2004	Oct	CAHN
>A>	AP		3MG/ML	A076500	001	Jun 16, 2004	Oct	CAHN
		@ TEVA PARENTERAL	3MG/ML	A078676	001	Jul 31, 2008	Mar	DISC
		@	3MG/ML	A076564	001	Jun 16, 2004	Jan	DISC

ALBUTEROL SULFATESOLUTION; INHALATIONALBUTEROL SULFATE

AN		TEVA PHARMS	EQ 0.083% BASE	A075343	001	Nov 09, 1999	Sep	CAHN
----	--	-------------	----------------	---------	-----	--------------	-----	------

ALBUTEROL SULFATE; IPRATROPIUM BROMIDESOLUTION; INHALATIONALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

AN		RITEDOSE CORP	EQ 0.083% BASE;0.017%	A202496	001	Oct 01, 2012	Sep	NEWA
		@ SANDOZ INC	EQ 0.083% BASE;0.017%	A076867	001	Dec 21, 2006	Apr	DISC
AN		TEVA PHARMS	EQ 0.083% BASE;0.017%	A076724	001	Dec 31, 2007	Sep	CAHN

ALCLOMETASONE DIPROPIONATECREAM; TOPICALALCLOMETASONE DIPROPIONATE

AB		FOUGERA PHARMS	0.05%	A076973	001	Jul 12, 2005	Jan	CAHN
----	--	----------------	-------	---------	-----	--------------	-----	------

OINTMENT; TOPICALALCLOMETASONE DIPROPIONATE

AB		FOUGERA PHARMS	0.05%	A076884	001	Jul 18, 2005	Jan	CAHN
----	--	----------------	-------	---------	-----	--------------	-----	------

ALENDRONATE SODIUMTABLET, EFFERVESCENT; ORALBINOSTO

+		MISSION PHARMA	EQ 70MG BASE	N202344	001	Mar 12, 2012	Mar	NEWA
---	--	----------------	--------------	---------	-----	--------------	-----	------

ALFUZOSIN HYDROCHLORIDETABLET, EXTENDED RELEASE; ORALALFUZOSIN HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	10MG	A079060	001	Aug 30, 2012	Aug	NEWA
AB		INVAGEN PHARMS	10MG	A090284	001	Jan 17, 2012	Jan	NEWA
AB		WOCKHARDT LTD	10MG	A090221	001	Aug 10, 2012	Jul	NEWA

ALGLUCERASEINJECTABLE; INJECTIONCEREDASE

@		GENZYME	80 UNITS/ML	N020057	003	Apr 05, 1991	Mar	DISC
---	--	---------	-------------	---------	-----	--------------	-----	------

ALPRAZOLAMTABLET; ORALALPRAZOLAM

AB		MYLAN PHARMS INC	0.25MG	A074046	001	Oct 19, 1993	Sep	CAHN
AB			0.5MG	A074046	002	Oct 19, 1993	Sep	CAHN
AB			1MG	A074046	003	Oct 19, 1993	Sep	CAHN
AB			2MG	A074046	004	May 07, 1997	Sep	CAHN

TABLET, EXTENDED RELEASE; ORALALPRAZOLAM

@		SANDOZ INC	0.5MG	A077777	001	Jun 30, 2006	Mar	DISC
@			1MG	A077777	002	Jun 30, 2006	Mar	DISC

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

@ SANDOZ INC	2MG	A077777 003	Jun 30, 2006	Mar	DISC
@	3MG	A077777 004	Jun 30, 2006	Mar	DISC
@ VINTAGE PHARMS	0.5MG	A078442 001	Oct 15, 2007	Jul	DISC
@	1MG	A078442 002	Oct 15, 2007	Jul	DISC
@	2MG	A078442 003	Oct 15, 2007	Jul	DISC
@	3MG	A078442 004	Oct 15, 2007	Jul	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

NIRAVAM

AB	UCB INC	0.25MG	N021726 001	Jan 19, 2005	Jan	CAHN
AB		0.5MG	N021726 002	Jan 19, 2005	Jan	CAHN
AB	+	1MG	N021726 003	Jan 19, 2005	Jan	CAHN
AB		2MG	N021726 004	Jan 19, 2005	Jan	CAHN

ALVIMOPAN

CAPSULE; ORAL

ENTEREG

+	CUBIST PHARMS	12MG	N021775 001	May 20, 2008	Feb	CAHN
---	---------------	------	-------------	--------------	-----	------

AMCINONIDE

CREAM; TOPICAL

AMCINONIDE

AB	+	FOUGERA PHARMS	0.1%	A076065 001	May 15, 2003	Jan	CAHN
----	---	----------------	------	-------------	--------------	-----	------

LOTION; TOPICAL

AMCINONIDE

+	FOUGERA PHARMS	0.1%	A076329 001	Nov 06, 2002	Jan	CAHN
---	----------------	------	-------------	--------------	-----	------

OINTMENT; TOPICAL

AMCINONIDE

AB	+	FOUGERA PHARMS	0.1%	A076096 001	Nov 19, 2002	Jan	CAHN
----	---	----------------	------	-------------	--------------	-----	------

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

>D>	@	BAXTER HLTHCARE	EQ 50MG BASE/ML	A063274 001	May 18, 1992	Oct	CAHN
>D>	@		EQ 250MG BASE/ML	A063275 001	May 18, 1992	Oct	CAHN
>A>	@	HIKMA MAPLE	EQ 50MG BASE/ML	A063274 001	May 18, 1992	Oct	CAHN
>A>	@		EQ 250MG BASE/ML	A063275 001	May 18, 1992	Oct	CAHN
	@	HOSPIRA	EQ 50MG BASE/ML	A063263 001	Nov 30, 1994	Jun	DISC

AMINO ACIDS

INJECTABLE; INJECTION

AMINO ACIDS

B BRAUN	15%(150GM/1000ML)	A091112 001	Apr 13, 2012	Mar	NEWA
	15%(300GM/2000ML)	A091112 002	Apr 13, 2012	Mar	NEWA
CLINISOL 15% SULFITE FREE IN PLASTIC CONTAINER					
BAXTER HLTHCARE	15% (15GM/100ML)	A020512 001	Aug 30, 1996	Jun	CAHN
NOVAMINE 15%					
@ HOSPIRA INC	15% (75GM/500ML)	N017957 004	Nov 28, 1986	Mar	CPOT

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMICAR

@ CLOVER PHARMS	250MG/ML	N015229 002		Mar	CAHN
-----------------	----------	-------------	--	-----	------

SYRUP; ORAL

AMICAR

AA	+	CLOVER PHARMS	1.25GM/5ML	N015230 002		Mar	CAHN
----	---	---------------	------------	-------------	--	-----	------

TABLET; ORAL

AMICAR

AB		CLOVER PHARMS	500MG	N015197 001		Mar	CAHN
	+		1GM	N015197 002	Jun 24, 2004	Mar	CAHN

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

	@ BEDFORD	50MG/ML	A076018 001	Oct 15, 2002	Jun	DISC
	@ BEDFORD LABS	50MG/ML	A076299 001	Oct 24, 2002	Jun	DISC
	@ TEVA PARENTERAL	50MG/ML	A076163 001	Sep 05, 2003	Jan	DISC

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB		MURTY PHARMS	200MG	A077069 001	Apr 08, 2005	May	CAHN
AB			400MG	A077069 002	Apr 08, 2005	May	CAHN

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

AB		CARACO	10MG	A040816 002	Jun 27, 2008	Apr	NEWA
AB			50MG	A040816 003	Jun 27, 2008	Apr	NEWA
AB			75MG	A040816 004	Jun 27, 2008	Apr	NEWA
AB			100MG	A040816 005	Jun 27, 2008	Apr	NEWA
AB			150MG	A040816 006	Jun 27, 2008	Apr	NEWA

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET; ORAL

CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

	MYLAN PHARMS INC	EQ 12.5MG BASE;5MG	A071297 002	Dec 10, 1986	Feb	CTEC
+		EQ 25MG BASE;10MG	A071297 001	Dec 10, 1986	Feb	CRLD
	LIMBITROL					
	@ VALEANT PHARM INTL	EQ 12.5MG BASE;5MG	N016949 001		Feb	DISC
	LIMBITROL DS					
	@ VALEANT PHARM INTL	EQ 25MG BASE;10MG	N016949 002		Feb	DISC

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

>D>	AB	LEK PHARMS DD	EQ 2.5MG BASE	A076859 001	Sep 10, 2007	Oct	DISC
>D>	AB		EQ 5MG BASE	A076859 002	Sep 10, 2007	Oct	DISC
>D>	AB		EQ 10MG BASE	A076859 003	Sep 10, 2007	Oct	DISC
	AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A201380 001	Apr 13, 2012	Mar	NEWA
	AB		EQ 10MG BASE	A201380 002	Apr 13, 2012	Mar	NEWA
>A>		@ SANDOZ	EQ 2.5MG BASE	A076859 001	Sep 10, 2007	Oct	DISC
>A>		@	EQ 5MG BASE	A076859 002	Sep 10, 2007	Oct	DISC
>A>		@	EQ 10MG BASE	A076859 003	Sep 10, 2007	Oct	DISC

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE; ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	EQ 2.5MG BASE;10MG	A202239 001	Sep 05, 2012	Aug	NEWA
AB			EQ 5MG BASE;10MG	A202239 002	Sep 05, 2012	Aug	NEWA
AB			EQ 5MG BASE;20MG	A202239 003	Sep 05, 2012	Aug	NEWA

CAPSULE; ORALAMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 5MG BASE;40MG	A202239 004	Sep 05, 2012	Aug	NEWA
AB		EQ 10MG BASE;20MG	A202239 005	Sep 05, 2012	Aug	NEWA
AB		EQ 10MG BASE;40MG	A202239 006	Sep 05, 2012	Aug	NEWA

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTANTABLET; ORALEXFORGE HCT

AB	NOVARTIS	5MG;12.5MG;160MG	N022314 001	Apr 30, 2009	Sep	CFTG
AB		5MG;25MG;160MG	N022314 002	Apr 30, 2009	Sep	CFTG
AB		10MG;12.5MG;160MG	N022314 003	Apr 30, 2009	Sep	CFTG
AB		10MG;25MG;160MG	N022314 004	Apr 30, 2009	Sep	CFTG
AB	+	10MG;25MG;320MG	N022314 005	Apr 30, 2009	Sep	CFTG

AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTANTABLET; ORALAMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	TEVA PHARMS	5MG;12.5MG;160MG	A200435 001	Sep 25, 2012	Sep	NEWA
AB		5MG;25MG;160MG	A200435 002	Sep 25, 2012	Sep	NEWA
AB		10MG;12.5MG;160MG	A200435 005	Sep 25, 2012	Sep	NEWA
AB		10MG;25MG;160MG	A200435 003	Sep 25, 2012	Sep	NEWA
AB		10MG;25MG;320MG	A200435 004	Sep 25, 2012	Sep	NEWA

AMMONIUM LACTATECREAM; TOPICALAMMONIUM LACTATE

>D>	AB	PADDOCK LLC	EQ 12% BASE	A076829 001	Feb 07, 2006	Oct	CAHN
>A>	AB	WATSON LABS INC	EQ 12% BASE	A076829 001	Feb 07, 2006	Oct	CAHN

LOTION; TOPICALAMMONIUM LACTATE

>D>	AB	PADDOCK LLC	EQ 12% BASE	A075575 001	Jun 11, 2002	Oct	CAHN
>A>	AB	WATSON LABS INC	EQ 12% BASE	A075575 001	Jun 11, 2002	Oct	CAHN

AMOXICILLINCAPSULE; ORALAMOXICILLIN

>D>	AB	AM ANTIBIOTICS	250MG	A062058 001		Oct	CAHN
>A>	AB		250MG	A062058 001		Oct	CAHN
>D>	AB		500MG	A062058 002		Oct	CAHN
>A>	AB		500MG	A062058 002		Oct	CAHN

TABLET, FOR SUSPENSION; ORALDISPERMOX@ RANBAXY LABS LTD

600MG

A065159 001 Dec 04, 2003 Apr DISC

AMOXICILLIN; CLAVULANATE POTASSIUMFOR SUSPENSION; ORALAMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SANDOZ INC	200MG/5ML;EQ 28.5MG BASE/5ML	A065098 001	Dec 16, 2002	Jul	CAHN
AB		400MG/5ML;EQ 57MG BASE/5ML	A065098 002	Dec 16, 2002	Jul	CAHN
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A065358 001	Aug 13, 2007	Jul	CAHN

TABLET; ORALAMOXICILLIN AND CLAVULANATE POTASSIUM

AB	AUROBINDO PHARMA LTD	250MG;EQ 125MG BASE	A091569 001	Jan 20, 2012	Jan	NEWA
AB		500MG;EQ 125MG BASE	A091569 002	Jan 20, 2012	Jan	NEWA
AB		875MG;EQ 125MG BASE	A091568 001	Jan 20, 2012	Jan	NEWA

TABLET; ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SANDOZ INC	500MG;EQ 125MG BASE	A065117 001	Nov 27, 2002	Jul	CAHN
AB		875MG;EQ 125MG BASE	A065093 001	Nov 21, 2002	Jul	CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

ADDERALL XR 10						
AB	SHIRE	2.5MG;2.5MG;2.5MG;2.5MG	N021303 001	Oct 11, 2001	Jun	CFTG
ADDERALL XR 15						
AB	SHIRE	3.75MG;3.75MG;3.75MG;3.75MG	N021303 006	May 22, 2002	Jun	CFTG
ADDERALL XR 20						
AB	SHIRE	5MG;5MG;5MG;5MG	N021303 002	Oct 11, 2001	Jun	CFTG
ADDERALL XR 25						
AB	SHIRE	6.25MG;6.25MG;6.25MG;6.25MG	N021303 004	May 22, 2002	Jun	CFTG
ADDERALL XR 30						
AB	+ SHIRE	7.5MG;7.5MG;7.5MG;7.5MG	N021303 003	Oct 11, 2001	Jun	CFTG
ADDERALL XR 5						
AB	SHIRE	1.25MG;1.25MG;1.25MG;1.25MG	N021303 005	May 22, 2002	Jun	CFTG
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE						
AB	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A077302 001	Jun 22, 2012	Jun	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A077302 002	Jun 22, 2012	Jun	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A077302 003	Jun 22, 2012	Jun	NEWA
AB		5MG;5MG;5MG;5MG	A077302 004	Jun 22, 2012	Jun	NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A077302 005	Jun 22, 2012	Jun	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A077302 006	Jun 22, 2012	Jun	NEWA

AMPHETAMINE SULFATE

TABLET; ORAL

AMPHETAMINE SULFATE

	INDEPENDENCE PHARMS	5MG	A200166 001	Aug 09, 2012	Jul	NEWA
+		10MG	A200166 002	Aug 09, 2012	Jul	NEWA

AMPHOTERICIN B

INJECTABLE, LIPID COMPLEX; INJECTION

AMPHOTEC

+	ALKOPHARMA USA	50MG/VIAL	N050729 001	Nov 22, 1996	May	CAHN
+		100MG/VIAL	N050729 002	Nov 22, 1996	May	CAHN

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

AP	ANTIBIOTICE	EQ 250MG BASE/VIAL	A090354 001	Dec 28, 2009	Aug	CAHN
AP		EQ 500MG BASE/VIAL	A090354 002	Dec 28, 2009	Aug	CAHN
AP		EQ 1GM BASE/VIAL	A090354 003	Dec 28, 2009	Aug	CAHN
AP		EQ 2GM BASE/VIAL	A090354 004	Dec 28, 2009	Aug	CAHN
>D>	@ BAXTER HLTHCARE	EQ 125MG BASE/VIAL	A062692 001	Jun 24, 1986	Oct	CAHN
>D>	@	EQ 250MG BASE/VIAL	A062692 002	Jun 24, 1986	Oct	CAHN
>D>	@	EQ 500MG BASE/VIAL	A062692 003	Jun 24, 1986	Oct	CAHN
>D>	@	EQ 1GM BASE/VIAL	A062692 004	Jun 24, 1986	Oct	CAHN
>D>	@	EQ 2GM BASE/VIAL	A062692 005	Jun 24, 1986	Oct	CAHN
>D>	@	EQ 10GM BASE/VIAL	A062692 006	Jun 24, 1986	Oct	CAHN
>A>	@ HIKMA MAPLE	EQ 125MG BASE/VIAL	A062692 001	Jun 24, 1986	Oct	CAHN
>A>	@	EQ 250MG BASE/VIAL	A062692 002	Jun 24, 1986	Oct	CAHN
>A>	@	EQ 500MG BASE/VIAL	A062692 003	Jun 24, 1986	Oct	CAHN

INJECTABLE; INJECTIONAMPICILLIN SODIUM

>A>	@ HIKMA MAPLE	EQ 1GM BASE/VIAL	A062692 004	Jun 24, 1986	Oct	CAHN
>A>	@	EQ 2GM BASE/VIAL	A062692 005	Jun 24, 1986	Oct	CAHN
>A>	@	EQ 10GM BASE/VIAL	A062692 006	Jun 24, 1986	Oct	CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUMINJECTABLE; INJECTIONAMPICILLIN AND SULBACTAM

>D>	AP	BAXTER HLTHCARE	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065074 001	Mar 19, 2002	Oct	CAHN
>D>	AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065074 002	Mar 19, 2002	Oct	CAHN
>D>	AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065076 001	Mar 19, 2002	Oct	CAHN
>A>	AP	HIKMA MAPLE	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065074 001	Mar 19, 2002	Oct	CAHN
>A>	AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065074 002	Mar 19, 2002	Oct	CAHN
>A>	AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065076 001	Mar 19, 2002	Oct	CAHN

ANAGRELIDE HYDROCHLORIDECAPSULE; ORALAGRYLIN

AB		SHIRE LLC	EQ 0.5MG BASE	N020333 001	Mar 14, 1997	Jan	CAHN
		<u>ANAGRELIDE HYDROCHLORIDE</u>					
AB		MYLAN PHARMS INC	EQ 0.5MG BASE	A077613 001	Jun 27, 2006	Sep	CAHN
AB			EQ 1MG BASE	A077613 002	Jun 27, 2006	Sep	CAHN
		@ SANDOZ INC	EQ 0.5MG BASE	A076683 001	Apr 18, 2005	Mar	DISC
		@	EQ 1MG BASE	A076683 002	Apr 18, 2005	Mar	DISC

ANASTROZOLETABLET; ORALANASTROZOLE

AB		APOTEX INC	1MG	A200654 001	May 11, 2012	Apr	NEWA
AB		IMPAX LABS INC	1MG	A091242 001	May 31, 2012	May	NEWA

APREPITANTCAPSULE; ORALAPREPITANT

AB		SANDOZ	40MG	A090999 001	Sep 24, 2012	Sep	NEWA
AB			80MG	A090999 002	Sep 24, 2012	Sep	NEWA
AB			125MG	A090999 003	Sep 24, 2012	Sep	NEWA
		<u>EMEND</u>					
AB		MERCK	40MG	N021549 003	Jun 30, 2006	Sep	CFTG
AB			80MG	N021549 001	Mar 26, 2003	Sep	CFTG
AB	+		125MG	N021549 002	Mar 26, 2003	Sep	CFTG

APROTINININJECTABLE; INJECTIONTRASYLOL

		@ BAYER HLTHCARE	10,000KIU/ML	N020304 001	Dec 29, 1993	May	DISC
--	--	------------------	--------------	-------------	--------------	-----	------

ARGATROBANINJECTABLE; INJECTIONACOVA

AP	+	PFIZER	250MG/2.5ML (100MG/ML)	N020883 001	Jun 30, 2000	Jan	CTNA
----	---	--------	------------------------	-------------	--------------	-----	------

INJECTABLE; INJECTIONARGATROBAN

AP	HIKMA PHARM CO LTD	250MG/2.5ML (100MG/ML)	N203049 001	Jan 05, 2012	Jan	NEWA
----	--------------------	------------------------	-------------	--------------	-----	------

ARMODAFINILTABLET; ORALARMODAFINIL

AB	MYLAN PHARMS INC	50MG	A200043 001	Jun 01, 2012	May	NEWA
AB		150MG	A200043 002	Jun 01, 2012	May	NEWA
AB		250MG	A200043 003	Jun 01, 2012	May	NEWA
	WATSON LABS INC	100MG	A200156 002	Aug 29, 2012	Aug	NEWA
		200MG	A200156 004	Aug 29, 2012	Aug	NEWA

NUVIGIL

AB	CEPHALON	50MG	N021875 001	Jun 15, 2007	May	CFTG
AB		150MG	N021875 003	Jun 15, 2007	May	CFTG
AB	+	250MG	N021875 004	Jun 15, 2007	May	CFTG

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATEFOR SOLUTION; ORALASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

AA	NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9GM;2.691GM ;7.5GM	A090145 001	Jan 25, 2012	Jan	NEWA
AA	+	MOVIPREP				
AA	SALIX PHARMS	4.7GM;100GM;1.015GM;5.9GM;2.691GM ;7.5GM	N021881 001	Aug 02, 2006	Jan	CFTG

ASENAPINE MALEATETABLET; SUBLINGUALSAPHRIS

	ORGANON SUB MERCK	EQ 5MG BASE	N022117 001	Aug 13, 2009	Jul	CAHN
+		EQ 10MG BASE	N022117 002	Aug 13, 2009	Jul	CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATECAPSULE; ORALBUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE
@ VINTAGE PHARMS LLC

325MG;50MG;40MG;30MG	A075351 001	Mar 05, 1999	Sep	CAHN
----------------------	-------------	--------------	-----	------

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATETABLET; ORALINVAGESIC

>D>	AB	SANDOZ	385MG;30MG;25MG	A074817 001	Nov 27, 1996	Oct	DISC
>A>		@	385MG;30MG;25MG	A074817 001	Nov 27, 1996	Oct	DISC
		INVAGESIC FORTE					
>D>	AB	SANDOZ	770MG;60MG;50MG	A074817 002	Nov 27, 1996	Oct	DISC
>A>		@	770MG;60MG;50MG	A074817 002	Nov 27, 1996	Oct	DISC

ASPIRIN; CARISOPRODOLTABLET; ORALCARISOPRODOL AND ASPIRIN

AB	PROSAM LABS	325MG;200MG	A040252 001	Dec 10, 1997	Feb	CAHN
----	-------------	-------------	-------------	--------------	-----	------

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATETABLET; ORALCARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB	PROSAM LABS	325MG;200MG;16MG	A040283 001	Dec 29, 1998	Feb	CAHN
----	-------------	------------------	-------------	--------------	-----	------

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL

ATOMOXETINE HYDROCHLORIDE

@ ZYDUS PHARMS USA INC	18MG	A079017 001	Sep 17, 2010	Jun	DISC
@	25MG	A079017 002	Sep 17, 2010	Jun	DISC
@	40MG	A079017 003	Sep 17, 2010	Jun	DISC
@	60MG	A079017 004	Sep 17, 2010	Jun	DISC
@	80MG	A079017 005	Sep 17, 2010	Jun	DISC
@	100MG	A079017 006	Sep 17, 2010	Jun	DISC

STRATTERA

LILLY

	10MG	N021411 002	Nov 26, 2002	Jun	CTEC
	18MG	N021411 003	Nov 26, 2002	Jun	CTEC
	25MG	N021411 004	Nov 26, 2002	Jun	CTEC
	40MG	N021411 005	Nov 26, 2002	Jun	CTEC
+	60MG	N021411 006	Nov 26, 2002	Jun	CTEC
	80MG	N021411 007	Feb 14, 2005	Jun	CTEC
	100MG	N021411 008	Feb 14, 2005	Jun	CTEC

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB	APOTEX INC	EQ 10MG BASE	A090548 001	May 29, 2012	May	NEWA
AB		EQ 20MG BASE	A090548 002	May 29, 2012	May	NEWA
AB		EQ 40MG BASE	A090548 003	May 29, 2012	May	NEWA
AB		EQ 80MG BASE	A090548 004	May 29, 2012	May	NEWA
AB	DR REDDYS LABS LTD	EQ 10MG BASE	A091650 001	Jul 17, 2012	Jul	NEWA
AB		EQ 20MG BASE	A091650 002	Jul 17, 2012	Jul	NEWA
AB		EQ 40MG BASE	A091650 003	Jul 17, 2012	Jul	NEWA
AB		EQ 80MG BASE	A202357 001	Jul 17, 2012	Jul	NEWA
AB	MYLAN PHARMS INC	EQ 10MG BASE	A091226 001	May 29, 2012	May	NEWA
AB		EQ 20MG BASE	A091226 002	May 29, 2012	May	NEWA
AB		EQ 40MG BASE	A091226 003	May 29, 2012	May	NEWA
AB		EQ 80MG BASE	A091226 004	May 29, 2012	May	NEWA
AB	SANDOZ INC	EQ 10MG BASE	A077575 001	May 29, 2012	May	NEWA
AB		EQ 20MG BASE	A077575 002	May 29, 2012	May	NEWA
AB		EQ 40MG BASE	A077575 003	May 29, 2012	May	NEWA
AB		EQ 80MG BASE	A077575 004	May 29, 2012	May	NEWA
AB	TEVA PHARMS	EQ 10MG BASE	A078773 001	May 29, 2012	May	NEWA
AB		EQ 20MG BASE	A078773 002	May 29, 2012	May	NEWA
AB		EQ 40MG BASE	A078773 003	May 29, 2012	May	NEWA
AB		EQ 80MG BASE	A078773 004	May 29, 2012	May	NEWA

ATRACURIUM BESYLATE

INJECTABLE; INJECTION

ATRACURIUM BESYLATE

AP	+	BEDFORD	10MG/ML	A074901 001	Jul 18, 1997	Feb	CTEC
>A>	AP	HOSPIRA INC	10MG/ML	A090761 001	Oct 18, 2012	Oct	NEWA
	AP	SAGENT PHARMS	10MG/ML	A091489 001	Feb 17, 2012	Feb	NEWA
		ATRACURIUM BESYLATE PRESERVATIVE FREE					
AP	+	BEDFORD	10MG/ML	A074900 001	Jul 18, 1997	Feb	CTEC
>A>	AP	HOSPIRA INC	10MG/ML	A090782 001	Oct 18, 2012	Oct	NEWA
	AP	SAGENT PHARMS	10MG/ML	A091488 001	Feb 17, 2012	Feb	NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

SOLUTION; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA	+	ROXANE	0.025MG/5ML;2.5MG/5ML	A087708 001	May 03, 1982	Apr	CRLD
		LOMOTIL					
		@ GD SEARLE LLC	0.025MG/5ML;2.5MG/5ML	N012699 001		Apr	DISC

AVANAFIL

TABLET; ORAL

STENDRA

VIVUS

		50MG	N202276 001	Apr 27, 2012	Apr	NEWA
		100MG	N202276 002	Apr 27, 2012	Apr	NEWA
+		200MG	N202276 003	Apr 27, 2012	Apr	NEWA

AXITINIB

TABLET; ORAL

INLYTA

PFIZER

		1MG	N202324 001	Jan 27, 2012	Jan	NEWA
+		5MG	N202324 002	Jan 27, 2012	Jan	NEWA

AZELAIC ACID

GEL; TOPICAL

FINACEA

+	BAYER HLTHCARE	15%	N021470 001	Dec 24, 2002	Jun	CAHN
---	----------------	-----	-------------	--------------	-----	------

AZELASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

AZELASTINE HYDROCHLORIDE

AT		ALCON PHARMA	0.05%	A202305 001	May 31, 2012	May	NEWA
----	--	--------------	-------	-------------	--------------	-----	------

SPRAY, METERED; NASAL

ASTEPRO

AB	+	MEDA PHARMS	EQ 0.1876MG BASE/SPRAY	N022371 001	Aug 31, 2009	Aug	CFTG
----	---	-------------	------------------------	-------------	--------------	-----	------

AZELASTINE HYDROCHLORIDE

AB		APOTEX INC	EQ 0.1876MG BASE/SPRAY	A201846 001	Aug 31, 2012	Aug	NEWA
----	--	------------	------------------------	-------------	--------------	-----	------

AB		SUN PHARMA GLOBAL	EQ 0.125MG BASE/SPRAY	A090423 001	May 23, 2012	May	NEWA
----	--	-------------------	-----------------------	-------------	--------------	-----	------

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

DYMISTA

+	MEDA PHARMS	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	N202236 001	May 01, 2012	May	NEWA
---	-------------	---------------------------------------	-------------	--------------	-----	------

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

EDARBI

TAKEDA PHARMS USA

		EQ 40MG MEDOXOMIL	N200796 001	Feb 25, 2011	Apr	CAHN
--	--	-------------------	-------------	--------------	-----	------

+		EQ 80MG MEDOXOMIL	N200796 002	Feb 25, 2011	Apr	CAHN
---	--	-------------------	-------------	--------------	-----	------

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL

EDARBYCLOR

TAKEDA PHARMS USA

		EQ 40MG MEDOXOMIL;12.5MG	N202331 001	Dec 20, 2011	Apr	CAHN
--	--	--------------------------	-------------	--------------	-----	------

+		EQ 40MG MEDOXOMIL;25MG	N202331 002	Dec 20, 2011	Apr	CAHN
---	--	------------------------	-------------	--------------	-----	------

AZITHROMYCIN

FOR SUSPENSION; ORAL

AZITHROMYCIN

>D>	AB	SANDOZ	EQ 100MG BASE/5ML	A065297 001	Sep 18, 2006	Oct	DISC
>A>		@	EQ 100MG BASE/5ML	A065297 001	Sep 18, 2006	Oct	DISC
>D>	AB		EQ 200MG BASE/5ML	A065297 002	Sep 18, 2006	Oct	DISC
>A>		@	EQ 200MG BASE/5ML	A065297 002	Sep 18, 2006	Oct	DISC

INJECTABLE; INJECTION

AZITHROMYCIN

@ PLIVA HRVATSKA DOO

@ TEVA PARENTERAL

@

EQ 500MG BASE/VIAL

EQ 500MG BASE/VIAL

EQ 2.5GM BASE/VIAL

A065265 001 Jan 18, 2007 Jul DISC

N050809 001 Dec 19, 2006 Jun DISC

N050809 002 Dec 19, 2006 Jun DISC

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

AT		AKORN	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065213 001	Jul 25, 2012	Jul	NEWA
AT	+	BAUSCH AND LOMB	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A064068 001	Oct 30, 1995	Jul	CTEC

BACLOFEN

INJECTABLE; INTRATHECAL

GABLOFEN

CNS THERAPS INC

1MG/ML

N022462 004 Jun 22, 2012 Jun NEWA

TABLET; ORAL

BACLOFEN

AB MYLAN PHARMS INC

10MG

A090334 001 Feb 18, 2010 Sep CAHN

AB

20MG

A090334 002 Feb 18, 2010 Sep CAHN

AB

PROSAM LABS

10MG

A077089 001 Oct 31, 2007 Feb CAHN

AB

20MG

A077088 001 Oct 31, 2007 Feb CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

KEMSTRO

@ UCB INC

@

10MG

20MG

N021589 001 Oct 30, 2003 Jan CAHN

N021589 002 Oct 30, 2003 Jan CAHN

BALSALAZIDE DISODIUM

TABLET; ORAL

GIAZO

+ SALIX PHARMS

1.1GM

N022205 001 Feb 03, 2012 Feb NEWA

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; NASAL

QNASL

+ TEVA BRANDED PHARM

0.08MG/ACTUATION

N202813 001 Mar 23, 2012 Sep CPOT

+

0.08MG/ACTIVATION

N202813 001 Mar 23, 2012 Mar NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

LOTENSIN

AB US PHARMS HOLDINGS I

5MG

N019851 001 Jun 25, 1991 Sep CAHN

AB

10MG

N019851 002 Jun 25, 1991 Sep CAHN

AB

20MG

N019851 003 Jun 25, 1991 Sep CAHN

AB +

40MG

N019851 004 Jun 25, 1991 Sep CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

>D>	AB	MYLAN	5MG;6.25MG	A076612 001	Feb 11, 2004	Oct	DISC
>D>	AB		10MG;12.5MG	A076612 002	Feb 11, 2004	Oct	DISC
>D>	AB		20MG;12.5MG	A076612 003	Feb 11, 2004	Oct	DISC
>D>	AB		20MG;25MG	A076612 004	Feb 11, 2004	Oct	DISC
>A>		@ MYLAN PHARMS INC	5MG;6.25MG	A076612 001	Feb 11, 2004	Oct	DISC
>A>		@	10MG;12.5MG	A076612 002	Feb 11, 2004	Oct	DISC
>A>		@	20MG;12.5MG	A076612 003	Feb 11, 2004	Oct	DISC
>A>		@	20MG;25MG	A076612 004	Feb 11, 2004	Oct	DISC

LOTENSIN HCT

AB	US PHARMS HOLDINGS I	5MG;6.25MG	N020033 001	May 19, 1992	Sep	CAHN
AB		10MG;12.5MG	N020033 002	May 19, 1992	Sep	CAHN
AB		20MG;12.5MG	N020033 004	May 19, 1992	Sep	CAHN
AB	+	20MG;25MG	N020033 003	May 19, 1992	Sep	CAHN

BENZONATATE

CAPSULE; ORAL

BENZONATATE

@	NESHER PHARMS	100MG	A040795 001	Oct 31, 2007	Jun	DISC
@		200MG	A040795 002	Oct 31, 2007	Jun	DISC

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL

BENZACLIN

BT	+	VALEANT INTL	5%;EQ 1% BASE	N050756 002	Apr 20, 2007	Apr	CAHN
AB			5%;EQ 1% BASE	N050756 001	Dec 21, 2000	Apr	CAHN

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

AB	MYLAN PHARMS INC	5%;EQ 1% BASE	A065443 001	Aug 11, 2009	Sep	CAHN
AB	PERRIGO ISRAEL	5%;1.2%	A090979 001	Jun 26, 2012	Jun	NEWA

DUAC

AB	+	STIEFEL	5%;1.2%	N050741 001	Aug 26, 2002	Jun	CFTG
----	---	---------	---------	-------------	--------------	-----	------

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN

AB	+	VALEANT INTL	5%;3%	N050557 001	Oct 26, 1984	Jan	CAHN
		BENZAMYCIN PAK					
	+	VALEANT INTL	5%;3%	N050769 001	Nov 27, 2000	Jun	CAHN

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

AA	EMCURE PHARMS LTD	50MG	A202061 001	Jan 27, 2012	Jan	NEWA
----	-------------------	------	-------------	--------------	-----	------

BENZTROPINE MESYLATE

INJECTABLE; INJECTION

BENZTROPINE MESYLATE

AP	APP PHARMS LLC	1MG/ML	A090233 001	Jul 28, 2009	May	CAHN
----	----------------	--------	-------------	--------------	-----	------

COGENTIN

AP	+	OAK PHARMS AKORN	1MG/ML	N012015 001		Feb	CAHN
----	---	------------------	--------	-------------	--	-----	------

TABLET; ORAL

BENZTROPINE MESYLATE

@	LANNETT HOLDINGS INC	0.5MG	A088877 001	Apr 11, 1985	Jan	DISC
---	----------------------	-------	-------------	--------------	-----	------

TABLET; ORAL

BENZTROPINE MESYLATE						
@ LANNETT HOLDINGS INC			1MG	A088894	001	Apr 11, 1985 Jan DISC
@			2MG	A088895	001	Apr 11, 1985 Jan DISC
AA	PROSAM LABS	0.5MG		A040699	001	Feb 14, 2008 Feb CMFD
AA		1MG		A040705	001	Feb 14, 2008 Feb CMFD
AA		2MG		A040706	001	Feb 14, 2008 Feb CMFD
AA	+	USL PHARMA	0.5MG	A040103	001	Dec 12, 1996 Jan CRLD
AA	+		1MG	A040103	002	Dec 12, 1996 Jan CRLD
AA	+		2MG	A040103	003	Dec 12, 1996 Jan CRLD

BETAMETHASONE

SYRUP; ORAL

CELESTONE

@ SCHERING	0.6MG/5ML	N014215	002		May	DISC
------------	-----------	---------	-----	--	-----	------

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

BETAMETHASONE DIPROPIONATE						
AB	+	FOUGERA PHARMS	EQ 0.05% BASE	N019137	001	Jun 26, 1984 Jan CAHN
CREAM, AUGMENTED; TOPICAL						
BETAMETHASONE DIPROPIONATE						
AB		FOUGERA PHARMS	EQ 0.05% BASE	A076215	001	Dec 09, 2003 Jan CAHN
GEL, AUGMENTED; TOPICAL						
BETAMETHASONE DIPROPIONATE						
AB	+	FOUGERA PHARMS	EQ 0.05% BASE	A075276	001	May 13, 2003 Jan CAHN
LOTION, AUGMENTED; TOPICAL						
BETAMETHASONE DIPROPIONATE						
AB		FOUGERA PHARMS	EQ 0.05% BASE	A077111	001	May 21, 2007 Jan CAHN
OINTMENT, AUGMENTED; TOPICAL						
BETAMETHASONE DIPROPIONATE						
AB		FOUGERA PHARMS	EQ 0.05% BASE	A075373	001	Jun 22, 1999 Jan CAHN

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

SUSPENSION; TOPICAL

>A>	TACLONEX					
>A>	+	LEO PHARM	0.064%;0.005%	N022185	001	May 09, 2008 Oct CTNA
>D>	TACLONEX SCALP					
>D>	+	LEO PHARM PRODS	0.064%;0.005%	N022185	001	May 09, 2008 Oct CTNA

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE						
AB		FOUGERA PHARMS	EQ 0.05% BASE;1%	A075502	001	Jun 05, 2001 Jan CAHN
LOTRISONE						
>A>	AB	+	MERCK SHARP DOHME	EQ 0.05% BASE;1%	N018827	001 Jul 10, 1984 Oct CAHN
>D>	AB	+	SCHERING	EQ 0.05% BASE;1%	N018827	001 Jul 10, 1984 Oct CAHN
LOTION; TOPICAL						
CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE						
AB		FOUGERA PHARMS	EQ 0.05% BASE;1%	A076516	001	Jun 16, 2005 Jan CAHN
LOTRISONE						
AB	+	SCHERING CORP	EQ 0.05% BASE;1%	N020010	001	Dec 08, 2000 Feb CAHN

BETAMETHASONE VALERATEAEROSOL, FOAM; TOPICAL
LUXIQ

+ STIEFEL EQ 0.12% BASE N020934 001 Feb 28, 1999 Jan CAHN

BISOPROLOL FUMARATETABLET; ORAL
ZEBETA

AB TEVA WOMENS 5MG N019982 002 Jul 31, 1992 Jan CAHN

AB + 10MG N019982 001 Jul 31, 1992 Jan CAHN

BOCEPREVIRCAPSULE; ORAL
VICTRELIS

+ MERCK SHARP DOHME 200MG N020258 001 May 13, 2011 Mar CAHN

BORTEZOMIBINJECTABLE; INTRAVENOUS, SUBCUTANEOUS
VELCADE

+ MILLENNIUM PHARMS 3.5MG/VIAL N021602 001 May 13, 2003 Jan CDJR

BOSENTANTABLET; ORAL
TRACLEER

+ ACTELION PHARMS LTD 62.5MG N021290 001 Nov 20, 2001 May CAHN

+ 125MG N021290 002 Nov 20, 2001 May CAHN

BOSUTINIB MONOHYDRATETABLET; ORAL
BOSULIF

+ WYETH PHARMS INC EQ 100MG BASE N0203341 001 Sep 04, 2012 Sep NEWA

+ EQ 500MG BASE N0203341 002 Sep 04, 2012 Sep NEWA

BRETYLIUM TOSYLATEINJECTABLE; INJECTION
BRETYLIUM TOSYLATE

>D> @ BAXTER HLTHCARE 50MG/ML A070545 001 May 14, 1986 Oct CAHN

>D> @ 50MG/ML A070546 001 May 14, 1986 Oct CAHN

>A> @ HIKMA MAPLE 50MG/ML A070545 001 May 14, 1986 Oct CAHN

>A> @ 50MG/ML A070546 001 May 14, 1986 Oct CAHN

BROMOCRIPTINE MESYLATECAPSULE; ORAL
PARLODEL

AB + US PHARMS HOLDINGS I EQ 5MG BASE N017962 002 Mar 01, 1982 Sep CAHN

TABLET; ORAL
PARLODEL

AB + US PHARMS HOLDINGS I EQ 2.5MG BASE N017962 001 Sep CAHN

BUDESONIDEPOWDER, METERED; INHALATION
PULMICORT

@ ASTRAZENECA 0.16MG/INH N020441 002 Jun 24, 1997 Jun DISC

SUSPENSION; INHALATIONBUDESONIDE

AN	TEVA PHARMS	0.25MG/2ML	A077519 001	Nov 18, 2008	Sep	CAHN
AN		0.5MG/2ML	A077519 002	Nov 18, 2008	Sep	CAHN
AN	WATSON LABS INC	0.25MG/2ML	A078404 001	Jul 31, 2012	Jul	NEWA
AN		0.5MG/2ML	A078404 002	Jul 31, 2012	Jul	NEWA

BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATEAEROSOL, METERED; INHALATIONSYMBICORT

+	ASTRAZENECA	0.08MG/INH;0.0045MG/INH	N021929 001	Jul 21, 2006	Jan	CDFR
+		0.16MG/INH;0.0045MG/INH	N021929 002	Jul 21, 2006	Jan	CDFR

BUMETANIDEINJECTABLE; INJECTIONBUMETANIDE

>D>	AP	BAXTER HLTHCARE	0.25MG/ML	A079196 001	Apr 30, 2008	Oct	CAHN
>A>	AP	HIKMA MAPLE	0.25MG/ML	A079196 001	Apr 30, 2008	Oct	CAHN

BUPIVACAINEINJECTABLE, LIPOSOMAL; INJECTIONEXPAREL

@	PACIRA PHARMS INC	133MG/10ML (13.3MG/ML)	N022496 001	Oct 28, 2011	Jul	DISC
---	-------------------	------------------------	-------------	--------------	-----	------

BUPRENORPHINE HYDROCHLORIDETABLET; SUBLINGUALBUPRENORPHINE HYDROCHLORIDE

AB	+	ROXANE	EQ 8MG BASE	A078633 002	Oct 08, 2009	Aug	CRLD
		SUBUTEX					
	@	RECKITT BENCKISER	EQ 2MG BASE	N020732 002	Oct 08, 2002	Aug	DISC
	@		EQ 8MG BASE	N020732 003	Oct 08, 2002	Aug	DISC

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDEFILM; SUBLINGUALSUBOXONE

	RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N022410 001	Aug 30, 2010	Apr	CAIN
		EQ 4MG BASE;EQ 1MG BASE	N022410 003	Aug 10, 2012	Aug	NEWA
+		EQ 8MG BASE;EQ 2MG BASE	N022410 002	Aug 30, 2010	Apr	CAIN
		EQ 12MG BASE;EQ 3MG BASE	N022410 004	Aug 10, 2012	Aug	NEWA

TABLET; SUBLINGUALSUBOXONE

	RECKITT BENCKISER	EQ 2MG BASE;EQ 0.5MG BASE	N020733 001	Oct 08, 2002	Apr	CPOT
+		EQ 8MG BASE;EQ 2MG BASE	N020733 002	Oct 08, 2002	Apr	CPOT

BUPROPION HYDROCHLORIDETABLET, EXTENDED RELEASE; ORALBUPROPION HYDROCHLORIDE

BX	IMPAX LABS	300MG	A077415 002	Dec 15, 2006	Sep	CTEC
AB1	WOCKHARDT LTD	100MG	A201331 001	Aug 30, 2012	Aug	NEWA
AB1		150MG	A201331 002	Aug 30, 2012	Aug	NEWA
AB1		200MG	A201331 003	Aug 30, 2012	Aug	NEWA
	FORFIVO XL					
+	EDGEMONT PHARMS LLC	450MG	N022497 001	Nov 10, 2011	Mar	CAHN
	WELLBUTRIN SR					
AB1	GLAXOSMITHKLINE	150MG	N020358 003	Oct 04, 1996	Sep	CRLD
AB1	+	200MG	N020358 004	Jun 14, 2002	Sep	CRLD

TABLET, EXTENDED RELEASE; ORAL

WELLBUTRIN XL

AB3	VALEANT INTL	150MG	N021515 001	Aug 28, 2003	Sep	CRLD
AB3 +		300MG	N021515 002	Aug 28, 2003	Sep	CRLD

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

	@ APOTEX	5MG	A075521 001	Apr 05, 2002	Mar	DISC
	@	10MG	A075521 002	Apr 05, 2002	Mar	DISC
	@	15MG	A075521 003	Apr 05, 2002	Mar	DISC
	@ EGIS	5MG	A075119 001	Mar 14, 2002	Mar	DISC
	@	10MG	A075119 002	Mar 14, 2002	Mar	DISC
	@	15MG	A075119 003	Jan 23, 2003	Mar	DISC
	@ NESHER PHARMS	5MG	A075572 001	Feb 27, 2002	Jun	DISC
	@	10MG	A075572 002	Feb 27, 2002	Jun	DISC
	@	15MG	A075572 003	Feb 27, 2002	Jun	DISC
	@ PROSAM LABS	5MG	A075388 001	May 09, 2002	Mar	DISC
AB		5MG	A075388 001	May 09, 2002	Feb	CMFD
	@	10MG	A075388 002	May 09, 2002	Mar	DISC
AB		10MG	A075388 002	May 09, 2002	Feb	CMFD
	@	15MG	A075388 003	May 09, 2002	Mar	DISC
AB		15MG	A075388 003	May 09, 2002	Feb	CMFD
AB		30MG	A078302 001	Dec 17, 2007	Feb	CMFD

BUTOCONAZOLE NITRATE

CREAM; VAGINAL

BUTOCONAZOLE NITRATE

	@ PERRIGO ISRAEL	2%	A200923 001	May 18, 2012	Apr	NEWA
--	------------------	----	-------------	--------------	-----	------

CAFFEINE CITRATE

SOLUTION; INTRAVENOUS

CAFCIT

AP	+ BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793 001	Sep 21, 1999	Jan	CAHN
----	----------------	------------------------------------	-------------	--------------	-----	------

CAFFEINE CITRATE

AP	SAGENT PHARMS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A090827 001	Aug 29, 2012	Aug	NEWA
----	---------------	------------------------------------	-------------	--------------	-----	------

SOLUTION; ORAL

CAFCIT

AA	+ BEDFORD LABS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793 002	Apr 12, 2000	Jan	CAHN
----	----------------	------------------------------------	-------------	--------------	-----	------

CAFFEINE CITRATE

AA	SAGENT PHARMS	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A091102 001	Aug 29, 2012	Aug	NEWA
----	---------------	------------------------------------	-------------	--------------	-----	------

CALCIPOTRIENE

CREAM; TOPICAL

CALCIPOTRIENE

AB	TOLMAR	0.005%	A200935 001	May 30, 2012	May	NEWA
----	--------	--------	-------------	--------------	-----	------

DOVONEX

AB	+ LEO PHARMA AS	0.005%	N020554 001	Jul 22, 1996	May	CFTG
----	-----------------	--------	-------------	--------------	-----	------

SOLUTION; TOPICAL

CALCIPOTRIENE

AT	FOUGERA PHARMS	0.005%	A078305 001	May 06, 2008	Jan	CAHN
----	----------------	--------	-------------	--------------	-----	------

CALCIUM ACETATE

CAPSULE; ORAL

CALCIUM ACETATE

AB	PADDOK LLC	EQ 169MG CALCIUM	A091312 001	Jun 01, 2012	May	NEWA
----	------------	------------------	-------------	--------------	-----	------

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; IRRIGATION

LACTATED RINGER'S IN PLASTIC CONTAINER

>D>	AT	B BRAUN	20MG/100ML;30MG/100ML;600MG/100ML ;310MG/100ML	N018681 001	Dec 27, 1982	Oct	CRLD
>A>	AT	+	20MG/100ML;30MG/100ML;600MG/100ML ;310MG/100ML	N018681 001	Dec 27, 1982	Oct	CRLD
>D>	AT	BAXTER HLTHCARE	20MG/100ML;30MG/100ML;600MG/100ML ;310MG/100ML	N019933 001	Aug 29, 1989	Oct	CRLD
>D>	AT		20MG/100ML;30MG/100ML;600MG/100ML ;310MG/100ML	N018921 001	Apr 03, 1984	Oct	CRLD
>A>	AT	+	20MG/100ML;30MG/100ML;600MG/100ML ;310MG/100ML	N018921 001	Apr 03, 1984	Oct	CRLD
>A>	AT	+	20MG/100ML;30MG/100ML;600MG/100ML ;310MG/100ML	N019933 001	Aug 29, 1989	Oct	CRLD
>D>	AT	HOSPIRA	20MG/100ML;30MG/100ML;600MG/100ML ;310MG/100ML	N019416 001	Jan 17, 1986	Oct	CRLD
>A>	AT	+	20MG/100ML;30MG/100ML;600MG/100ML ;310MG/100ML	N019416 001	Jan 17, 1986	Oct	CRLD

CAPTOPRIL

TABLET; ORAL

CAPTOPRIL

@ VINTAGE PHARMS LLC

12.5MG

A074418 001 Feb 13, 1996 Sep CAHN

@

25MG

A074418 002 Feb 13, 1996 Sep CAHN

@

50MG

A074418 003 Feb 13, 1996 Sep CAHN

@

100MG

A074418 004 Feb 13, 1996 Sep CAHN

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

@ VINTAGE PHARMS LLC

25MG;15MG

A074788 001 Dec 29, 1997 Sep CAHN

@

25MG;25MG

A074788 002 Dec 29, 1997 Sep CAHN

@

50MG;15MG

A074788 004 Dec 29, 1997 Sep CAHN

@

50MG;25MG

A074788 003 Dec 29, 1997 Sep CAHN

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE; ORAL

CARBAMAZEPINE

AB	TEVA PHARMS	100MG	A078592 001	Sep 20, 2012	Sep	NEWA
----	-------------	-------	-------------	--------------	-----	------

AB		200MG	A078592 002	Sep 20, 2012	Sep	NEWA
----	--	-------	-------------	--------------	-----	------

AB		300MG	A078592 003	Sep 20, 2012	Sep	NEWA
----	--	-------	-------------	--------------	-----	------

CARBIDOPA; ENTACAPONE; LEVODOPA

TABLET; ORAL

CARBIDOPA, LEVODOPA AND ENTACAPONE

AB	SUN PHARMA GLOBAL	25MG;200MG;100MG	A079085 001	May 10, 2012	Apr	NEWA
----	-------------------	------------------	-------------	--------------	-----	------

AB		37.5MG;200MG;150MG	A079085 002	May 10, 2012	Apr	NEWA
----	--	--------------------	-------------	--------------	-----	------

AB	STALEVO 100					
----	-------------	--	--	--	--	--

AB	ORION PHARMA	25MG;200MG;100MG	N021485 002	Jun 11, 2003	Apr	CFTG
----	--------------	------------------	-------------	--------------	-----	------

AB	STALEVO 150					
----	-------------	--	--	--	--	--

AB	ORION PHARMA	37.5MG;200MG;150MG	N021485 003	Jun 11, 2003	Apr	CFTG
----	--------------	--------------------	-------------	--------------	-----	------

CARBIDOPA; LEVODOPA

TABLET, ORALLY DISINTEGRATING; ORAL
PARCOPA

AB	UCB INC	10MG;100MG	A076699 001	Aug 27, 2004	Jan	CAHN
AB		25MG;100MG	A076699 002	Aug 27, 2004	Jan	CAHN
AB	+	25MG;250MG	A076699 003	Aug 27, 2004	Jan	CAHN

CARBOPLATIN

INJECTABLE; INJECTION
CARBOPLATIN

AP	CIPLA LTD	50MG/VIAL	A077383 001	Jan 27, 2006	Mar	CAHN
AP		150MG/VIAL	A077383 002	Jan 27, 2006	Mar	CAHN
AP		450MG/VIAL	A077383 003	Jan 27, 2006	Mar	CAHN
AP	ONCO THERAPIES LTD	50MG/VIAL	A091510 001	May 29, 2012	May	NEWA
AP		150MG/VIAL	A091510 002	May 29, 2012	May	NEWA
AP		450MG/VIAL	A091510 003	May 29, 2012	May	NEWA

PARAPLATIN

@ CORDEN PHARMA

@

@

50MG/VIAL
150MG/VIAL
450MG/VIAL

N019880 001 Mar 03, 1989 Feb CAHN
N019880 002 Mar 03, 1989 Feb CAHN
N019880 003 Mar 03, 1989 Feb CAHN

INJECTABLE; IV (INFUSION)

CARBOPLATIN

AP	ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732 001	Feb 06, 2012	Jan	NEWA
AP		150MG/15ML (10MG/ML)	A078732 002	Feb 06, 2012	Jan	NEWA
AP		450MG/45ML (10MG/ML)	A078732 003	Feb 06, 2012	Jan	NEWA
AP		600MG/60ML (10MG/ML)	A078732 004	Feb 06, 2012	Jan	NEWA
AP	CIPLA LTD	50MG/5ML (10MG/ML)	A077861 001	Jan 18, 2007	Mar	CAHN
AP		150MG/15ML (10MG/ML)	A077861 002	Jan 18, 2007	Mar	CAHN
AP		450MG/45ML (10MG/ML)	A077861 003	Jan 18, 2007	Mar	CAHN
AP		600MG/60ML (10MG/ML)	A077861 004	Jan 18, 2007	Mar	CAHN

CARFILZOMIB

POWDER; INTRAVENOUS

KYPROLIS

+ ONYX PHARMS 60MG/VIAL

N202714 001 Jul 20, 2012 Jul NEWA

CARISOPRODOL

TABLET; ORAL

CARISOPRODOL

AA	PROSAM LABS	350MG	A040188 001	Mar 07, 1997	Feb	CAHN
----	-------------	-------	-------------	--------------	-----	------

CEFACLOR

CAPSULE; ORAL

CEFACLOR

@ RANBAXY

@

EQ 250MG BASE
EQ 500MG BASE

A064156 001 Aug 28, 1997 Apr DISC
A064156 002 Aug 28, 1997 Apr DISC

FOR SUSPENSION; ORAL

CEFACLOR

@ RANBAXY

AB	+	EQ 125MG BASE/5ML	A064166 001	Oct 02, 1997	Apr	DISC
		EQ 125MG BASE/5ML	A064166 001	Oct 02, 1997	Feb	CTEC
	@	EQ 187MG BASE/5ML	A064165 001	Oct 02, 1997	Apr	DISC
AB	+	EQ 187MG BASE/5ML	A064165 001	Oct 02, 1997	Feb	CTEC
	@	EQ 250MG BASE/5ML	A064164 001	Oct 02, 1997	Apr	DISC
AB	+	EQ 250MG BASE/5ML	A064164 001	Oct 02, 1997	Feb	CTEC
	@	EQ 375MG BASE/5ML	A064155 001	Oct 02, 1997	Apr	DISC

FOR SUSPENSION; ORAL

CEFACLOR

AB	+	RANBAXY	EQ 375MG BASE/5ML	A064155	001	Oct 02,	1997	Feb	CTEC
AB		YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065412	001	Feb 17,	2012	Feb	NEWA
AB			EQ 187MG BASE/5ML	A065412	002	Feb 17,	2012	Feb	NEWA
AB			EQ 250MG BASE/5ML	A065412	003	Feb 17,	2012	Feb	NEWA
AB			EQ 375MG BASE/5ML	A065412	004	Feb 17,	2012	Feb	NEWA

TABLET, CHEWABLE; ORAL

RANICLOR

	@	RANBAXY LABS LTD	EQ 125MG BASE	A065092	001	Dec 22,	2003	Apr	DISC
	@		EQ 187MG BASE	A065092	002	Dec 22,	2003	Apr	DISC
	@		EQ 250MG BASE	A065092	003	Dec 22,	2003	Apr	DISC
	@		EQ 375MG BASE	A065092	004	Dec 22,	2003	Apr	DISC

CEFADROXIL/CEFADROXIL HEMIHYDRATE

CAPSULE; ORAL

CEFADROXIL

	@	RANBAXY LABS LTD	EQ 500MG BASE	A065015	001	Jun 22,	1999	Apr	DISC
--	---	------------------	---------------	---------	-----	---------	------	-----	------

TABLET; ORAL

CEFADROXIL

	@	RANBAXY	EQ 1GM BASE	A065018	001	Apr 23,	1999	Apr	DISC
+		TEVA PHARMS	EQ 1GM BASE	A062774	001	Apr 08,	1987	Aug	CAHN

CEFAZOLIN SODIUM

INJECTABLE; INJECTION

CEFAZOLIN AND DEXTROSE

		B BRAUN	EQ 2GM BASE/VIAL	N050779	003	Jan 13,	2012	May	NEWA
--	--	---------	------------------	---------	-----	---------	------	-----	------

CEFAZOLIN SODIUM

>D>	@	ELKINS SINN	EQ 250MG BASE/VIAL	A062807	001	Jan 12,	1988	Oct	CAHN
>D>	@		EQ 500MG BASE/VIAL	A062807	002	Jan 12,	1988	Oct	CAHN
>D>	@		EQ 1GM BASE/VIAL	A062807	003	Jan 12,	1988	Oct	CAHN
>D>	@		EQ 5GM BASE/VIAL	A062807	004	Jan 12,	1988	Oct	CAHN
>D>	@		EQ 10GM BASE/VIAL	A062807	005	Jan 12,	1988	Oct	CAHN
>D>	@		EQ 20GM BASE/VIAL	A062807	006	Jan 12,	1988	Oct	CAHN
>A>	@	HIKMA MAPLE	EQ 250MG BASE/VIAL	A062807	001	Jan 12,	1988	Oct	CAHN
>A>	@		EQ 500MG BASE/VIAL	A062807	002	Jan 12,	1988	Oct	CAHN
>A>	@		EQ 1GM BASE/VIAL	A062807	003	Jan 12,	1988	Oct	CAHN
>A>	@		EQ 5GM BASE/VIAL	A062807	004	Jan 12,	1988	Oct	CAHN
>A>	@		EQ 10GM BASE/VIAL	A062807	005	Jan 12,	1988	Oct	CAHN
>A>	@		EQ 20GM BASE/VIAL	A062807	006	Jan 12,	1988	Oct	CAHN
>D>	@	TEVA	EQ 250MG BASE/VIAL	A063016	001	Mar 14,	1989	Oct	CAHN
>D>	@		EQ 500MG BASE/VIAL	A063016	002	Mar 14,	1989	Oct	CAHN
>D>	@		EQ 1GM BASE/VIAL	A063016	003	Mar 14,	1989	Oct	CAHN
>D>	@		EQ 5GM BASE/VIAL	A063018	001	Mar 05,	1990	Oct	CAHN
>D>	@		EQ 10GM BASE/VIAL	A063018	002	Mar 05,	1990	Oct	CAHN
>A>	@	TEVA PHARMS	EQ 250MG BASE/VIAL	A063016	001	Mar 14,	1989	Oct	CAHN
>A>	@		EQ 500MG BASE/VIAL	A063016	002	Mar 14,	1989	Oct	CAHN
>A>	@		EQ 1GM BASE/VIAL	A063016	003	Mar 14,	1989	Oct	CAHN
>A>	@		EQ 5GM BASE/VIAL	A063018	001	Mar 05,	1990	Oct	CAHN
>A>	@		EQ 10GM BASE/VIAL	A063018	002	Mar 05,	1990	Oct	CAHN

CEFDITOREN PIVOXIL

TABLET; ORAL

SPECTRACEF

		VANSEN PHARMA	200MG	N021222	001	Aug 29,	2001	Mar	CAHN
+			400MG	N021222	002	Jul 21,	2008	Mar	CAHN

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION

CEFEPIME HYDROCHLORIDE

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A202268 001	Jul 30, 2012	Jul	NEWA
AP		EQ 2GM BASE/VIAL	A202268 002	Jul 30, 2012	Jul	NEWA

CEFIXIME

CAPSULE; ORAL

SUPRAX

+	LUPIN LTD	400MG	N203195 001	Jun 01, 2012	Jun	NEWA
---	-----------	-------	-------------	--------------	-----	------

CEFOTAXIME SODIUM

INJECTABLE; INJECTION

CLAFORAN

AP	+	SANOFI AVENTIS US	EQ 1GM BASE/VIAL	A062659 001	Jan 13, 1987	Mar	CRLD
AP	+		EQ 2GM BASE/VIAL	A062659 002	Jan 13, 1987	Mar	CRLD

CEFOXITIN SODIUM

INJECTABLE; INJECTION

CEFOXITIN

AP	ANTIBIOTICOS BRASIL	EQ 1GM BASE/VIAL	A065467 001	Aug 31, 2011	Jul	CAIN	
AP		EQ 2GM BASE/VIAL	A065467 002	Aug 31, 2011	Jul	CAIN	
AP		EQ 10GM BASE/VIAL	A065464 001	Aug 31, 2011	Jul	CAIN	
>D>	AP	BAXTER HLTHCARE	EQ 1GM BASE/VIAL	A065051 001	Sep 11, 2000	Oct	CAHN
>D>	AP		EQ 2GM BASE/VIAL	A065051 002	Sep 11, 2000	Oct	CAHN
>D>	AP		EQ 10GM BASE/VIAL	A065050 001	Sep 11, 2000	Oct	CAHN
>A>	AP	HIKMA MAPLE	EQ 1GM BASE/VIAL	A065051 001	Sep 11, 2000	Oct	CAHN
>A>	AP		EQ 2GM BASE/VIAL	A065051 002	Sep 11, 2000	Oct	CAHN
>A>	AP		EQ 10GM BASE/VIAL	A065050 001	Sep 11, 2000	Oct	CAHN

CEFPROZIL

FOR SUSPENSION; ORAL

CEFPROZIL

AB	APOTEX INC	125MG/5ML	A065351 001	Feb 29, 2012	Feb	NEWA
AB		250MG/5ML	A065351 002	Feb 29, 2012	Feb	NEWA
	@ RANBAXY LABS LTD	125MG/5ML	A065202 001	Jun 30, 2006	Apr	DISC
	@	250MG/5ML	A065202 002	Jun 30, 2006	Apr	DISC

TABLET; ORAL

CEFPROZIL

@ RANBAXY LABS LTD

@

CEFZIL

@ CORDEN PHARMA

@

250MG	A065198 001	Dec 13, 2006	Apr	DISC
500MG	A065198 002	Dec 13, 2006	Apr	DISC
250MG	N050664 001	Dec 23, 1991	Feb	CAHN
500MG	N050664 002	Dec 23, 1991	Feb	CAHN

CEFTAZIDIME

INJECTABLE; INJECTION

FORTAZ

AP	+	COVIS PHARMA	500MG/VIAL	N050578 001	Jul 19, 1985	Apr	CAHN
AP	+		1GM/VIAL	N050578 002	Jul 19, 1985	Apr	CAHN
AP	+		2GM/VIAL	N050578 003	Jul 19, 1985	Apr	CAHN
AP	+		6GM/VIAL	N050578 004	Jul 19, 1985	Apr	CAHN

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

FORTAZ IN PLASTIC CONTAINER

@ COVIS PHARMA	EQ 10MG BASE/ML	N050634 001	Apr 28, 1989	Apr	CAHN
+	EQ 20MG BASE/ML	N050634 002	Apr 28, 1989	Apr	CAHN
+	EQ 40MG BASE/ML	N050634 003	Apr 28, 1989	Apr	CAHN

CEFTRIAZONE SODIUM

INJECTABLE; IM-IV

CEFTRIAZONE

>A>	AP	AKORN INC	EQ 250MG BASE/VIAL	A065305 001	Jan 11, 2008	Oct	CAHN
>A>	AP		EQ 500MG BASE/VIAL	A065305 002	Jan 11, 2008	Oct	CAHN
>A>	AP		EQ 1GM BASE/VIAL	A065305 003	Jan 11, 2008	Oct	CAHN
>A>	AP		EQ 2GM BASE/VIAL	A065305 004	Jan 11, 2008	Oct	CAHN
>D>	AP	LUITPOLD	EQ 250MG BASE/VIAL	A065305 001	Jan 11, 2008	Oct	CAHN
>D>	AP		EQ 500MG BASE/VIAL	A065305 002	Jan 11, 2008	Oct	CAHN
>D>	AP		EQ 1GM BASE/VIAL	A065305 003	Jan 11, 2008	Oct	CAHN
>D>	AP		EQ 2GM BASE/VIAL	A065305 004	Jan 11, 2008	Oct	CAHN
>D>	AP	TEVA PARENTERAL	EQ 250MG BASE/VIAL	A065227 001	Mar 15, 2007	Oct	CAHN
>D>	AP		EQ 500MG BASE/VIAL	A065227 002	Mar 15, 2007	Oct	CAHN
>D>	AP		EQ 1GM BASE/VIAL	A065227 003	Mar 15, 2007	Oct	CAHN
>D>	AP		EQ 2GM BASE/VIAL	A065227 004	Mar 15, 2007	Oct	CAHN
>A>	AP	TEVA PHARMS	EQ 250MG BASE/VIAL	A065227 001	Mar 15, 2007	Oct	CAHN
>A>	AP		EQ 500MG BASE/VIAL	A065227 002	Mar 15, 2007	Oct	CAHN
>A>	AP		EQ 1GM BASE/VIAL	A065227 003	Mar 15, 2007	Oct	CAHN
>A>	AP		EQ 2GM BASE/VIAL	A065227 004	Mar 15, 2007	Oct	CAHN

INJECTABLE; INJECTION

CEFTRIAZONE

AP		HOSPIRA INC	EQ 1GM BASE/VIAL	A202563 001	Aug 20, 2012	Aug	NEWA
AP			EQ 2GM BASE/VIAL	A202563 002	Aug 20, 2012	Aug	NEWA
AP	+	SANDOZ INC	EQ 1GM BASE/VIAL	A065204 001	May 03, 2005	Mar	CRLD
AP	+		EQ 2GM BASE/VIAL	A065204 002	May 03, 2005	Mar	CRLD

CEFUROXIME AXETIL

TABLET; ORAL

CEFUROXIME AXETIL

@ RANBAXY LABS LTD	EQ 125MG BASE	A065043 003	Feb 15, 2002	Apr	DISC
@	EQ 250MG BASE	A065043 002	Feb 15, 2002	Apr	DISC
@	EQ 500MG BASE	A065043 001	Feb 15, 2002	Apr	DISC

CEFUROXIME SODIUM

INJECTABLE; IM-IV

CEFUROXIME SODIUM

>D>	AB	TEVA	EQ 750MG BASE/VIAL	A064192 002	Apr 16, 1998	Oct	CAHN
>A>	AB	TEVA PHARMS	EQ 750MG BASE/VIAL	A064192 002	Apr 16, 1998	Oct	CAHN
		ZINACEF					
	AB	+ COVIS PHARMA	EQ 750MG BASE/VIAL	N050558 002	Oct 19, 1983	Apr	CAHN
		INJECTABLE; INJECTION					
		CEFUROXIME SODIUM					
>D>	AP	TEVA	EQ 1.5GM BASE/VIAL	A064192 001	Apr 16, 1998	Oct	CAHN
>D>	AP		EQ 7.5GM BASE/VIAL	A064191 001	Apr 16, 1998	Oct	CAHN
>A>	AP	TEVA PHARMS	EQ 1.5GM BASE/VIAL	A064192 001	Apr 16, 1998	Oct	CAHN
>A>	AP		EQ 7.5GM BASE/VIAL	A064191 001	Apr 16, 1998	Oct	CAHN
		ZINACEF					
	AP	+ COVIS PHARMA	EQ 1.5GM BASE/VIAL	N050558 003	Oct 19, 1983	Apr	CAHN

INJECTABLE; INJECTION

ZINACEF

AP	+	COVIS PHARMA	EQ 7.5GM BASE/VIAL	N050558 004	Oct 23, 1986	Apr	CAHN
		ZINACEF IN PLASTIC CONTAINER					
	+	COVIS PHARMA	EQ 15MG BASE/ML	N050643 001	Apr 28, 1989	Apr	CAHN
	+		EQ 30MG BASE/ML	N050643 002	Apr 28, 1989	Apr	CAHN

CEPHALEXIN

FOR SUSPENSION; ORAL

KEFLEX

	@	SHIONOGI INC	EQ 100MG BASE/ML	N050406 003		Jul	CAHN
	@		EQ 125MG BASE/5ML	N050406 001		Jul	CAHN
	@		EQ 250MG BASE/5ML	N050406 002		Jul	CAHN

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEPHAPIRIN SODIUM

>D>	@	BAXTER HLTHCARE	EQ 500MG BASE/VIAL	A062720 001	Jul 02, 1987	Oct	CAHN
>D>	@		EQ 1GM BASE/VIAL	A062720 002	Jul 02, 1987	Oct	CAHN
>D>	@		EQ 2GM BASE/VIAL	A062720 003	Jul 02, 1987	Oct	CAHN
>D>	@		EQ 20GM BASE/VIAL	A062720 004	Jul 02, 1987	Oct	CAHN
>A>	@	HIKMA MAPLE	EQ 500MG BASE/VIAL	A062720 001	Jul 02, 1987	Oct	CAHN
>A>	@		EQ 1GM BASE/VIAL	A062720 002	Jul 02, 1987	Oct	CAHN
>A>	@		EQ 2GM BASE/VIAL	A062720 003	Jul 02, 1987	Oct	CAHN
>A>	@		EQ 20GM BASE/VIAL	A062720 004	Jul 02, 1987	Oct	CAHN

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CETIRIZINE HYDROCHLORIDE

	@	RANBAXY LABS LTD	5MG/5ML	A077472 001	Jun 18, 2008	Jul	DISC
AA		SILARX	5MG/5ML	A078876 001	May 11, 2012	Apr	NEWA

CHLORAMBUCIL

TABLET; ORAL

LEUKERAN

	+	ASPEN GLOBAL INC	2MG	N010669 002		May	CAHN
--	---	------------------	-----	-------------	--	-----	------

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX

AB		CORNERSTONE THERAP	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	A091671 001	Jun 29, 2012	Jun	NEWA
----	--	--------------------	---	-------------	--------------	-----	------

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLORPROMAZINE HYDROCHLORIDE

>D>	+	BAXTER HLTHCARE	25MG/ML	A083329 001		Oct	CAHN
>A>	+	HIKMA MAPLE	25MG/ML	A083329 001		Oct	CAHN

CHOLESTYRAMINE

POWDER; ORAL

LOCHOLEST

>D>	AB	SANDOZ	EQ 4GM RESIN/PACKET	A074561 001	Aug 15, 1996	Oct	DISC
>D>	AB		EQ 4GM RESIN/SC00PFUL	A074561 002	Aug 15, 1996	Oct	DISC
>A>	@		EQ 4GM RESIN/PACKET	A074561 001	Aug 15, 1996	Oct	DISC
>A>	@		EQ 4GM RESIN/SC00PFUL	A074561 002	Aug 15, 1996	Oct	DISC

POWDER; ORAL

>D>		LOCHOLEST LIGHT							
>D>	AB	SANDOZ	EQ 4GM RESIN/PACKET	A074562	001	Aug 15,	1996	Oct	DISC
>D>	AB		EQ 4GM RESIN/SC00PFUL	A074562	002	Aug 15,	1996	Oct	DISC
>A>		@	EQ 4GM RESIN/PACKET	A074562	001	Aug 15,	1996	Oct	DISC
>A>		@	EQ 4GM RESIN/SC00PFUL	A074562	002	Aug 15,	1996	Oct	DISC

CHOLINE C-11

INJECTABLE; INTRAVENOUS

CHOLINE C-11

+	MCPRF	4-33.1mCi/ML	N203155	001	Sep 12,	2012	Sep	NEWA
---	-------	--------------	---------	-----	---------	------	-----	------

CICLESONIDE

AEROSOL, METERED; INHALATION

ALVESCO

	NYCOMED GMBH	0.08MG/INH	N021658	002	Jan 10,	2008	May	CAHN
+		0.16MG/INH	N021658	003	Jan 10,	2008	May	CAHN

AEROSOL, METERED; NASAL

ZETONNA

+	NYCOMED GMBH	0.037MG/INH	N202129	001	Jan 20,	2012	Jan	NEWA
---	--------------	-------------	---------	-----	---------	------	-----	------

SPRAY, METERED; NASAL

OMNARIS

+	NYCOMED GMBH	0.05MG/INH	N022004	001	Oct 20,	2006	May	CAHN
---	--------------	------------	---------	-----	---------	------	-----	------

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

AB	FOUGERA PHARMS	0.77%	A076435	001	Dec 29,	2004	Jan	CAHN
----	----------------	-------	---------	-----	---------	------	-----	------

GEL; TOPICAL

CICLOPIROX

AB	FOUGERA PHARMS	0.77%	A077896	001	Jun 10,	2008	Jan	CAHN
AB	GLENMARK GENERICS	0.77%	A091595	001	Feb 29,	2012	Feb	NEWA

SHAMPOO; TOPICAL

CICLOPIROX

AT	FOUGERA PHARMS	1%	A090146	001	May 25,	2010	Jan	CAHN	
>D>	AT	PADDOCK LLC	1%	A090490	001	Nov 24,	2009	Oct	CAHN
>A>	AT	WATSON LABS INC	1%	A090490	001	Nov 24,	2009	Oct	CAHN

SOLUTION; TOPICAL

CICLOPIROX

AT	MYLAN PHARMS INC	8%	A078567	001	Sep 18,	2007	Feb	CAHN
----	------------------	----	---------	-----	---------	------	-----	------

SUSPENSION; TOPICAL

CICLOPIROX

AB	FOUGERA PHARMS	0.77%	A076422	001	Aug 06,	2004	Jan	CAHN
----	----------------	-------	---------	-----	---------	------	-----	------

CIDOFOVIR

INJECTABLE; INJECTION

CIDOFOVIR

AP	EMCURE PHARMS LTD	EQ 75MG BASE/ML	A202501	001	Jul 26,	2012	Jul	NEWA	
AP	MYLAN LLC	EQ 75MG BASE/ML	A201276	001	Jun 27,	2012	Jun	NEWA	
AP	+	GILEAD SCIENCES INC	EQ 75MG BASE/ML	N020638	001	Jun 26,	1996	Jun	CFTG

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

AB	BIOKEY	50MG	A077722	001	Sep 24,	2012	Sep	NEWA
----	--------	------	---------	-----	---------	------	-----	------

TABLET; ORAL

CILOSTAZOL

AB	BIOKEY	100MG	A077831 001	Sep 24, 2012	Sep	NEWA
AB	MYLAN PHARMS INC	50MG	A077019 001	Nov 23, 2004	Sep	CAHN
AB		100MG	A077019 002	Nov 23, 2004	Sep	CAHN

CIMETIDINE

TABLET; ORAL

CIMETIDINE

>D>	AB	SANDOZ	200MG	A074506 001	Jan 24, 1996	Oct	DISC
>A>		@	200MG	A074506 001	Jan 24, 1996	Oct	DISC
>D>	AB		300MG	A074506 002	Jan 24, 1996	Oct	DISC
>A>		@	300MG	A074506 002	Jan 24, 1996	Oct	DISC
>D>	AB		400MG	A074506 003	Jan 24, 1996	Oct	DISC
>A>		@	400MG	A074506 003	Jan 24, 1996	Oct	DISC
>D>	AB		800MG	A074506 004	Jan 24, 1996	Oct	DISC
>A>		@	800MG	A074506 004	Jan 24, 1996	Oct	DISC
		@ VINTAGE PHARMS LLC	200MG	A074281 001	May 17, 1994	Sep	CAHN
		@	300MG	A074281 002	May 17, 1994	Sep	CAHN
		@	400MG	A074281 003	May 17, 1994	Sep	CAHN
		@	800MG	A074329 001	May 17, 1994	Sep	CAHN

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

@	HOSPIRA	EQ 300MG BASE/2ML	A074344 001	Jan 31, 1995	Jun	DISC
@		EQ 300MG BASE/2ML	A074345 001	Jan 31, 1995	Jun	DISC
@	VINTAGE PHARMS LLC	EQ 300MG BASE/2ML	A074005 001	Aug 31, 1994	Sep	CAHN

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

@	VINTAGE PHARMS LLC	EQ 300MG BASE/5ML	A074251 001	Dec 22, 1994	Sep	CAHN
---	--------------------	-------------------	-------------	--------------	-----	------

CIPROFLOXACIN

INJECTABLE; INJECTION

CIPROFLOXACIN

@	TEVA PARENTERAL	200MG/20ML (10MG/ML)	A077782 001	Aug 28, 2006	Mar	DISC
@		400MG/40ML (10MG/ML)	A077782 002	Aug 28, 2006	Jan	DISC

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	200MG/100ML	A077888 001	Mar 18, 2008	Jun	DISC
@		400MG/200ML	A077888 002	Mar 18, 2008	Jun	DISC

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

@	PLIVA	EQ 100MG BASE	A076426 001	Jun 15, 2005	Jan	DISC
@		EQ 250MG BASE	A076426 002	Jun 15, 2005	Jan	DISC
@		EQ 500MG BASE	A076426 003	Jun 15, 2005	Jan	DISC
@		EQ 750MG BASE	A076426 004	Jun 15, 2005	Jan	DISC

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

AB	DR REDDYS LABS LTD	212.6MG;EQ 287.5MG BASE	A077701 002	Oct 31, 2007	Apr	NEWA
----	--------------------	-------------------------	-------------	--------------	-----	------

CISATRACURIUM BESYLATE

INJECTABLE; INJECTION

CISATRACURIUM BESYLATE

AP	SANDOZ INC	EQ 2MG BASE/ML	A200159 001	Feb 03, 2012	Jan	NEWA
	CISATRACURIUM BESYLATE PRESERVATIVE FREE					
AP	SANDOZ INC	EQ 2MG BASE/ML	A200154 001	Feb 03, 2012	Jan	NEWA
AP		EQ 10MG BASE/ML	A200154 002	Feb 03, 2012	Jan	NEWA
	NIMBEX					
AP	+ ABBOTT	EQ 2MG BASE/ML	N020551 001	Dec 15, 1995	Jan	CFTG
	NIMBEX PRESERVATIVE FREE					
AP	+ ABBOTT	EQ 2MG BASE/ML	N020551 003	Dec 15, 1995	Jan	CFTG
AP	+	EQ 10MG BASE/ML	N020551 002	Dec 15, 1995	Jan	CFTG

CISPLATIN

INJECTABLE; INJECTION

CISPLATIN

AP	ONCO THERAPIES LTD	1MG/ML	A091062 001	Apr 18, 2012	Apr	NEWA
	@ TEVA PARENTERAL	1MG/ML	A074814 001	May 16, 2000	Mar	DISC

CITALOPRAM HYDROBROMIDE

CAPSULE; ORAL

CITALOPRAM HYDROBROMIDE

	MYLAN PHARMS INC	EQ 10MG BASE	A077668 001	Feb 28, 2007	Sep	CAHN
		EQ 20MG BASE	A077668 002	Feb 28, 2007	Sep	CAHN
+		EQ 40MG BASE	A077668 003	Feb 28, 2007	Sep	CAHN

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

AB	MYLAN PHARMS INC	EQ 10MG BASE	A077037 001	Nov 05, 2004	Sep	CAHN
AB		EQ 20MG BASE	A077037 002	Nov 05, 2004	Sep	CAHN
AB		EQ 40MG BASE	A077037 003	Nov 05, 2004	Sep	CAHN
	@ SANDOZ	EQ 10MG BASE	A077035 001	Oct 28, 2004	Aug	DISC
	@	EQ 20MG BASE	A077035 002	Oct 28, 2004	Aug	DISC
	@	EQ 40MG BASE	A077035 003	Oct 28, 2004	Aug	DISC
AB	TEVA PHARMS	EQ 10MG BASE	A077048 001	Nov 16, 2004	Aug	CAHN
AB		EQ 20MG BASE	A077048 002	Nov 16, 2004	Aug	CAHN
AB		EQ 40MG BASE	A077048 003	Nov 16, 2004	Aug	CAHN

CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE

FOR SOLUTION; ORAL

PREPOPIK

+	FERRING PHARMS AS	12GM/PACKET;3.5GM/PACKET;10MG/PAC KET	N202535 001	Jul 16, 2012	Jul	NEWA
---	-------------------	--	-------------	--------------	-----	------

CLARITHROMYCIN

TABLET; ORAL

CLARITHROMYCIN

AB	AUROBINDO	250MG	A065489 001	Jul 25, 2012	Jul	NEWA
AB		500MG	A065489 002	Jul 25, 2012	Jul	NEWA

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

	@ SANDOZ	500MG	A065250 001	Aug 25, 2005	Aug	DISC
--	----------	-------	-------------	--------------	-----	------

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL

CLINDAMYCIN HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 75MG BASE	A091225 001	May 31, 2011	Sep	CAHN
AB		EQ 150MG BASE	A091225 002	May 31, 2011	Sep	CAHN
AB		EQ 300MG BASE	A091225 003	May 31, 2011	Sep	CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	LYNE	EQ 75MG BASE/5ML	A201821 001	Aug 28, 2012	Aug	NEWA
----	------	------------------	-------------	--------------	-----	------

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLINDAMYCIN PHOSPHATE

AB	FOUGERA PHARMS	EQ 2% BASE	A065139 001	Dec 27, 2004	Jan	CAHN
----	----------------	------------	-------------	--------------	-----	------

GEL; TOPICAL

CLINDAMYCIN PHOSPHATE

AB	FOUGERA PHARMS	EQ 1% BASE	A064160 001	Jan 28, 2000	Jan	CAHN
----	----------------	------------	-------------	--------------	-----	------

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	PHARMACIA AND UPJOHN	EQ 6MG BASE/ML	N050639 001	Aug 30, 1989	May	CFTG
AP	+		EQ 12MG BASE/ML	N050639 002	Aug 30, 1989	May	CFTG
AP	+		EQ 18MG BASE/ML	N050639 003	Apr 10, 1991	May	CFTG

CLINDAMYCIN PHOSPHATE

>D>	@	BAXTER HLTHCARE	EQ 150MG BASE/ML	A062953 001	Apr 21, 1988	Oct	CAHN
>D>	AP		EQ 150MG BASE/ML	A062889 001	Apr 25, 1988	Oct	CAHN
>D>	@		EQ 150MG BASE/ML	A063068 001	Aug 28, 1989	Oct	CAHN
>D>	@		EQ 150MG BASE/ML	A062806 001	Oct 15, 1987	Oct	CAHN
>A>	@	HIKMA MAPLE	EQ 150MG BASE/ML	A062953 001	Apr 21, 1988	Oct	CAHN
>A>	@		EQ 150MG BASE/ML	A063068 001	Aug 28, 1989	Oct	CAHN
>A>	@		EQ 150MG BASE/ML	A062806 001	Oct 15, 1987	Oct	CAHN
>A>	AP		EQ 150MG BASE/ML	A062889 001	Apr 25, 1988	Oct	CAHN

CLINDAMYCIN PHOSPHATE IN 5% DEXTROSE IN PLASTIC CONTAINER

AP		SANDOZ INC	EQ 6MG BASE/ML	A201692 001	May 31, 2012	May	NEWA
AP			EQ 12MG BASE/ML	A201692 002	May 31, 2012	May	NEWA
AP			EQ 18MG BASE/ML	A201692 003	May 31, 2012	May	NEWA

LOTION; TOPICAL

CLINDAMYCIN PHOSPHATE

AB		FOUGERA PHARMS	EQ 1% BASE	A065067 001	Jan 31, 2002	Jan	CAHN
----	--	----------------	------------	-------------	--------------	-----	------

SOLUTION; TOPICAL

CLINDAMYCIN PHOSPHATE

>D>	@	ACTAVIS MID ATLANTIC	EQ 1% BASE	A062811 001	Sep 01, 1988	Oct	CAHN
AT		FOUGERA PHARMS	EQ 1% BASE	A065254 001	Feb 14, 2006	Jan	CAHN
>A>	@	G AND W LABS INC	EQ 1% BASE	A062811 001	Sep 01, 1988	Oct	CAHN
	@	RENAISSANCE PHARMA	EQ 1% BASE	A064108 001	Sep 27, 1996	Sep	CAHN

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

VELTIN

BX	+	STIEFEL GSK	1.2%;0.025%	N050803 001	Jul 16, 2010	May	CRLD
----	---	-------------	-------------	-------------	--------------	-----	------

CLOBAZAM

TABLET; ORAL

ONFI

LUNDBECK LLC	5MG	N202067 001	Oct 21, 2011	Mar	CAHN
	10MG	N202067 002	Oct 21, 2011	Mar	CAHN
+	20MG	N202067 003	Oct 21, 2011	Mar	CAHN

CLOBETASOL PROPIONATE

AEROSOL, FOAM; TOPICAL

CLOBETASOL PROPIONATE

AB1	PERRIGO ISRAEL	0.05%	A077763 001	Mar 10, 2008	Jul	CTEC
AB2		0.05%	A201402 001	Aug 14, 2012	Jul	NEWA

OLUX

AB1	+ STIEFEL LABS INC	0.05%	N021142 001	May 26, 2000	Jul	CTEC
-----	--------------------	-------	-------------	--------------	-----	------

OLUX E

AB2	+ STIEFEL LABS INC	0.05%	N022013 001	Jan 12, 2007	Jul	CFTG
-----	--------------------	-------	-------------	--------------	-----	------

CREAM; TOPICAL

CLOBETASOL PROPIONATE

@ G AND W LABS INC 0.05%

A074139 001 Aug 03, 1994 Jun CAHN

@ RENAISSANCE PHARMA 0.05%

A075338 001 Feb 09, 2001 Aug CAHN

CLOBETASOL PROPIONATE (EMOLLIENT)

AB2	FOUGERA PHARMS	0.05%	A075430 001	May 26, 1999	Jan	CAHN
-----	----------------	-------	-------------	--------------	-----	------

@ RENAISSANCE PHARMA 0.05%

A075733 001 Aug 22, 2001 Aug CAHN

TEMOVATE

AB1	+ FOUGERA PHARMS	0.05%	N019322 001	Dec 27, 1985	Jan	CAHN
-----	------------------	-------	-------------	--------------	-----	------

GEL; TOPICAL

CLOBETASOL PROPIONATE

AB	FOUGERA PHARMS	0.05%	A075368 001	Feb 15, 2000	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

TEMOVATE

AB	+ FOUGERA PHARMS	0.05%	N020337 001	Apr 29, 1994	Jan	CAHN
----	------------------	-------	-------------	--------------	-----	------

LOTION; TOPICAL

CLOBETASOL PROPIONATE

AB	TARO	0.05%	A200302 001	Jul 02, 2012	Jun	NEWA
----	------	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

CLOBETASOL PROPIONATE

AB	FOUGERA PHARMS	0.05%	A074407 001	Feb 23, 1996	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

@ RENAISSANCE PHARMA 0.05%

A075057 001 Aug 12, 1998 Aug CAHN

TEMOVATE

AB	+ FOUGERA PHARMS	0.05%	N019323 001	Dec 27, 1985	Jan	CAHN
----	------------------	-------	-------------	--------------	-----	------

SHAMPOO; TOPICAL

CLOBETASOL PROPIONATE

AB	PERRIGO ISRAEL	0.05%	A090974 001	Aug 09, 2012	Jul	NEWA
----	----------------	-------	-------------	--------------	-----	------

SOLUTION; TOPICAL

CLOBETASOL PROPIONATE

AT	FOUGERA PHARMS	0.05%	A075391 001	Feb 08, 1999	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

@ G AND W LABS INC 0.05%

A074331 001 Dec 15, 1995 Jun CAHN

TEMOVATE

AT	+ FOUGERA PHARMS	0.05%	N019966 001	Feb 22, 1990	Jan	CAHN
----	------------------	-------	-------------	--------------	-----	------

CLONAZEPAM

TABLET; ORAL

CLONAZEPAM

AB	MYLAN PHARMS INC	0.5MG	A074940 001	Oct 30, 1997	Sep	CAHN
AB		1MG	A074940 002	Oct 30, 1997	Sep	CAHN
AB		2MG	A074940 003	Oct 30, 1997	Sep	CAHN

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DURACLON

AP	MYLAN INSTITUTIONAL	1 MG/10 ML (0.1 MG/ML)	N020615 001	Oct 02, 1996	Feb	CAHN
AP	+	5 MG/10 ML (0.5 MG/ML)	N020615 002	Apr 27, 1999	Feb	CAHN

TABLET, EXTENDED RELEASE; ORAL

KAPVAY

SHIONOGI INC

0.2MG

N022331 004 Sep 28, 2010 May CMFD

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB	APOTEX INC	EQ 75MG BASE	A076274 001	May 17, 2012	Apr	NEWA
AB	AUROBINDO PHARMA LTD	EQ 75MG BASE	A090540 001	May 17, 2012	Apr	NEWA
AB	DR REDDYS LABS INC	EQ 75MG BASE	A076273 001	Jan 14, 2008	Mar	CMFD
AB	DR REDDYS LABS LTD	EQ 300MG BASE	A091023 001	May 17, 2012	Apr	NEWA
AB	GATE PHARMS	EQ 300MG BASE	A091216 001	May 17, 2012	Apr	NEWA
AB	MYLAN PHARMS INC	EQ 75MG BASE	A077665 001	May 17, 2012	Apr	NEWA
AB		EQ 300MG BASE	A077665 002	May 17, 2012	Apr	NEWA
AB	ROXANE	EQ 75MG BASE	A078004 001	May 17, 2012	Apr	NEWA
AB	SUN PHARMA GLOBAL	EQ 75MG BASE	A090494 001	May 17, 2012	Apr	NEWA
AB	TEVA	EQ 75MG BASE	A076999 001	May 17, 2012	Apr	NEWA
AB	TEVA PHARMS	EQ 300MG BASE	A090625 001	May 17, 2012	Apr	NEWA
AB	TORRENT PHARMS LTD	EQ 75MG BASE	A090844 001	May 17, 2012	Apr	NEWA
AB	WOCKHARDT LTD	EQ 75MG BASE	A202266 001	Aug 14, 2012	Jul	NEWA
AB	ZYDUS PHARMS USA INC	EQ 75MG BASE	A201686 001	Oct 10, 2012	Sep	NEWA
PLAVIX						
AB	SANOFI AVENTIS US	EQ 75MG BASE	N020839 001	Nov 17, 1997	Mar	CTEC
AB	+	EQ 300MG BASE	N020839 002	Sep 20, 2007	Apr	CTEC

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL

TRANXENE

@ LUNDBECK LLC

3.75MG

N017105 001

Mar CAHN

@

7.5MG

N017105 002

Mar CAHN

@

15MG

N017105 003

Mar CAHN

TABLET; ORAL

TRANXENE

AB	LUNDBECK LLC	3.75MG	N017105 006		Mar	CAHN
AB		7.5MG	N017105 007		Mar	CAHN
AB	+	15MG	N017105 008		Mar	CAHN
TRANXENE SD						
	@ LUNDBECK LLC	11.25MG	N017105 005		Mar	CAHN
	@	22.5MG	N017105 004		Mar	CAHN

CLOTTRIMAZOLE

CREAM; TOPICAL

CLOTTRIMAZOLE

AB	FOUGERA PHARMS	1%	A078338 001	Sep 02, 2008	Jan	CAHN
----	----------------	----	-------------	--------------	-----	------

CLOZAPINE

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO ODT

JAZZ

12.5MG

N021590 004 May 30, 2007 Apr CAHN

25MG

N021590 001 Feb 10, 2004 Apr CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

FAZACLO ODT

	@ JAZZ	50MG	N021590 003	Jun 03, 2005	Apr	CAHN
+		100MG	N021590 002	Feb 10, 2004	Apr	CAHN
		150MG	N021590 005	Jul 09, 2010	Apr	CAHN
		200MG	N021590 006	Jul 09, 2010	Apr	CAHN
	JAZZ PHARMS III	12.5MG	N021590 004	May 30, 2007	Jun	CAHN
		25MG	N021590 001	Feb 10, 2004	Jun	CAHN
	@	50MG	N021590 003	Jun 03, 2005	Jun	CAHN
+		100MG	N021590 002	Feb 10, 2004	Jun	CAHN
		150MG	N021590 005	Jul 09, 2010	Jun	CAHN
		200MG	N021590 006	Jul 09, 2010	Jun	CAHN

COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

STRIBILD

+	GILEAD SCIENCES INC	150MG;150MG;200MG;300MG	N203100 001	Aug 27, 2012	Aug	NEWA
---	---------------------	-------------------------	-------------	--------------	-----	------

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA	TRIS PHARMA INC	10MG/5ML;6.25MG/5ML	A200386 001	Jun 29, 2012	Jun	NEWA
----	-----------------	---------------------	-------------	--------------	-----	------

COLCHICINE

TABLET; ORAL

COLCRYS

>D>	+	AR HOLDING CO INC	0.6MG	N022352 001	Jul 29, 2009	Oct	CAHN
>A>	+	TAKEDA PHARMS USA	0.6MG	N022352 001	Jul 29, 2009	Oct	CAHN

COLISTIMETHATE SODIUM

INJECTABLE; INJECTION

COLISTIMETHATE SODIUM

AP	EMCURE PHARMS LTD	EQ 150MG BASE/VIAL	A202359 001	Sep 28, 2012	Sep	NEWA
----	-------------------	--------------------	-------------	--------------	-----	------

COPPER

INTRAUTERINE DEVICE; INTRAUTERINE

PARAGARD T 380A

+	TEVA WOMENS	309MG/COPPER	N018680 001	Nov 15, 1984	May	CAHN
---	-------------	--------------	-------------	--------------	-----	------

COSYNTROPIN

INJECTABLE; INJECTION

COSYNTROPIN

AP	INNOPHARMA INC	0.25MG/VIAL	A202147 001	Jun 29, 2012	Jun	NEWA
AP	SANDOZ	0.25MG/VIAL	A202147 001	Jun 29, 2012	Sep	CAHN

CROMOLYN SODIUM

AEROSOL, METERED; INHALATION

INTAL

@	KING PFIZER	0.8MG/INH	N018887 001	Dec 05, 1985	Jun	DISC
---	-------------	-----------	-------------	--------------	-----	------

CONCENTRATE; ORAL

GASTROCROM

AA	+	JAZZ PHARMS COMMERCL	100MG/5ML	N020479 001	Feb 29, 1996	Mar	CAHN
AA	+	JAZZ PHARMS INTL	100MG/5ML	N020479 001	Feb 29, 1996	Jun	CAHN

SOLUTION; INHALATION

CROMOLYN SODIUM

AN	+	TEVA PHARMS	10MG/ML	A075271 001	Jan 18, 2000	Sep	CAHN
----	---	-------------	---------	-------------	--------------	-----	------

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

>D>	@ BAXTER HLTHCARE	1MG/ML	A080515 002	Oct	CAHN
>A>	@ HIKMA MAPLE	1MG/ML	A080515 002	Oct	CAHN

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HYDROCHLORIDE

AB	MYLAN PHARMS INC	5MG	A073144 002	Feb 03, 2006	Jul	CRLD
AB	+	10MG	A073144 001	May 30, 1991	Jul	CRLD
AB	PROSAM LABS	5MG	A077291 001	Feb 03, 2006	Feb	CAHN
AB		10MG	A077209 001	Oct 04, 2005	Feb	CAHN
	FLEXERIL					
	@ JANSSEN RES AND DEV	5MG	N017821 001		Jul	DISC
	@	10MG	N017821 002		Jul	DISC

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

CYTOXAN

AP	+	BAXTER HLTHCARE	500MG/VIAL	N012142 003	Apr	CRLD
AP	+		1GM/VIAL	N012142 004	Aug 30, 1982	Apr
AP	+		2GM/VIAL	N012142 005	Aug 30, 1982	Apr

CYCLOSPORINE

CAPSULE; ORAL

CYCLOSPORINE

AB1	WATSON LABS INC	25MG	A065044 002	Dec 20, 2000	May	CAHN
AB1		100MG	A065044 001	Dec 20, 2000	May	CAHN

SOLUTION; ORAL

CYCLOSPORINE

AB1	ABBVIE	100MG/ML	A065025 001	Mar 03, 2000	Sep	CAHN
-----	--------	----------	-------------	--------------	-----	------

CYSTEAMINE HYDROCHLORIDE

>A>	SOLUTION/DROPS; OPHTHALMIC					
>A>	CYSTARAN					
>A>	+ SIGMA TAU	EQ 0.44% BASE	N200740 001	Oct 02, 2012	Oct	NEWA

CYTARABINE

INJECTABLE; INJECTION

CYTARABINE

AP	ONCO THERAPIES LTD	100MG/ML	A201784 001	Jan 30, 2012	Jan	NEWA
----	--------------------	----------	-------------	--------------	-----	------

DACTINOMYCIN

INJECTABLE; INJECTION

COSMEGEN

AP	+	LUNDBECK LLC	0.5MG/VIAL	N050682 001	Mar	CAHN
----	---	--------------	------------	-------------	-----	------

DANTROLENE SODIUM

CAPSULE; ORAL

DANTROLENE SODIUM

	@ MIKAH PHARMA	25MG	A076686 001	Oct 24, 2005	Jul	CAHN
	@	50MG	A076686 002	Oct 24, 2005	Jul	CAHN
	@	100MG	A076686 003	Oct 24, 2005	Jul	CAHN

DAPIPRAZOLE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DAPIPRAZOLE HYDROCHLORIDE

@ FERA PHARMS

0.5%

N019849 001 Dec 31, 1990 Jul CTNA

DARUNAVIR ETHANOLATE

SUSPENSION; ORAL

PREZISTA

+ JANSSEN PRODS

EQ 100MG BASE/ML

N202895 001 Dec 16, 2011 Feb CAHN

TABLET; ORAL

PREZISTA

JANSSEN PRODS

EQ 75MG BASE

N021976 004 Dec 18, 2008 Feb CAHN

EQ 150MG BASE

N021976 005 Dec 18, 2008 Feb CAHN

@

EQ 300MG BASE

N021976 001 Jun 23, 2006 Feb CAHN

EQ 400MG BASE

N021976 003 Oct 21, 2008 Feb CAHN

+

EQ 600MG BASE

N021976 002 Feb 25, 2008 Feb CAHN

DEMECLOCYCLINE HYDROCHLORIDE

TABLET; ORAL

DECELOMYCIN

@ COREPHARMA

150MG

N050261 002

Jul DISC

@

300MG

N050261 003

Jul DISC

DEMECLOCYCLINE HYDROCHLORIDE

AB + AMNEAL PHARM

300MG

A065425 002 Feb 27, 2008 Jul CRLD

DESFLURANE

LIQUID; INHALATION

SUPRANE

+ BAXTER HLTHCARE

99.9%

N020118 001 Sep 18, 1992 Jul CAHN

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL

NORPRAMIN

>D> AB + SANOFI AVENTIS US

50MG

N014399 003

Oct CRLD

>A> AB

50MG

N014399 003

Oct CRLD

DESLOMATADINE

TABLET; ORAL

DESLOMATADINE

AB BELCHER PHARMS

5MG

A078355 001 Apr 19, 2012 Apr NEWA

AB MYLAN PHARMS INC

5MG

A078351 001 Feb 10, 2012 Jan NEWA

DESMOPRESSIN ACETATE

SOLUTION; NASAL

DDAVP

AB + SANOFI AVENTIS US

0.01%

N017922 001

Mar CFTG

DESMOPRESSIN ACETATE

AB SUN PHARM INDS

0.01%

A077212 001 Apr 12, 2012 Mar NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28

EMOQUETTE

AB VINTAGE PHARMS LLC

0.15MG;0.03MG

A076675 001 Feb 25, 2011 Sep CAHN

MIRCETTE

AB + TEVA BRANDED PHARM

0.15MG,N/A;0.02MG,0.01MG

N020713 001 Apr 22, 1998 Jun CAHN

TABLET; ORAL-28

VIORELE

AB	GLENMARK GENERICS	0.15MG,N/A;0.02MG,0.01MG	A091346 001	Apr 02, 2012	Mar	NEWA
----	-------------------	--------------------------	-------------	--------------	-----	------

DESONIDE

LOTION; TOPICAL

DESONIDE

AB	FOUGERA PHARMS	0.05%	A075860 001	Mar 19, 2002	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

OINTMENT; TOPICAL

DESONIDE

AB	FOUGERA PHARMS	0.05%	A075751 001	Mar 12, 2001	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

DESOXIMETASONE

CREAM; TOPICAL

DESOXIMETASONE

AB	FOUGERA PHARMS	0.25%	A078369 001	Jun 29, 2010	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

TOPICORT

+	TARO	0.05%	A073210 001	Nov 30, 1990	Apr	CTNA
---	------	-------	-------------	--------------	-----	------

AB	+	0.25%	A073193 001	Nov 30, 1990	Sep	CTEC
----	---	-------	-------------	--------------	-----	------

+		0.25%	A073193 001	Nov 30, 1990	Apr	CTNA
---	--	-------	-------------	--------------	-----	------

@ TARO PHARMS NORTH

0.25%

N017856 001

Apr DISC

TOPICORT LP

@ TARO PHARMS NORTH

0.05%

N018309 001

Apr DISC

GEL; TOPICAL

TOPICORT

AB	+	TARO	0.05%	A074904 001	Jul 14, 1998	Apr	CTNA
----	---	------	-------	-------------	--------------	-----	------

@ TARO PHARMS NORTH

0.05%

N018586 001

Mar 29, 1982

Apr DISC

OINTMENT; TOPICAL

DESOXIMETASONE

AB	FOUGERA PHARMS	0.25%	A078657 001	Sep 28, 2012	Sep	NEWA
----	----------------	-------	-------------	--------------	-----	------

AB	+	TARO	0.25%	A074286 001	Jun 07, 1996	Mar	CRLD
----	---	------	-------	-------------	--------------	-----	------

TOPICORT

AB	+	TARO	0.25%	A074286 001	Jun 07, 1996	Sep	CTEC
----	---	------	-------	-------------	--------------	-----	------

+		0.25%	A074286 001	Jun 07, 1996	Apr	CTNA
---	--	-------	-------------	--------------	-----	------

@ TARO PHARMS NORTH

0.25%

N018763 001

Sep 30, 1983

Mar DISC

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

AP	+	APP PHARMS LLC	EQ 10MG PHOSPHATE/ML	A040572 001	Apr 22, 2005	Feb	CRLD
----	---	----------------	----------------------	-------------	--------------	-----	------

>D>		@ BAXTER HLTHCARE	EQ 4MG PHOSPHATE/ML	A084282 001		Oct	CAHN
-----	--	-------------------	---------------------	-------------	--	-----	------

>D>	AP	+	EQ 10MG PHOSPHATE/ML	A087702 001	Sep 07, 1982	Oct	CAHN
-----	----	---	----------------------	-------------	--------------	-----	------

>A>		@ HIKMA MAPLE	EQ 4MG PHOSPHATE/ML	A084282 001		Oct	CAHN
-----	--	---------------	---------------------	-------------	--	-----	------

>A>	AP	+	EQ 10MG PHOSPHATE/ML	A087702 001	Sep 07, 1982	Oct	CAHN
-----	----	---	----------------------	-------------	--------------	-----	------

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION

TOTECT

+	APRICUS PHARMS	EQ 500MG BASE/VIAL	N022025 001	Sep 06, 2007	Jun	CAHN
---	----------------	--------------------	-------------	--------------	-----	------

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

@ VINTAGE PHARMS LLC 5MG

A040299 001

May 13, 1999

Sep CAHN

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

AA	TRIS PHARMA INC	15MG/5ML;6.25MG/5ML	A091687 001	Jun 28, 2012	Jun	NEWA
----	-----------------	---------------------	-------------	--------------	-----	------

DIAZEPAM

INJECTABLE; INJECTION

DIAZEPAM

@	HIKMA MAPLE	5MG/ML	A070311 001	Dec 16, 1985	Jul	CAHN
@		5MG/ML	A070312 001	Dec 16, 1985	Jul	CAHN
@		5MG/ML	A071308 001	Jul 17, 1987	Jul	CAHN
@		5MG/ML	A070313 001	Dec 16, 1985	Jul	CAHN
@		5MG/ML	A071310 001	Jul 17, 1987	Jul	CAHN
@		5MG/ML	A071309 001	Jul 17, 1987	Jul	CAHN
@	HOSPIRA	5MG/ML	A071584 001	Oct 13, 1987	Apr	DISC

DICLOFENAC POTASSIUM

CAPSULE; ORAL

ZIPSOR

+	DEPOMED INC	25MG	N022202 001	Jun 16, 2009	Jun	CAHN
---	-------------	------	-------------	--------------	-----	------

DICLOFENAC SODIUM

TABLET, DELAYED RELEASE; ORAL

DICLOFENAC SODIUM

AB	MYLAN PHARMS INC	50MG	A075281 002	Feb 12, 2002	Sep	CAHN
AB		75MG	A075281 003	Feb 12, 2002	Sep	CAHN

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE; ORAL

ARTHROTEC

AB	GD SEARLE LLC	50MG;0.2MG	N020607 001	Dec 24, 1997	Jun	CFTG
AB	+	75MG;0.2MG	N020607 002	Dec 24, 1997	Jun	CFTG

DICLOFENAC SODIUM AND MISOPROSTOL

AB	WATSON LABS INC	50MG;0.2MG	A201089 001	Jul 09, 2012	Jun	NEWA
AB		75MG;0.2MG	A201089 002	Jul 09, 2012	Jun	NEWA

DIDANOSINE

CAPSULE, DELAYED REL PELLETS; ORAL

DIDANOSINE

AB	MYLAN PHARMS INC	125MG	A090788 001	Apr 08, 2010	Sep	CAHN
AB		200MG	A090788 002	Apr 08, 2010	Sep	CAHN
AB		250MG	A090788 003	Apr 08, 2010	Sep	CAHN
AB		400MG	A090788 004	Apr 08, 2010	Sep	CAHN

TABLET, CHEWABLE; ORAL

DIDANOSINE

AUROBINDO	100MG	A077275 001	Aug 14, 2012	Jul	NEWA
	150MG	A077275 002	Aug 14, 2012	Jul	NEWA
	200MG	A077275 003	Aug 14, 2012	Jul	NEWA

DIFLORASONE DIACETATE

CREAM; TOPICAL

DIFLORASONE DIACETATE

AB1	+	FOUGERA PHARMS	0.05%	A075187 001	Mar 30, 1998	Jan	CAHN
BX	+		0.05%	A076263 001	Dec 20, 2002	Jan	CAHN

OINTMENT; TOPICAL									
DIFLORASONE DIACETATE									
AB	FOUGERA PHARMS		0.05%	A075374	001	Apr 27, 1999	Jan	CAHN	
<u>DIFLUNISAL</u>									
TABLET; ORAL									
DIFLUNISAL									
AB	EMCURE PHARMS USA		500MG	A202845	001	Mar 08, 2012	Feb	NEWA	
AB	+	TEVA	500MG	A073673	001	Jul 31, 1992	Feb	CTEC	
<u>DIGOXIN</u>									
INJECTABLE; INJECTION									
DIGOXIN									
AP	HIKMA MAPLE		0.25MG/ML	A083391	001		Jul	CAHN	
	@	HOSPIRA	0.25MG/ML	A040093	001	May 16, 1996	Jun	DISC	
TABLET; ORAL									
DIGOXIN									
	@	MYLAN PHARMS INC	0.125MG	A040282	001	Dec 23, 1999	Jul	CAHN	
	@		0.25MG	A040282	002	Dec 23, 1999	Jul	CAHN	
<u>DILTIAZEM HYDROCHLORIDE</u>									
CAPSULE, EXTENDED RELEASE; ORAL									
DILTIAZEM HYDROCHLORIDE									
AB4	ACTAVIS ELIZABETH		120MG	A091022	001	Sep 28, 2012	Sep	NEWA	
AB4			180MG	A091022	002	Sep 28, 2012	Sep	NEWA	
AB4			240MG	A091022	003	Sep 28, 2012	Sep	NEWA	
AB4			300MG	A091022	004	Sep 28, 2012	Sep	NEWA	
AB4			360MG	A091022	005	Sep 28, 2012	Sep	NEWA	
AB4			420MG	A091022	006	Sep 28, 2012	Sep	NEWA	
INJECTABLE; INJECTION									
DILTIAZEM HYDROCHLORIDE									
AP	AGILA SPECLTS		5MG/ML	A075375	001	Sep 30, 1999	Sep	CAHN	
AP	HIKMA FARMACEUTICA		5MG/ML	A202651	001	Aug 09, 2012	Jul	NEWA	
AP	HIKMA MAPLE		5MG/ML	A078538	001	Dec 17, 2008	Jul	CAHN	
	@	TEVA PARENTERAL	5MG/ML	A074894	001	Aug 26, 1997	Jan	DISC	
<u>DINOPROSTONE</u>									
INSERT, EXTENDED RELEASE; VAGINAL									
CERVIDIL									
	+	FERRING CONTROLLED	10MG	N020411	001	Mar 30, 1995	Jul	CAHN	
<u>DIPHENHYDRAMINE HYDROCHLORIDE</u>									
INJECTABLE; INJECTION									
BENADRYL									
	@	MCNEIL CONS	50MG/ML	N006146	002		Mar	DISC	
BENADRYL PRESERVATIVE FREE									
	@	MCNEIL CONS	50MG/ML	N009486	001		Mar	DISC	
DIPHENHYDRAMINE HYDROCHLORIDE									
AP	+	BAXTER HLTHCARE	50MG/ML	A080817	002		Apr	CRLD	
	@	HIKMA MAPLE	50MG/ML	A083183	001		Jul	CAHN	
AP	+		50MG/ML	A080817	002		Jul	CAHN	
<u>DIPYRIDAMOLE</u>									
INJECTABLE; INJECTION									
DIPYRIDAMOLE									
AP	HIKMA MAPLE		5MG/ML	A074521	001	Oct 18, 1996	Jul	CAHN	

INJECTABLE; INJECTION

DIPYRIDAMOLE

@ TEVA PARENTERAL

5MG/ML

A074952 001 Nov 26, 1997 Jan DISC

TABLET; ORAL

DIPYRIDAMOLE

AB PROSAM LABS

25MG

A040542 001 Apr 21, 2006 Feb CAHN

AB

50MG

A040542 002 Apr 21, 2006 Feb CAHN

AB

75MG

A040542 003 Apr 21, 2006 Feb CAHN

DISOPYRAMIDE PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL

DISOPYRAMIDE PHOSPHATE

@ NESHER PHARMS

EQ 150MG BASE

A071200 001 Dec 15, 1987 Jun DISC

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

AB DR REDDYS LABS LTD

EQ 250MG VALPROIC ACID

A090161 001 Mar 15, 2012 Feb NEWA

AB

REDDYS

EQ 500MG VALPROIC ACID

A090070 001 Mar 12, 2012 Feb NEWA

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

AP ACCORD HLTHCARE

20MG/ML (20MG/ML)

N201195 003 Apr 20, 2012 Apr NEWA

AP

20MG/0.5ML (40MG/ML)

N201195 001 Jun 08, 2011 Jan CTEC

AP

80MG/4ML (20MG/ML)

N201195 004 Apr 20, 2012 Apr NEWA

AP

80MG/2ML (40MG/ML)

N201195 002 Jun 08, 2011 Jan CTEC

160MG/8ML (20MG/ML)

N201195 005 Apr 20, 2012 Apr NEWA

AP

APOTEX INC

20MG/0.5ML (40MG/ML)

N022312 001 Jan 11, 2012 Jan NEWA

AP

80MG/2ML (40MG/ML)

N022312 002 Jan 11, 2012 Jan NEWA

TAXOTERE

AP + SANOFI AVENTIS US

20MG/ML (20MG/ML)

N020449 003 Aug 03, 2010 Apr CTEC

AP

+

80MG/4ML (20MG/ML)

N020449 004 Aug 02, 2010 Apr CTEC

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB INDICUS PHARMA

5MG

A201634 001 Jun 13, 2012 Jul NEWA

AB

10MG

A201634 002 Jun 13, 2012 Jul NEWA

AB MACLEODS PHARMS LTD

5MG

A201146 001 Aug 17, 2012 Aug NEWA

AB

10MG

A201146 002 Aug 17, 2012 Aug NEWA

AB MYLAN PHARMS INC

5MG

A090521 001 May 31, 2011 Sep CAHN

AB

10MG

A090521 002 May 31, 2011 Sep CAHN

AB PRINSTON INC

5MG

A200292 001 May 31, 2011 Jun CAHN

AB

10MG

A200292 002 May 31, 2011 Jun CAHN

>A>

AB ZYDUS PHARMS USA INC

5MG

A090100 001 Oct 24, 2012 Oct NEWA

>A>

AB

10MG

A090100 002 Oct 24, 2012 Oct NEWA

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

COSOPT PF

+ MERCK SHARP DOHME

EQ 2% BASE;EQ 0.5% BASE

N202667 001 Feb 01, 2012 Feb NEWA

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT TEVA PHARMS

EQ 2% BASE;EQ 0.5% BASE

A078704 001 Sep 28, 2009 Sep CAHN

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

@ NESHER PHARMS	EQ 1MG BASE	A075609 001	Oct 18, 2000	Feb	DISC
@	EQ 2MG BASE	A075609 002	Oct 18, 2000	Feb	DISC
@	EQ 4MG BASE	A075609 003	Oct 18, 2000	Feb	DISC
@	EQ 8MG BASE	A075609 004	Oct 18, 2000	Feb	DISC

DOXEPIN HYDROCHLORIDE

CREAM; TOPICAL

ZONALON

+ FOUGERA PHARMS	5%	N020126 001	Apr 01, 1994	Jan	CAHN
------------------	----	-------------	--------------	-----	------

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

>A>	AP	ALVOGEN INC	2MG/ML	A065515 001	Nov 08, 2012	Oct	NEWA
	AP	ONCO THERAPIES LTD	2MG/ML	A200901 001	Feb 14, 2012	Jan	NEWA
	AP	SANDOZ INC	2MG/ML	A200146 001	Jul 18, 2012	Jul	NEWA
	AP	SUN PHARM INDS	2MG/ML	A091418 001	Feb 15, 2012	Jan	NEWA

INJECTABLE, LIPOSOMAL; INJECTION

DOXIL

	+	JANSSEN R AND D	20MG/10ML (2MG/ML)	N050718 001	Nov 17, 1995	Jan	CAHN
	+		50MG/25ML (2MG/ML)	N050718 002	Jun 13, 2000	Jan	CAHN

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	MYLAN PHARMS INC	EQ 150MG BASE	A202778 001	Jun 08, 2012	May	NEWA
	@ SANDOZ INC	EQ 50MG BASE	A065032 001	Jun 30, 2000	Mar	DISC
	@	EQ 100MG BASE	A065032 002	Jun 30, 2000	Mar	DISC

MONODOX

AB	AQUA PHARMS	EQ 50MG BASE	N050641 002	Feb 10, 1992	Jul	CAHN
AB		EQ 75MG BASE	N050641 003	Oct 18, 2006	Jul	CAHN
AB	+	EQ 100MG BASE	N050641 001	Dec 29, 1989	Jul	CAHN

TABLET; ORAL

DOXYCYCLINE

	@ SANDOZ INC	EQ 50MG BASE	A065353 001	Nov 27, 2006	Mar	DISC
	@	EQ 75MG BASE	A065353 002	Nov 27, 2006	Mar	DISC
	@	EQ 100MG BASE	A065353 003	Nov 27, 2006	Mar	DISC

DOXYCYCLINE HYCLATE

INJECTABLE; INJECTION

DOXYCYCLINE

	@ HIKMA MAPLE	EQ 100MG BASE/VIAL	A062450 001	Oct 27, 1983	Jul	CAHN
	@	EQ 200MG BASE/VIAL	A062450 002	Oct 27, 1983	Jul	CAHN
AP	PFIZER	EQ 100MG BASE/VIAL	A091406 001	Aug 21, 2012	Aug	NEWA

DOXYCYCLINE HYCLATE

	@ HIKMA MAPLE	EQ 100MG BASE/VIAL	A062992 001	Feb 16, 1989	Jul	CAHN
	@	EQ 200MG BASE/VIAL	A062992 002	Feb 16, 1989	Jul	CAHN

TABLET; ORAL

DOXYCYCLINE HYCLATE

	AB	LARKEN LABS	EQ 20MG BASE	A065287 001	Feb 28, 2006	Apr	CMFD
>D>	AB	WATSON LABS	EQ 100MG BASE	A062421 001	Feb 02, 1983	Oct	CAHN
>A>	AB	WATSON LABS INC FL	EQ 100MG BASE	A062421 001	Feb 02, 1983	Oct	CAHN

TABLET, DELAYED RELEASE; ORAL

DORYX

AB	+	MAYNE PHARMA	EQ 150MG BASE	N050795 003	Jun 20, 2008	Jan	CTEC
----	---	--------------	---------------	-------------	--------------	-----	------

DOXYCYCLINE HYCLATE

AB		MYLAN PHARMS INC	EQ 150MG BASE	A091052 001	Feb 08, 2012	Jan	NEWA
----	--	------------------	---------------	-------------	--------------	-----	------

DROSPIRENONE; ESTRADIOL

TABLET; ORAL

ANGELIQ

		BAYER HLTHCARE	0.25MG;0.5MG	N021355 001	Feb 29, 2012	Feb	NEWA
--	--	----------------	--------------	-------------	--------------	-----	------

ECONAZOLE NITRATE

CREAM; TOPICAL

ECONAZOLE NITRATE

AB	+	FOUGERA PHARMS	1%	A076075 001	Nov 26, 2002	Jan	CAHN
----	---	----------------	----	-------------	--------------	-----	------

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

COMPLERA

	+	GILEAD SCIENCES INC	200MG;EQ 25MG BASE;300MG	N202123 001	Aug 10, 2011	Apr	CAIN
--	---	---------------------	--------------------------	-------------	--------------	-----	------

ENALAPRIL MALEATE

TABLET; ORAL

ENALAPRIL MALEATE

	@	SANDOZ INC	2.5MG	A075621 001	Aug 22, 2000	Feb	DISC
--	---	------------	-------	-------------	--------------	-----	------

	@		2.5MG	A075496 001	Aug 22, 2000	Jan	DISC
--	---	--	-------	-------------	--------------	-----	------

	@		5MG	A075621 002	Aug 22, 2000	Feb	DISC
--	---	--	-----	-------------	--------------	-----	------

	@		5MG	A075496 002	Aug 22, 2000	Jan	DISC
--	---	--	-----	-------------	--------------	-----	------

	@		10MG	A075621 003	Aug 22, 2000	Feb	DISC
--	---	--	------	-------------	--------------	-----	------

	@		10MG	A075459 001	Aug 22, 2000	Jan	DISC
--	---	--	------	-------------	--------------	-----	------

	@		20MG	A075621 004	Aug 22, 2000	Feb	DISC
--	---	--	------	-------------	--------------	-----	------

	@		20MG	A075459 002	Aug 22, 2000	Jan	DISC
--	---	--	------	-------------	--------------	-----	------

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

	@	SANDOZ INC	5MG;12.5MG	A076116 001	Sep 19, 2001	Mar	DISC
--	---	------------	------------	-------------	--------------	-----	------

	@		10MG;25MG	A076116 002	Sep 19, 2001	Mar	DISC
--	---	--	-----------	-------------	--------------	-----	------

ENFLURANE

LIQUID; INHALATION

ETHRANE

AN	+	BAXTER HLTHCARE	99.9%	N017087 001		Jul	CAHN
----	---	-----------------	-------	-------------	--	-----	------

ENTACAPONE

TABLET; ORAL

COMTAN

AB	+	ORION PHARMA	200MG	N020796 001	Oct 19, 1999	Jul	CFTG
----	---	--------------	-------	-------------	--------------	-----	------

	+		200MG	N020796 001	Oct 19, 1999	May	CAHN
--	---	--	-------	-------------	--------------	-----	------

ENTACAPONE

AB		SUN PHARMA GLOBAL	200MG	A090690 001	Jul 16, 2012	Jul	NEWA
----	--	-------------------	-------	-------------	--------------	-----	------

AB		WOCKHARDT LTD	200MG	A078941 001	Aug 16, 2012	Jul	NEWA
----	--	---------------	-------	-------------	--------------	-----	------

ENZALUTAMIDE

CAPSULE; ORAL

XTANDI

+ ASTELLAS 40MG

N203415 001 Aug 31, 2012 Sep CAHN

+ MEDIVATION 40MG

N203415 001 Aug 31, 2012 Aug NEWA

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

EPINASTINE HYDROCHLORIDE

AT LUITPOLD 0.05%

A090951 001 Oct 31, 2011 Mar CAHN

EPINEPHRINE

INJECTABLE; IM-SC

ADRENALCLIC

BX + COREPHARMA EQ 0.15MG/DELIVERY

N020800 003 Nov 25, 2009 Mar CAHN

BX + EQ 0.3MG/DELIVERY

N020800 004 Nov 25, 2009 Mar CAHN

AUVI-Q

BX + INTELLIJECT EQ 0.15MG/DELIVERY

N201739 002 Aug 10, 2012 Aug NEWA

BX EQ 0.3MG/DELIVERY

N201739 001 Aug 10, 2012 Aug NEWA

TWINJECT 0.15

BX + COREPHARMA EQ 0.15MG/DELIVERY

N020800 002 May 28, 2004 Mar CAHN

TWINJECT 0.3

BX + COREPHARMA EQ 0.3MG/DELIVERY

N020800 001 May 30, 2003 Mar CAHN

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

@ HIKMA MAPLE 0.01MG/ML;1%

A080406 001 Sep CAHN

@ 0.01MG/ML;2%

A080406 002 Sep CAHN

OCTOCAINE

AP + SEPTODONT 0.01MG/ML;2%

A084048 001 May CRLD

XYLOCAINE DENTAL WITH EPINEPHRINE

@ DENTSPLY PHARM 0.01MG/ML;2%

N021381 001 May DISC

@ 0.02MG/ML;2%

N021381 002 May DISC

EPIRUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

EPIRUBICIN HYDROCHLORIDE

AP CIPLA LTD 50MG/25ML (2MG/ML)

A065361 001 Oct 22, 2007 Mar CAHN

AP 200MG/100ML (2MG/ML)

A065361 002 Oct 22, 2007 Mar CAHN

AP HISUN PHARM HANGZHOU 50MG/25ML (2MG/ML)

A090075 001 Mar 25, 2010 Mar CAHN

AP 200MG/100ML (2MG/ML)

A090075 002 Mar 25, 2010 Mar CAHN

AP ONCO THERAPIES LTD 50MG/25ML (2MG/ML)

A091599 001 Mar 12, 2012 Mar NEWA

AP 200MG/100ML (2MG/ML)

A091599 002 Mar 12, 2012 Mar NEWA

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION

VELETRI

ACTELION PHARMS LTD EQ 0.5MG BASE/VIAL

N022260 002 Jun 28, 2012 Jun NEWA

+ EQ 1.5MG BASE/VIAL

N022260 001 Jun 27, 2008 May CAHN

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYC

AB WARNER CHILCOTT LLC 250MG

A062338 001 Jun CAHN

GEL; TOPICAL									
E-GLADES									
	@ COREPHARMA	2%		A065009	001	Mar 18, 2002	Jul	DISC	
	@ RENAISSANCE PHARMA	2%		A065009	001	Mar 18, 2002	Aug	CAHN	
ERYTHROMYCIN									
AT	FOUGERA PHARMS	2%		A064184	001	Sep 30, 1997	Jan	CAHN	
SOLUTION; TOPICAL									
C-SOLVE-2									
AT	FOUGERA PHARMS	2%		A062468	001	Jul 03, 1985	Jan	CMFD	
ERYTHROMYCIN									
	@ RENAISSANCE PHARMA	2%		A064127	001	Feb 14, 1997	Aug	CAHN	
SWAB; TOPICAL									
ERYCETTE									
	@ JOHNSON AND JOHNSON	2%		N050594	001	Feb 15, 1985	Apr	CAHN	
ERYTHROMYCIN									
AT	+ FOUGERA PHARMS	2%		A065320	001	Jul 25, 2006	Jan	CAHN	
	@ RENAISSANCE PHARMA	2%		A064128	001	Jul 03, 1996	Sep	CAHN	
<u>ESCITALOPRAM OXALATE</u>									
SOLUTION; ORAL									
ESCITALOPRAM OXALATE									
AA	AMNEAL PHARMS	EQ 5MG BASE/5ML		A202227	001	Mar 14, 2012	Feb	NEWA	
AA	AUROBINDO PHARMA LTD	EQ 5MG BASE/5ML		A079062	001	Apr 02, 2012	Mar	NEWA	
AA	HETERO LABS LTD III	EQ 5MG BASE/5ML		A202221	001	Jun 12, 2012	May	NEWA	
AA	TARO	EQ 5MG BASE/5ML		A079121	001	May 03, 2012	Apr	NEWA	
LEXAPRO									
AA	+ FOREST LABS	EQ 5MG BASE/5ML		N021365	001	Nov 27, 2002	Feb	CFTG	
TABLET; ORAL									
ESCITALOPRAM OXALATE									
AB	ACCORD HLTHCARE	EQ 5MG BASE		A202389	001	Sep 11, 2012	Aug	NEWA	
AB		EQ 10MG BASE		A202389	002	Sep 11, 2012	Aug	NEWA	
AB		EQ 20MG BASE		A202389	003	Sep 11, 2012	Aug	NEWA	
AB	APOTEX INC	EQ 5MG BASE		A078777	001	Sep 11, 2012	Aug	NEWA	
AB		EQ 10MG BASE		A078777	002	Sep 11, 2012	Aug	NEWA	
AB		EQ 20MG BASE		A078777	003	Sep 11, 2012	Aug	NEWA	
AB	AUROBINDO PHARMA LTD	EQ 5MG BASE		A090432	001	Sep 11, 2012	Aug	NEWA	
AB		EQ 10MG BASE		A090432	002	Sep 11, 2012	Aug	NEWA	
AB		EQ 20MG BASE		A090432	003	Sep 11, 2012	Aug	NEWA	
AB	HIKMA PHARMS	EQ 5MG BASE		A078766	001	Sep 11, 2012	Aug	NEWA	
AB		EQ 10MG BASE		A078766	002	Sep 11, 2012	Aug	NEWA	
AB		EQ 20MG BASE		A078766	003	Sep 11, 2012	Aug	NEWA	
AB	INVAGEN PHARMS	EQ 5MG BASE		A078604	001	Sep 11, 2012	Aug	NEWA	
AB		EQ 10MG BASE		A078604	002	Sep 11, 2012	Aug	NEWA	
AB		EQ 20MG BASE		A078604	003	Sep 11, 2012	Aug	NEWA	
AB	IVAX SUB TEVA PHARMS	EQ 5MG BASE		A076765	001	Mar 14, 2012	Feb	NEWA	
AB		EQ 10MG BASE		A076765	002	Mar 14, 2012	Feb	NEWA	
AB		EQ 20MG BASE		A076765	003	Mar 14, 2012	Feb	NEWA	
AB	JUBILANT ORGANOSYS	EQ 5MG BASE		A202280	001	Sep 12, 2012	Aug	NEWA	
AB		EQ 10MG BASE		A202280	002	Sep 12, 2012	Aug	NEWA	
AB		EQ 20MG BASE		A202280	003	Sep 12, 2012	Aug	NEWA	
AB	LUPIN LTD	EQ 5MG BASE		A078169	001	Sep 11, 2012	Aug	NEWA	
AB		EQ 10MG BASE		A078169	002	Sep 11, 2012	Aug	NEWA	
AB		EQ 20MG BASE		A078169	003	Sep 11, 2012	Aug	NEWA	
AB	MACLEODS PHARMS LTD	EQ 5MG BASE		A202210	001	Sep 11, 2012	Aug	NEWA	
AB		EQ 10MG BASE		A202210	002	Sep 11, 2012	Aug	NEWA	
AB		EQ 20MG BASE		A202210	003	Sep 11, 2012	Aug	NEWA	

TABLET; ORAL

ESCITALOPRAM OXALATE

AB	STI PHARMA LLC	EQ 5MG BASE	A077512 001	Sep 12, 2012	Aug	NEWA
AB		EQ 10MG BASE	A077512 002	Sep 12, 2012	Aug	NEWA
AB		EQ 20MG BASE	A077512 003	Sep 12, 2012	Aug	NEWA
AB	TORRENT PHARMS LTD	EQ 5MG BASE	A090939 001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A090939 002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A090939 003	Sep 11, 2012	Aug	NEWA
AB	ZYDUS PHARMS USA INC	EQ 5MG BASE	A077734 001	Sep 11, 2012	Aug	NEWA
AB		EQ 10MG BASE	A077734 002	Sep 11, 2012	Aug	NEWA
AB		EQ 20MG BASE	A077734 003	Sep 11, 2012	Aug	NEWA

LEXAPRO

AB	FOREST LABS	EQ 5MG BASE	N021323 001	Aug 14, 2002	Feb	CFTG
AB		EQ 10MG BASE	N021323 002	Aug 14, 2002	Feb	CFTG
AB	+	EQ 20MG BASE	N021323 003	Aug 14, 2002	Feb	CFTG

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION

BREVIBLOC

AP	+	BAXTER HLTHCARE	10MG/ML	N019386 006	Feb 25, 2003	Jun	CAHN
		@	10MG/ML	N019386 003	Aug 15, 1988	Jun	CAHN
		@	20MG/ML	N019386 007	May 28, 2003	Jun	CAHN
		BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER					
	+	BAXTER HLTHCARE	2GM/100ML	N019386 005	Jan 27, 2003	Jun	CAHN
		BREVIBLOC IN PLASTIC CONTAINER					
	+	BAXTER HLTHCARE	1GM/100ML	N019386 004	Feb 16, 2001	Jun	CAHN

ESOMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE; ORAL

NEXIUM

ASTRAZENECA

EQ 2.5MG BASE/PACKET
EQ 5MG BASE/PACKET

N021957 003 Dec 15, 2011 Jun NEWA
N021957 004 Dec 15, 2011 Jun NEWA

ESTRADIOL

CREAM; VAGINAL

ESTRACE

+	WARNER CHILCOTT US	0.01%	A086069 001	Jan 31, 1984	Jun	CAHN
---	--------------------	-------	-------------	--------------	-----	------

FILM, EXTENDED RELEASE; TRANSDERMAL

MINIVELLE

>A>						
>A>		NOVEN	0.0375MG/24HR	N203752 001	Oct 29, 2012	Oct NEWA
>A>			0.05MG/24HR	N203752 003	Oct 29, 2012	Oct NEWA
>A>			0.075MG/24HR	N203752 002	Oct 29, 2012	Oct NEWA
>A>	+		0.1MG/24HR	N203752 004	Oct 29, 2012	Oct NEWA

GEL, METERED; TRANSDERMAL

ELESTRIN

+	JAZZ PHARMS COMMERCL	0.06% (0.87GM/ACTIVATION)	N021813 001	Dec 15, 2006	Jun	CAHN
>D>	+	JAZZ PHARMS II	0.06% (0.87GM/ACTIVATION)	N021813 001	Dec 15, 2006	Oct CAHN
	+		0.06% (0.87GM/ACTIVATION)	N021813 001	Dec 15, 2006	Sep CAHN
>A>	+	MEDA PHARMS	0.06% (0.87GM/ACTIVATION)	N021813 001	Dec 15, 2006	Oct CAHN

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE; VAGINAL

FEMRING

WARNER IRELAND

EQ 0.05MG BASE/24HR
EQ 0.1MG BASE/24HR

N021367 001 Mar 20, 2003 May CAHN
N021367 002 Mar 20, 2003 May CAHN

TABLET; ORAL

FEMTRACE

	WARNER CHILCOTT LLC	0.45MG	N021633 001	Aug 20, 2004	Jun	CAHN
		0.9MG	N021633 002	Aug 20, 2004	Jun	CAHN
+		1.8MG	N021633 003	Aug 20, 2004	Jun	CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

ESTRADIOL AND NORETHINDRONE ACETATE

AB	TEVA PHARMS USA	0.5MG;0.1MG	A200747 001	Mar 08, 2012	Feb	NEWA
----	-----------------	-------------	-------------	--------------	-----	------

ESTROGENS, CONJUGATED SYNTHETIC A

TABLET; ORAL

CENESTIN

	TEVA BRANDED PHARM	0.3MG	N020992 001	Jun 21, 2002	Jun	CAHN
		0.45MG	N020992 005	Feb 05, 2004	Jun	CAHN
		0.625MG	N020992 002	Mar 24, 1999	Jun	CAHN
		0.9MG	N020992 003	Mar 24, 1999	Jun	CAHN
+		1.25MG	N020992 004	Mar 13, 2000	Jun	CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL AND ETHINYL ESTRADIOL

>A>	AB	LUPIN LTD	0.03MG;0.15MG	A091440 001	Oct 23, 2012	Oct	NEWA	
	+	WATSON LABS	0.02MG;0.09MG	A079218 001	Jun 06, 2011	May	CRLD	
		LOSEASONIQUE						
	AB	TEVA BRANDED PHARM	0.02MG,0.01MG;0.1MG,N/A	N022262 001	Oct 24, 2008	Jun	CAHN	
		LYBREL						
		@ WYETH PHARMS INC	0.02MG;0.09MG	N021864 001	May 22, 2007	May	DISC	
		PREVEN EMERGENCY CONTRACEPTIVE KIT						
		@ TEVA BRANDED PHARM	0.05MG;0.25MG	N020946 001	Sep 01, 1998	Jun	CAHN	
		SEASONALE						
	AB	+	TEVA BRANDED PHARM	0.03MG;0.15MG	N021544 001	Sep 05, 2003	Jul	CAHN
		SEASONIQUE						
	AB	+	TEVA BRANDED PHARM	0.03MG,0.01MG;0.15MG,N/A	N021840 001	May 25, 2006	Jun	CAHN
		TABLET; ORAL-21						
		NORDETTE-21						
		@ TEVA BRANDED PHARM	0.03MG;0.15MG	N018668 001	May 10, 1982	Jun	CAHN	
		TABLET; ORAL-28						
		FALMINA						
	AB1	NOVAST LABS LTD	0.02MG;0.1MG	A090721 001	Mar 28, 2012	Mar	NEWA	
>A>		KURVELO						
>A>	AB	LUPIN LTD	0.03MG;0.15MG	A091408 001	Oct 17, 2012	Oct	NEWA	
		MARLISSA						
	AB	GLENMARK GENERICS	0.03MG;0.15MG	A091452 001	Feb 29, 2012	Feb	NEWA	
		MYZILRA						
	AB	VINTAGE PHARMS	0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG	A077502 001	Nov 23, 2011	May	CDFR	
	AB	VINTAGE PHARMS LLC	0.03MG,0.04MG,0.03MG;0.05MG,0.075 MG,0.125MG	A077502 001	Nov 23, 2011	Sep	CAHN	
		NORDETTE-28						
	AB	+	TEVA BRANDED PHARM	0.03MG;0.15MG	N018782 001	Jul 21, 1982	Jun	CAHN
		ORSYTHIA						
	AB1	VINTAGE PHARMS LLC	0.02MG;0.1MG	A077099 001	May 11, 2011	Sep	CAHN	

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE; TRANSDERMAL
ORTHO EVRA

+ JANSSEN PHARMS 0.75MG;6MG N021180 001 Nov 20, 2001 Jun CPOT

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

ALYACEN 1/35

AB GLENMARK GENERICS 0.035MG;1MG A091634 001 Jan 19, 2012 Jan NEWA

ALYACEN 7/7/7

AB GLENMARK GENERICS 0.035MG,0.035MG,0.035MG;0.5MG,0.7 5MG,1MG A091636 001 Jan 19, 2012 Jan NEWA

CYCLAFEM 1/35

AB VINTAGE PHARMS LLC 0.035MG;1MG A076337 001 Nov 12, 2010 Sep CAHN

CYCLAFEM 7/7/7

AB VINTAGE PHARMS LLC 0.035MG,0.035MG,0.035MG;0.5MG,0.7 5MG,1MG A076338 001 Nov 16, 2010 Sep CAHN

NORETHINDRONE AND ETHINYL ESTRADIOL

>A> AB VINTAGE PHARMS 0.035MG;0.4MG A078376 001 Nov 06, 2012 Oct NEWA

OVCON-35

AB + WARNER CHILCOTT LLC 0.035MG;0.4MG N017716 001 Jun CAHN

OVCON-50

+ WARNER CHILCOTT LLC 0.05MG;1MG N017576 001 Jun CAHN

WERA

AB NOVAST LABS LTD 0.035MG;0.5MG A091204 001 Mar 27, 2012 Mar NEWA

TABLET, CHEWABLE; ORAL
FEMCON FE

AB + WARNER CHILCOTT LLC 0.035MG;0.4MG N021490 001 Nov 14, 2003 Jun CAHN

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL

FEMHRT

AB + WARNER CHILCOTT LLC 0.0025MG;0.5MG N021065 001 Jan 14, 2005 Jun CAHN

0.005MG;1MG N021065 002 Oct 15, 1999 Jun CAHN

LO LOESTRIN FE

+ WARNER CHILCOTT LLC 0.01MG,0.01MG;1MG,N/A N022501 001 Oct 21, 2010 Jun CAHN

TABLET; ORAL-21

ESTROSTEP 21

@ WARNER CHILCOTT LLC 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG N020130 001 Oct 09, 1996 Jun CAHN

LOESTRIN 21 1.5/30

AB WARNER CHILCOTT LLC 0.03MG;1.5MG N017875 001 Jun CAHN

LOESTRIN 21 1/20

AB WARNER CHILCOTT LLC 0.02MG;1MG N017876 001 Jun CAHN

TABLET; ORAL-28

ESTROSTEP FE

AB + WARNER CHILCOTT LLC 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG N020130 002 Oct 09, 1996 Jun CAHN

GILDESS FE 1.5/30

AB VINTAGE PHARMS LLC 0.03MG;1.5MG A077075 001 Apr 28, 2005 Sep CAHN

GILDESS FE 1/20

AB VINTAGE PHARMS LLC 0.02MG;1MG A077077 001 May 20, 2005 Sep CAHN

LOESTRIN FE 1.5/30

AB + WARNER CHILCOTT LLC 0.03MG;1.5MG N017355 001 Jun CAHN

ETHINYL ESTRADIOL; NORGESTIMATE

TABLET; ORAL-28

MONO-LINYAH

AB	NOVAST LABS LTD	0.035MG;0.25MG	A090523 001	May 23, 2012	May	NEWA
NORGESTIMATE AND ETHINYL ESTRADIOL						
AB	GLENMARK GENERICS	0.035MG;0.25MG	A200538 001	Apr 05, 2012	Mar	NEWA
AB	LUPIN PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG	A200541 001	Jun 25, 2012	Jun	NEWA
PREVIFEM						
AB	VINTAGE PHARMS LLC	0.035MG;0.25MG	A076334 001	Jan 09, 2004	Sep	CAHN
TRI-LINYAH						
AB	NOVAST LABS LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A090524 001	May 30, 2012	May	NEWA
TRI-PREVIFEM						
AB	VINTAGE PHARMS LLC	0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG	A076335 001	Mar 26, 2004	Sep	CAHN

ETHINYL ESTRADIOL; NORGESTREL

TABLET; ORAL-28

ELINEST

AB	NOVAST LABS LTD	0.03MG;0.3MG	A091105 001	Mar 28, 2012	Mar	NEWA
----	-----------------	--------------	-------------	--------------	-----	------

ETHOSUXIMIDE

CAPSULE; ORAL

ETHOSUXIMIDE

AB	ZYDUS PHARMS USA INC	250MG	A200892 001	Sep 25, 2012	Sep	NEWA
----	----------------------	-------	-------------	--------------	-----	------

ETHOTOIN

TABLET; ORAL

PEGANONE

+	LUNDBECK LLC	250MG	N010841 001		Aug	CAHN
@		500MG	N010841 003		Aug	CAHN

ETODOLAC

CAPSULE; ORAL

ETODOLAC

@ VINTAGE PHARMS LLC

200MG

A074842 001 Jul 17, 1997 Sep CAHN

@

300MG

A074842 002 Jul 17, 1997 Sep CAHN

TABLET; ORAL

ETODOLAC

AB	PROSAM LABS	400MG	A074819 001	Feb 28, 1997	Feb	CMFD
AB		500MG	A074819 002	Apr 28, 1998	Feb	CMFD
	@ VINTAGE PHARMS LLC	400MG	A074841 001	Jun 27, 1997	Sep	CAHN

TABLET, EXTENDED RELEASE; ORAL

ETODOLAC

>A>	@ ACTAVIS ELIZABETH	400MG	A075696 001	Jul 31, 2000	Oct	CAHN
>D>	@ POINT HOLDINGS	400MG	A075696 001	Jul 31, 2000	Oct	CAHN

ETOMIDATE

INJECTABLE; INJECTION

ETOMIDATE

AP	MYLAN INSTITUTIONAL	2MG/ML	A091297 001	Jun 20, 2012	Jun	NEWA
----	---------------------	--------	-------------	--------------	-----	------

ETOPOSID

CAPSULE; ORAL

VEPESID

@ CORDEN PHARMA

50MG

N019557 001 Dec 30, 1986 Feb CAHN

@

100MG

N019557 002 Dec 30, 1986 Feb CAHN

INJECTABLE; INJECTION

ETOPOSID

AP + APP PHARMS LLC

20MG/ML

A074983 001 Sep 30, 1998 Mar CRLD

AP BEDFORD

20MG/ML

A074290 001 Jul 17, 1995 Mar CRLD

VEPESID

@ CORDEN PHARMA

20MG/ML

N018768 001 Nov 10, 1983 Feb CAHN

ETRAVIRINE

TABLET; ORAL

INTELENCE

JANSSEN R AND D

25MG

N022187 003 Mar 26, 2012 Mar NEWA

100MG

N022187 001 Jan 18, 2008 Feb CAHN

+

200MG

N022187 002 Dec 22, 2010 Feb CAHN

EVEROLIMUS

TABLET; ORAL

AFINITOR

NOVARTIS

7.5MG

N022334 004 Mar 30, 2012 Apr NEWA

TABLET, FOR SUSPENSION; ORAL

AFINITOR DISPERZ

NOVARTIS PHARM

2MG

N203985 001 Aug 29, 2012 Aug NEWA

3MG

N203985 002 Aug 29, 2012 Aug NEWA

+

5MG

N203985 003 Aug 29, 2012 Aug NEWA

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS

BYDUREON

+ AMYLIN

2MG/VIAL

N022200 001 Jan 27, 2012 Jan NEWA

EZETIMIBE

TABLET; ORAL

ZETIA

+ MSD INTL GMBH

10MG

N021445 001 Oct 25, 2002 Feb CAHN

+ MSP SINGAPORE

10MG

N021445 001 Oct 25, 2002 Jan CAHN

EZETIMIBE; SIMVASTATIN

TABLET; ORAL

VYTORIN

MSD INTL

10MG;10MG

N021687 001 Jul 23, 2004 Jan CAHN

10MG;20MG

N021687 002 Jul 23, 2004 Jan CAHN

10MG;40MG

N021687 003 Jul 23, 2004 Jan CAHN

+

10MG;80MG

N021687 004 Jul 23, 2004 Jan CAHN

EZOGABINE

TABLET; ORAL

POTIGA

GLAXOSMITHKLINE

50MG

N022345 001 Jun 10, 2011 May CAHN

200MG

N022345 002 Jun 10, 2011 May CAHN

300MG

N022345 003 Jun 10, 2011 May CAHN

+

400MG

N022345 004 Jun 10, 2011 May CAHN

FAMCICLOVIR

TABLET; ORAL

FAMCICLOVIR

AB	MACLEODS PHARMS LTD	125MG	A201022 001	Jan 12, 2012	Jan	NEWA
AB		250MG	A201022 002	Jan 12, 2012	Jan	NEWA
AB		500MG	A201022 003	Jan 12, 2012	Jan	NEWA

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

AP	+	HIKMA MAPLE	10MG/ML	A075799 001	Apr 30, 2002	Jul	CAHN
AP	+		10MG/ML	A075488 001	Apr 16, 2001	Jul	CAHN

FAMOTIDINE PRESERVATIVE FREE

AP	+	HIKMA MAPLE	10MG/ML	A075486 001	Apr 16, 2001	Jul	CAHN
AP	+		10MG/ML	A075789 001	Apr 30, 2002	Jul	CAHN

TABLET; ORAL

FAMOTIDINE

>D>	AB	MYLAN	20MG	A075457 001	Apr 18, 2001	Oct	DISC
>D>	AB		40MG	A075457 002	Apr 18, 2001	Oct	DISC
>A>		@ MYLAN PHARMS INC	20MG	A075457 001	Apr 18, 2001	Oct	DISC
>A>		@	40MG	A075457 002	Apr 18, 2001	Oct	DISC
>D>	AB	SANDOZ	20MG	A075607 001	May 10, 2001	Oct	DISC
>A>		@	20MG	A075607 001	May 10, 2001	Oct	DISC
>D>	AB		40MG	A075607 002	May 10, 2001	Oct	DISC
>A>		@	40MG	A075607 002	May 10, 2001	Oct	DISC

PEPCID

AB	MARATHON PHARMS	20MG	N019462 001	Oct 15, 1986	Jan	CAHN
AB	+	40MG	N019462 002	Oct 15, 1986	Jan	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

FLUXID

	@ UCB INC	20MG	N021712 001	Sep 24, 2004	Jan	CAHN
	@	40MG	N021712 002	Sep 24, 2004	Jan	CAHN

FEBUXOSTAT

TABLET; ORAL

ULORIC

	TAKEDA PHARMS USA	40MG	N021856 001	Feb 13, 2009	Apr	CAHN
+		80MG	N021856 002	Feb 13, 2009	Apr	CAHN

FELODIPINE

TABLET, EXTENDED RELEASE; ORAL

FELODIPINE

AB	VINTAGE PHARMS LLC	2.5MG	A200815 001	Oct 28, 2011	Sep	CAHN
AB		5MG	A200815 002	Oct 28, 2011	Sep	CAHN
AB		10MG	A200815 003	Oct 28, 2011	Sep	CAHN
AB	WOCKHARDT LTD	2.5MG	A091484 001	Aug 15, 2012	Jul	NEWA
AB		5MG	A091484 002	Aug 15, 2012	Jul	NEWA
AB		10MG	A091484 003	Aug 15, 2012	Jul	NEWA

FENOFIBRATE

CAPSULE; ORAL

ANTARA (MICRONIZED)

AB	LUPIN ATLANTIS	43MG	N021695 001	Nov 30, 2004	Feb	CFTG
AB	+	130MG	N021695 003	Nov 30, 2004	Feb	CFTG

CAPSULE; ORAL

FENOFIBRATE (MICRONIZED)

AB	DR REDDYS LABS SA	43MG	A090859	001	Mar 01, 2012	Feb	NEWA
AB		130MG	A090859	002	Mar 01, 2012	Feb	NEWA
>A>	MYLAN PHARMS INC	67MG	A202676	001	Oct 23, 2012	Oct	NEWA
>A>		134MG	A202676	002	Oct 23, 2012	Oct	NEWA
>A>		200MG	A202676	003	Oct 23, 2012	Oct	NEWA

TABLET; ORAL

FENOFIBRATE

AB	IMPAX LABS	160MG	A076509	002	Mar 26, 2008	May	CRLD
AB	+	160MG	A076509	002	Mar 26, 2008	Mar	CRLD
AB	TEVA	54MG	A076433	001	May 13, 2005	May	CMFD
	@	54MG	A076433	001	May 13, 2005	Mar	DISC
AB	+	160MG	A076433	002	May 13, 2005	May	CMFD
	@	160MG	A076433	002	May 13, 2005	Mar	DISC
AB	VALEANT INTL	48MG	A090715	001	Apr 05, 2012	Mar	NEWA
AB		145MG	A090715	002	Apr 05, 2012	Mar	NEWA

FENOPROFEN CALCIUM

CAPSULE; ORAL

NALFON

+	XSPIRE	EQ 200MG BASE	N017604	003		Aug	CAHN
	@	EQ 300MG BASE	N017604	002		Aug	CAHN
		EQ 400MG BASE	N017604	004	Jul 21, 2009	Aug	CAHN

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

FENTANYL-100

AB	AVEVA	100MCG/HR	A077449	004	Oct 20, 2008	Jun	CAHN
	FENTANYL-25						
AB	AVEVA	25MCG/HR	A077449	001	Oct 20, 2008	Jun	CAHN
	FENTANYL-50						
AB	AVEVA	50MCG/HR	A077449	002	Oct 20, 2008	Jun	CAHN
	FENTANYL-75						
AB	AVEVA	75MCG/HR	A077449	003	Oct 20, 2008	Jun	CAHN

SPRAY; SUBLINGUAL

SUBSYS

	INSYS THERAP	0.1MG	N202788	001	Jan 04, 2012	Mar	CPOT
		0.1MCG	N202788	001	Jan 04, 2012	Jan	NEWA
		0.2MG	N202788	002	Jan 04, 2012	Mar	CPOT
		0.2MCG	N202788	002	Jan 04, 2012	Jan	NEWA
+		0.4MG	N202788	003	Jan 04, 2012	Mar	CPOT
+		0.4MCG	N202788	003	Jan 04, 2012	Jan	NEWA
		0.6MG	N202788	004	Jan 04, 2012	Mar	CPOT
		0.6MCG	N202788	004	Jan 04, 2012	Jan	NEWA
		0.8MG	N202788	005	Jan 04, 2012	Mar	CPOT
		0.8MCG	N202788	005	Jan 04, 2012	Jan	NEWA

FENTANYL CITRATE

SPRAY, METERED; NASAL

LAZANDA

	ARCHIMEDES	EQ 0.1MG BASE	N022569	001	Jun 30, 2011	Jan	CPOT
+		EQ 0.4MG BASE	N022569	002	Jun 30, 2011	Jan	CPOT

TROCHE/LOZENGE; TRANSMUCOSAL

FENTANYL CITRATE

AB	PAR PHARM	EQ 0.2MG BASE	A077312	001	Oct 30, 2009	Feb	CAHN
----	-----------	---------------	---------	-----	--------------	-----	------

TROCHE/LOZENGE; TRANSMUCOSALFENTANYL CITRATE

AB	PAR PHARM	EQ 0.4MG BASE	A077312 002	Oct 30, 2009	Feb	CAHN
AB		EQ 0.6MG BASE	A077312 003	Oct 30, 2009	Feb	CAHN
AB		EQ 0.8MG BASE	A077312 004	Oct 30, 2009	Feb	CAHN
AB		EQ 1.2MG BASE	A077312 005	Oct 30, 2009	Feb	CAHN
AB		EQ 1.6MG BASE	A077312 006	Oct 30, 2009	Feb	CAHN

FERUMOXIDESINJECTABLE; INJECTIONFERIDEX I.V.

	@ AMAG PHARMS INC	EQ 11.2MG IRON/ML	N020416 001	Aug 30, 1996	Jun	DISC
--	-------------------	-------------------	-------------	--------------	-----	------

FEXOFENADINE HYDROCHLORIDESUSPENSION; ORALALLEGRA

AB	+ SANOFI AVENTIS US	30MG/5ML	N021963 001	Oct 16, 2006	Jul	CFTG
	FEXOFENADINE HYDROCHLORIDE					
AB	ACTAVIS MID ATLANTIC	30MG/5ML	A201311 001	Jul 25, 2012	Jul	NEWA

FLORBETAPIR F-18SOLUTION; INTRAVENOUSAMYVID

+	AVID RADIOPHARMS INC	10-50ML (13.5-51MCI/ML)	N202008 003	Apr 06, 2012	Jun	CPOT
+		10-50ML (13.5-51MCI/ML)	N202008 003	Apr 06, 2012	Apr	NEWA
+		10-30ML (13.5-51MCI/ML)	N202008 002	Apr 06, 2012	Apr	NEWA
+		10ML (13.5-51MCI/ML)	N202008 001	Apr 06, 2012	Apr	NEWA

FLUCONAZOLEINJECTABLE; INJECTIONFLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	AGILA SPECLTS	200MG/100ML (2MG/ML)	A076888 001	Mar 25, 2005	Aug	CAHN
AP		400MG/200ML (2MG/ML)	A076888 002	Mar 25, 2005	Aug	CAHN
AP	HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078764 001	Jan 30, 2012	Jan	NEWA
AP		400MG/200ML (2MG/ML)	A078764 002	Jan 30, 2012	Jan	NEWA

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER@ AGILA SPECLTS@

AP	HIKMA FARMACEUTICA	200MG/100ML (2MG/ML)	A078698 001	Jan 30, 2012	Jan	NEWA
AP		400MG/200ML (2MG/ML)	A078698 002	Jan 30, 2012	Jan	NEWA
AP	TEVA PARENTERAL	200MG/100ML (2MG/ML)	A076837 001	Jan 13, 2005	Oct	CAHN
AP		400MG/200ML (2MG/ML)	A076837 002	Jan 13, 2005	Oct	CAHN
AP	TEVA PHARMS	200MG/100ML (2MG/ML)	A076837 001	Jan 13, 2005	Oct	CAHN
AP		400MG/200ML (2MG/ML)	A076837 002	Jan 13, 2005	Oct	CAHN

TABLET; ORALFLUCONAZOLE

AB	HARRIS PHARM	50MG	A078423 001	Mar 07, 2011	Jul	CAHN
AB		100MG	A078423 002	Mar 07, 2011	Jul	CAHN
AB		150MG	A078423 003	Mar 07, 2011	Jul	CAHN
AB		200MG	A078423 004	Mar 07, 2011	Jul	CAHN
AB	MYLAN	50MG	A076042 001	Jul 29, 2004	Oct	DISC
AB		100MG	A076042 002	Jul 29, 2004	Oct	DISC
AB		150MG	A076042 003	Jul 29, 2004	Oct	DISC
AB		200MG	A076042 004	Jul 29, 2004	Oct	DISC
	@ MYLAN PHARMS INC	50MG	A076042 001	Jul 29, 2004	Oct	DISC
	@	100MG	A076042 002	Jul 29, 2004	Oct	DISC

TABLET; ORAL

FLUCONAZOLE

>A>	@ MYLAN PHARMS INC	150MG	A076042 003	Jul 29, 2004	Oct	DISC
>A>	@	200MG	A076042 004	Jul 29, 2004	Oct	DISC
	@ PLIVA	50MG	A076424 001	Jul 29, 2004	Feb	DISC
	@	100MG	A076424 002	Jul 29, 2004	Feb	DISC
	@	150MG	A076424 003	Jul 29, 2004	Feb	DISC
	@	200MG	A076424 004	Jul 29, 2004	Feb	DISC
	@ RANBAXY LABS LTD	50MG	A076386 001	Jul 29, 2004	Apr	DISC
	@	100MG	A076386 002	Jul 29, 2004	Apr	DISC
	@	150MG	A076386 003	Jul 29, 2004	Apr	DISC
	@	200MG	A076386 004	Jul 29, 2004	Apr	DISC

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARA

@ GENZYME CORP 50MG/VIAL

N020038 001 Apr 18, 1991 Mar DISC

FLUDARABINE PHOSPHATE

AP	+	HOSPIRA	50MG/VIAL	A077790 001	Apr 06, 2007	Mar	CRLD
>A>	AP	ONCO THERAPIES LTD	50MG/VIAL	A200648 001	Oct 16, 2012	Oct	NEWA

TABLET; ORAL

OFORTA

@ SANOFI AVENTIS US 10MG

N022273 001 Dec 18, 2008 May DISC

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

AP	HIKMA MAPLE	0.5MG/5ML (0.1MG/ML)	A076787 002	Oct 12, 2004	Jul	CAHN
AP		1MG/10ML (0.1MG/ML)	A076787 001	Oct 12, 2004	Jul	CAHN
AP	SAGENT PHARMS	0.5MG/5ML (0.1MG/ML)	A090584 001	Aug 28, 2012	Aug	NEWA
AP		1MG/10ML (0.1MG/ML)	A090584 002	Aug 28, 2012	Aug	NEWA
	@ TEVA PARENTERAL	0.5MG/5ML (0.1MG/ML)	A076589 002	Oct 12, 2004	Jan	DISC
	@	1MG/10ML (0.1MG/ML)	A076589 001	Oct 12, 2004	Jan	DISC

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROSPAN HFA

+ ACTON PHARMS EQ 78MG BASE/INH

N021247 001 Jan 27, 2006 Jul CPOT

SPRAY, METERED; NASAL

FLUNISOLIDE

AB	HI TECH PHARMA CO	0.025MG/SPRAY	A077704 001	Aug 03, 2006	Aug	CAHN
----	-------------------	---------------	-------------	--------------	-----	------

FLUOCINOLONE ACETONIDE

OIL/DROPS; OTIC

FLUOCINOLONE ACETONIDE

AT	IDENTI PHARMS INC	0.01%	A091306 001	Oct 17, 2011	Jan	CPOT
----	-------------------	-------	-------------	--------------	-----	------

FLUOCINONIDE

CREAM; TOPICAL

FLUOCINONIDE

	AB1	G AND W LABS INC	0.05%	A073085 001	Feb 14, 1992	Sep	CAHN
>D>	AB1	TARO	0.05%	N019117 001	Jun 26, 1984	Oct	CRLD
>A>	AB1	+	0.05%	N019117 001	Jun 26, 1984	Oct	CRLD
		FLUOCINONIDE EMULSIFIED	BASE				
	AB2	FOUGERA PHARMS	0.05%	A076586 001	Jun 23, 2004	Jan	CAHN
		@ G AND W LABS INC	0.05%	A074204 001	Jun 13, 1995	May	CAHN

CREAM; TOPICAL

FLUOCINONIDE EMULSIFIED BASE

>D>	AB2	TARO	0.05%	A072494 001	Jan 19, 1989	Oct	CRLD
>A>	AB2	+	0.05%	A072494 001	Jan 19, 1989	Oct	CRLD
>D>		LIDEX					
>D>	AB1	+	MEDICIS	0.05%	N016908 002	Oct	DISC
>A>		@	0.05%	N016908 002		Oct	DISC
>D>		LIDEX-E					
>D>	AB2	+	MEDICIS	0.05%	N016908 003	Oct	DISC
>A>		@	0.05%	N016908 003		Oct	DISC

OINTMENT; TOPICAL

FLUOCINONIDE

AB	FOUGERA PHARMS	0.05%	A074905 001	Aug 26, 1997	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

SOLUTION; TOPICAL

FLUOCINONIDE

AT	G AND W LABS INC	0.05%	A071535 001	Dec 02, 1988	Sep	CAHN
----	------------------	-------	-------------	--------------	-----	------

FLUORESCEIN SODIUM

INJECTABLE; INTRAVENOUS

AK-FLUOR 25%

>D>	@ AKORN	EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	N022186 002	Aug 08, 2008	Oct	CMFD
>A>		EQ 500MG BASE/2ML (EQ 250MG BASE/ML)	N022186 002	Aug 08, 2008	Oct	CMFD

FLUOROURACIL

CREAM; TOPICAL

CARAC

+	VALEANT INTL	0.5%	N020985 001	Oct 27, 2000	Jul	CAHN
---	--------------	------	-------------	--------------	-----	------

FLUOROPLEX

+	AQUA PHARMS	1%	N016988 001		Jan	CAHN
---	-------------	----	-------------	--	-----	------

INJECTABLE; INJECTION

FLUOROURACIL

AP	ONCO THERAPIES LTD	500MG/10ML (50MG/ML)	A202668 001	Jul 17, 2012	Jul	NEWA
AP		1GM/20ML (50MG/ML)	A202668 002	Jul 17, 2012	Jul	NEWA
AP		2.5GM/50ML (50MG/ML)	A202669 001	Jul 17, 2012	Jul	NEWA
AP		5GM/100ML (50MG/ML)	A202669 002	Jul 17, 2012	Jul	NEWA
	@ SPECTRUM PHARMS	50MG/ML	A087792 001	Oct 13, 1982	Sep	CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL

FLUOXETINE HYDROCHLORIDE

AB1	HERITAGE PHARMS INC	EQ 10MG BASE	A201336 001	Oct 01, 2012	Sep	NEWA
AB1		EQ 20MG BASE	A201336 002	Oct 01, 2012	Sep	NEWA
AB		EQ 40MG BASE	A201336 003	Oct 01, 2012	Sep	NEWA
AB1	MYLAN PHARMS INC	EQ 10MG BASE	A075577 001	Jan 29, 2002	Sep	CAHN
AB1		EQ 20MG BASE	A075577 002	Jan 29, 2002	Sep	CAHN

PROZAC

AB1	ELI LILLY AND CO	EQ 10MG BASE	N018936 006	Dec 23, 1992	Apr	CAHN
AB1		EQ 20MG BASE	N018936 001	Dec 29, 1987	Apr	CAHN
AB	+	EQ 40MG BASE	N018936 003	Jun 15, 1999	Apr	CAHN
	@	EQ 60MG BASE	N018936 004	Jun 15, 1999	Apr	CAHN

SARAFEM

AB2	ELI LILLY AND CO	EQ 10MG BASE	N018936 007	Jul 06, 2000	Apr	CAHN
AB2	+	EQ 20MG BASE	N018936 008	Jul 06, 2000	Apr	CAHN

TABLET; ORAL

SARAFEM

	WARNER CHILCOTT LLC	EQ 10MG BASE	N021860 001	May 19, 2006	Jun	CAHN
		EQ 15MG BASE	N021860 002	May 19, 2006	Jun	CAHN
+		EQ 20MG BASE	N021860 003	May 19, 2006	Jun	CAHN

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE; ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

>A>	AB	PAR PHARM	EQ 25MG BASE;EQ 3MG BASE	A077742 001	Nov 02, 2012	Oct	NEWA
>A>	AB		EQ 25MG BASE;EQ 6MG BASE	A077742 002	Nov 02, 2012	Oct	NEWA
>A>	AB		EQ 25MG BASE;EQ 12MG BASE	A077742 003	Nov 02, 2012	Oct	NEWA
>A>	AB		EQ 50MG BASE;EQ 6MG BASE	A077742 004	Nov 02, 2012	Oct	NEWA
>A>	AB		EQ 50MG BASE;EQ 12MG BASE	A077742 005	Nov 02, 2012	Oct	NEWA
	AB	TEVA PHARMS	EQ 25MG BASE;EQ 6MG BASE	A077528 001	Jun 19, 2012	Jun	NEWA
	AB		EQ 25MG BASE;EQ 12MG BASE	A077528 002	Jun 19, 2012	Jun	NEWA
	AB		EQ 50MG BASE;EQ 6MG BASE	A077528 003	Jun 19, 2012	Jun	NEWA
	AB		EQ 50MG BASE;EQ 12MG BASE	A077528 004	Jun 19, 2012	Jun	NEWA
		SYMBYAX					
	AB	LILLY	EQ 25MG BASE;EQ 6MG BASE	N021520 002	Dec 24, 2003	Jun	CFTG
	AB		EQ 25MG BASE;EQ 12MG BASE	N021520 004	Dec 24, 2003	Jun	CFTG
	AB	+	EQ 50MG BASE;EQ 6MG BASE	N021520 003	Dec 24, 2003	Jun	CFTG
	AB		EQ 50MG BASE;EQ 12MG BASE	N021520 005	Dec 24, 2003	Jun	CFTG

FLURANDRENOLIDE

CREAM; TOPICAL

CORDRAN SP

+	AQUA PHARMS	0.025%	N012806 003		Aug	CRLD
		0.025%	N012806 003		Jul	CAHN
+		0.05%	N012806 002		Aug	CRLD
		0.05%	N012806 002		Jul	CAHN
	WATSON PHARMS	0.05%	N012806 002		Apr	CMFD

LOTION; TOPICAL

CORDRAN

+	AQUA PHARMS	0.05%	N013790 001		Jul	CAHN
---	-------------	-------	-------------	--	-----	------

OINTMENT; TOPICAL

CORDRAN

@	AQUA PHARMS	0.025%	N012806 004		Jul	CAHN
@		0.05%	N012806 001		Jul	CAHN

FLUTAMIDE

CAPSULE; ORAL

FLUTAMIDE

AB	+	IVAX SUB TEVA PHARMS	125MG	A075780 001	Sep 19, 2001	Mar	CRLD
>A>		@ SANDOZ	125MG	A075818 001	Sep 18, 2001	Oct	DISC
>D>	AB	SANDOZ INC	125MG	A075818 001	Sep 18, 2001	Oct	DISC
	AB		125MG	A075818 001	Sep 18, 2001	Mar	CRLD
	AB	WATSON LABS INC FL	125MG	A075820 001	Sep 18, 2001	Sep	CAHN

FLUTICASONE PROPIONATE

CREAM; TOPICAL

CUTIVATE

AB	+	FOUGERA PHARMS	0.05%	N019958 001	Dec 18, 1990	Jan	CAHN
		FLUTICASONE PROPIONATE					
AB		FOUGERA PHARMS	0.05%	A076451 001	May 14, 2004	Jan	CAHN
	@	NESHER PHARMS	0.05%	A076865 001	Sep 10, 2004	Jun	DISC

OINTMENT; TOPICAL

FLUTICASONE PROPIONATE

AB	FOUGERA PHARMS	0.005%	A076300 001	May 14, 2004	Jan	CAHN
----	----------------	--------	-------------	--------------	-----	------

FLUVASTATIN SODIUM

CAPSULE; ORAL

FLUVASTATIN SODIUM

AB	MYLAN PHARMS INC	EQ 20MG BASE	A090595 001	Apr 11, 2012	Mar	NEWA
AB		EQ 40MG BASE	A090595 002	Apr 11, 2012	Mar	NEWA
AB	TEVA PHARMS	EQ 20MG BASE	A078407 001	Jun 12, 2012	May	NEWA
AB		EQ 40MG BASE	A078407 002	Jun 12, 2012	May	NEWA
LESCOL						
AB	NOVARTIS	EQ 20MG BASE	N020261 001	Dec 31, 1993	Mar	CFTG
AB	+	EQ 40MG BASE	N020261 002	Dec 31, 1993	Mar	CFTG

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

LUVOX CR

	JAZZ PHARMS	100MG	N022033 001	Feb 28, 2008	Jun	CAHN
+		150MG	N022033 002	Feb 28, 2008	Jun	CAHN

FOMEPIZOLE

INJECTABLE; INJECTION

FOMEPIZOLE

AP	MYLAN LLC	1.5GM/1.5ML (1GM/ML)	A078639 001	Mar 03, 2008	Sep	CAHN
----	-----------	----------------------	-------------	--------------	-----	------

FORMOTEROL FUMARATE

SOLUTION; INHALATION

PERFOROMIST

+	MYLAN SPECLT	0.02MG/2ML	N022007 001	May 11, 2007	Sep	CAHN
---	--------------	------------	-------------	--------------	-----	------

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED; INHALATION

DULERA

+	MERCK SHARP DOHME	0.005MG/INH;0.1MG/INH	N022518 001	Jun 22, 2010	Jun	CAHN
+		0.005MG/INH;0.2MG/INH	N022518 002	Jun 22, 2010	Jun	CAHN

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

@ RANBAXY LABS LTD

	10MG	A076580 001	Apr 23, 2004	Apr	DISC
@	20MG	A076580 002	Apr 23, 2004	Apr	DISC
@	40MG	A076580 003	Apr 23, 2004	Apr	DISC

MONOPRIL

@ BRISTOL MYERS SQUIBB

	10MG	N019915 002	May 16, 1991	Mar	DISC
@	20MG	N019915 003	May 16, 1991	Mar	DISC
@	40MG	N019915 004	Mar 28, 1995	Mar	DISC

FOSINOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

>A>	AB	EMCURE PHARMS INDIA	10MG;12.5MG	A079025 001	Sep 17, 2010	Oct	CAHN
>A>	AB		20MG;12.5MG	A079025 002	Sep 17, 2010	Oct	CAHN
>D>	AB	EMCURE PHARMS USA	10MG;12.5MG	A079025 001	Sep 17, 2010	Oct	CAHN
>D>	AB		20MG;12.5MG	A079025 002	Sep 17, 2010	Oct	CAHN

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

FOSPHENYTOIN SODIUM

AP	HIKMA MAPLE	EQ 50MG PHENYTOIN NA/ML	A077989 001	Aug 06, 2007	Jul	CAHN
	@ TEVA PARENTERAL	EQ 50MG PHENYTOIN NA/ML	A076886 001	Aug 06, 2007	Mar	DISC

FOSPROPOFOL DISODIUM

SOLUTION; INTRAVENOUS

LUSEDRA

@ EISAI INC	1050MG/30ML (35MG/ML)	N022244 001	Dec 12, 2008	Jul	DISC
-------------	-----------------------	-------------	--------------	-----	------

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

@ HIKMA MAPLE	10MG/ML	A071439 001	Sep 14, 1990	Sep	CAHN
@	10MG/ML	N018267 001		Sep	CAHN
@ HOSPIRA	10MG/ML	A070578 001	Jul 08, 1987	Jun	DISC

GABAPENTIN

SOLUTION; ORAL

GABAPENTIN

AA	ACELLA PHARMS LLC	250MG/5ML	A076403 001	May 01, 2012	Jun	CAHN
AA	AMNEAL PHARMS	250MG/5ML	A202024 001	Mar 23, 2012	Mar	NEWA
AA	KIEL	250MG/5ML	A076403 001	May 01, 2012	Apr	NEWA

TABLET; ORAL

GABAPENTIN

>A>	AB	INVAGEN PHARMS	600MG	A202764 001	Oct 16, 2012	Oct	NEWA
>A>	AB		800MG	A202764 002	Oct 16, 2012	Oct	NEWA
	AB	MYLAN PHARMS INC	600MG	A090335 001	Jun 01, 2010	Sep	CAHN
	AB		800MG	A090335 002	Jun 01, 2010	Sep	CAHN

GANCICLOVIR

CAPSULE; ORAL

GANCICLOVIR

@ RANBAXY LABS LTD	250MG	A076457 001	Jun 27, 2003	Apr	DISC
@	500MG	A076457 002	Jun 27, 2003	Apr	DISC

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

AP	EMCURE PHARMS LTD	EQ 200MG BASE/VIAL	A202063 001	Sep 11, 2012	Aug	NEWA	
AP		EQ 1GM BASE/VIAL	A202063 002	Sep 11, 2012	Aug	NEWA	
AP	HAMELN RDS GMBH	EQ 200MG BASE/VIAL	A090663 001	Sep 10, 2012	Aug	NEWA	
AP		EQ 1GM BASE/VIAL	A090663 002	Sep 10, 2012	Aug	NEWA	
	+	HOSPIRA INC	200MG/5.26ML (38MG/ML)	N200795 001	Aug 04, 2011	Apr	CTNA
	+		1GM/26.3ML (38MG/ML)	N200795 002	Aug 04, 2011	Apr	CTNA
	+		2GM/52.6ML (38MG/ML)	N200795 003	Aug 04, 2011	Apr	CTNA
>D>	AP	TEVA PARENTERAL	EQ 200MG BASE/VIAL	A077983 002	Jan 25, 2011	Oct	CAHN
>D>	AP		EQ 1GM BASE/VIAL	A077983 001	Jan 25, 2011	Oct	CAHN
>A>	AP	TEVA PHARMS	EQ 200MG BASE/VIAL	A077983 002	Jan 25, 2011	Oct	CAHN
>A>	AP		EQ 1GM BASE/VIAL	A077983 001	Jan 25, 2011	Oct	CAHN

GENTAMICIN SULFATE

INJECTABLE; INJECTION

GENTAMICIN SULFATE

@ HIKMA MAPLE

EQ 10MG BASE/ML

A062251 002

Sep CAHN

@

EQ 40MG BASE/ML

A062251 001

Sep CAHN

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

AB	AUROBINDO PHARMA LTD	1MG	A202759 001	Jun 29, 2012	Jun	NEWA
AB		2MG	A202759 002	Jun 29, 2012	Jun	NEWA
AB		4MG	A202759 003	Jun 29, 2012	Jun	NEWA
AB	MICRO LABS USA	1MG	A091220 001	Jun 29, 2012	Jun	NEWA
AB		2MG	A091220 002	Jun 29, 2012	Jun	NEWA
		3MG	A091220 003	Jun 29, 2012	Jun	NEWA
AB		4MG	A091220 004	Jun 29, 2012	Jun	NEWA
		6MG	A091220 005	Jun 29, 2012	Jun	NEWA
AB		8MG	A091220 006	Jun 29, 2012	Jun	NEWA
	@ RANBAXY LABS LTD	1MG	A076875 001	Oct 06, 2005	Apr	DISC
	@	2MG	A076875 002	Oct 06, 2005	Apr	DISC
	@	4MG	A076875 003	Oct 06, 2005	Apr	DISC
	@	8MG	A076875 004	Oct 06, 2005	Apr	DISC

GLIMEPIRIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

DUETACT

+ TAKEDA PHARMS USA

2MG;30MG

N021925 001 Jul 28, 2006 Aug CAHN

4MG;30MG

N021925 002 Jul 28, 2006 Aug CAHN

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

@ VINTAGE PHARMS LLC

5MG

A074378 001 Nov 28, 1994 Sep CAHN

@

10MG

A074378 002 Nov 28, 1994 Sep CAHN

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

AB	HERITAGE PHARMS INC	1.25MG;250MG	A079009 001	Jun 03, 2009	Sep	CAHN
AB		2.5MG;500MG	A079009 002	Jun 03, 2009	Sep	CAHN
AB		5MG;500MG	A079009 003	Jun 03, 2009	Sep	CAHN

GLYCOPYRROLATE

SOLUTION; ORAL

CUVPOSA

+ MERZ PHARMS

1MG/5ML

N022571 001 Jul 28, 2010 Aug CAHN

TABLET; ORAL

GLYCOPYRROLATE

AA	EXCELLIUM	1MG	A090195 001	Sep 21, 2012	Sep	NEWA
AA		2MG	A090195 002	Sep 21, 2012	Sep	NEWA
AA	NEXGEN PHARMA	1.5MG	A091522 001	Mar 12, 2012	Feb	NEWA

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

AP	CIPLA LTD	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078262 001	Dec 31, 2007	Mar	CAHN
AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078258 001	Jun 30, 2008	Mar	CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078258 002	Jun 30, 2008	Mar	CAHN
AP	HIKMA MAPLE	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077177 001	Dec 31, 2007	Sep	CAHN
GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE						
AP	+ APP PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078096 001	Jun 30, 2008	Apr	CRLD
	@ TEVA PARENTERAL	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077165 001	Dec 31, 2007	Apr	DISC

>D> GRISEOFULVIN

>D> SUSPENSION; ORAL

>D> GRISEOFULVIN

>D>	AB	VINTAGE	125MG/5ML	A065438 001	Oct 08, 2010	Oct	CAIN
-----	----	---------	-----------	-------------	--------------	-----	------

>D> GRISEOFULVIN, MICROCRYSTALLINE

>D> SUSPENSION; ORAL

>D> GRIFULVIN V

>D>	AB	+ VALEANT PHARM NORTH	125MG/5ML	A062483 001	Jan 26, 1984	Oct	CAIN
-----	----	-----------------------	-----------	-------------	--------------	-----	------

	AB	+	125MG/5ML	A062483 001	Jan 26, 1984	Feb	CAHN
--	----	---	-----------	-------------	--------------	-----	------

>D> GRISEOFULVIN

>D>	AB	ACTAVIS MID ATLANTIC	125MG/5ML	A065394 001	Jul 06, 2007	Oct	CAIN
-----	----	----------------------	-----------	-------------	--------------	-----	------

>D>	AB	IVAX SUB TEVA PHARMS	125MG/5ML	A065354 001	Sep 10, 2007	Oct	CAIN
-----	----	----------------------	-----------	-------------	--------------	-----	------

>D>	AB	PERRIGO CO TENNESSEE	125MG/5ML	A065200 001	Mar 02, 2005	Oct	CAIN
-----	----	----------------------	-----------	-------------	--------------	-----	------

TABLET; ORAL

GRIFULVIN V

>D>		@ VALEANT INTL	125MG	A062279 001		Oct	CAHN
-----	--	----------------	-------	-------------	--	-----	------

		@	125MG	A062279 001		Jul	CAHN
--	--	---	-------	-------------	--	-----	------

>D>		@	250MG	A062279 002		Oct	CAHN
-----	--	---	-------	-------------	--	-----	------

		@	250MG	A062279 002		Jul	CAHN
--	--	---	-------	-------------	--	-----	------

>D>		+	500MG	A062279 003		Oct	CAHN
-----	--	---	-------	-------------	--	-----	------

		+	500MG	A062279 003		Jul	CAHN
--	--	---	-------	-------------	--	-----	------

>A>		@ VALEANT LUXEMBOURG	125MG	A062279 001		Oct	CAHN
-----	--	----------------------	-------	-------------	--	-----	------

>A>		@	250MG	A062279 002		Oct	CAHN
-----	--	---	-------	-------------	--	-----	------

>A> GRISEOFULVIN, MICROSIZE

>A> SUSPENSION; ORAL

>A> GRIFULVIN V

>A>	AB	+ VALEANT PHARM NORTH	125MG/5ML	A062483 001	Jan 26, 1984	Oct	CAIN
-----	----	-----------------------	-----------	-------------	--------------	-----	------

>A> GRISEOFULVIN

>A>	AB	ACTAVIS MID ATLANTIC	125MG/5ML	A065394 001	Jul 06, 2007	Oct	CAIN
-----	----	----------------------	-----------	-------------	--------------	-----	------

>A>	AB	IVAX SUB TEVA PHARMS	125MG/5ML	A065354 001	Sep 10, 2007	Oct	CAIN
-----	----	----------------------	-----------	-------------	--------------	-----	------

>A>	AB	PERRIGO CO TENNESSEE	125MG/5ML	A065200 001	Mar 02, 2005	Oct	CAIN
-----	----	----------------------	-----------	-------------	--------------	-----	------

>A>	AB	VINTAGE PHARMS	125MG/5ML	A065438 001	Oct 08, 2010	Oct	CAIN
-----	----	----------------	-----------	-------------	--------------	-----	------

TABLET; ORAL

GRIFULVIN V

>A>	AB	+ VALEANT LUXEMBOURG	500MG	A062279 003		Oct	CAHN
-----	----	----------------------	-------	-------------	--	-----	------

>A> GRISEOFULVIN

>A>	AB	SIGMAPHARM LABS LLC	500MG	A202482 001	Oct 22, 2012	Oct	NEWA
-----	----	---------------------	-------	-------------	--------------	-----	------

GRISEOFULVIN, ULTRAMICROCRYSTALLINE

TABLET; ORAL

GRIS-PEG

>D>	PEDINOL	125MG	N050475 001	Oct	CTEC
>D>	+	250MG	N050475 002	Oct	CTEC

GRISEOFULVIN, ULTRAMICROSIZE

TABLET; ORAL

>A>	GRISEOFULVIN,ULTRAMICROSIZE				
>A>	AB SIGMAPHARM LABS LLC	125MG	A202545 001	Oct 22, 2012	Oct NEWA
>A>	AB	250MG	A202545 002	Oct 22, 2012	Oct NEWA
	GRIS-PEG				
>A>	AB PEDINOL	125MG	N050475 001		Oct CTEC
>A>	AB +	250MG	N050475 002		Oct CTEC

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	EQ 1MG BASE	A200881 001	Oct 05, 2012	Sep NEWA
AB		EQ 2MG BASE	A200881 002	Oct 05, 2012	Sep NEWA
AB		EQ 3MG BASE	A200881 003	Oct 05, 2012	Sep NEWA
AB		EQ 4MG BASE	A200881 004	Oct 05, 2012	Sep NEWA
	INTUNIV				
AB	SHIRE	EQ 1MG BASE	N022037 001	Sep 02, 2009	Sep CFTG
AB		EQ 2MG BASE	N022037 002	Sep 02, 2009	Sep CFTG
AB		EQ 3MG BASE	N022037 003	Sep 02, 2009	Sep CFTG
AB	+	EQ 4MG BASE	N022037 004	Sep 02, 2009	Sep CFTG

HALOBETASOL PROPIONATE

CREAM; TOPICAL

HALOBETASOL PROPIONATE

AB	FOUGERA PHARMS	0.05%	A077001 001	Dec 16, 2004	Jan CAHN
	OINTMENT; TOPICAL				
	HALOBETASOL PROPIONATE				
AB	FOUGERA PHARMS	0.05%	A076903 001	Dec 16, 2004	Jan CAHN
	@ VENUS PHARMS	0.05%	A077109 001	Jun 14, 2005	Jun CAHN

HEPARIN SODIUM

INJECTABLE; INJECTION

HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	+	B BRAUN	200 UNITS/100ML	N019953 001	Jul 20, 1992	Jul CRLD
		HEPARIN SODIUM 10,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER				
		@ BAXTER HLTHCARE	2,000 UNITS/100ML	N018814 002	Jul 09, 1985	Mar DISC
		HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER				
		@ BAXTER HLTHCARE	4,000 UNITS/100ML	N018814 001	Oct 31, 1983	Mar DISC
		HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
AP	+	B BRAUN	4,000 UNITS/100ML	N019952 001	Jul 20, 1992	Jul CRLD
		HEPARIN SODIUM 25,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER				
		@ BAXTER HLTHCARE	5,000 UNITS/100ML	N018814 003	Jul 09, 1985	Mar DISC
		@	10,000 UNITS/100ML	N018814 004	Jul 02, 1987	Mar DISC
		HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER				
AP	+	B BRAUN	5,000 UNITS/100ML	N019952 004	Jul 20, 1992	Jul CRLD
AP	+		10,000 UNITS/100ML	N019952 005	Jul 20, 1992	Jul CRLD

HEXAMINOLEVULINATE HYDROCHLORIDEFOR SOLUTION; INTRAVESICAL
CYSVIEW KIT

+ PHOTOCURE ASA 100MG/VIAL N022555 001 May 28, 2010 May CAHN

HYALURONIDASEINJECTABLE; INJECTION
HYDASE

@ AKORN INC 150 UNITS/ML N021716 001 Oct 25, 2005 Jun DISC

HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

HYDROCHLOROTHIAZIDE

AB LANNETT HOLDINGS INC 12.5MG A091662 001 Jan 27, 2012 Jan NEWA

TABLET; ORAL

HYDROCHLOROTHIAZIDE

AB ACCORD HLTHCARE 12.5MG A202556 001 Sep 24, 2012 Sep NEWA

AB 25MG A202556 002 Sep 24, 2012 Sep NEWA

AB 50MG A202556 003 Sep 24, 2012 Sep NEWA

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

AVALIDE

AB + SANOFI AVENTIS 12.5MG;150MG N020758 002 Sep 30, 1997 Mar CFTG

AB + 12.5MG;300MG N020758 003 Aug 31, 1998 Mar CFTG

+ 12.5MG;300MG N020758 003 Aug 31, 1998 Feb CRLD

IRBESARTAN AND HYDROCHLOROTHIAZIDE

>A> AB ALEMBIC LTD 12.5MG;150MG A091370 001 Oct 15, 2012 Oct NEWA

>A> AB 12.5MG;300MG A091370 002 Oct 15, 2012 Oct NEWA

>A> AB APOTEX INC 12.5MG;150MG A201505 001 Oct 15, 2012 Oct NEWA

>A> AB 12.5MG;300MG A201505 002 Oct 15, 2012 Oct NEWA

AB DR REDDYS LABS LTD 12.5MG;150MG A203500 001 Sep 27, 2012 Sep NEWA

AB 12.5MG;300MG A203500 002 Sep 27, 2012 Sep NEWA

AB MACLEODS PHARMS LTD 12.5MG;150MG A202414 001 Sep 27, 2012 Sep NEWA

AB 12.5MG;300MG A202414 002 Sep 27, 2012 Sep NEWA

AB MYLAN PHARMS INC 12.5MG;150MG A077969 001 Sep 27, 2012 Sep NEWA

AB 12.5MG;300MG A077969 002 Sep 27, 2012 Sep NEWA

>A> AB ROXANE 12.5MG;150MG A090351 001 Oct 15, 2012 Oct NEWA

>A> AB 12.5MG;300MG A090351 002 Oct 15, 2012 Oct NEWA

AB SANDOZ 12.5MG;150MG A077446 001 Sep 27, 2012 Sep NEWA

AB 12.5MG;300MG A077446 002 Sep 27, 2012 Sep NEWA

AB TEVA 12.5MG;150MG A077369 001 Mar 30, 2012 Mar NEWA

AB 12.5MG;300MG A077369 002 Mar 30, 2012 Mar NEWA

@ 25MG;300MG A077369 003 Mar 30, 2012 Apr DISC

25MG;300MG A077369 003 Mar 30, 2012 Mar NEWA

>A> AB WATSON LABS INC 12.5MG;150MG A091539 001 Oct 22, 2012 Oct NEWA

>A> AB 12.5MG;300MG A091539 002 Oct 22, 2012 Oct NEWA

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB ALEMBIC LTD 12.5MG;50MG A091617 001 Feb 17, 2012 Feb NEWA

AB 12.5MG;100MG A091617 002 Feb 17, 2012 Feb NEWA

AB 25MG;100MG A091617 003 Feb 17, 2012 Feb NEWA

AB ALEMBIC PHARMS LTD 12.5MG;50MG A091617 001 Feb 17, 2012 Sep CAHN

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

AB	ALEMBIC PHARMS LTD	12.5MG;100MG	A091617 002	Feb 17, 2012	Sep	CAHN
AB		25MG;100MG	A091617 003	Feb 17, 2012	Sep	CAHN
AB	CADISTA PHARMS	12.5MG;50MG	A201845 001	Sep 18, 2012	Sep	NEWA
AB		12.5MG;100MG	A201845 002	Sep 18, 2012	Sep	NEWA
AB		25MG;100MG	A201845 003	Sep 18, 2012	Sep	NEWA
AB	MACLEODS PHARMS LTD	12.5MG;50MG	A202289 001	Aug 09, 2012	Jul	NEWA
AB		12.5MG;100MG	A202289 002	Aug 09, 2012	Jul	NEWA
AB		25MG;100MG	A202289 003	Aug 09, 2012	Jul	NEWA

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

	ASTRAZENECA	12.5MG;EQ 25MG TARTRATE	N021956 001	Aug 28, 2006	Jan	CMFD
		12.5MG;EQ 50MG TARTRATE	N021956 002	Aug 28, 2006	Jan	CMFD
+		12.5MG;EQ 100MG TARTRATE	N021956 003	Aug 28, 2006	Apr	CRLD
		12.5MG;EQ 100MG TARTRATE	N021956 003	Aug 28, 2006	Jan	CMFD

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR HCT

AB	US PHARMS HOLDINGS I	25MG;50MG	N018303 001	Dec 31, 1984	Sep	CAHN
AB	+	25MG;100MG	N018303 002	Dec 31, 1984	Sep	CAHN
	@	50MG;100MG	N018303 003	Dec 31, 1984	Sep	CAHN
	METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE					
AB	MYLAN	50MG;100MG	A076792 003	Aug 20, 2004	Jan	CTEC
AB	SUN PHARM INDS	25MG;50MG	A090654 001	Jan 19, 2012	Jan	NEWA
AB		25MG;100MG	A090654 002	Jan 19, 2012	Jan	NEWA
AB		50MG;100MG	A090654 003	Jan 19, 2012	Jan	NEWA

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	@ PADDOCK LLC	12.5MG;7.5MG	A090096 001	Sep 25, 2008	Jan	DISC
	@	12.5MG;15MG	A090096 002	Sep 25, 2008	Jan	DISC
	@	25MG;15MG	A090096 003	Sep 25, 2008	Jan	DISC

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

DIOVAN HCT

AB	NOVARTIS	12.5MG;80MG	N020818 001	Mar 06, 1998	Sep	CFTG
AB		12.5MG;160MG	N020818 002	Mar 06, 1998	Sep	CFTG
AB		12.5MG;320MG	N020818 004	Apr 28, 2006	Sep	CFTG
AB		25MG;160MG	N020818 003	Jan 17, 2002	Sep	CFTG
AB	+	25MG;320MG	N020818 005	Apr 28, 2006	Sep	CFTG

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	MYLAN PHARMS INC	12.5MG;80MG	A078020 001	Sep 21, 2012	Sep	NEWA
AB		12.5MG;160MG	A078020 002	Sep 21, 2012	Sep	NEWA
AB		12.5MG;320MG	A078020 004	Sep 21, 2012	Sep	NEWA
AB		25MG;160MG	A078020 003	Sep 21, 2012	Sep	NEWA
AB		25MG;320MG	A078020 005	Sep 21, 2012	Sep	NEWA

HYDROCORTISONE

CREAM; TOPICAL

HYTONE

@ VALEANT INTL

1%

A080472 003

Sep CAHN

@

2.5%

A080472 004

Sep CAHN

NUTRACORT

@ DOW PHARM

0.5%

A080442 002

Jun CAHN

@

1%

A080442 003

Jun CAHN

LOTION; TOPICAL

CETACORT

@ DOW PHARM

0.5%

A080426 002

Jun CAHN

@

1%

A080426 001

Jun CAHN

HYDROCORTISONE

AT + FOUGERA PHARMS

2.5%

A040351 001 Jul 25, 2000 Jan CAHN

HYTONE

@ VALEANT INTL

1%

A080473 003

Sep CAHN

@

2.5%

A080473 004 Nov 30, 1982 Sep CAHN

NUTRACORT

@ DOW PHARM

0.5%

A080443 002

Jun CAHN

AT

1%

A080443 003

Jun CAHN

AT

2.5%

A087644 001 Aug 24, 1982 Jun CAHN

OINTMENT; TOPICAL

HYDROCORTISONE

AT + FOUGERA PHARMS

1%

A080692 001

Jan CAHN

HYDROCORTISONE ACETATE; UREA

CREAM; TOPICAL

CARMOL HC

AT FOUGERA PHARMS

1%;10%

A080505 001

Jan CAHN

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL

LOCOID

AB + PRECISION DERMAT

0.1%

N018514 001 Mar 31, 1982 Jun CAHN

LOCOID LIPOCREAM

+ PRECISION DERMAT

0.1%

N020769 001 Sep 08, 1997 Jun CAHN

LOTION; TOPICAL

LOCOID

+ PRECISION DERMAT

0.1%

N022076 001 May 18, 2007 May CAHN

OINTMENT; TOPICAL

LOCOID

AB + PRECISION DERMAT

0.1%

N018652 001 Oct 29, 1982 May CAHN

SOLUTION; TOPICAL

LOCOID

AT + PRECISION DERMAT

0.1%

N019116 001 Feb 25, 1987 Jun CAHN

HYDROCORTISONE VALERATE

CREAM; TOPICAL

HYDROCORTISONE VALERATE

AB + TARO

0.2%

A075042 001 Aug 25, 1998 Mar CRLD

WESTCORT

@ RANBAXY

0.2%

N017950 001

Mar DISC

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

AB FOUGERA PHARMS

0.2%

A075085 001 Jul 31, 2001 Jan CAHN

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

AT	ALCON PHARMS LTD	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	A062423 001	Aug 25, 1983	Sep	CAHN
----	------------------	-------------------------------------	-------------	--------------	-----	------

HYDROFLUMETHIAZIDE

TABLET; ORAL

SALURON

AB	+ SHIRE LLC	50MG	N011949 001		Jan	CAHN
----	-------------	------	-------------	--	-----	------

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

@ NESHER PHARMS 2MG

A077311 001 Nov 09, 2005 Jun DISC

@ 4MG

A077311 002 Nov 09, 2005 Jun DISC

@ 8MG

A077311 003 Nov 09, 2005 Jun DISC

TABLET, EXTENDED RELEASE; ORAL

EXALGO

MALLINCKRODT INC 32MG

N021217 004 Aug 24, 2012 Aug NEWA

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL

HYDROXYCHLOROQUINE SULFATE

>D> AB SANDOZ 200MG

A040150 001 Jan 27, 1996 Oct DISC

>A> @ 200MG

A040150 001 Jan 27, 1996 Oct DISC

HYDROXYZINE HYDROCHLORIDE

SYRUP; ORAL

HYDROXYZINE HYDROCHLORIDE

@ STI PHARMA LLC 10MG/5ML

A086880 001 Feb CAHN

TABLET; ORAL

HYDROXYZINE HYDROCHLORIDE

@ MIKAH PHARMA 10MG

A040600 001 Dec 28, 2004 Jul CAHN

@ 25MG

A040602 001 Dec 28, 2004 Jul CAHN

@ 50MG

A040604 001 Dec 28, 2004 Jul CAHN

HYDROXYZINE PAMOATE

SUSPENSION; ORAL

VISTARIL

@ PFIZER EQ 25MG HCL/5ML

N011795 001 Jul DISC

IBANDRONATE SODIUM

TABLET; ORAL

BONIVA

AB + HOFFMANN LA ROCHE EQ 150MG BASE

N021455 002 Mar 24, 2005 Mar CFTG

IBANDRONATE SODIUM

AB APOTEX INC EQ 150MG BASE

A078948 001 Mar 19, 2012 Mar NEWA

AB DR REDDYS LABS LTD EQ 150MG BASE

A078997 001 Apr 30, 2012 Apr NEWA

AB MUTUAL PHARM CO INC EQ 150MG BASE

A078996 001 Aug 15, 2012 Jul NEWA

AB MYLAN PHARMS INC EQ 150MG BASE

A078995 001 Mar 19, 2012 Mar NEWA

AB ORCHID HLTHCARE EQ 150MG BASE

A078998 001 Mar 19, 2012 Mar NEWA

AB WATSON LABS INC EQ 150MG BASE

A079003 001 Mar 20, 2012 Mar NEWA

IBUPROFEN

TABLET; ORAL

IBUPROFEN

@ NORTHSTAR HLTHCARE	400MG	A078132 001	Sep 10, 2007	Jun	DISC
@	600MG	A078132 002	Sep 10, 2007	Jun	DISC
@	800MG	A078132 003	Sep 10, 2007	Jun	DISC
@ OHM LABS	400MG	A070818 001	Dec 26, 1985	Jun	DISC

IBUPROFEN LYSINE

INJECTABLE; INTRAVENOUS

NEOPROFEN

+ LUNDBECK LLC	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903 001	Apr 13, 2006	Mar	CAHN
----------------	------------------------------------	-------------	--------------	-----	------

ICOSAPENT ETHYL

CAPSULE; ORAL

VASCEPA

+ AMARIN PHARMA INC	1GM	N202057 001	Jul 26, 2012	Jul	NEWA
---------------------	-----	-------------	--------------	-----	------

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

IDARUBICIN HYDROCHLORIDE

AP	ONCO THERAPIES LTD	1MG/ML	A200144 001	Oct 11, 2012	Sep	NEWA
	@ TEVA PARENTERAL	5MG/VIAL	A065037 003	May 01, 2002	Mar	DISC
	@	10MG/VIAL	A065037 002	May 01, 2002	Mar	DISC
	@	20MG/VIAL	A065037 001	May 01, 2002	Mar	DISC

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

>A>	AB	EXCELLIUM	10MG	A040903 001	Oct 24, 2012	Oct	NEWA
>A>	AB		25MG	A040903 002	Oct 24, 2012	Oct	NEWA
>A>	AB		50MG	A040903 003	Oct 24, 2012	Oct	NEWA
	AB	PROSAM LABS	10MG	A040753 001	Feb 28, 2008	Feb	CMFD
	AB		25MG	A040752 001	Feb 28, 2008	Feb	CMFD
	AB		50MG	A040751 001	Feb 28, 2008	Feb	CMFD

IMIQUIMOD

CREAM; TOPICAL

IMIQUIMOD

AB	APOTEX INC	5%	A091308 001	Apr 06, 2012	Mar	NEWA
AB	FOUGERA PHARMS	5%	A078548 001	Feb 25, 2010	Jan	CAHN
AB	GLENMARK GENERICS	5%	A201994 001	Mar 06, 2012	Feb	NEWA

INDAPAMIDE

TABLET; ORAL

INDAPAMIDE

	AB	MYLAN PHARMS INC	1.25MG	A075105 001	Jul 23, 1998	Sep	CAHN
	AB		2.5MG	A075105 002	Jul 23, 1998	Sep	CAHN
>D>	AB	SANDOZ	1.25MG	A074594 001	May 23, 1996	Oct	DISC
>A>		@	1.25MG	A074594 001	May 23, 1996	Oct	DISC
>D>	AB		2.5MG	A074594 002	May 23, 1996	Oct	DISC
>A>		@	2.5MG	A074594 002	May 23, 1996	Oct	DISC

INDOMETHACINCAPSULE, EXTENDED RELEASE; ORAL
INDOMETHACIN

AB	HETERO LABS LTD III	75MG	A201807 001	Sep 28, 2012	Sep	NEWA
----	---------------------	------	-------------	--------------	-----	------

INDOMETHACIN SODIUMINJECTABLE; INJECTION
INDOCIN

AP	+	LUNDBECK LLC	EQ 1MG BASE/VIAL	N018878 001	Jan 30, 1985	Mar	CAHN
----	---	--------------	------------------	-------------	--------------	-----	------

INGENOL MEBUTATEGEL; TOPICAL
PICATO

LEO PHARMA AS

0.015%

N202833 001	Jan 23, 2012	Jan	NEWA
-------------	--------------	-----	------

+

0.05%

N202833 002	Jan 23, 2012	Jan	NEWA
-------------	--------------	-----	------

INSULIN LISPRO PROTAMINE RECOMBINANT; INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG MIX 50/50 PEN

@ LILLY

50 UNITS/ML;50 UNITS/ML

N021018 003	Dec 22, 1999	Jun	DISC
-------------	--------------	-----	------

HUMALOG MIX 75/25 PEN

@ LILLY

75 UNITS/ML;25 UNITS/ML

N021017 003	Dec 22, 1999	Jun	DISC
-------------	--------------	-----	------

INSULIN LISPRO RECOMBINANT

INJECTABLE; INJECTION

HUMALOG PEN

@ LILLY

100 UNITS/ML

N020563 002	Aug 06, 1998	Jun	DISC
-------------	--------------	-----	------

IOTHALAMATE SODIUM I-125

INJECTABLE; INJECTION

GLOFIL-125

@ ISOTEX

250-300uCi/ML

N017279 001		Oct	CMFD
-------------	--	-----	------

>D>

250-300uCi/ML

N017279 001		Oct	CMFD
-------------	--	-----	------

>A>

IPRATROPIUM BROMIDE

SOLUTION; INHALATION

IPRATROPIUM BROMIDE

AN	TEVA PHARMS	0.02%
----	-------------	-------

A075313 001	Feb 07, 2000	Sep	CAHN
-------------	--------------	-----	------

IRBESARTAN

TABLET; ORAL

AVAPRO

AB	SANOFI AVENTIS US	75MG
----	-------------------	------

N020757 001	Sep 30, 1997	Mar	CFTG
-------------	--------------	-----	------

AB		150MG
----	--	-------

N020757 002	Sep 30, 1997	Mar	CFTG
-------------	--------------	-----	------

AB	+	300MG
----	---	-------

N020757 003	Sep 30, 1997	Mar	CFTG
-------------	--------------	-----	------

IRBESARTAN

>A>	AB	ALEMBIC PHARMS LTD	75MG
-----	----	--------------------	------

A091236 001	Oct 15, 2012	Oct	NEWA
-------------	--------------	-----	------

>A>	AB		150MG
-----	----	--	-------

A091236 002	Oct 15, 2012	Oct	NEWA
-------------	--------------	-----	------

>A>	AB		300MG
-----	----	--	-------

A091236 003	Oct 15, 2012	Oct	NEWA
-------------	--------------	-----	------

>A>	AB	APOTEX INC	75MG
-----	----	------------	------

A200832 001	Oct 15, 2012	Oct	NEWA
-------------	--------------	-----	------

>A>	AB		150MG
-----	----	--	-------

A200832 002	Oct 15, 2012	Oct	NEWA
-------------	--------------	-----	------

>A>	AB		300MG
-----	----	--	-------

A200832 003	Oct 15, 2012	Oct	NEWA
-------------	--------------	-----	------

AB	AUROBINDO PHARMA LTD	75MG
----	----------------------	------

A203081 001	Sep 27, 2012	Sep	NEWA
-------------	--------------	-----	------

AB		150MG
----	--	-------

A203081 002	Sep 27, 2012	Sep	NEWA
-------------	--------------	-----	------

AB		300MG
----	--	-------

A203081 003	Sep 27, 2012	Sep	NEWA
-------------	--------------	-----	------

TABLET; ORAL

IRBESARTAN

>A>	AB	CIPLA LTD	75MG	A077205 001	Nov 14, 2012	Oct	NEWA
>A>	AB		150MG	A077205 002	Nov 14, 2012	Oct	NEWA
>A>	AB		300MG	A077205 003	Nov 14, 2012	Oct	NEWA
	AB	DR REDDYS LABS LTD	75MG	A203161 001	Sep 27, 2012	Sep	NEWA
	AB		150MG	A203161 002	Sep 27, 2012	Sep	NEWA
	AB		300MG	A203161 003	Sep 27, 2012	Sep	NEWA
	AB	HETERO LABS LTD V	75MG	A202910 001	Sep 27, 2012	Sep	NEWA
	AB		150MG	A202910 002	Sep 27, 2012	Sep	NEWA
	AB		300MG	A202910 003	Sep 27, 2012	Sep	NEWA
>A>	AB	LUPIN LTD	75MG	A201531 001	Oct 15, 2012	Oct	NEWA
>A>	AB		150MG	A201531 002	Oct 15, 2012	Oct	NEWA
>A>	AB		300MG	A201531 003	Oct 15, 2012	Oct	NEWA
	AB	MACLEODS PHARMS LTD	75MG	A202254 001	Oct 03, 2012	Sep	NEWA
	AB		150MG	A202254 002	Oct 03, 2012	Sep	NEWA
	AB		300MG	A202254 003	Oct 03, 2012	Sep	NEWA
	AB	MYLAN PHARMS INC	75MG	A200461 001	Sep 27, 2012	Sep	NEWA
	AB		150MG	A200461 002	Sep 27, 2012	Sep	NEWA
	AB		300MG	A200461 003	Sep 27, 2012	Sep	NEWA
	AB	PRINSTON INC	75MG	A203071 001	Sep 27, 2012	Sep	NEWA
	AB		150MG	A203071 002	Sep 27, 2012	Sep	NEWA
	AB		300MG	A203071 003	Sep 27, 2012	Sep	NEWA
>A>	AB	ROXANE	75MG	A090201 001	Oct 15, 2012	Oct	NEWA
>A>	AB		150MG	A090201 002	Oct 15, 2012	Oct	NEWA
>A>	AB		300MG	A090201 003	Oct 15, 2012	Oct	NEWA
	AB	SANDOZ	75MG	A077466 001	Sep 27, 2012	Sep	NEWA
	AB		150MG	A077466 002	Sep 27, 2012	Sep	NEWA
	AB		300MG	A077466 003	Sep 27, 2012	Sep	NEWA
	AB	TEVA PHARMS	75MG	A077159 001	Mar 30, 2012	Mar	NEWA
	AB		150MG	A077159 002	Mar 30, 2012	Mar	NEWA
	AB		300MG	A077159 003	Mar 30, 2012	Mar	NEWA
	AB	WATSON LABS INC	75MG	A090720 001	Oct 12, 2012	Sep	NEWA
	AB		150MG	A090720 002	Oct 12, 2012	Sep	NEWA
	AB		300MG	A090720 003	Oct 12, 2012	Sep	NEWA
	AB	ZYDUS PHARMS USA INC	75MG	A079213 001	Sep 27, 2012	Sep	NEWA
	AB		150MG	A079213 002	Sep 27, 2012	Sep	NEWA
	AB		300MG	A079213 003	Sep 27, 2012	Sep	NEWA

IRINOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

IRINOTECAN HYDROCHLORIDE

AP	CIPLA LTD	40MG/2ML (20MG/ML)	A077219 001	Feb 20, 2008	Mar	CAHN
AP		100MG/5ML (20MG/ML)	A077219 002	Feb 20, 2008	Mar	CAHN
AP	EMCURE PHARMS LTD	40MG/2ML (20MG/ML)	A200771 001	Feb 14, 2012	Jan	NEWA
AP		100MG/5ML (20MG/ML)	A200771 002	Feb 14, 2012	Jan	NEWA
AP	HISUN PHARM HANGZHOU	40MG/2ML (20MG/ML)	A090016 001	Jan 28, 2009	Mar	CAHN
AP		100MG/5ML (20MG/ML)	A090016 002	Jan 28, 2009	Mar	CAHN
AP	TEVA PARENTERAL	40MG/2ML (20MG/ML)	A090101 002	Feb 27, 2008	Jun	NEWA
AP		100MG/5ML (20MG/ML)	A090101 003	Feb 27, 2008	Jun	NEWA
AP		500MG/25ML (20MG/ML)	A090101 001	Nov 26, 2008	Jun	CMFD
	@	500MG/25ML (20MG/ML)	A090101 001	Nov 26, 2008	Mar	DISC

ISOFLURANELIQUID; INHALATION
FORANE

AN	+	BAXTER HLTHCARE	99.9%	N017624 001		Jul	CAHN
----	---	-----------------	-------	-------------	--	-----	------

ISOSORBIDE MONONITRATETABLET; ORAL
MONOKET

>A>	AB	KREMERS URBAN PHARMS	10MG	N020215 002	Jun 30, 1993	Oct	CAHN
>A>	AB	+	20MG	N020215 001	Jun 30, 1993	Oct	CAHN
>D>	AB	UCB INC	10MG	N020215 002	Jun 30, 1993	Oct	CAHN
>D>	AB	+	20MG	N020215 001	Jun 30, 1993	Oct	CAHN

TABLET, EXTENDED RELEASE; ORAL
ISOSORBIDE MONONITRATE

AB		ALKERMES GAINESVILLE	60MG	A075041 001	Sep 22, 1998	Jun	CAHN
		@ SKYEPHARMA AG	60MG	A075166 001	Oct 07, 1999	Jan	DISC

ISOSULFAN BLUEINJECTABLE; INJECTION
ISOSULFAN BLUE

>A>	AP	MYLAN INSTITUTIONAL	1%	A090874 001	Jul 20, 2010	Oct	CAHN
>D>	AP	SYNERX	1%	A090874 001	Jul 20, 2010	Oct	CAHN

ISOTRETINOINCAPSULE; ORAL
ABSORICA

BX		CIPHER	10MG	N021951 001	May 25, 2012	Sep	CTEC
			10MG	N021951 001	May 25, 2012	May	NEWA
BX			20MG	N021951 002	May 25, 2012	Sep	CTEC
			20MG	N021951 002	May 25, 2012	May	NEWA
BX			30MG	N021951 003	May 25, 2012	Sep	CTEC
			30MG	N021951 003	May 25, 2012	May	NEWA
BX			40MG	N021951 004	May 25, 2012	Sep	CTEC
			40MG	N021951 004	May 25, 2012	May	NEWA

MYORISAN

AB		DOUGLAS PHARMS	10MG	A076485 001	Jan 19, 2012	Jan	NEWA
AB			20MG	A076485 002	Jan 19, 2012	Jan	NEWA
AB			40MG	A076485 003	Jan 19, 2012	Jan	NEWA

ITRACONAZOLECAPSULE; ORAL
ITRACONAZOLE

AB		MYLAN PHARMS INC	100MG	A200463 001	Jul 20, 2012	Jul	NEWA
----	--	------------------	-------	-------------	--------------	-----	------

IVACAFTORTABLET; ORAL
KALYDECO

+		VERTEX PHARMS	150MG	N203188 001	Jan 31, 2012	Jan	NEWA
---	--	---------------	-------	-------------	--------------	-----	------

IVERMECTINLOTION; TOPICAL
SKLICE

+		SANOFI PASTEUR	0.5%	N202736 001	Feb 07, 2012	Feb	NEWA
---	--	----------------	------	-------------	--------------	-----	------

KANAMYCIN SULFATE

INJECTABLE; INJECTION

KANAMYCIN

@ HIKMA MAPLE

EQ 75MG BASE/2ML

A062324 001

Sep CAHN

@

EQ 500MG BASE/2ML

A062324 002

Sep CAHN

@

EQ 1GM BASE/3ML

A062324 003

Sep CAHN

KETOCONAZOLE

CREAM; TOPICAL

KETOCONAZOLE

AB FOUGERA PHARMS

2%

A076294 001 Apr 28, 2004 Jan CAHN

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

DORADO PHARMA

25MG

A074014 001 Jan 29, 1993 Jul CAHN

AB

50MG

A074014 002 Jan 29, 1993 Jul CAHN

AB

75MG

A074014 003 Jan 29, 1993 Jul CAHN

CAPSULE, EXTENDED RELEASE; ORAL

KETOPROFEN

>D>

AB

ALKERMES GAINESVILLE

200MG

A074879 001 Dec 10, 1997 Oct DISC

>A>

@

200MG

A074879 001 Dec 10, 1997 Oct DISC

AB

200MG

A074879 001 Dec 10, 1997 Jun CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP

HIKMA MAPLE

15MG/ML

A075299 001 Nov 03, 1999 Sep CAHN

AP

15MG/ML

A075772 001 Jul 21, 2004 Sep CAHN

AP

30MG/ML

A075299 002 Nov 03, 1999 Sep CAHN

AP

30MG/ML

A075772 002 Jul 21, 2004 Sep CAHN

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

AP

GLAND PHARMA LTD

5MG/ML

A090699 001 Apr 03, 2012 Mar NEWA

TABLET; ORAL

LABETALOL HYDROCHLORIDE

AB

PAR FORM

100MG

A200908 001 Jul 10, 2012 Jun NEWA

AB

200MG

A200908 002 Jul 10, 2012 Jun NEWA

AB

300MG

A200908 003 Jul 10, 2012 Jun NEWA

LACTULOSE

FOR SOLUTION; ORAL

LACTULOSE

+ CUMBERLAND PHARMS

10GM/PACKET

A074712 001 Dec 10, 1997 Jun CAHN

+

20GM/PACKET

A074712 002 Dec 10, 1997 Jun CAHN

SOLUTION; ORAL

LACTULOSE

AA

FRESENIUS KABI

10GM/15ML

A090503 001 Jan 25, 2012 Jan NEWA

SOLUTION; ORAL, RECTAL

LACTULOSE

AA

FRESENIUS KABI

10GM/15ML

A090502 001 Jan 25, 2012 Jan NEWA

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

LAMIVUDINE AND ZIDOVUDINE

AB	AUROBINDO PHARMA LTD	150MG;300MG	A202418 001	May 15, 2012	Apr	NEWA
AB	LUPIN LTD	150MG;300MG	A090246 001	May 15, 2012	Apr	NEWA

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

AB	GLENMARK GENERICS	25MG	A090169 001	May 12, 2012	Apr	NEWA
AB		100MG	A090169 002	May 12, 2012	Apr	NEWA
AB		150MG	A090169 003	May 12, 2012	Apr	NEWA
AB		200MG	A090169 004	May 12, 2012	Apr	NEWA
BX	UPSHER SMITH	25MG	A078310 001	Feb 04, 2009	Aug	CTEC
BX		100MG	A078310 002	Feb 04, 2009	Aug	CTEC
BX		150MG	A078310 003	Feb 04, 2009	Aug	CTEC
BX		200MG	A078310 004	Feb 04, 2009	Aug	CTEC

LANREOTIDE ACETATE

INJECTABLE; SUBCUTANEOUS

SOMATULINE DEPOT

+	IPSEN INC	EQ 60MG BASE	N022074 001	Aug 30, 2007	Apr	CAHN
+		EQ 90MG BASE	N022074 002	Aug 30, 2007	Apr	CAHN
+		EQ 120MG BASE	N022074 003	Aug 30, 2007	Apr	CAHN
+	IPSEN PHARMA	EQ 60MG BASE	N022074 001	Aug 30, 2007	May	CAHN
+		EQ 90MG BASE	N022074 002	Aug 30, 2007	May	CAHN
+		EQ 120MG BASE	N022074 003	Aug 30, 2007	May	CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

AB	MYLAN PHARMS INC	15MG	A090763 001	Nov 10, 2009	Sep	CAHN
AB		30MG	A090763 002	Nov 10, 2009	Sep	CAHN
AB	WOCKHARDT USA	15MG	A202176 001	Sep 14, 2012	Aug	NEWA
AB		30MG	A202176 002	Sep 14, 2012	Aug	NEWA

PREVACID

AB	TAKEDA PHARMS USA	15MG	N020406 001	May 10, 1995	Mar	CAHN
AB	+	30MG	N020406 002	May 10, 1995	Mar	CAHN

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING; ORAL

LANSOPRAZOLE

@ TEVA PHARMS

@

PREVACID

TAKEDA PHARMS USA

+		15MG	N021428 001	Aug 30, 2002	Mar	CTEC
		30MG	N021428 002	Aug 30, 2002	Mar	CTEC

LANTHANUM CARBONATE

TABLET, CHEWABLE; ORAL

FOSRENOL

@ SHIRE LLC

		EQ 250MG BASE	N021468 001	Oct 26, 2004	Feb	CAHN
		EQ 500MG BASE	N021468 002	Oct 26, 2004	Feb	CAHN
		EQ 750MG BASE	N021468 003	Nov 23, 2005	Feb	CAHN
+		EQ 1GM BASE	N021468 004	Nov 23, 2005	Feb	CAHN

LATANOPROST

SOLUTION/DROPS; OPHTHALMIC

LATANOPROST

AT	AKORN	0.005%	A090887 001	Jul 19, 2011	Sep	CAHN
----	-------	--------	-------------	--------------	-----	------

LENALIDOMIDE

CAPSULE; ORAL

REVLIMID

CELGENE

15MG

N021880 003	Jun 29, 2006	Sep	CRLD
-------------	--------------	-----	------

LETROZOLE

TABLET; ORAL

LETROZOLE

AB	APOTEX INC	2.5MG
----	------------	-------

A091303 001	Apr 19, 2012	Apr	NEWA
-------------	--------------	-----	------

AB	VINTAGE PHARMS LLC	2.5MG
----	--------------------	-------

A090789 001	Jun 03, 2011	Sep	CAHN
-------------	--------------	-----	------

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

@ TEVA PARENTERAL

EQ 50MG BASE/VIAL

A081278 001	Sep 28, 1993	Mar	DISC
-------------	--------------	-----	------

LEUCOVORIN CALCIUM PRESERVATIVE FREE

AP	SAGENT PHARMS	EQ 50MG BASE/VIAL
----	---------------	-------------------

A200753 001	Sep 06, 2012	Aug	NEWA
-------------	--------------	-----	------

AP		EQ 100MG BASE/VIAL
----	--	--------------------

A200753 002	Sep 06, 2012	Aug	NEWA
-------------	--------------	-----	------

AP		EQ 200MG BASE/VIAL
----	--	--------------------

A200753 003	Sep 06, 2012	Aug	NEWA
-------------	--------------	-----	------

AP		EQ 350MG BASE/VIAL
----	--	--------------------

A200855 001	Sep 06, 2012	Aug	NEWA
-------------	--------------	-----	------

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LUPRON DEPOT

+ ABBOTT ENDOCRINE 3.75MG/VIAL

N020011 001	Oct 22, 1990	May	CAHN
-------------	--------------	-----	------

+ 7.5MG/VIAL

N019732 001	Jan 26, 1989	May	CAHN
-------------	--------------	-----	------

+ 11.25MG/VIAL

N020708 001	Mar 07, 1997	May	CAHN
-------------	--------------	-----	------

LEVETIRACETAM

INJECTABLE; IV (INFUSION)

LEVETIRACETAM

AP	APP PHARMS LLC	500MG/5ML (100MG/ML)
----	----------------	----------------------

A090813 001	May 26, 2010	May	CAHN
-------------	--------------	-----	------

AP	HOSPIRA INC	500MG/ML (100MG/ML)
----	-------------	---------------------

A202869 001	Apr 06, 2012	Mar	NEWA
-------------	--------------	-----	------

AP	LUITPOLD	500MG/5ML (100MG/ML)
----	----------	----------------------

A202143 001	Jan 31, 2012	Aug	CAHN
-------------	--------------	-----	------

AP	PHARMAFORCE	500MG/5ML (100MG/ML)
----	-------------	----------------------

A202143 001	Jan 31, 2012	Jan	NEWA
-------------	--------------	-----	------

AP	X GEN PHARMS	500MG/5ML (100MG/ML)
----	--------------	----------------------

A091485 001	Aug 05, 2011	Jul	CAHN
-------------	--------------	-----	------

SOLUTION; ORAL

LEVETIRACETAM

AA	HI-TECH PHARMACAL	100MG/ML
----	-------------------	----------

A090601 001	Feb 28, 2012	Feb	NEWA
-------------	--------------	-----	------

AA	VINTAGE PHARMS	100MG/ML
----	----------------	----------

A090079 001	Apr 11, 2012	Mar	NEWA
-------------	--------------	-----	------

TABLET; ORAL

LEVETIRACETAM

AB	LOTUS PHARM CO LTD	500MG
----	--------------------	-------

A090906 001	Nov 05, 2010	Jul	CAHN
-------------	--------------	-----	------

AB	WATSON LABS INC	250MG
----	-----------------	-------

A078797 002	Jan 15, 2009	Apr	NEWA
-------------	--------------	-----	------

AB		500MG
----	--	-------

A078797 003	Jan 15, 2009	Apr	NEWA
-------------	--------------	-----	------

AB		750MG
----	--	-------

A078797 004	Jan 15, 2009	Apr	NEWA
-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

AB	BOCA PHARMA	500MG
----	-------------	-------

A201464 001	May 25, 2012	May	NEWA
-------------	--------------	-----	------

AB		750MG
----	--	-------

A201464 002	May 25, 2012	May	NEWA
-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

LEVETIRACETAM

AB	ROUSES POINT PHARMS	500MG	A202524 001	Aug 27, 2012	Aug	NEWA
AB		750MG	A202524 002	Aug 27, 2012	Aug	NEWA
>A>	SANDOZ	500MG	A091668 001	Nov 01, 2012	Oct	NEWA
>A>		750MG	A091668 002	Nov 01, 2012	Oct	NEWA
AB	TORRENT PHARMS LTD	500MG	A091338 001	May 29, 2012	May	NEWA
AB		750MG	A091338 002	May 29, 2012	May	NEWA

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET; ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB	HETERO LABS LTD III	5MG	A091264 001	Jun 29, 2012	Jun	NEWA
----	---------------------	-----	-------------	--------------	-----	------

LEVOFLOXACIN

TABLET; ORAL

LEVOFLOXACIN

AB	CIPLA LTD	250MG	A076890 001	Mar 30, 2012	Mar	NEWA
AB		500MG	A076890 002	Mar 30, 2012	Mar	NEWA
AB		750MG	A076890 003	Mar 30, 2012	Mar	NEWA
AB	MACLEODS PHARMS LTD	250MG	A200839 001	Mar 22, 2012	Mar	NEWA
AB		500MG	A200839 002	Mar 22, 2012	Mar	NEWA
AB		750MG	A200839 003	Mar 22, 2012	Mar	NEWA
AB	ORCHID HLTHCARE	250MG	A202200 001	Jan 30, 2012	Jan	NEWA
AB		500MG	A202200 002	Jan 30, 2012	Jan	NEWA
AB		750MG	A202200 003	Jan 30, 2012	Jan	NEWA
AB	ZYDUS PHARMS USA INC	250MG	A077652 001	Sep 07, 2012	Aug	NEWA
AB		500MG	A077652 002	Sep 07, 2012	Aug	NEWA
AB		750MG	A077652 003	Sep 07, 2012	Aug	NEWA

LEVOLEUCOVORIN CALCIUM

SOLUTION; IV (INFUSION)

FUSILEV

@ SPECTRUM PHARMS EQ 250MG BASE/25ML (EQ 10MG BASE/ML)

N020140 003 Apr 29, 2011 Jun DISC

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

AB	WATSON LABS INC	1.5MG	A200670 001	Jul 12, 2012	Jun	NEWA
	PLAN B					
AB	+ TEVA BRANDED PHARM	0.75MG	N021045 002	Aug 24, 2006	May	CAHN
	@	0.75MG	N021045 001	Jul 28, 1999	May	CAHN
	PLAN B ONE-STEP					
AB	+ DURAMED	1.5MG	N021998 001	Jul 10, 2009	Jun	CFTG

LIDOCAINE

PATCH; TOPICAL

LIDOCAINE

AB	WATSON LABS INC	5%	A200675 001	Aug 23, 2012	Aug	NEWA
	LIDODERM					
AB	+ TEIKOKU PHARMA USA	5%	N020612 001	Mar 19, 1999	Aug	CFTG

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HYDROCHLORIDE

	@ HIKMA MAPLE	1%	A080407 001		Sep	CAHN
	@	2%	A080407 002		Sep	CAHN
AP	PFIZER	0.5%	A091056 001	Dec 08, 2010	Sep	CAHN
AP		0.5%	A091058 001	Sep 30, 2010	Sep	CAHN
AP		1%	A091056 002	Dec 08, 2010	Sep	CAHN
AP		1%	A091058 002	Sep 30, 2010	Sep	CAHN
	LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE					
	@ HIKMA MAPLE	1%	A084625 001		Sep	CAHN
	@	2%	A084625 002		Sep	CAHN
AP	PFIZER	2%	A090665 001	Sep 27, 2010	Sep	CAHN
	XYLOCAINE DENTAL					
	@ DENTSPLY PHARM	2%	N021380 001		May	DISC

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL

LIDOCAINE AND PRILOCAINE

AB	FOUGERA PHARMS	2.5%;2.5%	A076453 001	Aug 18, 2003	Jan	CAHN
----	----------------	-----------	-------------	--------------	-----	------

LIDOCAINE; TETRACAINE

CREAM; TOPICAL

PLIAGLIS

+	GALDERMA LABS LP	7%;7%	N021717 001	Jun 29, 2006	Jun	CTNA
---	------------------	-------	-------------	--------------	-----	------

LINACLOTIDE

CAPSULE; ORAL

LINZESS

	FOREST LABS INC	145MCG	N202811 001	Aug 30, 2012	Aug	NEWA
+		290MCG	N202811 002	Aug 30, 2012	Aug	NEWA

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

TABLET; ORAL

JENTADUETO

	BOEHRINGER INGELHEIM	2.5MG;500MG	N201281 001	Jan 30, 2012	Jan	NEWA
		2.5MG;850MG	N201281 002	Jan 30, 2012	Jan	NEWA
+		2.5MG;1GM	N201281 003	Jan 30, 2012	Jan	NEWA

LINEZOLID

INJECTABLE; INJECTION

LINEZOLID

AP	TEVA PHARMS	200MG/100ML	A200222 001	Jun 22, 2012	Jun	NEWA
AP	ZYVOX					
+	PHARMACIA AND UPJOHN	200MG/100ML	N021131 001	Apr 18, 2000	Jun	CFTG

LITHIUM CARBONATE

TABLET, EXTENDED RELEASE; ORAL

LITHIUM CARBONATE

AB	MYLAN PHARMS INC	300MG	A202288 001	Jun 29, 2012	Jun	NEWA
AB		450MG	A202219 001	Aug 08, 2012	Jul	NEWA

LUCINACTANT

SUSPENSION; INTRATRACHEAL
SURFAXIN

+ DISCOVERY LABS 8.5ML N021746 001 Mar 06, 2012 Apr NEWA

LURASIDONE HYDROCHLORIDE

TABLET; ORAL
LATUDA

>D>	+	SUNOVION PHARMS INC	20MG	N200603 003	Dec 07, 2011	Oct	CRLD
>A>			20MG	N200603 003	Dec 07, 2011	Oct	CRLD
	+		20MG	N200603 003	Dec 07, 2011	Aug	CRLD
			20MG	N200603 003	Dec 07, 2011	Apr	NEWA
>D>			40MG	N200603 001	Oct 28, 2010	Oct	CRLD
>A>	+		40MG	N200603 001	Oct 28, 2010	Oct	CRLD
			40MG	N200603 001	Oct 28, 2010	Aug	CRLD
	+		40MG	N200603 001	Oct 28, 2010	Apr	CRLD
			80MG	N200603 002	Oct 28, 2010	Apr	CRLD
			120MG	N200603 004	Apr 26, 2012	Apr	NEWA

LUTROPIN ALFA

INJECTABLE; SUBCUTANEOUS
LUVERIS

@ EMD SERONO 75 IU/VIAL N021322 001 Oct 08, 2004 Jun DISC

MAFENIDE ACETATE

CREAM; TOPICAL
SULFAMYLON

+ MYLAN LLC EQ 85MG BASE/GM N016763 001 Jun CAHN

FOR SOLUTION; TOPICAL
SULFAMYLON

+ MYLAN LLC 5% N019832 003 Jun 05, 1998 Jun CAHN

MAGNESIUM HYDROXIDE; OMEPRAZOLE; SODIUM BICARBONATE

TABLET; ORAL

MAGNESIUM HYDROXIDE AND OMEPRAZOLE AND SODIUM BICARBONATE

@ SANTARUS 343MG;20MG;750MG N022456 001 Dec 04, 2009 Jun DISC

@ 343MG;40MG;750MG N022456 002 Dec 04, 2009 Jun DISC

MAGNESIUM SULFATE

INJECTABLE; INJECTION

MAGNESIUM SULFATE IN PLASTIC CONTAINER

HOSPIRA 20GM/500ML (40MG/ML) N020309 004 Jan 18, 1995 Jan NEWA

40GM/1000ML (40MG/ML) N020309 005 Jan 18, 1995 Jan NEWA

MALATHION

LOTION; TOPICAL

MALATHION

AT MYLAN PHARMS INC 0.5% A078743 001 Mar 06, 2009 Feb CAHN

AT SUVEN LIFE 0.5% A091559 001 May 23, 2012 May NEWA

MANNITOL

POWDER; INHALATION

ARIDOL KIT

+ PHARMAXIS LTD N/A, 5MG, 10MG, 20MG, 40MG N022368 001 Oct 05, 2010 May CAHN

MECASERMIN RECOMBINANT

INJECTABLE; SUBCUTANEOUS
INCRELEX

+ IPSEN INC 40MG/4ML (10MG/ML) N021839 001 Aug 30, 2005 May CAHN

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HYDROCHLORIDE

AA	EPIC PHARMA LLC	12.5MG	A200294 001	Apr 13, 2012	Mar	NEWA
AA		25MG	A200294 002	Apr 13, 2012	Mar	NEWA
AA	MYLAN PHARMS INC	12.5MG	A202640 001	Sep 17, 2012	Sep	NEWA
AA		25MG	A202640 002	Sep 17, 2012	Sep	NEWA
AA		50MG	A202640 003	Sep 17, 2012	Sep	NEWA

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

MEDROXYPROGESTERONE ACETATE

@ TEVA PARENTERAL 150MG/ML

A076552 001 Oct 27, 2004 Apr DISC

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

MELPHALAN HYDROCHLORIDE

AP MYLAN INSTITUTIONAL EQ 50MG BASE/VIAL A090270 001 Jun 09, 2009 Sep CAHN

MEMANTINE HYDROCHLORIDE

TABLET; ORAL

MEMANTINE HYDROCHLORIDE

@ ORCHID HLTHCARE 5MG

A090044 001 Mar 12, 2012 Mar DISC

AB 5MG A090044 001 Mar 12, 2012 Feb NEWA

@ 10MG

A090044 002 Mar 12, 2012 Mar DISC

AB 10MG A090044 002 Mar 12, 2012 Feb NEWA

NAMENDA

FOREST LABS 5MG

N021487 001 Oct 16, 2003 Mar CTEC

AB 5MG N021487 001 Oct 16, 2003 Feb CTEC

+ 10MG

N021487 002 Oct 16, 2003 Mar CTEC

AB + 10MG N021487 002 Oct 16, 2003 Feb CTEC

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HYDROCHLORIDE

AP HIKMA MAPLE 25MG/ML A080455 007 Sep CAHN

AP 25MG/ML A080445 001 Sep CAHN

AP 50MG/ML A080445 002 Sep CAHN

AP 50MG/ML A080455 008 Sep CAHN

AP 75MG/ML A080455 009 Sep CAHN

AP 75MG/ML A080445 003 Sep CAHN

AP 100MG/ML A080445 004 Sep CAHN

AP 100MG/ML A080455 010 Sep CAHN

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

AP HIKMA MAPLE 10MG/ML A081002 001 Jul 30, 1993 Sep CAHN

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

POLOCAINE

@ DENTSPLY PHARM 3%

A088653 001 Aug 21, 1984 May DISC

MEQUINOL; TRETINOIN

SOLUTION; TOPICAL

SOLAGE

@ AQUA PHARMS 2%;0.01%

N020922 001 Dec 10, 1999 Jun DISC

MESALAMINE

SUPPOSITORY; RECTAL

CANASA

@ APTALIS PHARMA US 500MG
1GM

N021252 001 Jan 05, 2001 Jul CAHN

N021252 002 Nov 05, 2004 Jul CAHN

ROWASA

@ MEDA PHARMS 500MG

N019919 001 Dec 18, 1990 Jan CAHN

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP MYLAN INSTITUTIONAL 100MG/ML

>A> AP SAGENT AGILA 100MG/ML

>D> AP SAGENT STRIDES 100MG/ML

A076488 001 Mar 08, 2012 Feb NEWA

A090913 001 Apr 13, 2010 Oct CAHN

A090913 001 Apr 13, 2010 Oct CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB MARKSANS PHARMA 500MG

AB 850MG

AB 1GM

AB MYLAN PHARMS INC 500MG

AB 850MG

AB 1GM

A090888 001 Mar 12, 2012 Feb NEWA

A090888 002 Mar 12, 2012 Feb NEWA

A090888 003 Mar 12, 2012 Feb NEWA

A075969 001 Jan 29, 2002 Sep CAHN

A075969 002 Jan 29, 2002 Sep CAHN

A075969 003 Jan 29, 2002 Sep CAHN

TABLET, EXTENDED RELEASE; ORAL

METFORMIN HYDROCHLORIDE

AB1 AUROBINDO PHARMA LTD 500MG

AB 750MG

AB1 INVENTIA HLTHCARE 500MG

AB2 MYLAN PHARMS INC 500MG

AB 1GM

>D> AB1 NOSTRUM 500MG

>A> AB1 NOSTRUM PHARMS LLC 500MG

@ RANBAXY LABS LTD 500MG

@ 750MG

A079118 001 Jul 20, 2012 Jul NEWA

A079118 002 Jul 20, 2012 Jul NEWA

A201991 001 Jan 18, 2012 Jan NEWA

A200690 001 Aug 01, 2012 Jul NEWA

A200690 002 Aug 01, 2012 Jul NEWA

A076756 001 Jul 26, 2006 Oct CAHN

A076756 001 Jul 26, 2006 Oct CAHN

A076413 001 Jun 18, 2004 Apr DISC

A077211 001 Jun 29, 2005 Apr DISC

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOPLUS MET

AB TAKEDA PHARMS USA 500MG;EQ 15MG BASE

AB + 850MG;EQ 15MG BASE

N021842 001 Aug 29, 2005 Aug CAHN

N021842 002 Aug 29, 2005 Aug CAHN

TABLET, EXTENDED RELEASE; ORAL

ACTOPLUS MET XR

TAKEDA PHARMS USA 1GM;EQ 15MG BASE

+ 1GM;EQ 30MG BASE

N022024 001 May 12, 2009 Aug CAHN

N022024 002 May 12, 2009 Aug CAHN

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KOMBIGLYZE XR

BRISTOL MYERS SQUIBB 500MG;EQ 5MG BASE

N200678 001 Nov 05, 2010 Apr CAIN

TABLET, EXTENDED RELEASE; ORAL

KOMBIGLYZE XR

	BRISTOL MYERS SQUIBB	1GM;EQ 2.5MG BASE	N200678 003	Nov 05, 2010	Apr	CAIN
+		1GM;EQ 5MG BASE	N200678 002	Nov 05, 2010	Apr	CAIN

METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUMET

	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N022044 001	Mar 30, 2007	May	CAHN
+		1GM;EQ 50MG BASE	N022044 002	Mar 30, 2007	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

JANUMET XR

	MERCK SHARP DOHME	500MG;EQ 50MG BASE	N202270 001	Feb 02, 2012	Feb	NEWA
		1GM;EQ 50MG BASE	N202270 002	Feb 02, 2012	Feb	NEWA
+		1GM;EQ 100MG BASE	N202270 003	Feb 02, 2012	Feb	NEWA

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB	BOCA PHARMA	5MG	A202068 001	Mar 07, 2012	Feb	NEWA
AB		10MG	A202068 002	Mar 07, 2012	Feb	NEWA

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL

AA	SOLCO HLTHCARE	500MG	A086989 001		Mar	CMFD
AA		750MG	A086988 001		Mar	CMFD

METHOTREXATE SODIUM

INJECTABLE; INJECTION

METHOTREXATE PRESERVATIVE FREE

AP	APP PHARMS LLC	EQ 1GM BASE/VIAL	A040266 001	Feb 26, 1999	Jan	CMFD
AP	PHARMACHEMIE BV	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A200171 001	Feb 27, 2012	Feb	NEWA

METHOTREXATE SODIUM

AP	+	BEDFORD	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341 001	Sep 16, 1986	Feb	CTEC
----	---	---------	-------------------------------------	-------------	--------------	-----	------

METHOTREXATE SODIUM PRESERVATIVE FREE

AP	+	MYLAN INSTITUTIONAL	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A040767 001	Apr 30, 2007	Feb	CAHN
AP	+		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A040768 001	Apr 30, 2007	Sep	CAHN
AP	+		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A040716 001	Apr 30, 2007	Sep	CAHN
AP		ONCO THERAPIES LTD	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A201529 001	Mar 29, 2012	Mar	NEWA
AP			EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A201529 002	Mar 29, 2012	Mar	NEWA
AP			EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A201529 003	Mar 29, 2012	Mar	NEWA
AP			EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529 004	Mar 29, 2012	Mar	NEWA
AP			EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530 001	Mar 29, 2012	Mar	NEWA

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

AA	BAYSHORE PHARMS LLC	2.5MG	A200602 001	Sep 24, 2012	Sep	NEWA
AA		5MG	A200602 002	Sep 24, 2012	Sep	NEWA

METHYLCLOTHIAZIDE

TABLET; ORAL

ENDURON

@ ABBOTT LABS PHARM 2.5MG

N012524 001

Mar DISC

@ 5MG

N012524 004

Mar DISC

METHYLCLOTHIAZIDE

AB + MYLAN PHARMS INC 5MG

A087672 001 Aug 17, 1982 Mar CRLD

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION

METHYLDOPATE HYDROCHLORIDE

@ TEVA PARENTERAL 50MG/ML

A072974 001 Nov 22, 1991 Mar DISC

METHYLERGONOVINE MALEATE

INJECTABLE; INJECTION

METHERGINE

AP + US PHARMS HOLDINGS I 0.2MG/ML

N006035 004

Sep CAHN

TABLET; ORAL

METHERGINE

AB + US PHARMS HOLDINGS I 0.2MG

N006035 003

Sep CAHN

METHYLNALTREXONE BROMIDE

INJECTABLE; SUBCUTANEOUS

RELISTOR

SALIX PHARMS 8MG/0.4ML

N021964 002 Sep 27, 2010 May CAHN

+ 12MG/0.6ML (12MG/0.6ML)

N021964 003 Apr 24, 2008 Jun NEWA

SOLUTION; SUBCUTANEOUS

RELISTOR

+ SALIX PHARMS 12MG/0.6ML (12MG/0.6ML)

N021964 001 Apr 24, 2008 May CAHN

METHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

METADATE CD

AB UCB INC 10MG

N021259 003 May 27, 2003 Jul CFTG

AB2 20MG

N021259 001 Apr 03, 2001 Jul CFTG

AB2 30MG

N021259 002 Jun 19, 2003 Jul CFTG

AB2 40MG

N021259 004 Feb 19, 2006 Jul CFTG

AB 50MG

N021259 005 Feb 19, 2006 Jul CFTG

AB + 60MG

N021259 006 Feb 19, 2006 Jul CFTG

METHYLPHENIDATE HYDROCHLORIDE

AB1 ACTAVIS 20MG

A078458 001 Dec 01, 2011 Jul CTEC

AB1 30MG

A078458 002 Dec 01, 2011 Jul CTEC

AB1 40MG

A078458 003 Dec 01, 2011 Jul CTEC

AB1 BARR LABS INC 20MG

A079031 001 Jul 13, 2012 Jul CTEC

AB 20MG

A079031 001 Jul 13, 2012 Jun NEWA

AB1 30MG

A079031 002 Jul 13, 2012 Jul CTEC

AB 30MG

A079031 002 Jul 13, 2012 Jun NEWA

AB1 40MG

A079031 003 Jul 13, 2012 Jul CTEC

AB 40MG

A079031 003 Jul 13, 2012 Jun NEWA

AB TEVA PHARMS 10MG

A077707 001 Jul 19, 2012 Jul NEWA

AB2 20MG

A077707 002 Jul 19, 2012 Jul NEWA

AB2 30MG

A077707 003 Jul 19, 2012 Jul NEWA

AB2 40MG

A078873 001 Jul 19, 2012 Jul NEWA

AB 50MG

A078873 002 Jul 19, 2012 Jul NEWA

AB 60MG

A078873 003 Jul 19, 2012 Jul NEWA

CAPSULE, EXTENDED RELEASE; ORAL

RITALIN LA

AB1	NOVARTIS	20MG	N021284 001	Jun 05, 2002	Jul	CTEC
AB1		30MG	N021284 002	Jun 05, 2002	Jul	CTEC
AB1	+	40MG	N021284 003	Jun 05, 2002	Jul	CTEC

FOR SUSPENSION, EXTENDED RELEASE; ORAL

QUILLIVANT XR

+	NEXTWAVE PHARMS	5MG/ML	N202100 001	Sep 27, 2012	Sep	NEWA
---	-----------------	--------	-------------	--------------	-----	------

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	SUN PHARM INDS INC	5MG	A090710 001	Mar 15, 2012	Feb	NEWA
AB		10MG	A090710 002	Mar 15, 2012	Feb	NEWA
AB		20MG	A090710 003	Mar 15, 2012	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL

METADATE ER

@	UCB INC	10MG	A040306 001	Oct 20, 1999	Jul	DISC
---	---------	------	-------------	--------------	-----	------

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

A-METHAPRED

AP	HOSPIRA INC	EQ 40MG BASE/VIAL	A040793 001	Nov 25, 2008	Aug	CAHN
AP		EQ 125MG BASE/VIAL	A040827 001	Nov 25, 2008	Aug	CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

@	BEDFORD LABS	EQ 40MG BASE/VIAL	A040662 001	Feb 21, 2007	Jun	DISC
@		EQ 125MG BASE/VIAL	A040641 002	Feb 21, 2007	Jun	DISC
@		EQ 500MG BASE/VIAL	A040641 003	Feb 21, 2007	Jun	DISC
@		EQ 500MG BASE/VIAL	A040709 001	Feb 21, 2007	Jun	DISC
@		EQ 1GM BASE/VIAL	A040709 002	Feb 21, 2007	Jun	DISC
@		EQ 1GM BASE/VIAL	A040641 004	Feb 21, 2007	Jun	DISC
@	TEVA PARENTERAL	EQ 125MG BASE/VIAL	A081266 001	Nov 30, 1992	Mar	DISC

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HYDROCHLORIDE

@	TEVA PARENTERAL	EQ 5MG BASE/ML	A073135 001	Nov 27, 1991	Jan	DISC
---	-----------------	----------------	-------------	--------------	-----	------

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

>D>	AB	ACTAVIS ELIZABETH	EQ 10MG BASE	A070581 001	Oct 17, 1985	Oct	CAHN
>A>	AB	PAR PHARM INC	EQ 10MG BASE	A070581 001	Oct 17, 1985	Oct	CAHN

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

AB	DR REDDYS LABS LTD	EQ 25MG TARTRATE	A090617 001	Aug 01, 2012	Jul	NEWA
AB		EQ 50MG TARTRATE	A090617 002	Aug 01, 2012	Jul	NEWA
	@ NESHER PHARMS	EQ 100MG TARTRATE	A076640 002	May 18, 2007	Jun	DISC
	@	EQ 200MG TARTRATE	A076640 001	May 18, 2007	Jun	DISC
AB	REDDYS	EQ 100MG BASE	A078889 001	Aug 15, 2012	Jul	NEWA
AB		EQ 200MG BASE	A078889 002	Aug 15, 2012	Jul	NEWA
	@ SANDOZ	EQ 25MG TARTRATE	A076969 001	Jul 31, 2006	Aug	DISC
	@	EQ 50MG TARTRATE	A076969 002	May 18, 2007	Aug	DISC
	@	EQ 100MG TARTRATE	A076969 003	Mar 20, 2008	Aug	DISC
	@	EQ 200MG TARTRATE	A076969 004	Mar 20, 2008	Aug	DISC

METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR

AB	US PHARMS HOLDINGS I	50MG	N017963 001	Sep	CAHN
AB		100MG	N017963 002	Sep	CAHN

METRONIDAZOLE

CREAM; TOPICAL

METRONIDAZOLE

AB	FOUGERA PHARMS	0.75%	A076408 001	May 28, 2004	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

NORITATE

+	VALEANT INTL	1%	N020743 001	Sep 26, 1997	Apr	CAHN
---	--------------	----	-------------	--------------	-----	------

GEL; TOPICAL

METRONIDAZOLE

AB	FOUGERA PHARMS	0.75%	A077018 001	Jun 06, 2006	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

INJECTABLE; INJECTION

METRONIDAZOLE

@ HIKMA MAPLE 500MG/100ML

N018907 001	Mar 30, 1984	Sep	CAHN
-------------	--------------	-----	------

LOTION; TOPICAL

METRONIDAZOLE

AB	FOUGERA PHARMS	0.75%	A077197 001	May 24, 2006	Jan	CAHN
----	----------------	-------	-------------	--------------	-----	------

METYRAPONE

CAPSULE; ORAL

METOPIRONE

+	HRA PHARMA	250MG	N012911 002	Aug 09, 1996	Jun	CAHN
---	------------	-------	-------------	--------------	-----	------

TABLET; ORAL

METOPIRONE

@ HRA PHARMA 250MG

N012911 001		Jun	CAHN
-------------	--	-----	------

METYROSINE

CAPSULE; ORAL

DEMSEER

+	BIOVAIL TECHNOLOGIES	250MG	N017871 001		May	CAHN
---	----------------------	-------	-------------	--	-----	------

MICONAZOLE

TABLET; BUCCAL

ORAVIG

>D>	+	BIOALLIANCE PHARMA	50MG	N022404 001	Apr 16, 2010	Sep	CAHN
-----	---	--------------------	------	-------------	--------------	-----	------

>A>	+	VESTIQ PHARMS	50MG	N022404 001	Apr 16, 2010	Sep	CAHN
-----	---	---------------	------	-------------	--------------	-----	------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

AP	GLAND PHARMA LTD	EQ 1MG BASE/ML	A090696 001	Feb 29, 2012	Feb	NEWA
AP		EQ 5MG BASE/ML	A090850 001	Jan 25, 2012	Jan	NEWA
AP	HIKMA MAPLE	EQ 1MG BASE/ML	A075324 001	Jun 20, 2000	Sep	CAHN
AP		EQ 1MG BASE/ML	A075243 001	Jun 20, 2000	Sep	CAHN
AP		EQ 5MG BASE/ML	A075243 002	Jun 20, 2000	Sep	CAHN
AP		EQ 5MG BASE/ML	A075324 002	Jun 20, 2000	Sep	CAHN

MIDODRINE HYDROCHLORIDE

TABLET; ORAL

PROAMATINE

AB	SHIRE LLC	2.5MG	N019815 001	Sep 06, 1996	Jan	CAHN
----	-----------	-------	-------------	--------------	-----	------

TABLET; ORAL									
PROAMATINE									
AB	+ SHIRE LLC	5MG	N019815	002	Sep 06, 1996	Jan	CAHN		
AB		10MG	N019815	003	Mar 20, 2002	Jan	CAHN		
<u>MIFEPRISTONE</u>									
TABLET; ORAL									
KORLYM									
	+ CORCEPT THERAP	300MG	N202107	001	Feb 17, 2012	Feb	NEWA		
<u>MILRINONE LACTATE</u>									
INJECTABLE; INJECTION									
MILRINONE LACTATE									
AP	@ HIKMA MAPLE	EQ 1MG BASE/ML	A075852	001	May 28, 2002	Sep	CAHN		
		EQ 1MG BASE/ML	A075530	001	May 28, 2002	Sep	CAHN		
	MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER								
	@ HIKMA MAPLE	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A075510	001	May 28, 2002	Sep	CAHN		
<u>MINOCYCLINE HYDROCHLORIDE</u>									
CAPSULE; ORAL									
MINOCIN									
AB	PRECISION DERMAT	EQ 50MG BASE	N050649	001	May 31, 1990	May	CAHN		
	@	EQ 75MG BASE	N050649	003	Feb 12, 2001	May	CAHN		
AB		EQ 100MG BASE	N050649	002	May 31, 1990	May	CAHN		
CAPSULE, EXTENDED RELEASE; ORAL									
XIMINO									
	RANBAXY LABS LTD	EQ 45MG BASE	N201922	001	Jul 11, 2012	Jul	NEWA		
		EQ 67.5MG BASE	N201922	002	Jul 11, 2012	Jul	NEWA		
		EQ 90MG BASE	N201922	003	Jul 11, 2012	Jul	NEWA		
		EQ 112.5MG BASE	N201922	004	Jul 11, 2012	Jul	NEWA		
	+	EQ 135MG BASE	N201922	005	Jul 11, 2012	Jul	NEWA		
INJECTABLE; INJECTION									
MINOCIN									
	+ PRECISION DERMAT	EQ 100MG BASE/VIAL	N050444	001		May	CAHN		
SUSPENSION; ORAL									
MINOCIN									
	@ PRECISION DERMAT	EQ 50MG BASE/5ML	N050445	001		May	CAHN		
TABLET, EXTENDED RELEASE; ORAL									
MINOCYCLINE HYDROCHLORIDE									
AB	BARR LABS INC	EQ 65MG BASE	A065485	004	May 18, 2012	Sep	NEWA		
AB		EQ 115MG BASE	A065485	005	May 18, 2012	Sep	NEWA		
AB	MYLAN PHARMS INC	EQ 45MG BASE	A090911	001	Jul 20, 2010	Sep	CAHN		
AB		EQ 90MG BASE	A090911	002	Jul 20, 2010	Sep	CAHN		
AB		EQ 135MG BASE	A090911	003	Jul 20, 2010	Sep	CAHN		
SOLODYN									
AB	MEDICIS	EQ 65MG BASE	N050808	004	Jul 23, 2009	Sep	CFTG		
AB		EQ 115MG BASE	N050808	005	Jul 23, 2009	Sep	CFTG		
<u>MIRABEGRON</u>									
TABLET, EXTENDED RELEASE; ORAL									
MYRBETRIQ									
	APGDI	25MG	N202611	001	Jun 28, 2012	Jun	NEWA		
	+	50MG	N202611	002	Jun 28, 2012	Jun	NEWA		

MIRTAZAPINE

TABLET; ORAL

MIRTAZAPINE

AB	MYLAN PHARMS INC	15MG	A076176 001	Jun 19, 2003	Sep	CAHN
AB		30MG	A076176 002	Jun 19, 2003	Sep	CAHN
AB		45MG	A076176 003	Jun 19, 2003	Sep	CAHN

MISOPROSTOL

TABLET; ORAL

MISOPROSTOL

AB	NOVEL LABS INC	0.1MG	A091667 001	Jul 25, 2012	Jul	NEWA
AB		0.2MG	A091667 002	Jul 25, 2012	Jul	NEWA

MITOMYCIN

FOR SOLUTION; TOPICAL

MITOSOL

+ MOBIUS THERAP 0.2MG/VIAL

N022572 001 Feb 07, 2012 Feb NEWA

INJECTABLE; INJECTION

MITOMYCIN

AP	HIKMA MAPLE	5MG/VIAL	A064180 001	Dec 23, 1999	Sep	CAHN
AP		20MG/VIAL	A064180 002	Dec 23, 1999	Sep	CAHN

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

MITOXANTRONE HYDROCHLORIDE

@	FRESENIUS KABI ONCOL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A078606 001	May 14, 2008	Jun	DISC
---	----------------------	------------------------------------	-------------	--------------	-----	------

@		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A078606 002	May 14, 2008	Jun	DISC
---	--	--------------------------------------	-------------	--------------	-----	------

@		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A078606 003	May 14, 2008	Jun	DISC
---	--	------------------------------------	-------------	--------------	-----	------

MIVACURIUM CHLORIDE

INJECTABLE; INJECTION

MIVACURIUM CHLORIDE

@	STRIDES ARCOLAB LTD	EQ 2MG BASE/ML	A078562 001	Apr 30, 2009	Jun	CAHN
---	---------------------	----------------	-------------	--------------	-----	------

MODAFINIL

TABLET; ORAL

MODAFINIL

>A>	AB	ALEMBIC LTD	100MG	A202700 001	Oct 18, 2012	Oct	NEWA
>A>	AB		200MG	A202700 002	Oct 18, 2012	Oct	NEWA
	AB	AUROBINDO PHARMA LTD	100MG	A202566 001	Sep 27, 2012	Sep	NEWA
	AB		200MG	A202566 002	Sep 27, 2012	Sep	NEWA
>A>	AB	CARLSBAD	100MG	A076715 001	Nov 01, 2012	Oct	NEWA
>A>	AB		200MG	A076715 002	Nov 01, 2012	Oct	NEWA
	AB	HIKMA PHARMS	100MG	A090543 001	Sep 26, 2012	Sep	NEWA
	AB		200MG	A090543 002	Sep 26, 2012	Sep	NEWA
	AB	MYLAN PHARMS INC	100MG	A076594 001	Jul 16, 2012	Jun	NEWA
	AB		200MG	A076594 002	Jul 16, 2012	Jun	NEWA
	AB	ORCHID HLTHCARE	100MG	A078963 001	Sep 26, 2012	Sep	NEWA
	AB		200MG	A078963 002	Sep 26, 2012	Sep	NEWA

PROVIGIL

AB	CEPHALON	100MG	N020717 001	Dec 24, 1998	Jun	CFTG
AB	+	200MG	N020717 002	Dec 24, 1998	Jun	CFTG

MOMETASONE FUROATE

CREAM; TOPICAL

ELOCON

AB	+	MERCK SHARP DOHME	0.1%	N019625 001	May 06, 1987	Jun	CAHN
----	---	-------------------	------	-------------	--------------	-----	------

MOMETASONE FUROATE

AB		FOUGERA PHARMS	0.1%	A076171 001	Apr 08, 2005	Jan	CAHN
----	--	----------------	------	-------------	--------------	-----	------

LOTION; TOPICAL

ELOCON

AB	+	MERCK SHARP DOHME	0.1%	N019796 001	Mar 30, 1989	Jul	CAHN
----	---	-------------------	------	-------------	--------------	-----	------

MOMETASONE FUROATE

AB		FOUGERA PHARMS	0.1%	A075919 001	Nov 29, 2007	Jan	CAHN
----	--	----------------	------	-------------	--------------	-----	------

OINTMENT; TOPICAL

ELOCON

AB	+	MERCK SHARP DOHME	0.1%	N019543 001	Apr 30, 1987	May	CAHN
----	---	-------------------	------	-------------	--------------	-----	------

MOMETASONE FUROATE

AB		FOUGERA PHARMS	0.1%	A077061 001	Mar 28, 2005	Jan	CAHN
----	--	----------------	------	-------------	--------------	-----	------

MONTELUKAST SODIUM

GRANULE; ORAL

MONTELUKAST SODIUM

AB		DR REDDYS LABS LTD	EQ 4MG BASE/PACKET	A202906 001	Sep 17, 2012	Sep	NEWA
----	--	--------------------	--------------------	-------------	--------------	-----	------

AB		TEVA PHARMS	EQ 4MG BASE/PACKET	A090955 001	Aug 03, 2012	Jul	NEWA
----	--	-------------	--------------------	-------------	--------------	-----	------

SINGULAIR

AB	+	MERCK	EQ 4MG BASE/PACKET	N021409 001	Jul 26, 2002	Jul	CFTG
----	---	-------	--------------------	-------------	--------------	-----	------

TABLET; ORAL

MONTELUKAST SODIUM

AB		ACCORD HLTHCARE	EQ 10MG BASE	A202717 001	Sep 21, 2012	Sep	NEWA
----	--	-----------------	--------------	-------------	--------------	-----	------

AB		APOTEX CORP	EQ 10MG BASE	A201294 001	Aug 03, 2012	Jul	NEWA
----	--	-------------	--------------	-------------	--------------	-----	------

AB		AUROBINDO PHARMA LTD	EQ 10MG BASE	A202468 001	Aug 03, 2012	Jul	NEWA
----	--	----------------------	--------------	-------------	--------------	-----	------

AB		DR REDDYS LABS LTD	EQ 10MG BASE	A201582 001	Aug 06, 2012	Jul	NEWA
----	--	--------------------	--------------	-------------	--------------	-----	------

>D>	AB	ENDO PHARMS	EQ 10MG BASE	A091576 001	Aug 03, 2012	Oct	CAHN
-----	----	-------------	--------------	-------------	--------------	-----	------

AB			EQ 10MG BASE	A091576 001	Aug 03, 2012	Jul	NEWA
----	--	--	--------------	-------------	--------------	-----	------

AB		GLENMARK GENERICS	EQ 10MG BASE	A090926 001	Aug 03, 2012	Jul	NEWA
----	--	-------------------	--------------	-------------	--------------	-----	------

AB		KUDCO IRELAND	EQ 10MG BASE	A201522 001	Aug 03, 2012	Jul	NEWA
----	--	---------------	--------------	-------------	--------------	-----	------

AB		MYLAN PHARMS INC	EQ 10MG BASE	A079103 001	Aug 03, 2012	Jul	NEWA
----	--	------------------	--------------	-------------	--------------	-----	------

AB		ROXANE	EQ 10MG BASE	A090655 001	Aug 03, 2012	Jul	NEWA
----	--	--------	--------------	-------------	--------------	-----	------

AB		SANDOZ INC	EQ 10MG BASE	A200889 001	Aug 03, 2012	Jul	NEWA
----	--	------------	--------------	-------------	--------------	-----	------

AB		TEVA PHARMS	EQ 10MG BASE	A078605 001	Aug 03, 2012	Jul	NEWA
----	--	-------------	--------------	-------------	--------------	-----	------

AB		TORRENT PHARMS LTD	EQ 10MG BASE	A201515 001	Aug 03, 2012	Jul	NEWA
----	--	--------------------	--------------	-------------	--------------	-----	------

>A>	AB	VINTAGE PHARMS LLC	EQ 10MG BASE	A091576 001	Aug 03, 2012	Oct	CAHN
-----	----	--------------------	--------------	-------------	--------------	-----	------

SINGULAIR

AB	+	MERCK	EQ 10MG BASE	N020829 002	Feb 20, 1998	Jul	CFTG
----	---	-------	--------------	-------------	--------------	-----	------

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

AB		APOTEX INC	EQ 4MG BASE	A201508 001	Aug 03, 2012	Jul	NEWA
----	--	------------	-------------	-------------	--------------	-----	------

AB			EQ 5MG BASE	A201508 002	Aug 03, 2012	Jul	NEWA
----	--	--	-------------	-------------	--------------	-----	------

AB		AUROBINDO PHARMA LTD	EQ 4MG BASE	A202096 001	Aug 03, 2012	Jul	NEWA
----	--	----------------------	-------------	-------------	--------------	-----	------

AB			EQ 5MG BASE	A202096 002	Aug 03, 2012	Jul	NEWA
----	--	--	-------------	-------------	--------------	-----	------

AB		DR REDDYS LABS LTD	EQ 4MG BASE	A201581 001	Aug 06, 2012	Jul	NEWA
----	--	--------------------	-------------	-------------	--------------	-----	------

AB			EQ 5MG BASE	A201581 002	Aug 06, 2012	Jul	NEWA
----	--	--	-------------	-------------	--------------	-----	------

>D>	AB	ENDO PHARMS	EQ 4MG BASE	A091588 001	Aug 03, 2012	Oct	CAHN
-----	----	-------------	-------------	-------------	--------------	-----	------

AB			EQ 4MG BASE	A091588 001	Aug 03, 2012	Jul	NEWA
----	--	--	-------------	-------------	--------------	-----	------

>D>	AB		EQ 5MG BASE	A091588 002	Aug 03, 2012	Oct	CAHN
-----	----	--	-------------	-------------	--------------	-----	------

AB			EQ 5MG BASE	A091588 002	Aug 03, 2012	Jul	NEWA
----	--	--	-------------	-------------	--------------	-----	------

AB		KUDCO IRELAND	EQ 4MG BASE	A200405 001	Aug 03, 2012	Jul	NEWA
----	--	---------------	-------------	-------------	--------------	-----	------

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

AB	KUDCO IRELAND	EQ 5MG BASE	A200405 002	Aug 03, 2012	Jul	NEWA
AB	MYLAN PHARMS INC	EQ 4MG BASE	A079142 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A079142 002	Aug 03, 2012	Jul	NEWA
AB	ROXANE	EQ 4MG BASE	A091128 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A091128 002	Aug 03, 2012	Jul	NEWA
AB	SANDOZ INC	EQ 4MG BASE	A091414 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A091414 002	Aug 03, 2012	Jul	NEWA
AB	TEVA PHARMS	EQ 4MG BASE	A078723 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A078723 002	Aug 03, 2012	Jul	NEWA
AB	TORRENT PHARMS LTD	EQ 4MG BASE	A090984 001	Aug 03, 2012	Jul	NEWA
AB		EQ 5MG BASE	A090984 002	Aug 03, 2012	Jul	NEWA
>A>	AB	VINTAGE PHARMS LLC	EQ 4MG BASE	A091588 001	Aug 03, 2012	Oct CAHN
>A>	AB		EQ 5MG BASE	A091588 002	Aug 03, 2012	Oct CAHN
SINGULAIR						
AB	MERCK	EQ 4MG BASE	N020830 002	Mar 03, 2000	Jul	CFTG
AB	+	EQ 5MG BASE	N020830 001	Feb 20, 1998	Jul	CFTG

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL

KADIAN

ACTAVIS ELIZABETH

40MG

N020616 009 Jul 09, 2012 Jul NEWA

70MG

N020616 010 Jul 09, 2012 Jul NEWA

130MG

N020616 011 Jul 09, 2012 Jul NEWA

150MG

N020616 012 Jul 09, 2012 Jul NEWA

INJECTABLE; INJECTION

DURAMORPH PF

AP + HIKMA MAPLE 0.5MG/ML

N018565 001 Sep 18, 1984 Jun CAHN

AP + 1MG/ML

N018565 002 Sep 18, 1984 Jun CAHN

INFUMORPH

+ HIKMA MAPLE 10MG/ML

N018565 003 Jul 19, 1991 Jun CAHN

+ 25MG/ML

N018565 004 Jul 19, 1991 Jun CAHN

INJECTABLE, LIPOSOMAL; EPIDURAL

DEPODUR

@ PACIRA PHARMS INC

10MG/ML (10MG/ML)

N021671 001 May 18, 2004 May CAHN

@

15MG/1.5ML (10MG/ML)

N021671 002 May 18, 2004 May CAHN

@

20MG/2ML (10MG/ML)

N021671 003 May 18, 2004 May CAHN

SOLUTION; ORAL

MORPHINE SULFATE

AA PADDOCK LLC 100MG/5ML

A201574 001 Aug 06, 2012 Jul NEWA

TABLET, EXTENDED RELEASE; ORAL

MORPHINE SULFATE

AB RANBAXY LABS LTD 15MG

A078761 001 May 11, 2012 Apr NEWA

AB 30MG

A078761 002 May 11, 2012 Apr NEWA

AB 60MG

A078761 003 May 11, 2012 Apr NEWA

AB 100MG

A078761 004 May 11, 2012 Apr NEWA

AB 200MG

A078761 005 May 11, 2012 Apr NEWA

AB VINTAGE PHARMS LLC 15MG

A075295 001 Oct 28, 1998 Sep CAHN

AB 30MG

A075295 002 Oct 28, 1998 Sep CAHN

AB 60MG

A075295 003 Oct 28, 1998 Sep CAHN

AB 100MG

A075295 004 Sep 15, 2000 Sep CAHN

AB 200MG

A075295 005 Sep 15, 2000 Sep CAHN

ORAMORPH SR

@ XANODYNE PHARMS INC

15MG

N019977 004 Nov 23, 1994 May DISC

@

30MG

N019977 001 Aug 15, 1991 May DISC

TABLET, EXTENDED RELEASE; ORAL

ORAMORPH SR

@ XANODYNE PHARMS INC 60MG

N019977 002 Aug 15, 1991 May DISC

@ 100MG

N019977 003 Aug 15, 1991 May DISC

MUPIROCIIN

OINTMENT; TOPICAL

MUPIROCIIN

AB FOUGERA PHARMS 2%

A065192 001 Nov 30, 2005 Jan CAHN

MYCOPHENOLATE MOFETIL

CAPSULE; ORAL

MYCOPHENOLATE MOFETIL

AB VINTAGE PHARMS LLC 250MG

A090111 001 Dec 22, 2009 Sep CAHN

@ ZYDUS PHARMS USA INC 250MG

A065433 001 May 04, 2009 Sep DISC

TABLET; ORAL

MYCOPHENOLATE MOFETIL

AB VINTAGE PHARMS LLC 500MG

A090606 001 Jul 16, 2010 Sep CAHN

@ ZYDUS PHARMS USA INC 500MG

A065477 001 May 04, 2009 Sep DISC

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE; ORAL

MYCOPHENOLIC ACID

AB APOTEX INC 180MG

A091558 001 Aug 21, 2012 Aug NEWA

MYFORTIC

AB NOVARTIS 180MG

N050791 001 Feb 27, 2004 Aug CFTG

NABUMETONE

TABLET; ORAL

NABUMETONE

AB MYLAN PHARMS INC 500MG

A090516 001 Jul 12, 2010 Sep CAHN

AB 750MG

A090516 002 Jul 12, 2010 Sep CAHN

AB PROSAM LABS 500MG

A079093 001 Feb 27, 2009 Feb CMFD

AB 750MG

A079093 002 Feb 27, 2009 Feb CMFD

NAFCILLIN SODIUM

INJECTABLE; INJECTION

NAFCILLIN SODIUM

AP ANTIBIOTICE EQ 1GM BASE

A090560 001 Oct 03, 2011 Aug CAHN

AP EQ 2GM BASE

A090560 002 Oct 03, 2011 Aug CAHN

AP ASTRAL PHARM INDS EQ 1GM BASE/VIAL

A090582 001 Aug 24, 2012 Aug NEWA

AP EQ 2GM BASE/VIAL

A090582 002 Aug 24, 2012 Aug NEWA

AP EQ 10GM BASE/VIAL

A090580 001 Aug 24, 2012 Aug NEWA

NAFTIFINE HYDROCHLORIDE

CREAM; TOPICAL

NAFTIN

+ MERZ PHARMS 2%

N019599 002 Jan 13, 2012 Jan NEWA

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE

@ HIKMA MAPLE 0.4MG/ML

A070298 001 Sep 24, 1986 Jun CAHN

@ 0.4MG/ML

A070496 001 Sep 24, 1986 Jun CAHN

@ 0.4MG/ML

A070299 001 Sep 24, 1986 Jun CAHN

INJECTABLE; INJECTIONNALOXONE HYDROCHLORIDE

@ HIKMA MAPLE 0.02MG/ML
 @ 1MG/ML
 @ 1MG/ML
 @ 1MG/ML

A071272 001 May 24, 1988 Jun CAHN
 A071287 001 May 24, 1988 Jun CAHN
 A071274 001 May 24, 1988 Jun CAHN
 A071273 001 May 24, 1988 Jun CAHN

NALTREXONE HYDROCHLORIDETABLET; ORALNALTREXONE HYDROCHLORIDE

AB SUN PHARMA GLOBAL 50MG

A090356 001 Feb 24, 2012 Feb NEWA

NAPROXENTABLET, DELAYED RELEASE; ORALNAPROXEN

AB MYLAN PHARMS INC 375MG
 AB 500MG

A075390 001 Apr 19, 2001 Sep CAHN
 A075390 002 Apr 19, 2001 Sep CAHN

NAPROXEN SODIUMTABLET; ORALANAPROX

AB HOFFMANN LA ROCHE EQ 250MG BASE

N018164 001 May CAHN

ANAPROX DS

AB + HOFFMANN LA ROCHE EQ 500MG BASE

N018164 003 Sep 30, 1987 May CAHN

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATETABLET; ORALTREXIMET

+ SMITHKLINE BEECHAM 500MG;EQ 85MG BASE

N021926 001 Apr 15, 2008 May CAHN

NARATRIPTAN HYDROCHLORIDETABLET; ORALNARATRIPTAN

AB MYLAN PHARMS INC EQ 1MG BASE
 AB EQ 2.5MG BASE
 AB ORCHID HLTHCARE EQ 1MG BASE
 AB EQ 2.5MG BASE

A202431 001 May 31, 2012 May NEWA
 A202431 002 May 31, 2012 May NEWA
 A091441 001 Apr 30, 2012 Apr NEWA
 A091441 002 Apr 30, 2012 Apr NEWA

NATEGLINIDETABLET; ORALNATEGLINIDE

@ TEVA PHARMS 60MG
 @ 120MG

A077467 001 Sep 09, 2009 Jul DISC
 A077467 002 Sep 09, 2009 Jul DISC

NEDOCROMIL SODIUMSOLUTION/DROPS; OPHTHALMICALOCRI

AT + ALLERGAN 2%

N021009 001 Dec 08, 1999 Aug CFTG

NEDOCROMIL SODIUM

AT AKORN 2%

A090638 001 Aug 22, 2012 Aug NEWA

NEPAFENACSUSPENSION/DROPS; OPHTHALMICNEPAFENAC

>A>
 >A> + ALCON RES LTD 0.3%

N203491 001 Oct 16, 2012 Oct NEWA

NEVIRAPINE

SUSPENSION; ORAL

NEVIRAPINE

AA	AUROBINDO	50MG/5ML	A077702 001	May 22, 2012	May	NEWA
----	-----------	----------	-------------	--------------	-----	------

VIRAMUNE

AA	+ BOEHRINGER INGELHEIM	50MG/5ML	N020933 001	Sep 11, 1998	May	CFTG
----	------------------------	----------	-------------	--------------	-----	------

TABLET; ORAL

NEVIRAPINE

AB	APOTEX INC	200MG	A203021 001	May 22, 2012	May	NEWA
----	------------	-------	-------------	--------------	-----	------

AB	AUROBINDO	200MG	A077521 001	May 22, 2012	May	NEWA
----	-----------	-------	-------------	--------------	-----	------

AB	CIPLA	200MG	A077956 001	May 22, 2012	May	NEWA
----	-------	-------	-------------	--------------	-----	------

AB	HETERO LABS LTD III	200MG	A078584 001	May 22, 2012	May	NEWA
----	---------------------	-------	-------------	--------------	-----	------

AB	MICRO LABS LTD	200MG	A203080 001	May 22, 2012	May	NEWA
----	----------------	-------	-------------	--------------	-----	------

AB	MYLAN LABS	200MG	A078864 001	May 22, 2012	May	NEWA
----	------------	-------	-------------	--------------	-----	------

AB	MYLAN PHARMS INC	200MG	A202523 001	May 22, 2012	May	NEWA
----	------------------	-------	-------------	--------------	-----	------

AB	PRINSTON INC	200MG	A078644 001	May 22, 2012	May	NEWA
----	--------------	-------	-------------	--------------	-----	------

AB	SCIEGEN PHARMS INC	200MG	A203176 001	May 22, 2012	May	NEWA
----	--------------------	-------	-------------	--------------	-----	------

AB	STRIDES	200MG	A078195 001	May 22, 2012	May	NEWA
----	---------	-------	-------------	--------------	-----	------

VIRAMUNE

AB	+ BOEHRINGER INGELHEIM	200MG	N020636 001	Jun 21, 1996	May	CFTG
----	------------------------	-------	-------------	--------------	-----	------

NIFEDIPINE

TABLET, EXTENDED RELEASE; ORAL

NIFEDIPINE

AB1	ACTAVIS	90MG	A077899 003	May 25, 2012	May	NEWA
-----	---------	------	-------------	--------------	-----	------

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACRODANTIN

AB	ALMATICA	25MG	N016620 003		Jul	CAHN
----	----------	------	-------------	--	-----	------

AB		50MG	N016620 001		Jul	CAHN
----	--	------	-------------	--	-----	------

AB	+	100MG	N016620 002		Jul	CAHN
----	---	-------	-------------	--	-----	------

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL

MACROBID

AB	+ ALMATICA	75MG; 25MG	N020064 001	Dec 24, 1991	Jul	CAHN
----	------------	------------	-------------	--------------	-----	------

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

@ RANBAXY LABS LTD 75MG; 25MG

A076951 001	Mar 30, 2005	Apr	DISC
-------------	--------------	-----	------

NITROGLYCERIN

FILM, EXTENDED RELEASE; TRANSDERMAL

MINITRAN

AB1	MEDICIS	0.1MG/HR	A089771 001	Aug 30, 1996	Jul	CAHN
-----	---------	----------	-------------	--------------	-----	------

AB1		0.2MG/HR	A089772 001	Aug 30, 1996	Jul	CAHN
-----	--	----------	-------------	--------------	-----	------

AB1		0.4MG/HR	A089773 001	Aug 30, 1996	Jul	CAHN
-----	--	----------	-------------	--------------	-----	------

AB1		0.6MG/HR	A089774 001	Aug 30, 1996	Jul	CAHN
-----	--	----------	-------------	--------------	-----	------

NITROGLYCERIN

>D>	AB2	HERCON LABS	0.2MG/HR	A089884 001	Oct 30, 1998	Oct	CAHN
-----	-----	-------------	----------	-------------	--------------	-----	------

>D>	AB2		0.4MG/HR	A089885 001	Oct 30, 1998	Oct	CAHN
-----	-----	--	----------	-------------	--------------	-----	------

>D>	AB2		0.6MG/HR	A089886 001	Oct 30, 1998	Oct	CAHN
-----	-----	--	----------	-------------	--------------	-----	------

>A>	AB2	HERCON PHARM	0.2MG/HR	A089884 001	Oct 30, 1998	Oct	CAHN
-----	-----	--------------	----------	-------------	--------------	-----	------

>A>	AB2		0.4MG/HR	A089885 001	Oct 30, 1998	Oct	CAHN
-----	-----	--	----------	-------------	--------------	-----	------

>A>	AB2		0.6MG/HR	A089886 001	Oct 30, 1998	Oct	CAHN
-----	-----	--	----------	-------------	--------------	-----	------

OINTMENT; INTRA-ANAL
RECTIV

+ APTALIS PHARMA 0.4% N021359 001 Jun 21, 2011 Jan CAHN

NIZATIDINE

CAPSULE; ORAL

AXID

@ SMITHKLINE BEECHAM 150MG N019508 001 Apr 12, 1988 Mar DISC

@ 300MG N019508 002 Apr 12, 1988 Mar DISC

NIZATIDINE

@ MYLAN PHARMS INC 150MG A075934 001 Jul 09, 2002 Apr DISC

AB + 300MG A075806 002 Jul 05, 2002 Apr CRLD

@ 300MG A075934 002 Jul 09, 2002 Apr DISC

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

AP CLARIS LIFESCIENCES EQ 1MG BASE/ML A040859 001 Mar 27, 2012 May CAHN

AP SINTETICA EQ 1MG BASE/ML A040859 001 Mar 27, 2012 Mar NEWA

NORETHINDRONE ACETATE

TABLET; ORAL

NORETHINDRONE ACETATE

AB AMNEAL PHARMS 5MG A200275 001 Jul 30, 2012 Jul NEWA

NYSTATIN

CREAM; TOPICAL

NYSTATIN

AT FOUGERA PHARMS 100,000 UNITS/GM A062129 001 Jan CAHN

AT + TARO 100,000 UNITS/GM A064022 001 Jan 29, 1993 Aug CRLD

OINTMENT; TOPICAL

NYSTATIN

AT + FOUGERA PHARMS 100,000 UNITS/GM A062124 002 Sep 23, 1982 Jan CAHN

POWDER; TOPICAL

NYSTATIN

@ NESHER PHARMS 100,000 UNITS/GM A065321 001 Aug 18, 2006 Jun DISC

TABLET; ORAL

NYSTATIN

>D> @ HERITAGE PHARMS INC 500,000 UNITS A062474 001 Dec 22, 1983 Oct CMFD

>A> AA 500,000 UNITS A062474 001 Dec 22, 1983 Oct CMFD

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYKACET

@ G AND W LABS INC 100,000 UNITS/GM;0.1% A062367 001 May 28, 1985 Jun CAHN

OINTMENT; TOPICAL

MYKACET

@ G AND W LABS INC 100,000 UNITS/GM;0.1% A062733 001 Mar 09, 1987 Jun CAHN

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OFLOXACIN

@ SANDOZ 0.3% A076848 001 Nov 25, 2008 Aug DISC

TABLET; ORAL

OFLOXACIN

@ RANBAXY LABS LTD 200MG A076220 001 Sep 02, 2003 Apr DISC

TABLET; ORAL

OFLOXACIN

@ RANBAXY LABS LTD

300MG

A076220 002 Sep 02, 2003 Apr DISC

@

400MG

A076220 003 Sep 02, 2003 Apr DISC

OLANZAPINE

INJECTABLE; INTRAMUSCULAR

OLANZAPINE

AP LUITPOLD 10MG/VIAL

A201741 001 Mar 20, 2012 Sep CAHN

AP PHARMAFORCE 10MG/VIAL

A201741 001 Mar 20, 2012 Mar NEWA

AP SANDOZ INC 10MG/VIAL

A201588 001 Oct 24, 2011 Mar CAHN

TABLET; ORAL

OLANZAPINE

AB APOTEX INC 2.5MG

A090798 001 Apr 23, 2012 Apr NEWA

AB 5MG

A090798 002 Apr 23, 2012 Apr NEWA

AB 7.5MG

A090798 003 Apr 23, 2012 Apr NEWA

AB 10MG

A090798 004 Apr 23, 2012 Apr NEWA

AB 15MG

A090798 005 Apr 23, 2012 Apr NEWA

AB 20MG

A090798 006 Apr 23, 2012 Apr NEWA

AB AUROBINDO PHARMA LTD 2.5MG

A202050 001 Apr 23, 2012 Apr NEWA

AB 5MG

A202050 002 Apr 23, 2012 Apr NEWA

AB 7.5MG

A202050 003 Apr 23, 2012 Apr NEWA

AB 10MG

A202050 004 Apr 23, 2012 Apr NEWA

AB 15MG

A202050 005 Apr 23, 2012 Apr NEWA

AB 20MG

A202050 006 Apr 23, 2012 Apr NEWA

AB DR REDDYS LABS LTD 2.5MG

A076255 001 Apr 23, 2012 Apr NEWA

AB 5MG

A076255 002 Apr 23, 2012 Apr NEWA

AB 7.5MG

A076255 003 Apr 23, 2012 Apr NEWA

AB 10MG

A076255 004 Apr 23, 2012 Apr NEWA

AB 15MG

A076133 001 Apr 23, 2012 Apr NEWA

AB MYLAN 2.5MG

A076866 001 Apr 23, 2012 Apr NEWA

AB 5MG

A076866 002 Apr 23, 2012 Apr NEWA

AB 7.5MG

A076866 003 Apr 23, 2012 Apr NEWA

AB 10MG

A076866 004 Apr 23, 2012 Apr NEWA

AB 15MG

A076866 005 Apr 23, 2012 Apr NEWA

AB 20MG

A076866 006 Apr 23, 2012 Apr NEWA

AB ORCHID HLTHCARE 2.5MG

A202287 001 Apr 23, 2012 Apr NEWA

AB 5MG

A202287 002 Apr 23, 2012 Apr NEWA

AB 7.5MG

A202287 003 Apr 23, 2012 Apr NEWA

AB 10MG

A202287 004 Apr 23, 2012 Apr NEWA

AB 15MG

A202287 005 Apr 23, 2012 Apr NEWA

AB 20MG

A202287 006 Apr 23, 2012 Apr NEWA

AB SUN PHARM INDS 2.5MG

A091038 001 Apr 23, 2012 Apr NEWA

AB 5MG

A091038 002 Apr 23, 2012 Apr NEWA

AB 7.5MG

A091038 003 Apr 23, 2012 Apr NEWA

AB 10MG

A091038 004 Apr 23, 2012 Apr NEWA

AB 15MG

A091038 005 Apr 23, 2012 Apr NEWA

AB 20MG

A091038 006 Apr 23, 2012 Apr NEWA

AB TORRENT PHARMS LTD 2.5MG

A091434 001 Apr 23, 2012 Apr NEWA

AB 5MG

A091434 002 Apr 23, 2012 Apr NEWA

AB 7.5MG

A091434 003 Apr 23, 2012 Apr NEWA

AB 10MG

A091434 004 Apr 23, 2012 Apr NEWA

AB 15MG

A091434 005 Apr 23, 2012 Apr NEWA

AB 20MG

A091434 006 Apr 23, 2012 Apr NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

OLANZAPINE

AB	BARR LABS INC	5MG	A077243 001	Jan 30, 2012	Jan	NEWA
AB		10MG	A077243 002	Jan 30, 2012	Jan	NEWA
AB		15MG	A077243 003	Jan 30, 2012	Jan	NEWA
AB		20MG	A077243 004	Jan 30, 2012	Jan	NEWA
AB	JUBILANT ORGANOSYS	5MG	A200221 001	Sep 12, 2012	Aug	NEWA
AB		10MG	A200221 002	Sep 12, 2012	Aug	NEWA
AB		15MG	A200221 003	Sep 12, 2012	Aug	NEWA
AB		20MG	A200221 004	Sep 12, 2012	Aug	NEWA
AB	SUN PHARM INDS	5MG	A090881 001	Feb 28, 2012	Feb	NEWA
AB		10MG	A090881 002	Feb 28, 2012	Feb	NEWA
AB		15MG	A090881 003	Feb 28, 2012	Feb	NEWA
AB		20MG	A090881 004	Feb 28, 2012	Feb	NEWA

>A> OMACETAXINE MEPESUCCINATE

>A> POWDER; SUBCUTANEOUS

>A> SYNRIBO

>A> + IVAX INTL 3.5MG/VIAL N203585 001 Oct 26, 2012 Oct NEWA

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

OMEPRAZOLE

AB	DR REDDYS LABS LTD	10MG	A078490 002	Mar 16, 2009	Apr	NEWA
AB		20MG	A078490 003	Mar 16, 2009	Apr	NEWA
AB	SANDOZ	10MG	A075757 001	Jan 28, 2003	Aug	CAHN
AB		20MG	A075757 002	Jan 28, 2003	Aug	CAHN

ONDANSETRON

FILM; ORAL

ZUPLENZ

>D>	MONOSOL RX LLC	4MG	N022524 001	Jul 02, 2010	Sep	CAHN
>D>	+	8MG	N022524 002	Jul 02, 2010	Sep	CAHN
>A>	VESTIQ PHARMS	4MG	N022524 001	Jul 02, 2010	Sep	CAHN
>A>	+	8MG	N022524 002	Jul 02, 2010	Sep	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

ONDANSETRON

@ NESHER PHARMS

@

@ PAR PHARM

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

		4MG	A077717 001	Jun 25, 2007	Jun	DISC
		8MG	A077717 002	Jun 25, 2007	Jun	DISC
		4MG	A076506 001	Dec 26, 2006	Aug	DISC
		8MG	A076506 002	Dec 26, 2006	Aug	DISC
		16MG	A077406 001	Dec 26, 2006	Aug	DISC
		24MG	A077406 002	Dec 26, 2006	Aug	DISC

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

AP	GLAND PHARMA LTD	EQ 2MG BASE/ML	A090648 001	Jun 15, 2012	Jun	NEWA
AP	HIKMA MAPLE	EQ 2MG BASE/ML	A077365 001	Dec 26, 2006	Jun	CAHN
	@ SAGENT PHARMS	EQ 2MG BASE/ML	A078180 001	Mar 26, 2007	Aug	DISC
	ONDANSETRON HYDROCHLORIDE AND SODIUM CHLORIDE IN PLASTIC CONTAINER					
	@ BAXTER HLTHCARE	EQ 0.64MG BASE/ML	N021915 002	Dec 27, 2006	Sep	DISC
	ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP	HIKMA MAPLE	EQ 2MG BASE/ML	A077541 001	Dec 26, 2006	Jun	CAHN

TABLET; ORAL

ONDANSETRON HYDROCHLORIDE

DR REDDYS LABS LTD EQ 16MG BASE
 @ PAR PHARM EQ 4MG BASE
 @ EQ 8MG BASE
 @ EQ 24MG BASE
 @ WEST WARD PHARM CORP EQ 4MG BASE
 @ EQ 8MG BASE
 @ EQ 24MG BASE

A076183 004 Dec 26, 2006 Sep NEWA
 A077303 001 Jun 25, 2007 Aug DISC
 A077303 002 Jun 25, 2007 Aug DISC
 A077303 004 Jun 25, 2007 Aug DISC
 A077545 001 Sep 06, 2007 Sep DISC
 A077545 002 Sep 06, 2007 Sep DISC
 A077545 003 Sep 06, 2007 Sep DISC

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL

ORPHENADRINE CITRATE

AB CNTY LINE PHARMS 100MG
 AB INVAGEN PHARMS 100MG

A040249 001 Jan 29, 1999 Jul CAHN
 A091158 001 Jul 27, 2012 Jul NEWA

OSELTAMIVIR PHOSPHATE

FOR SUSPENSION; ORAL

TAMIFLU

+ ROCHE EQ 6MG BASE/ML

N021246 002 Mar 21, 2011 Jan CRLD

OXACILLIN SODIUM

INJECTABLE; INJECTION

OXACILLIN SODIUM

AP SAGENT PHARMS EQ 1GM BASE/VIAL
 AP EQ 2GM BASE/VIAL
 AP EQ 10GM BASE/VIAL

A091246 001 Mar 30, 2012 Mar NEWA
 A091246 002 Mar 30, 2012 Mar NEWA
 A091245 001 Mar 30, 2012 Mar NEWA

OXALIPLATIN

INJECTABLE; IV (INFUSION)

OXALIPLATIN

AP ACTAVIS TOTOWA 50MG/VIAL
 AP 100MG/VIAL
 AP ONCO THERAPIES LTD 50MG/VIAL
 AP 50MG/10ML (5MG/ML)
 AP 100MG/20ML (5MG/ML)
 AP 100MG/VIAL
 AP + TEVA PHARMS 50MG/10ML (5MG/ML)
 AP + 100MG/20ML (5MG/ML)

A078803 001 Aug 08, 2012 Jul NEWA
 A078803 002 Aug 08, 2012 Jul NEWA
 A200979 001 Aug 08, 2012 Jul NEWA
 A091358 001 Aug 07, 2012 Jul NEWA
 A091358 002 Aug 07, 2012 Jul NEWA
 A200979 002 Aug 08, 2012 Jul NEWA
 N022160 001 Aug 07, 2009 Mar CRLD
 N022160 002 Aug 07, 2009 Mar CRLD

OXAPROZIN

TABLET; ORAL

OXAPROZIN

>D> AB MYLAN 600MG
 >A> @ MYLAN PHARMS INC 600MG

A075847 001 Feb 28, 2001 Oct DISC
 A075847 001 Feb 28, 2001 Oct DISC

OXCARBAZEPINE

SUSPENSION; ORAL

OXCARBAZEPINE

AB AMNEAL PHARMS 300MG/5ML
 AB ROXANE 300MG/5ML

A202961 001 Sep 17, 2012 Aug NEWA
 A201193 001 Oct 03, 2012 Sep NEWA

>A> TABLET, EXTENDED RELEASE; ORAL

>A> OXTELLAR XR

>A> SUPERNUS PHARMS 150MG

>A> 300MG

>A> + 600MG

N202810 001 Oct 19, 2012 Oct NEWA

N202810 002 Oct 19, 2012 Oct NEWA

N202810 003 Oct 19, 2012 Oct NEWA

OXICONAZOLE NITRATE

CREAM; TOPICAL

OXISTAT

+	FOUGERA PHARMS	EQ 1% BASE	N019828 001	Dec 30, 1988	Jan	CAHN
---	----------------	------------	-------------	--------------	-----	------

OXTRIPHYLLINE

TABLET, EXTENDED RELEASE; ORAL

CHOLEDYL SA

+	WARNER CHILCOTT LLC	400MG	A087863 001	May 24, 1983	Jun	CAHN
---	---------------------	-------	-------------	--------------	-----	------

+		600MG	A086742 001		Jun	CAHN
---	--	-------	-------------	--	-----	------

OXYBUTYNIN

GEL, METERED; TRANSDERMAL

ANTUROL

+	ARROW INTL	3%	N202513 001	Dec 07, 2011	Apr	CAHN
---	------------	----	-------------	--------------	-----	------

+	WATSON LABS INC	3%	N202513 001	Dec 07, 2011	Feb	CAHN
---	-----------------	----	-------------	--------------	-----	------

OXYBUTYNIN CHLORIDE

TABLET; ORAL

DITROPAN

@ JANSSEN PHARMS 5MG

N017577 001		Mar	DISC
-------------	--	-----	------

OXYBUTYNIN CHLORIDE

AB	+	VINTAGE PHARMS	5MG	A075079 001	Oct 31, 1997	Mar	CRLD
----	---	----------------	-----	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

OXYBUTYNIN CHLORIDE

AB		MYLAN PHARMS INC	15MG	A076644 002	May 10, 2007	Mar	NEWA
----	--	------------------	------	-------------	--------------	-----	------

OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE HYDROCHLORIDE

AB		COASTAL PHARMS	5MG	A203107 001	Jul 26, 2012	Jul	NEWA
----	--	----------------	-----	-------------	--------------	-----	------

AB	+	LEHIGH VALLEY	5MG	N200534 001	Oct 20, 2010	Jul	CFTG
----	---	---------------	-----	-------------	--------------	-----	------

SOLUTION; ORAL

OXYCODONE HYDROCHLORIDE

AA	+	LEHIGH VALLEY	100MG/5ML	N200535 001	Oct 20, 2010	Jul	CFTG
----	---	---------------	-----------	-------------	--------------	-----	------

	+	VISTAPHARM	5MG/5ML	N201194 001	Jan 12, 2012	Jan	NEWA
--	---	------------	---------	-------------	--------------	-----	------

AA			100MG/5ML	A202537 001	Jul 30, 2012	Jul	NEWA
----	--	--	-----------	-------------	--------------	-----	------

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

AB		MALLINCKRODT INC	5MG	A076758 003	Mar 19, 2007	Apr	NEWA
----	--	------------------	-----	-------------	--------------	-----	------

ROXICODONE

>A>	AB		MALLINCKRODT INC	5MG	N021011 003	May 15, 2009	Oct	CAHN
-----	----	--	------------------	-----	-------------	--------------	-----	------

>A>	AB	+		15MG	N021011 001	Aug 31, 2000	Oct	CAHN
-----	----	---	--	------	-------------	--------------	-----	------

>A>	AB			30MG	N021011 002	Aug 31, 2000	Oct	CAHN
-----	----	--	--	------	-------------	--------------	-----	------

>D>	AB		XANODYNE PHARMS	5MG	N021011 003	May 15, 2009	Oct	CAHN
-----	----	--	-----------------	-----	-------------	--------------	-----	------

>D>	AB	+		15MG	N021011 001	Aug 31, 2000	Oct	CAHN
-----	----	---	--	------	-------------	--------------	-----	------

>D>	AB			30MG	N021011 002	Aug 31, 2000	Oct	CAHN
-----	----	--	--	------	-------------	--------------	-----	------

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

OPANA ER

@ ENDO PHARMS 5MG

N021610 001	Jun 22, 2006	May	DISC
-------------	--------------	-----	------

>D>			7.5MG	N201655 002	Dec 09, 2011	Oct	DISC
-----	--	--	-------	-------------	--------------	-----	------

>A>			7.5MG	N201655 002	Dec 09, 2011	Oct	DISC
-----	--	--	-------	-------------	--------------	-----	------

	@		10MG	N021610 002	Jun 22, 2006	May	DISC
--	---	--	------	-------------	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

OPANA ER									
>D>	ENDO PHARMS	15MG		N201655	004	Dec 09,	2011	Oct	DISC
>A>		15MG		N201655	004	Dec 09,	2011	Oct	DISC
	@	20MG		N021610	003	Jun 22,	2006	May	DISC
	@	30MG		N021610	007	Feb 29,	2008	May	DISC
+		40MG		N201655	007	Dec 09,	2011	Aug	CRLD
	@	40MG		N021610	004	Jun 22,	2006	May	DISC
OXYMORPHONE HYDROCHLORIDE									
	IMPAX LABS	5MG		A079087	001	Jun 14,	2010	May	CTEC
		10MG		A079087	003	Jun 14,	2010	May	CTEC
		20MG		A079087	005	Jun 14,	2010	May	CTEC
		30MG		A079087	006	Jul 22,	2010	May	CTEC
		40MG		A079087	007	Jun 14,	2010	May	CTEC

OXYTOCIN

INJECTABLE; INJECTION

OXYTOCIN

@	TEVA PARENTERAL	10USP UNITS/ML (10USP UNITS/ML)		A077453	001	Jan 24,	2008	Jan	DISC
@		100USP UNITS/10ML (10USP UNITS/ML)		A077453	002	Jan 24,	2008	Mar	DISC

PITOCIN

JHP PHARMS	500USP UNITS/50ML (10USP UNITS/ML)		N018261	003	Sep 05,	2012	Aug	NEWA
------------	------------------------------------	--	---------	-----	---------	------	-----	------

PACLITAXEL

INJECTABLE; INJECTION

PACLITAXEL

>D>	AP	TEVA PARENTERAL	6MG/ML		A075184	001	Jan 25,	2002	Oct	CAHN
>A>	AP	TEVA PHARMS	6MG/ML		A075184	001	Jan 25,	2002	Oct	CAHN
		TAXOL								
	@	CORDEN PHARMA	6MG/ML		N020262	001	Dec 29,	1992	Mar	CAHN

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION

AREDIA

@	NOVARTIS	30MG/VIAL		N020036	001	Oct 31,	1991	Mar	DISC
---	----------	-----------	--	---------	-----	---------	------	-----	------

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

CAPSULE, DELAYED RELEASE; ORAL

CREON

	ABBOTT LABS	15,000USP UNITS;3,000USP UNITS;9,500USP UNITS		N020725	004	Jul 12,	2011	Jun	NEWA
		30,000USP UNITS;6,000USP UNITS;19,000USP UNITS		N020725	001	Apr 30,	2009	Feb	CAHN
		60,000USP UNITS;12,000USP UNITS;38,000USP UNITS		N020725	002	Apr 30,	2009	Feb	CAHN
+		120,000USP UNITS;24,000USP UNITS;76,000USP UNITS		N020725	003	Apr 30,	2009	Feb	CAHN

PERTZYE

	DIGESTIVE CARE INC	30,250USP/UNITS;8,000USP/UNITS;28,750USP/UNITS		N022175	001	May 17,	2012	May	NEWA
+		60,500USP/UNITS;16,000USP/UNITS;57,500USP/UNITS		N022175	002	May 17,	2012	May	NEWA

ULTRESA

	APTALIS PHARMA US	27,600USP UNITS;13,800USP UNITS;27,600USP UNITS		N022222	001	Mar 01,	2012	Mar	NEWA
		41,400USP UNITS;20,700USP UNITS;41,400USP UNITS		N022222	002	Mar 01,	2012	Mar	NEWA

CAPSULE, DELAYED RELEASE; ORAL

ULTRESA

+	APTALIS PHARMA US	46,000USP UNITS;23,000USP UNITS;46,000USP UNITS	N022222 003	Mar 01, 2012	Mar	NEWA
---	-------------------	---	-------------	--------------	-----	------

ZENPEP

	APTALIS PHARMA US	16,000USP UNITS;3,000USP UNITS;10,000USP UNITS	N022210 005	Jun 15, 2011	Apr	NEWA
		109,000USP UNITS;20,000USP UNITS;68,000USP UNITS	N022210 004	Aug 27, 2009	Apr	CRLD
+		136,000USP UNITS;25,000USP UNITS;85,000USP UNITS	N022210 006	Jul 13, 2011	Apr	NEWA

TABLET; ORAL

VIOKACE

	APTALIS PHARMA US	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542 001	Mar 01, 2012	Mar	NEWA
+		78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542 002	Mar 01, 2012	Mar	NEWA

PANTOPRAZOLE SODIUM

INJECTABLE; IV (INFUSION)

>A> PANTOPRAZOLE SODIUM

>A>	AP	AKORN INC	EQ 40MG BASE/VIAL	A079197 001	Nov 08, 2012	Oct	NEWA
-----	----	-----------	-------------------	-------------	--------------	-----	------

PROTONIX IV

>D>	+	WYETH PHARMS INC	EQ 40MG BASE/VIAL	N020988 001	Mar 22, 2001	Oct	CFTG
-----	---	------------------	-------------------	-------------	--------------	-----	------

>A>	AP	+	EQ 40MG BASE/VIAL	N020988 001	Mar 22, 2001	Oct	CFTG
-----	----	---	-------------------	-------------	--------------	-----	------

TABLET, DELAYED RELEASE; ORAL

PANTOPRAZOLE SODIUM

AB	APOTEX INC	EQ 20MG BASE	A090807 001	May 02, 2012	Apr	NEWA
AB		EQ 40MG BASE	A090807 002	May 02, 2012	Apr	NEWA
AB	AUROBINDO PHARMA LTD	EQ 20MG BASE	A202038 001	Sep 28, 2012	Sep	NEWA
AB		EQ 40MG BASE	A202038 002	Sep 28, 2012	Sep	NEWA
AB	MACLEODS PHARMS LTD	EQ 20MG BASE	A200821 001	Feb 16, 2012	Jan	NEWA
AB		EQ 40MG BASE	A200821 002	Feb 16, 2012	Jan	NEWA
AB	MYLAN PHARMS INC	EQ 20MG BASE	A090970 001	Jan 19, 2011	Sep	CAHN
AB		EQ 40MG BASE	A090970 002	Jan 19, 2011	Sep	CAHN
AB	RANBAXY LABS LTD	EQ 20MG BASE	A200794 001	May 02, 2012	Apr	NEWA
AB		EQ 40MG BASE	A200794 002	May 02, 2012	Apr	NEWA

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAROXETINE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	EQ 10MG BASE	A076968 001	Jun 21, 2010	Feb	CMFD
AB		EQ 20MG BASE	A076968 002	Jun 21, 2010	Feb	CMFD
AB		EQ 30MG BASE	A076968 003	Jun 21, 2010	Feb	CMFD
AB		EQ 40MG BASE	A076968 004	Jun 21, 2010	Feb	CMFD
AB	MYLAN PHARMS INC	EQ 10MG BASE	A075716 001	Mar 08, 2004	Sep	CAHN
AB		EQ 20MG BASE	A075716 002	Mar 08, 2004	Sep	CAHN
AB		EQ 30MG BASE	A075716 003	Mar 08, 2004	Sep	CAHN
AB		EQ 40MG BASE	A075716 004	Mar 08, 2004	Sep	CAHN
AB	PROSAM LABS	EQ 10MG BASE	A076968 001	Jun 21, 2010	Sep	CAHN
AB		EQ 20MG BASE	A076968 002	Jun 21, 2010	Sep	CAHN
AB		EQ 30MG BASE	A076968 003	Jun 21, 2010	Sep	CAHN
AB		EQ 40MG BASE	A076968 004	Jun 21, 2010	Sep	CAHN

PEGAPTANIB SODIUM

INJECTABLE; INTRAVITREAL

MACUGEN

+	VALEANT PHARMS LLC	EQ 0.3MG ACID/0.09ML	N021756 001	Dec 17, 2004	May	CAHN
---	--------------------	----------------------	-------------	--------------	-----	------

PEGINESATIDE ACETATE

SOLUTION; INTRAVENOUS, SUBCUTANEOUS

OMONTYS

+	AFFYMAX	EQ 10MG BASE/ML (EQ 10MG BASE/ML)	N202799 007	Mar 27, 2012	Mar	NEWA
+		EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N202799 008	Mar 27, 2012	Mar	NEWA

OMONTYS PRESERVATIVE FREE

+	AFFYMAX	EQ 1MG BASE/0.5ML (EQ 1MG BASE/0.5ML)	N202799 001	Mar 27, 2012	Mar	NEWA
+		EQ 2MG BASE/0.5ML (EQ 2MG BASE/0.5ML)	N202799 002	Mar 27, 2012	Mar	NEWA
+		EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N202799 003	Mar 27, 2012	Mar	NEWA
+		EQ 4MG BASE/0.5ML (EQ 4MG BASE/0.5ML)	N202799 004	Mar 27, 2012	Mar	NEWA
+		EQ 5MG BASE/0.5ML (EQ 5MG BASE/0.5ML)	N202799 005	Mar 27, 2012	Mar	NEWA
+		EQ 6MG BASE/0.5ML (EQ 6MG BASE/0.5ML)	N202799 006	Mar 27, 2012	Mar	NEWA

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM

AP	IBI	5,000,000 UNITS/VIAL	A065448 001	Aug 18, 2009	Sep	CAHN
AP		20,000,000 UNITS/VIAL	A065448 002	Aug 18, 2009	Sep	CAHN

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUM

+	OAK PHARMS	50MG/ML	A083246 001		Feb	CAHN
---	------------	---------	-------------	--	-----	------

>A> PERAMPANEL

>A> TABLET; ORAL

>A> FYCOMPA

>A>	EISAI INC	2MG	N202834 001	Oct 20, 2012	Oct	NEWA
>A>		4MG	N202834 002	Oct 22, 2012	Oct	NEWA
>A>		6MG	N202834 003	Oct 22, 2012	Oct	NEWA
>A>		8MG	N202834 004	Oct 22, 2012	Oct	NEWA
>A>		10MG	N202834 005	Oct 22, 2012	Oct	NEWA
>A>	+	12MG	N202834 006	Oct 22, 2012	Oct	NEWA

PERINDOPRIL ERBUMINE

TABLET; ORAL

ACEON

AB	XOMA	2MG	N020184 001	Dec 30, 1993	Jan	CAHN
AB		4MG	N020184 002	Dec 30, 1993	Jan	CAHN
AB	+	8MG	N020184 003	Dec 30, 1993	Jan	CAHN

PERMETHRIN

CREAM; TOPICAL

ELIMITE

AB	+	RENAISSANCE PHARMA	5%	N019855 001	Aug 25, 1989	May	CAHN
----	---	--------------------	----	-------------	--------------	-----	------

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIBENZYLINE

AB	+	WELLSPRING PHARM	10MG	N008708 001		Jun	CFTG
----	---	------------------	------	-------------	--	-----	------

CAPSULE; ORAL

PHENOXYBENZAMINE HYDROCHLORIDE

AB	ROXANE	10MG	A201050 001	Jul 16, 2012	Jun	NEWA
----	--------	------	-------------	--------------	-----	------

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

AA	ELITE LABS	15MG	A202248 001	Sep 28, 2012	Sep	NEWA
AA		30MG	A202248 002	Sep 28, 2012	Sep	NEWA
AA	LANNETT	15MG	A087022 002	Jan 20, 2012	Feb	NEWA
	@ MIKAH PHARMA	15MG	A040460 001	Jan 14, 2003	Jul	CAHN
	@	30MG	A040448 001	Jan 22, 2003	Jul	CAHN
	@	30MG	A040227 001	Jun 18, 1997	Jul	CAHN
	@	37.5MG	A040228 001	Jun 19, 1997	Jul	CAHN

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

>D>	AA	ACTAVIS ELIZABETH	37.5MG	A040276 001	Nov 25, 1998	Oct	DISC
>A>		@	37.5MG	A040276 001	Nov 25, 1998	Oct	DISC
		@ MIKAH PHARMA	37.5MG	A040190 001	May 30, 1997	Jul	CAHN
	AA	MIRROR PHARMS	37.5MG	A091451 001	Sep 21, 2012	Sep	NEWA
		@ SANDOZ INC	30MG	A088605 001	Sep 28, 1987	Feb	DISC

TABLET, ORALLY DISINTEGRATING; ORAL

SUPRENZA

		CITIUS PHARMS	30MG	N202088 002	Jun 13, 2011	Apr	CRLD
	+		37.5MG	N202088 003	Mar 27, 2012	Apr	CRLD
			37.5MG	N202088 003	Mar 27, 2012	Mar	NEWA

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE; ORAL

QSYMIA

VIVUS

		EQ 3.75MG BASE;23MG	N022580 001	Jul 17, 2012	Jul	NEWA
		EQ 7.5MG BASE;46MG	N022580 002	Jul 17, 2012	Jul	NEWA
		EQ 11.25MG BASE;69MG	N022580 003	Jul 17, 2012	Jul	NEWA
	+	EQ 15MG BASE;92MG	N022580 004	Jul 17, 2012	Jul	NEWA

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

PHENTERMINE RESIN COMPLEX

	+	LANNETT HOLDINGS INC	EQ 15MG BASE	A040872 001	Jul 28, 2011	Jan	CRLD
	+		EQ 30MG BASE	A040872 002	Jul 28, 2011	Jan	CRLD

PHENYTOIN SODIUM

INJECTABLE; INJECTION

PHENYTOIN SODIUM

AP	+	HIKMA MAPLE	50MG/ML	A084307 001		Jun	CAHN
----	---	-------------	---------	-------------	--	-----	------

PHYTONADIONE

INJECTABLE; INJECTION

PHYTONADIONE

BP	+	INTL MEDICATION	1MG/0.5ML	A083722 001		Feb	CRLD
----	---	-----------------	-----------	-------------	--	-----	------

TABLET; ORAL

MEPHYTON

	+	VALEANT PHARMS	5MG	N010104 003		Jun	CAHN
--	---	----------------	-----	-------------	--	-----	------

PIMECROLIMUS

CREAM; TOPICAL

ELIDEL

>A>	+	VALEANT BERMUDA	1%	N021302 001	Dec 13, 2001	Oct	CAHN
>D>	+	VALEANT INTL	1%	N021302 001	Dec 13, 2001	Oct	CAHN

PINDOLOL

TABLET; ORAL

PINDOLOL

@ MYLAN PHARMS INC

5MG

A074013 001 Sep 24, 1992 May CAHN

@

10MG

A074018 001 Sep 24, 1992 May CAHN

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

ACTOS

AB		TAKEDA PHARMS USA	EQ 15MG BASE	N021073 001	Jul 15, 1999	Aug	CFTG
			EQ 15MG BASE	N021073 001	Jul 15, 1999	Mar	CAHN
AB			EQ 30MG BASE	N021073 002	Jul 15, 1999	Aug	CFTG
			EQ 30MG BASE	N021073 002	Jul 15, 1999	Mar	CAHN
AB	+		EQ 45MG BASE	N021073 003	Jul 15, 1999	Aug	CFTG
	+		EQ 45MG BASE	N021073 003	Jul 15, 1999	Mar	CAHN

PIOGLITAZONE HYDROCHLORIDE

AB		MYLAN PHARMS INC	EQ 15MG BASE	A076801 001	Aug 17, 2012	Aug	NEWA
AB			EQ 30MG BASE	A076801 002	Aug 17, 2012	Aug	NEWA
AB			EQ 45MG BASE	A076801 003	Aug 17, 2012	Aug	NEWA
>A>	AB	WATSON LABS	EQ 15MG BASE	A076798 001	Oct 26, 2012	Oct	NEWA
>A>	AB		EQ 30MG BASE	A076798 002	Oct 26, 2012	Oct	NEWA
>A>	AB		EQ 45MG BASE	A076798 003	Oct 26, 2012	Oct	NEWA

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION; ORAL

CLENZ-LYTE

@ PADDOCK LLC

236GM/BOT;2.97GM/BOT;6.74GM/BOT;5 A090769 001 Jun 07, 2010 Sep DISC
.86GM/BOT;22.74GM/BOTPOLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES

@ PADDOCK LLC

240GM/BOT;2.98GM/BOT;6.72GM/BOT;5 A090712 001 Feb 25, 2010 Sep DISC
.84GM/BOT;22.72GM/BOTPOTASSIUM CHLORIDE

TABLET, EXTENDED RELEASE; ORAL

K+10

@ FUTURE PAK

10MEQ

A070999 001 Oct 22, 1987 Mar DISC

KAON CL-10

@ SAVAGE LABS

10MEQ

N017046 002 Mar DISC

KLOR-CON M20

AB + UPSHER SMITH LABS

20MEQ

A074726 001 Nov 20, 1998 Mar CRLD

KLOTRIX

@ APOTHECON

10MEQ

N017850 001 Mar DISC

POTASSIUM CHLORIDE

@ NESHER PHARMS

20MEQ

A076044 001 Apr 05, 2002 Mar DISC

@ SCHERING

10MEQ

N019439 002 Jun 13, 1986 Mar DISC

TABLET, EXTENDED RELEASE; ORAL

POTASSIUM CHLORIDE

@ SCHERING 20MEQ

N019439 001 Jun 13, 1986 Mar DISC

POTASSIUM CITRATE

FOR SOLUTION; ORAL

POTASSIUM CITRATE

@ NOVA K 10MEQ/PACKET

N019647 002 Oct 13, 1988 Feb CAHN

@ 20MEQ/PACKET

N019647 001 Oct 13, 1988 Feb CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET; ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB APOTEX INC 0.125MG

A090151 001 Apr 30, 2012 Apr NEWA

AB 0.25MG

A090151 002 Apr 30, 2012 Apr NEWA

AB 0.5MG

A090151 003 Apr 30, 2012 Apr NEWA

AB 0.75MG

A090151 006 Apr 30, 2012 Apr NEWA

AB 1MG

A090151 004 Apr 30, 2012 Apr NEWA

AB 1.5MG

A090151 005 Apr 30, 2012 Apr NEWA

>A> AB AUROBINDO PHARMA LTD 0.125MG

A202633 001 Oct 26, 2012 Oct NEWA

>A> AB 0.25MG

A202633 002 Oct 26, 2012 Oct NEWA

>A> AB 0.5MG

A202633 003 Oct 26, 2012 Oct NEWA

>A> AB 0.75MG

A202633 004 Oct 26, 2012 Oct NEWA

>A> AB 1MG

A202633 005 Oct 26, 2012 Oct NEWA

>A> AB 1.5MG

A202633 006 Oct 26, 2012 Oct NEWA

AB MACLEODS PHARMS LTD 0.125MG

A202164 001 Sep 20, 2012 Sep NEWA

AB 0.25MG

A202164 002 Sep 20, 2012 Sep NEWA

AB 0.5MG

A202164 003 Sep 20, 2012 Sep NEWA

AB 1MG

A202164 004 Sep 20, 2012 Sep NEWA

AB 1.5MG

A202164 005 Sep 20, 2012 Sep NEWA

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVASTATIN SODIUM

>D> AB MATRIX LABS LTD 10MG

A079187 001 May 27, 2010 Oct CAHN

>D> AB 20MG

A079187 002 May 27, 2010 Oct CAHN

>D> AB 40MG

A079187 003 May 27, 2010 Oct CAHN

>D> AB 80MG

A079187 004 May 27, 2010 Oct CAHN

>A> AB MYLAN PHARMS INC 10MG

A079187 001 May 27, 2010 Oct CAHN

>A> AB 20MG

A079187 002 May 27, 2010 Oct CAHN

>A> AB 40MG

A079187 003 May 27, 2010 Oct CAHN

>A> AB 80MG

A079187 004 May 27, 2010 Oct CAHN

@ PLIVA HRVATSKA DOO 10MG

A077730 001 Nov 21, 2006 Jun DISC

@ 20MG

A077730 002 Nov 21, 2006 Jun DISC

@ 30MG

A077730 003 Nov 21, 2006 Jun DISC

@ 40MG

A077730 005 Nov 21, 2006 Jun DISC

@ RANBAXY LABS LTD 10MG

A076445 001 Apr 23, 2007 Apr DISC

@ 20MG

A076445 002 Apr 23, 2007 Apr DISC

@ 40MG

A076445 003 Apr 23, 2007 Apr DISC

@ 80MG

A076445 004 Apr 23, 2007 Apr DISC

PREDNICARBATE

CREAM; TOPICAL

PREDNICARBATE

AB FOUGERA PHARMS 0.1%

A077287 001 Sep 19, 2006 Jan CAHN

OINTMENT; TOPICAL

PREDNICARBATE

AB	FOUGERA PHARMS	0.1%	A077236 001	Mar 09, 2007	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

PREDNISOLONE

SYRUP; ORAL

PREDNISOLONE

AA	+	HI TECH PHARMA CO	15MG/5ML	A040401 001	Feb 27, 2003	Jul	CRLD
		@ NESHER PHARMS	5MG/5ML	A040423 001	Oct 22, 2001	Jun	DISC
		@	15MG/5ML	A040364 001	Apr 10, 2002	Jun	DISC

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION; ORAL

PEDIAPRED

AA	+	SETON PHARM	EQ 5MG BASE/5ML	N019157 001	May 28, 1986	Sep	CAHN
		PREDNISOLONE SODIUM PHOSPHATE					
	+	MISSION PHARMA	EQ 25MG BASE/5ML	A091396 001	Sep 13, 2010	Jul	CAHN
		@ NESHER PHARMS	EQ 5MG BASE/5ML	A076982 001	May 24, 2005	Jun	DISC

PREDNISONE

TABLET; ORAL

PREDNISONE

>D>		@ WEST WARD	50MG	A088465 001	Jun 01, 1984	Oct	CMFD
>A>	AB	WEST WARD PHARM CORP	50MG	A088465 001	Jun 01, 1984	Oct	CMFD

TABLET, DELAYED RELEASE; ORAL

RAYOS

HORIZON PHARMA

			1MG	N202020 001	Jul 26, 2012	Jul	NEWA
			2MG	N202020 002	Jul 26, 2012	Jul	NEWA
	+		5MG	N202020 003	Jul 26, 2012	Jul	NEWA

PREGABALIN

CAPSULE; ORAL

LYRICA

AB		PF PRISM	25MG	N021446 001	Dec 30, 2004	Jun	CFTG
			25MG	N021446 001	Dec 30, 2004	Jan	CAHN
AB			50MG	N021446 002	Dec 30, 2004	Jun	CFTG
			50MG	N021446 002	Dec 30, 2004	Jan	CAHN
AB			75MG	N021446 003	Dec 30, 2004	Jun	CFTG
			75MG	N021446 003	Dec 30, 2004	Jan	CAHN
>D>			100MG	N021446 004	Dec 30, 2004	Oct	CFTG
>A>	AB		100MG	N021446 004	Dec 30, 2004	Oct	CFTG
			100MG	N021446 004	Dec 30, 2004	Jan	CAHN
AB			150MG	N021446 005	Dec 30, 2004	Jun	CFTG
			150MG	N021446 005	Dec 30, 2004	Jan	CAHN
AB			200MG	N021446 006	Dec 30, 2004	Jun	CFTG
			200MG	N021446 006	Dec 30, 2004	Jan	CAHN
AB			225MG	N021446 007	Dec 30, 2004	Jun	CFTG
			225MG	N021446 007	Dec 30, 2004	Jan	CAHN
AB	+		300MG	N021446 008	Dec 30, 2004	Jun	CFTG
	+		300MG	N021446 008	Dec 30, 2004	Jan	CAHN

PREGABALIN

AB		LUPIN LTD	25MG	A091040 001	Jul 03, 2012	Jun	NEWA
AB			50MG	A091040 002	Jul 03, 2012	Jun	NEWA
AB			75MG	A091040 003	Jul 03, 2012	Jun	NEWA
AB			100MG	A091040 004	Jul 03, 2012	Jun	NEWA
AB			150MG	A091040 005	Jul 03, 2012	Jun	NEWA

CAPSULE; ORAL							
PREGABALIN							
AB	LUPIN LTD	200MG	A091040 006	Jul 03, 2012	Jun	NEWA	
AB		225MG	A091040 007	Jul 03, 2012	Jun	NEWA	
AB		300MG	A091040 008	Jul 03, 2012	Jun	NEWA	
AB	TEVA PHARMS	25MG	A091219 001	Jul 03, 2012	Jun	NEWA	
AB		50MG	A091219 002	Jul 03, 2012	Jun	NEWA	
AB		75MG	A091224 001	Jul 03, 2012	Jun	NEWA	
AB		100MG	A091224 002	Jul 03, 2012	Jun	NEWA	
AB		150MG	A091224 003	Jul 03, 2012	Jun	NEWA	
AB		200MG	A091224 004	Jul 03, 2012	Jun	NEWA	
AB		225MG	A091224 005	Jul 03, 2012	Jun	NEWA	
AB		300MG	A091224 006	Jul 03, 2012	Jun	NEWA	
AB	WATSON LABS INC	25MG	A091221 001	Jul 03, 2012	Jun	NEWA	
AB		50MG	A091221 002	Jul 03, 2012	Jun	NEWA	
AB		75MG	A091221 003	Jul 03, 2012	Jun	NEWA	
AB		100MG	A091221 004	Jul 03, 2012	Jun	NEWA	
AB		150MG	A091221 005	Jul 03, 2012	Jun	NEWA	
AB		200MG	A091221 006	Jul 03, 2012	Jun	NEWA	
AB		225MG	A091221 007	Jul 03, 2012	Jun	NEWA	
AB		300MG	A091221 008	Jul 03, 2012	Jun	NEWA	
SOLUTION; ORAL							
LYRICA							
+	PF PRISM	20MG/ML	N022488 001	Jan 04, 2010	Jan	CAHN	
<u>PRILOCAINE HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
CITANEST PLAIN DENTAL							
	@ DENTSPLY PHARM	4%	N021382 001		May	DISC	
PRILOCAINE HYDROCHLORIDE							
+	SEPTODONT INC	4%	A079235 001	Sep 29, 2010	May	CRLD	
<u>PROCAINAMIDE HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
PROCAINAMIDE HYDROCHLORIDE							
	@ HIKMA MAPLE	100MG/ML	A089029 001	Apr 17, 1986	Jun	CAHN	
	@	500MG/ML	A089030 001	Apr 17, 1986	Jun	CAHN	
<u>PROCHLORPERAZINE EDISYLATE</u>							
INJECTABLE; INJECTION							
PROCHLORPERAZINE EDISYLATE							
	@ HIKMA MAPLE	EQ 5MG BASE/ML	A089523 001	May 03, 1988	Jun	CAHN	
AP	+	EQ 5MG BASE/ML	A089903 001	Aug 29, 1989	Jun	CAHN	
<u>PROGESTERONE</u>							
CAPSULE; ORAL							
PROGESTERONE							
AB	SOFGEN PHARMS	100MG	A200456 001	Sep 28, 2012	Sep	NEWA	
AB		200MG	A200456 002	Sep 28, 2012	Sep	NEWA	
AB	TEVA PHARMS	100MG	A202121 001	Feb 29, 2012	Feb	NEWA	
AB		200MG	A202121 002	Feb 29, 2012	Feb	NEWA	
PROMETRIUM							
AB	ABBOTT LABS	100MG	N019781 001	May 14, 1998	Feb	CFTG	
AB	+	200MG	N019781 002	Oct 15, 1999	Feb	CFTG	

PROMETHAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROMETHAZINE HYDROCHLORIDE

>D>	AP	BAXTER HLTHCARE	25MG/ML	A083312 001		Oct	CAHN
>D>	AP		50MG/ML	A083312 002		Oct	CAHN
>A>	AP	HIKMA MAPLE	25MG/ML	A083312 001		Oct	CAHN
>A>	AP		50MG/ML	A083312 002		Oct	CAHN

SUPPOSITORY; RECTAL

PROMETHAZINE HYDROCHLORIDE

>D>	AB	PADDOCK LLC	12.5MG	A040479 001	Jun 24, 2003	Oct	CAHN
>D>	AB		25MG	A040479 002	Jun 24, 2003	Oct	CAHN
>A>	AB	WATSON LABS INC	12.5MG	A040479 001	Jun 24, 2003	Oct	CAHN
>A>	AB		25MG	A040479 002	Jun 24, 2003	Oct	CAHN

SYRUP; ORAL

PROMETHAZINE HYDROCHLORIDE

AA		TRIS PHARMA INC	6.25MG/5ML	A091675 001	Jun 28, 2012	Jun	NEWA
----	--	-----------------	------------	-------------	--------------	-----	------

PROPAFENONE HYDROCHLORIDE

TABLET; ORAL

PROPAFENONE HYDROCHLORIDE

	@	NESHER PHARMS	150MG	A076193 001	Feb 07, 2002	Jun	DISC
	@		225MG	A076193 002	Feb 07, 2002	Jun	DISC
	@		300MG	A076193 003	Feb 07, 2002	Jun	DISC

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

PROPRANOLOL HYDROCHLORIDE

AB		APTALIS PHARMATECH	60MG	A078703 001	Jul 15, 2011	Sep	CAHN
AB			80MG	A078703 002	Jul 15, 2011	Sep	CAHN
AB			120MG	A078703 003	Jul 15, 2011	Sep	CAHN
AB			160MG	A078703 004	Jul 15, 2011	Sep	CAHN

PROTAMINE SULFATE

INJECTABLE; INJECTION

PROTAMINE SULFATE

>D>	@	BAXTER HLTHCARE	10MG/ML	A089475 001	Nov 05, 1986	Oct	CAHN
>D>	@		10MG/ML	A089474 001	Nov 05, 1986	Oct	CAHN
>A>	@	HIKMA MAPLE	10MG/ML	A089474 001	Nov 05, 1986	Oct	CAHN
>A>	@		10MG/ML	A089475 001	Nov 05, 1986	Oct	CAHN

PROTRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

VIVACTIL

	@	TEVA WOMENS R AND D	5MG	N016012 001		Jul	CAHN
	@		10MG	N016012 002		Jul	CAHN

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL

MESTINON

AB	+	VALEANT PHARMS LLC	60MG	N009829 002		Jun	CAHN
----	---	--------------------	------	-------------	--	-----	------

TABLET, EXTENDED RELEASE; ORAL

MESTINON

	+	VALEANT PHARMS LLC	180MG	N011665 001		Jun	CAHN
--	---	--------------------	-------	-------------	--	-----	------

QUETIAPINE FUMARATE

TABLET; ORAL

QUETIAPINE FUMARATE

AB	ACCORD HLTHCARE INC	EQ 25MG BASE	A202152 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A202152 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A202152 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A202152 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A202152 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A202152 006	Mar 27, 2012	Mar	NEWA
AB	APOTEX INC	EQ 25MG BASE	A090960 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A090960 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A090960 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A090960 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A090960 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A090960 006	Mar 27, 2012	Mar	NEWA
AB	AUROBINDO PHARMA LTD	EQ 25MG BASE	A091388 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A091388 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A091388 003	Mar 27, 2012	Mar	NEWA
AB		EQ 150MG BASE	A091388 004	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A091388 005	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A091388 006	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A091388 007	Mar 27, 2012	Mar	NEWA
AB	DR REDDYS LABS LTD	EQ 25MG BASE	A077380 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A077380 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A077380 003	Mar 27, 2012	Mar	NEWA
AB		EQ 150MG BASE	A077380 004	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A077380 005	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A077380 006	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A077380 007	Mar 27, 2012	Mar	NEWA
AB	LUPIN LTD	EQ 25MG BASE	A201109 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A201109 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A201109 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A201109 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A201109 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A201109 006	Mar 27, 2012	Mar	NEWA
AB	MYLAN PHARMS INC	EQ 25MG BASE	A090323 001	Mar 27, 2012	Mar	NEWA
AB	ROXANE	EQ 25MG BASE	A090120 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A090749 001	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A090749 002	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A090749 003	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A090749 004	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A090749 005	Mar 27, 2012	Mar	NEWA
AB	SUN PHARMA GLOBAL	EQ 25MG BASE	A201190 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A201190 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A201190 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A201190 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A201190 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A201190 006	Mar 27, 2012	Mar	NEWA
AB	TEVA PHARMS	EQ 25MG BASE	A077745 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A077745 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A077745 003	Mar 27, 2012	Mar	NEWA
AB		EQ 150MG BASE	A077745 004	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A077745 005	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A077745 006	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A077745 007	Mar 27, 2012	Mar	NEWA

TABLET; ORAL

QUETIAPINE FUMARATE

AB	TORRENT PHARMS LTD	EQ 25MG BASE	A200363 001	Mar 27, 2012	Mar	NEWA
AB		EQ 50MG BASE	A200363 002	Mar 27, 2012	Mar	NEWA
AB		EQ 100MG BASE	A200363 003	Mar 27, 2012	Mar	NEWA
AB		EQ 200MG BASE	A200363 004	Mar 27, 2012	Mar	NEWA
AB		EQ 300MG BASE	A200363 005	Mar 27, 2012	Mar	NEWA
AB		EQ 400MG BASE	A200363 006	Mar 27, 2012	Mar	NEWA

SEROQUEL

AB	+ ASTRAZENECA	EQ 25MG BASE	N020639 001	Sep 26, 1997	Mar	CFTG
AB		EQ 50MG BASE	N020639 007	Oct 04, 2005	Mar	CFTG
AB		EQ 100MG BASE	N020639 002	Sep 26, 1997	Mar	CFTG
AB		EQ 200MG BASE	N020639 003	Sep 26, 1997	Mar	CFTG
AB	+	EQ 300MG BASE	N020639 005	Jul 26, 2000	Mar	CFTG
AB		EQ 400MG BASE	N020639 006	Oct 04, 2005	Mar	CFTG

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

@ SANDOZ	EQ 5MG BASE	A076803 001	Mar 02, 2005	Aug	DISC
@	EQ 10MG BASE	A076803 002	Mar 02, 2005	Aug	DISC
@	EQ 20MG BASE	A076803 003	Mar 02, 2005	Aug	DISC
@	EQ 40MG BASE	A076803 004	Mar 02, 2005	Aug	DISC

QUININE SULFATE

CAPSULE; ORAL

QUALAQUIN

AB	+ AR HOLDING CO INC	324MG	N021799 001	Aug 12, 2005	Sep	CFTG
AB	QUININE SULFATE TEVA PHARMS	324MG	A091661 001	Sep 28, 2012	Sep	NEWA

RAMELTEON

TABLET; ORAL

ROZEREM

+	TAKEDA PHARMS USA	8MG	N021782 001	Jul 22, 2005	Jul	CAHN
---	-------------------	-----	-------------	--------------	-----	------

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

@ RANBAXY LABS LTD	5MG	A078849 001	Mar 06, 2009	Apr	DISC
@	10MG	A078849 002	Mar 06, 2009	Apr	DISC

TABLET; ORAL

ALTACE

@ KING PFIZER	1.25MG	N022021 001	Feb 27, 2007	Jan	DISC
@	2.5MG	N022021 002	Feb 27, 2007	Jan	DISC
@	5MG	N022021 003	Feb 27, 2007	Jan	DISC
@	10MG	N022021 004	Feb 27, 2007	Jan	DISC

RAMIPRIL

AB	MYLAN PHARMS INC	1.25MG	A090650 001	Jun 30, 2011	Sep	CAHN
AB		2.5MG	A090650 002	Jun 30, 2011	Sep	CAHN
AB		5MG	A090650 003	Jun 30, 2011	Sep	CAHN
AB		10MG	A090650 004	Jun 30, 2011	Sep	CAHN

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

ZANTAC

AP	+	COVIS PHARMA	EQ 25MG BASE/ML	N019090 001	Oct 19, 1984	Mar	CAHN
		ZANTAC IN PLASTIC CONTAINER					
	+	COVIS PHARMA	EQ 1MG BASE/ML	N019593 002	Sep 27, 1991	Mar	CAHN
	@		EQ 50MG BASE/100ML	N019593 001	Dec 17, 1986	Mar	CAHN
		SYRUP; ORAL					
		RANITIDINE HYDROCHLORIDE					
	@	RANBAXY	EQ 15MG BASE/ML	A078448 001	Dec 13, 2007	Sep	DISC

REGORAFENIB

TABLET; ORAL

STIVARGA

+	BAYER HLTHCARE	40MG	N203085 001	Sep 27, 2012	Sep	NEWA
---	----------------	------	-------------	--------------	-----	------

RIFAMPIN

CAPSULE; ORAL

RIMACTANE

AB		PROSAM LABS	300MG	N050429 001		Feb	CMFD
----	--	-------------	-------	-------------	--	-----	------

RILPIVIRINE HYDROCHLORIDE

TABLET; ORAL

EDURANT

+	JANSSEN PRODS	EQ 25MG BASE	N202022 001	May 20, 2011	Feb	CAHN
---	---------------	--------------	-------------	--------------	-----	------

RISEDRONATE SODIUM

TABLET; ORAL

ACTONEL

AB		WARNER CHILCOTT LLC	5MG	N020835 002	Apr 14, 2000	Jun	CAHN
AB			30MG	N020835 001	Mar 27, 1998	Jun	CAHN
AB	+		35MG	N020835 003	May 25, 2002	Jun	CAHN
	@		75MG	N020835 004	Apr 16, 2007	Jun	CAHN
	+		150MG	N020835 005	Apr 22, 2008	Jun	CAHN
		TABLET, DELAYED RELEASE; ORAL					
		ATELVIA					
	+	WARNER CHILCOTT LLC	35MG	N022560 001	Oct 08, 2010	Jun	CAHN

RISPERIDONE

TABLET; ORAL

RISPERIDONE

AB		PROSAM LABS	0.25MG	A078071 001	Jun 17, 2009	Feb	CMFD
AB			0.5MG	A078071 002	Jun 17, 2009	Feb	CMFD
AB			1MG	A078071 003	Jun 17, 2009	Feb	CMFD
AB			2MG	A078071 004	Jun 17, 2009	Feb	CMFD
AB			3MG	A078071 005	Jun 17, 2009	Feb	CMFD
AB			4MG	A078071 006	Jun 17, 2009	Feb	CMFD

TABLET, ORALLY DISINTEGRATING; ORAL

RISPERIDONE

AB		TEVA	0.5MG	A076908 001	Mar 12, 2012	Feb	NEWA
AB			1MG	A076908 002	Mar 12, 2012	Feb	NEWA
AB			2MG	A076908 003	Mar 12, 2012	Feb	NEWA

RIVASTIGMINE

FILM, EXTENDED RELEASE; TRANSDERMAL

EXELON

NOVARTIS

13.3MG/24HR

N022083 005 Aug 31, 2012 Aug NEWA

RIVASTIGMINE TARTRATE

CAPSULE; ORAL

RIVASTIGMINE TARTRATE

AB ALEMBIC PHARMS LTD

EQ 1.5MG BASE

A091689 001 Jun 12, 2012 May NEWA

AB

EQ 3MG BASE

A091689 002 Jun 12, 2012 May NEWA

AB

EQ 4.5MG BASE

A091689 003 Jun 12, 2012 May NEWA

AB

EQ 6MG BASE

A091689 004 Jun 12, 2012 May NEWA

ROCURONIUM BROMIDE

INJECTABLE; INJECTION

ROCURONIUM BROMIDE

AP TAMARANG

50MG/5ML (10MG/ML)

A091115 001 Aug 27, 2012 Aug NEWA

AP

100MG/10ML (10MG/ML)

A091115 002 Aug 27, 2012 Aug NEWA

AP TEVA PHARMS

50MG/5ML (10MG/ML)

A078717 001 Nov 26, 2008 Sep CAHN

AP

100MG/10ML (10MG/ML)

A078717 002 Nov 26, 2008 Sep CAHN

ROPINIROLE HYDROCHLORIDE

TABLET; ORAL

ROPINIROLE HYDROCHLORIDE

AB APOTEX

EQ 0.25MG BASE

A079165 001 Feb 07, 2012 Jan NEWA

AB

EQ 0.5MG BASE

A079165 002 Feb 07, 2012 Jan NEWA

AB

EQ 1MG BASE

A079165 003 Feb 07, 2012 Jan NEWA

AB

EQ 2MG BASE

A079165 004 Feb 07, 2012 Jan NEWA

AB

EQ 3MG BASE

A079165 005 Feb 07, 2012 Jan NEWA

AB

EQ 4MG BASE

A079165 006 Feb 07, 2012 Jan NEWA

AB

EQ 5MG BASE

A079165 007 Feb 07, 2012 Jan NEWA

TABLET, EXTENDED RELEASE; ORAL

REQUIP XL

AB + SMITHKLINE BEECHAM

EQ 2MG BASE

N022008 001 Jun 13, 2008 Apr CFTG

AB

EQ 4MG BASE

N022008 003 Jun 13, 2008 Apr CFTG

AB

EQ 6MG BASE

N022008 006 Apr 10, 2009 Apr CFTG

AB

EQ 8MG BASE

N022008 004 Jun 13, 2008 Apr CFTG

AB

EQ 12MG BASE

N022008 005 Oct 31, 2008 Apr CFTG

ROPINIROLE HYDROCHLORIDE

AB ACTAVIS

EQ 2MG BASE

A090869 001 May 17, 2012 Apr NEWA

AB

EQ 4MG BASE

A090869 002 May 17, 2012 Apr NEWA

AB

EQ 6MG BASE

A090869 003 May 17, 2012 Apr NEWA

AB

EQ 8MG BASE

A090869 004 May 17, 2012 Apr NEWA

AB

EQ 12MG BASE

A090869 005 May 17, 2012 Apr NEWA

AB DR REDDYS LABS LTD

EQ 2MG BASE

A201576 001 Jun 06, 2012 May NEWA

AB

EQ 4MG BASE

A201576 002 Jun 06, 2012 May NEWA

AB

EQ 6MG BASE

A201576 003 Jun 06, 2012 May NEWA

AB

EQ 8MG BASE

A201576 004 Jun 06, 2012 May NEWA

AB

EQ 12MG BASE

A201576 005 Jun 06, 2012 May NEWA

>A> AB MYLAN PHARMS INC

EQ 2MG BASE

A200462 001 Oct 15, 2012 Oct NEWA

>A>

EQ 3MG BASE

A200462 002 Oct 15, 2012 Oct NEWA

>A> AB

EQ 4MG BASE

A200462 003 Oct 15, 2012 Oct NEWA

>A> AB

EQ 6MG BASE

A200462 004 Oct 15, 2012 Oct NEWA

>A> AB

EQ 8MG BASE

A200462 005 Oct 15, 2012 Oct NEWA

>A> AB

EQ 12MG BASE

A200462 006 Oct 15, 2012 Oct NEWA

TABLET, EXTENDED RELEASE; ORAL

ROPINIROLE HYDROCHLORIDE

AB	SANDOZ INC	EQ 2MG BASE	A201047 001	Jun 06, 2012	May	NEWA
AB		EQ 4MG BASE	A201047 003	Jun 06, 2012	May	NEWA
AB		EQ 6MG BASE	A201047 004	Jun 06, 2012	May	NEWA
AB		EQ 8MG BASE	A201047 005	Jun 06, 2012	May	NEWA
AB		EQ 12MG BASE	A201047 006	Jun 06, 2012	May	NEWA
AB	WATSON LABS INC	EQ 2MG BASE	A200431 001	Jun 06, 2012	May	NEWA
AB		EQ 4MG BASE	A200431 002	Jun 06, 2012	May	NEWA
AB		EQ 6MG BASE	A200431 003	Jun 06, 2012	May	NEWA
AB		EQ 8MG BASE	A200431 004	Jun 06, 2012	May	NEWA
AB		EQ 12MG BASE	A200431 005	Jun 06, 2012	May	NEWA
AB	WOCKHARDT LTD	EQ 2MG BASE	A091395 001	Aug 27, 2012	Aug	NEWA
AB		EQ 4MG BASE	A091395 002	Aug 27, 2012	Aug	NEWA
AB		EQ 6MG BASE	A091395 003	Aug 27, 2012	Aug	NEWA
AB		EQ 8MG BASE	A091395 004	Aug 27, 2012	Aug	NEWA
AB		EQ 12MG BASE	A091395 005	Aug 27, 2012	Aug	NEWA

ROTIGOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NEUPRO

	UCB INC	1MG/24HR	N021829 004	Apr 02, 2012	Apr	NEWA
		2MG/24HR	N021829 001	May 09, 2007	Apr	CMFD
		3MG/24HR	N021829 005	Apr 02, 2012	Apr	NEWA
		4MG/24HR	N021829 002	May 09, 2007	Apr	CMFD
		6MG/24HR	N021829 003	May 09, 2007	Apr	CMFD
+		8MG/24HR	N021829 006	Apr 02, 2012	Apr	NEWA

SAMARIUM SM-153 LEXIDRONAM PENTASODIUM

INJECTABLE; INJECTION

QUADRAMET

+	JAZZ EUSA PHARMA	50mCi/ML	N020570 001	Mar 28, 1997	Jul	CAHN
---	------------------	----------	-------------	--------------	-----	------

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

@ VINTAGE PHARMS LLC 5MG

A074565 001 Aug 02, 1996 Sep CAHN

SERTACONAZOLE NITRATE

CREAM; TOPICAL

ERTACZO

+	VALEANT INTL	2%	N021385 001	Dec 10, 2003	Jan	CAHN
---	--------------	----	-------------	--------------	-----	------

SERTRALINE HYDROCHLORIDE

CONCENTRATE; ORAL

SERTRALINE HYDROCHLORIDE

@ RANBAXY LABS LTD EQ 20MG BASE/ML

A078053 001 Feb 05, 2007 Aug DISC

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

>D>	AB	MYLAN	EQ 25MG BASE	A076540 001	Mar 20, 2007	Oct	DISC
>D>	AB		EQ 50MG BASE	A076540 002	Mar 20, 2007	Oct	DISC
>D>	AB		EQ 100MG BASE	A076540 003	Mar 20, 2007	Oct	DISC
>A>		@ MYLAN PHARMS INC	EQ 25MG BASE	A076540 001	Mar 20, 2007	Oct	DISC
	AB		EQ 25MG BASE	A078626 001	Jan 31, 2008	Sep	CAHN
>A>		@	EQ 50MG BASE	A076540 002	Mar 20, 2007	Oct	DISC
	AB		EQ 50MG BASE	A078626 002	Jan 31, 2008	Sep	CAHN

TABLET; ORAL

SERTRALINE HYDROCHLORIDE

>A>	@ MYLAN PHARMS INC	EQ 100MG BASE	A076540 003	Mar 20, 2007	Oct	DISC
AB		EQ 100MG BASE	A078626 003	Jan 31, 2008	Sep	CAHN
AB	PROSAM LABS	EQ 25MG BASE	A078175 001	Jul 21, 2010	Feb	CMFD
AB		EQ 50MG BASE	A078175 002	Jul 21, 2010	Feb	CMFD
AB		EQ 100MG BASE	A078175 003	Jul 21, 2010	Feb	CMFD

SILDENAFIL CITRATE

FOR SUSPENSION; ORAL

REVATIO

+	PFIZER	10MG/ML	N203109 001	Aug 30, 2012	Aug	NEWA
---	--------	---------	-------------	--------------	-----	------

TABLET; ORAL

REVATIO

>D>	+	PFIZER	EQ 20MG BASE	N021845 001	Jun 03, 2005	Oct	CFTG
>A>	AB	+	EQ 20MG BASE	N021845 001	Jun 03, 2005	Oct	CFTG
>A>		SILDENAFIL CITRATE					
>A>	AB	APOTEX CORP	EQ 20MG BASE	A091379 001	Nov 06, 2012	Oct	NEWA
>A>	AB	DR REDDYS LABS LTD	EQ 20MG BASE	A202598 001	Nov 06, 2012	Oct	NEWA
>A>	AB	MYLAN PHARMS INC	EQ 20MG BASE	A201150 001	Nov 09, 2012	Oct	NEWA
>A>	AB	TORRENT PHARMS LTD	EQ 20MG BASE	A091479 001	Nov 06, 2012	Oct	NEWA
>A>	AB	WATSON LABS INC	EQ 20MG BASE	A202503 001	Nov 06, 2012	Oct	NEWA

SILODOSIN

CAPSULE; ORAL

RAPAFLO

>D>		WATSON LABS	4MG	N022206 001	Oct 08, 2008	Oct	CRLD
>A>	+		4MG	N022206 001	Oct 08, 2008	Oct	CRLD
>D>	+		8MG	N022206 002	Oct 08, 2008	Oct	CRLD
>A>			8MG	N022206 002	Oct 08, 2008	Oct	CRLD

SILVER SULFADIAZINE

CREAM; TOPICAL

THERMAZENE

AB	THEPHARMANETWORK LLC	1%	N018810 001	Dec 23, 1985	Jun	CAHN
----	----------------------	----	-------------	--------------	-----	------

SIMVASTATIN

TABLET; ORAL

SIMVASTATIN

AB	MYLAN PHARMS INC	5MG	A090868 001	Jun 08, 2010	Sep	CAHN
AB		10MG	A090868 002	Jun 08, 2010	Sep	CAHN
AB		20MG	A090868 003	Jun 08, 2010	Sep	CAHN
AB		40MG	A090868 004	Jun 08, 2010	Sep	CAHN
AB		80MG	A090868 005	Jun 08, 2010	Sep	CAHN
AB	PROSAM LABS	5MG	A078735 001	Aug 30, 2010	Feb	CMFD
AB		10MG	A078735 002	Aug 30, 2010	Feb	CMFD
AB		20MG	A078735 003	Aug 30, 2010	Feb	CMFD
AB		40MG	A078735 004	Aug 30, 2010	Feb	CMFD
AB		80MG	A078735 005	Aug 30, 2010	Feb	CMFD

SIMVASTATIN; SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JUVISYNC

	MERCK SHARP DOHME	10MG;EQ 50MG BASE	N202343 004	Sep 18, 2012	Sep	NEWA
		20MG;EQ 50MG BASE	N202343 005	Sep 18, 2012	Sep	NEWA
		40MG;EQ 50MG BASE	N202343 006	Sep 18, 2012	Sep	NEWA

SITAGLIPTIN PHOSPHATE

TABLET; ORAL

JANUVIA

MERCK SHARP DOHME

EQ 25MG BASE

N021995 001 Oct 16, 2006 May CAHN

EQ 50MG BASE

N021995 002 Oct 16, 2006 May CAHN

+

EQ 100MG BASE

N021995 003 Oct 16, 2006 May CAHN

SODIUM BICARBONATE; TARTARIC ACID

GRANULE, EFFERVESCENT; ORAL

BAROS

@ MALLINCKRODT INC

460MG/GM; 420MG/GM

N018509 001 Aug 07, 1985 Jan CAHN

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9%

AP

HIKMA (MAPLE)

9MG/ML

A201850 001 Jan 20, 2012 Jan NEWA

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

MEDEFIL

9MG/ML

N202832 001 Jan 06, 2012 Jan NEWA

SODIUM CHROMATE CR-51

INJECTABLE; INJECTION

CHROMITOPES SODIUM

@ BRACCO

200uCi/ML

N013993 001

Jun DISC

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE; INJECTION

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB

HIKMA PHARMS

62.5MG/5ML

A078215 001 Mar 31, 2011 May CAHN

SODIUM IODIDE I-123

CAPSULE; ORAL

SODIUM IODIDE I 123

@ GE HEALTHCARE

100uCi

N017630 001

May DISC

>D>

@ SYNCOR PHARMS

400uCi

N018671 003 May 27, 1982 Oct CMFD

>A>

400uCi

N018671 003 May 27, 1982 Oct CMFD

SOLUTION; ORAL

SODIUM IODIDE I 123

@ GE HEALTHCARE

2mCi/ML

N017630 002

Jul DISC

SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I-131

JUBILANT DRAXIMAGE

9-100mCi

N021305 006 May 19, 2005 Feb CAHN

@

2-200mCi

N021305 004 Nov 18, 2004 Jan DISC

SOLUTION; ORAL

HICON

@ JUBILANT DRAXIMAGE

1-500mCi/0.5ML

N021305 003 Jan 24, 2003 Feb DISC

@

1-250mCi/0.25ML

N021305 002 Jan 24, 2003 Feb DISC

@

1-1000mCi/ML

N021305 005 Apr 04, 2006 Feb DISC

+

250-1000mCi

N021305 007 Dec 05, 2011 Jan NEWA

SODIUM NITRITE

SOLUTION; INTRAVENOUS

SODIUM NITRITE

+

HOPE PHARMS

300MG/10ML (30MG/ML)

N203922 001 Feb 14, 2012 Feb NEWA

SODIUM OXYBATESOLUTION; ORAL
XYREM

+ JAZZ PHARMS 500MG/ML N021196 001 Jul 17, 2002 Jun CAHN

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

@ CITRUSPHARMA 454GM/BOT

A040909 001 Dec 03, 2008 Jun DISC

SODIUM THIOSULFATE

SOLUTION; INTRAVENOUS

SODIUM THIOSULFATE

+ HOPE PHARMS 12.5GM/50ML (250MG/ML) N203923 001 Feb 14, 2012 Feb NEWA

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION

NORDITROPIN

@ NOVO NORDISK INC 5MG/1.5ML

N021148 001 Jun 20, 2000 Jul DISC

@ 10MG/1.5ML

N021148 002 Jun 20, 2000 Jul DISC

@ 15MG/1.5ML

N021148 003 Jun 20, 2000 Jul DISC

NORDITROPIN NORDIFLEX

@ NOVO NORDISK INC 5MG/1.5ML

N021148 004 Oct 01, 2004 Sep DISC

@ 10MG/1.5ML

N021148 005 Oct 01, 2004 Sep DISC

@ 15MG/1.5ML

N021148 006 Oct 01, 2004 Sep DISC

SOTALOL HYDROCHLORIDE

TABLET; ORAL

SOTALOL HYDROCHLORIDE

AB2 EPIC PHARMA INC 80MG

A077070 001 Nov 04, 2005 Jun CAHN

AB2 120MG

A077070 002 Nov 04, 2005 Jun CAHN

AB2 160MG

A077070 003 Nov 04, 2005 Jun CAHN

SPINOSAD

SUSPENSION; TOPICAL

NATROBA

+ PARAPRO LLC 0.9% N022408 001 Jan 18, 2011 May CAHN

SUCCIMER

CAPSULE; ORAL

CHEMET

+ LUNDBECK LLC 100MG N019998 002 Jan 30, 1991 Mar CAHN

SUFENTANIL CITRATE

INJECTABLE; INJECTION

SUFENTANIL CITRATE

>D> AP BAXTER HLTHCARE EQ 0.05MG BASE/ML

A074413 001 Dec 15, 1995 Oct CAHN

>A> AP HIKMA MAPLE EQ 0.05MG BASE/ML

A074413 001 Dec 15, 1995 Oct CAHN

SULFACETAMIDE SODIUM

LOTION; TOPICAL

SULFACETAMIDE SODIUM

AB FOUGERA PHARMS 10%

A077015 001 Nov 17, 2006 Jan CAHN

SULFAMETHOXAZOLE; TRIMETHOPRIM

INJECTABLE; INJECTION

SULFAMETHOXAZOLE AND TRIMETHOPRIM

>D>	@ BAXTER HLTHCARE	80MG/ML;16MG/ML	A070627 001	Dec 29, 1987	Oct	CAHN
>D>	@	80MG/ML;16MG/ML	A070628 001	Dec 29, 1987	Oct	CAHN
>A>	@ HIKMA MAPLE	80MG/ML;16MG/ML	A070628 001	Dec 29, 1987	Oct	CAHN
>A>	@	80MG/ML;16MG/ML	A070627 001	Dec 29, 1987	Oct	CAHN

SUSPENSION; ORAL

SULFATRIM

@ STI PHARMA LLC 200MG/5ML;40MG/5ML

N018615 002 Jan 07, 1983 Aug CAHN

SULFATRIM PEDIATRIC

AB STI PHARMA LLC 200MG/5ML;40MG/5ML

N018615 001 Jan 07, 1983 Aug CAHN

SULFANILAMIDE

CREAM; VAGINAL

AVC

>D>	+ JAZZ PHARMS COMMERCL	15%	N006530 003	Jan 27, 1987	Mar	CAHN
>D>	+ JAZZ PHARMS II	15%	N006530 003	Jan 27, 1987	Oct	CAHN
	+	15%	N006530 003	Jan 27, 1987	Jul	CAHN
	+ JAZZ PHARMS III	15%	N006530 003	Jan 27, 1987	Jun	CAHN
>A>	+ MEDPOINTE	15%	N006530 003	Jan 27, 1987	Oct	CAHN

SUPPOSITORY; VAGINAL

AVC

>D>	@ JAZZ PHARMS COMMERCL	1.05GM	N006530 004	Jan 27, 1987	Mar	CAHN
>D>	@ JAZZ PHARMS II	1.05GM	N006530 004	Jan 27, 1987	Oct	CAHN
	@	1.05GM	N006530 004	Jan 27, 1987	Jul	CAHN
	@ JAZZ PHARMS III	1.05GM	N006530 004	Jan 27, 1987	Jun	CAHN
>A>	@ MEDPOINTE	1.05GM	N006530 004	Jan 27, 1987	Oct	CAHN

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS

ALSUMA

BX MERIDIAN MEDCL EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

N022377 001 Jun 29, 2010 Jun CRLD

SUMATRIPTAN SUCCINATE

AP INJECTALIA EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A090310 001 Aug 11, 2010 Mar CAHN

>D> AB SUN PHARM INDS INC EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A090358 001 Jun 21, 2011 Oct CAHN

>A> AB SUN PHARMA GLOBAL EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

A090358 001 Jun 21, 2011 Oct CAHN

SUMAVEL DOSEPRO

BX + ZOGENIX INC EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

N022239 001 Jul 15, 2009 Jun CTEC

TABLET; ORAL

SUMATRIPTAN SUCCINATE

AB APOTEX INC EQ 25MG BASE

A200263 001 Jun 19, 2012 Jun NEWA

AB EQ 50MG BASE

A200263 002 Jun 19, 2012 Jun NEWA

AB EQ 100MG BASE

A200263 003 Jun 19, 2012 Jun NEWA

TACROLIMUS

CAPSULE; ORAL

TACROLIMUS

AB ACCORD HLTHCARE EQ 0.5MG BASE

A091195 001 Aug 31, 2011 Sep CPOT

AB EQ 1MG BASE

A091195 002 Aug 31, 2011 Sep CPOT

AB EQ 5MG BASE

A091195 003 Aug 31, 2011 Sep CPOT

AB PANACEA BIOTEC LTD EQ 0.5MG BASE

A090802 001 Sep 28, 2012 Sep NEWA

CAPSULE; ORAL

TACROLIMUS

AB	PANACEA BIOTEC LTD	EQ 1MG BASE	A090802 002	Sep 28, 2012	Sep	NEWA
AB		EQ 5MG BASE	A090802 003	Sep 28, 2012	Sep	NEWA

TAFLUPROST

SOLUTION/DROPS; OPHTHALMIC

ZIOPTAN

+	MERCK SHARP DOHME	0.0015%	N202514 001	Feb 10, 2012	Feb	NEWA
---	-------------------	---------	-------------	--------------	-----	------

TALIGLUCERASE ALFA

POWDER; IV (INFUSION)

ELELYSO

+	PFIZER	200 UNITS/VIAL	N022458 001	May 01, 2012	May	NEWA
---	--------	----------------	-------------	--------------	-----	------

TAMOXIFEN CITRATE

SOLUTION; ORAL

SOLTAMOX

	ONCOGENERIX PHARMS	EQ 10MG BASE/5ML	N021807 001	Oct 29, 2005	Aug	CMFD
--	--------------------	------------------	-------------	--------------	-----	------

TABLET; ORAL

TAMOXIFEN CITRATE

@	AEGIS PHARMS	EQ 10MG BASE	A076398 001	Mar 31, 2003	Jun	DISC
---	--------------	--------------	-------------	--------------	-----	------

@		EQ 20MG BASE	A076398 002	Mar 31, 2003	Jun	DISC
---	--	--------------	-------------	--------------	-----	------

TAPENTADOL HYDROCHLORIDE

>A> SOLUTION; ORAL

>A> NUCYNTA

>A>	+	JANSSEN PHARMS	EQ 20MG BASE/ML	N203794 001	Oct 15, 2012	Oct	NEWA
-----	---	----------------	-----------------	-------------	--------------	-----	------

TAZAROTENE

AEROSOL, FOAM; TOPICAL

FABIOR

+	STIEFEL LABS INC	0.1%	N202428 001	May 11, 2012	May	NEWA
---	------------------	------	-------------	--------------	-----	------

TECHNETIUM TC-99M MEDRONATE

INJECTABLE; INJECTION

DRAXIMAGE MDP-10

@	JUBILANT DRAXIMAGE	N/A	N018035 001		May	CAHN
---	--------------------	-----	-------------	--	-----	------

DRAXIMAGE MDP-25

+	JUBILANT DRAXIMAGE	N/A	N018035 002	Feb 27, 2004	May	CAHN
---	--------------------	-----	-------------	--------------	-----	------

TEMAZEPAM

CAPSULE; ORAL

TEMAZEPAM

AB	NOVEL LABS INC	7.5MG	A071457 002	Jun 22, 2012	Jun	NEWA
----	----------------	-------	-------------	--------------	-----	------

AB		22.5MG	A071457 003	Jun 22, 2012	Jun	NEWA
----	--	--------	-------------	--------------	-----	------

TEMOZOLOMIDE

CAPSULE; ORAL

TEMODAR

AB	MERCK SHARP DOHME	5MG	N021029 001	Aug 11, 1999	Jun	CAHN
----	-------------------	-----	-------------	--------------	-----	------

AB		20MG	N021029 002	Aug 11, 1999	Jun	CAHN
----	--	------	-------------	--------------	-----	------

AB		100MG	N021029 003	Aug 11, 1999	Jun	CAHN
----	--	-------	-------------	--------------	-----	------

AB		140MG	N021029 005	Oct 19, 2006	Jun	CAHN
----	--	-------	-------------	--------------	-----	------

AB		180MG	N021029 006	Oct 19, 2006	Jun	CAHN
----	--	-------	-------------	--------------	-----	------

AB	+	250MG	N021029 004	Aug 11, 1999	Jun	CAHN
----	---	-------	-------------	--------------	-----	------

POWDER; INTRAVENOUS

TEMODAR

+	MERCK SHARP DOHME	100MG/VIAL	N022277 001	Feb 27, 2009	Jun	CAHN
---	-------------------	------------	-------------	--------------	-----	------

TENOFOVIR DISOPROXIL FUMARATE

POWDER; ORAL

VIREAD

+	GILEAD SCIENCES INC	40MG/SCOOPFUL	N022577 001	Jan 18, 2012	Jan	NEWA
---	---------------------	---------------	-------------	--------------	-----	------

TABLET; ORAL

VIREAD

	GILEAD SCIENCES INC	150MG	N021356 002	Jan 18, 2012	Apr	NEWA
		200MG	N021356 003	Jan 18, 2012	Apr	NEWA
		250MG	N021356 004	Jan 18, 2012	Apr	NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE; ORAL

TERAZOSIN HYDROCHLORIDE

	@ RANBAXY LABS LTD	EQ 1MG BASE	A076021 001	Aug 22, 2002	Apr	DISC
	@	EQ 2MG BASE	A076021 002	Aug 22, 2002	Apr	DISC
	@	EQ 5MG BASE	A076021 003	Aug 22, 2002	Apr	DISC
	@	EQ 10MG BASE	A076021 004	Aug 22, 2002	Apr	DISC

TERBUTALINE SULFATE

INJECTABLE; INJECTION

TERBUTALINE SULFATE

	@ TEVA PARENTERAL	1MG/ML	A076853 001	Jul 20, 2004	Jan	DISC
--	-------------------	--------	-------------	--------------	-----	------

TERCONAZOLE

CREAM; VAGINAL

TERCONAZOLE

AB	FOUGERA PHARMS	0.4%	A076712 001	Feb 18, 2005	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

SUPPOSITORY; VAGINAL

TERCONAZOLE

AB	FOUGERA PHARMS	80MG	A076850 001	Jul 12, 2006	Jan	CAHN
----	----------------	------	-------------	--------------	-----	------

TERIFLUNOMIDE

TABLET; ORAL

AUBAGIO

	SANOFI AVENTIS US	7MG	N202992 001	Sep 12, 2012	Sep	NEWA
+		14MG	N202992 002	Sep 12, 2012	Sep	NEWA

TESAMORELIN ACETATE

POWDER; SUBCUTANEOUS

EGRIFTA

	@ EMD SERONO	EQ 1MG BASE/VIAL	N022505 001	Nov 10, 2010	Jun	DISC
+		EQ 1MG BASE/VIAL	N022505 001	Nov 10, 2010	May	CAHN
+		EQ 2MG BASE/VIAL	N022505 002	Nov 29, 2011	Jun	NEWA

TESTOSTERONE

GEL; TRANSDERMAL

ANDROGEL

	ABBOTT LABS	1% (25MG/2.5GM PACKET)	N021015 001	Feb 28, 2000	Feb	CPOT
BX	+	1% (50MG/5GM PACKET)	N021015 002	Feb 28, 2000	Feb	CPOT
		ABBVIE	N022309 002	Sep 07, 2012	Sep	NEWA
	+	1.62% (40.5MG/2.5GM PACKET)	N022309 003	Sep 07, 2012	Sep	NEWA

GEL; TRANSDERMAL

TESTIM

BX	+	AUXILIUM PHARMS	1% (50MG/5GM PACKET)	N021454 001	Oct 31, 2002	Feb	CPOT
		TESTOSTERONE					
		TEVA PHARMS	25MG/2.5GM PACKET	N202763 001	Feb 14, 2012	Feb	NEWA
			50MG/5GM PACKET	N202763 002	Feb 14, 2012	Feb	NEWA

GEL, METERED; TRANSDERMAL

ANDROGEL

+	ABBOTT LABS	1% (1.25GM/ACTUATION)	N021015 003	Sep 26, 2003	Jun	CPOT
	FORTESTA					
+	ENDO PHARMS	10MG/0.5GM ACTUATION	N021463 001	Dec 29, 2010	Sep	CPOT

PELLET; IMPLANTATION

TESTOPEL

+	ACTIENT PHARMS	75MG	A080911 001		May	CAHN
---	----------------	------	-------------	--	-----	------

SOLUTION, METERED; TRANSDERMAL

AXIRON

+	ELI LILLY AND CO	30MG/1.5ML ACTUATION	N022504 001	Nov 23, 2010	Sep	CPOT
---	------------------	----------------------	-------------	--------------	-----	------

TESTOSTERONE CYPIONATE

INJECTABLE; INJECTION

TESTOSTERONE CYPIONATE

A0	HIKMA FARMACEUTICA	200MG/ML	A091244 001	May 01, 2012	Apr	NEWA
A0	MYLAN INSTITUTIONAL	200MG/ML	A040652 001	Dec 11, 2006	Feb	CAHN

TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

TESTOSTERONE ENANTHATE

A0	HIKMA FARMACEUTICA	200MG/ML	A091120 001	Sep 18, 2012	Sep	NEWA
A0	MYLAN INSTITUTIONAL	200MG/ML	A040647 001	Oct 05, 2009	Feb	CAHN

TETRABENAZINE

TABLET; ORAL

XENAZINE

>A>	VALEANT BERMUDA	12.5MG	N021894 001	Aug 15, 2008	Oct	CAHN
>A>	+	25MG	N021894 002	Aug 15, 2008	Oct	CAHN
>D>	VALEANT PHARMS	12.5MG	N021894 001	Aug 15, 2008	Oct	CAHN
		12.5MG	N021894 001	Aug 15, 2008	Apr	CAHN
>D>	+	25MG	N021894 002	Aug 15, 2008	Oct	CAHN
	+	25MG	N021894 002	Aug 15, 2008	Apr	CAHN

TETRAHYDROZOLINE HYDROCHLORIDE

SOLUTION; NASAL

TYZINE

+	FOUGERA PHARMS	0.05%	A086576 002		Jan	CAHN
		0.1%	A086576 001		Jan	CAHN

SPRAY; NASAL

TYZINE

+	FOUGERA PHARMS	0.1%	A086576 003		Jan	CAHN
---	----------------	------	-------------	--	-----	------

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

THEO-24

	UCB INC	100MG	A087942 001	Aug 22, 1983	May	CTEC
		200MG	A087943 001	Aug 22, 1983	May	CTEC
		300MG	A087944 001	Aug 22, 1983	May	CTEC
+		400MG	A081034 001	Feb 28, 1992	May	CRLD

CAPSULE, EXTENDED RELEASE; ORAL

THEOPHYLLINE

@ INWOOD LABS	100MG	A040052 001	Feb 14, 1994	May	DISC
@	125MG	A040052 002	Feb 14, 1994	May	DISC
@	200MG	A040052 003	Feb 14, 1994	May	DISC
@	300MG	A040052 004	Feb 14, 1994	May	DISC

INJECTABLE; INJECTION

THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

@ BAXTER HLTHCARE	4MG/ML	N018649 007	Jul 26, 1982	Mar	DISC
@	40MG/100ML	N018649 001	Jul 26, 1982	Mar	DISC
@	80MG/100ML	N018649 002	Jul 26, 1982	Mar	DISC
@	160MG/100ML	N018649 003	Jul 26, 1982	Mar	DISC
@	200MG/100ML	N018649 004	Jul 26, 1982	Mar	DISC
@	320MG/100ML	N018649 006	Nov 13, 1985	Mar	DISC
@	400MG/100ML	N018649 005	Jul 26, 1982	Mar	DISC

SOLUTION; ORAL

THEOPHYLLINE

AA + SILARX	80MG/15ML	A091156 001	Apr 13, 2011	Jun	CTEC
AA TRIS PHARMA INC	80MG/15ML	A091586 001	Jun 15, 2012	Jun	NEWA

TABLET; ORAL

THEOLAIR

+ MEDICIS	125MG	A086399 001		Jul	CAHN
+	250MG	A086399 002		Jul	CAHN

TABLET, EXTENDED RELEASE; ORAL

THEOPHYLLINE

>D> AB INWOOD LABS	450MG	A040034 001	Apr 28, 1995	Oct	DISC
>A> @	450MG	A040034 001	Apr 28, 1995	Oct	DISC
UNIPHYL					
@ RHODES PHARMS	400MG	A087571 001	Sep 01, 1982	Sep	CAHN
@	600MG	A040086 001	Apr 15, 1996	Sep	CAHN

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HYDROCHLORIDE

>D> @ BAXTER HLTHCARE	100MG/ML	A080575 001		Oct	CAHN
>A> @ HIKMA MAPLE	100MG/ML	A080575 001		Oct	CAHN
AP MYLAN INSTITUTIONAL	100MG/ML	A091623 001	Jun 25, 2012	Jun	NEWA

TIAGABINE HYDROCHLORIDE

TABLET; ORAL

GABITRIL

@ CEPHALON	6MG	N020646 006	Nov 29, 2005	Jan	DISC
@	8MG	N020646 007	Nov 29, 2005	Jan	DISC
@	10MG	N020646 008	Nov 29, 2005	Jan	DISC

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

TICLOPIDINE HYDROCHLORIDE

>D> AB SANDOZ	250MG	A075326 001	Aug 20, 1999	Oct	DISC
>A> @	250MG	A075326 001	Aug 20, 1999	Oct	DISC

TINIDAZOLE

TABLET; ORAL

TINDAMAX

AB MISSION PHARMA	250MG	N021618 001	May 17, 2004	Apr	CFTG
AB +	500MG	N021618 002	May 17, 2004	Apr	CFTG

TABLET; ORAL

TINIDAZOLE

AB	NOVEL LABS INC	250MG	A202044 001	Apr 30, 2012	Apr	NEWA
AB		500MG	A202044 002	Apr 30, 2012	Apr	NEWA
AB	ROXANE	250MG	A201172 001	Apr 30, 2012	Apr	NEWA
AB		500MG	A201172 002	Apr 30, 2012	Apr	NEWA

TINZAPARIN SODIUM

INJECTABLE; INJECTION

INNOHEP

@ LEO PHARMA AS	20,000 IU/ML	N020484 001	Jul 14, 2000	Jun	DISC
-----------------	--------------	-------------	--------------	-----	------

TIZANIDINE HYDROCHLORIDE

CAPSULE; ORAL

TIZANIDINE HYDROCHLORIDE

AB	APOTEX INC	EQ 2MG BASE	A078868 001	Feb 03, 2012	Jan	NEWA
AB		EQ 4MG BASE	A078868 002	Feb 03, 2012	Jan	NEWA
AB		EQ 6MG BASE	A078868 003	Feb 03, 2012	Jan	NEWA
>A>	MYLAN LABS	EQ 2MG BASE	A091502 001	Nov 09, 2012	Oct	NEWA
>A>		EQ 4MG BASE	A091502 002	Nov 09, 2012	Oct	NEWA
>A>		EQ 6MG BASE	A091502 003	Nov 09, 2012	Oct	NEWA
	ZANAFLEX					
AB	ACORDA	EQ 2MG BASE	N021447 001	Aug 29, 2002	Jan	CFTG
AB		EQ 4MG BASE	N021447 002	Aug 29, 2002	Jan	CFTG
AB	+	EQ 6MG BASE	N021447 003	Aug 29, 2002	Jan	CFTG

TABLET; ORAL

TIZANIDINE HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 2MG BASE	A076282 001	Dec 16, 2003	Sep	CAHN
AB		EQ 4MG BASE	A076282 002	Dec 16, 2003	Sep	CAHN
AB	PROSAM LABS	EQ 2MG BASE	A076281 001	Oct 20, 2003	Feb	CMFD
AB		EQ 4MG BASE	A076281 002	Oct 20, 2003	Feb	CMFD
AB	SANDOZ INC	EQ 2MG BASE	A076280 001	Nov 26, 2002	Feb	NEWA

TOBRAMYCIN

SOLUTION; INHALATION

>A>	BETHKIS					
>A>	CHIESI PHARMS INC	300MG/4ML	N201820 001	Oct 12, 2012	Oct	NEWA

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION

TOBRAMYCIN SULFATE

	@ APOTHECON	EQ 10MG BASE/ML	A064021 001	May 31, 1994	Sep	DISC
>D>	@ BAXTER HLTHCARE	EQ 10MG BASE/ML	A063113 001	Apr 26, 1991	Oct	CAHN
>D>	@	EQ 10MG BASE/ML	A063128 001	Nov 27, 1991	Oct	CAHN
>D>	@	EQ 40MG BASE/ML	A063127 001	Nov 27, 1991	Oct	CAHN
>D>	@	EQ 40MG BASE/ML	A063118 001	Jul 29, 1991	Oct	CAHN
>D>	AP	EQ 40MG BASE/ML	A063117 001	Apr 26, 1991	Oct	CAHN
>A>	@ HIKMA MAPLE	EQ 10MG BASE/ML	A063113 001	Apr 26, 1991	Oct	CAHN
>A>	@	EQ 10MG BASE/ML	A063128 001	Nov 27, 1991	Oct	CAHN
>A>	@	EQ 40MG BASE/ML	A063118 001	Jul 29, 1991	Oct	CAHN
>A>	@	EQ 40MG BASE/ML	A063127 001	Nov 27, 1991	Oct	CAHN
>A>	AP	EQ 40MG BASE/ML	A063117 001	Apr 26, 1991	Oct	CAHN
AP	PFIZER	EQ 40MG BASE/ML	A065407 001	Mar 11, 2008	Sep	CAHN

TOLBUTAMIDE

TABLET; ORAL

TOLBUTAMIDE

+	MYLAN PHARMS INC	500MG	A086445 001		Mar	CRLD
	@ WATSON LABS	500MG	A086109 001		Mar	DISC
	@	500MG	A087318 001		Mar	DISC

TOLCAPONE

TABLET; ORAL

TASMAR

+	VALEANT PHARMS LLC	100MG	N020697 001	Jan 29, 1998	May	CAHN
	@	200MG	N020697 002	Jan 29, 1998	May	CAHN

TOLTERODINE TARTRATE

TABLET; ORAL

DETROL

AB	PHARMACIA AND UPJOHN	1MG	N020771 001	Mar 25, 1998	Sep	CFTG
AB	+	2MG	N020771 002	Mar 25, 1998	Sep	CFTG
	TOLTERODINE TARTRATE					
AB	APOTEX CORP	1MG	A200164 001	Sep 25, 2012	Sep	NEWA
AB		2MG	A200164 002	Sep 25, 2012	Sep	NEWA

TOPOTECAN HYDROCHLORIDE

INJECTABLE; INJECTION

TOPOTECAN HYDROCHLORIDE

AP	INNOPHARMA INC	EQ 4MG BASE/VIAL	A201166 001	Aug 08, 2012	Jul	NEWA
AP	ONCO THERAPIES LTD	EQ 4MG BASE/VIAL	A091542 001	Aug 28, 2012	Aug	NEWA

TRAMADOL HYDROCHLORIDE

TABLET; ORAL

TRAMADOL HYDROCHLORIDE

AB	MYLAN PHARMS INC	50MG	A075980 001	Nov 21, 2002	Sep	CAHN
	@ SANDOZ	50MG	A075968 001	Jun 25, 2002	Aug	DISC

TABLET, EXTENDED RELEASE; ORAL

TRAMADOL HYDROCHLORIDE

AB2	ACTAVIS	100MG	A091609 001	Jun 27, 2012	Jun	NEWA
AB2		200MG	A091609 002	Jun 27, 2012	Jun	NEWA
AB2		300MG	A091609 003	Jun 27, 2012	Jun	NEWA
AB2	ANCHEN PHARMS	100MG	A200491 001	Jun 27, 2012	Jun	NEWA
AB2		200MG	A200491 002	Jun 27, 2012	Jun	NEWA
AB2		300MG	A200491 003	Jun 27, 2012	Jun	NEWA

TABLET, ORALLY DISINTEGRATING; ORAL

RYBIX ODT

+	SHIONOGI INC	50MG	N021693 001	May 05, 2005	Mar	CTNA
---	--------------	------	-------------	--------------	-----	------

TRANEXAMIC ACID

INJECTABLE; INJECTION

TRANEXAMIC ACID

AP	APP PHARMS LLC	100MG/ML	A091596 001	Mar 02, 2012	May	CAHN
AP	LUITPOLD	100MG/ML	A201885 001	Aug 10, 2011	Sep	CAHN
AP	NEXUS PHARMS	100MG/ML	A091596 001	Mar 02, 2012	Feb	NEWA

TRANLYCYPROMINE SULFATE

TABLET; ORAL

PARNATE

AB	+	COVIS PHARMA	EQ 10MG BASE	N012342 003	Aug 16, 1985	Jan	CAHN
----	---	--------------	--------------	-------------	--------------	-----	------

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

TRAZODONE HYDROCHLORIDE

AB		MYLAN PHARMS INC	50MG	A090514 001	Jun 02, 2009	Sep	CAHN
AB			100MG	A090514 002	Jun 02, 2009	Sep	CAHN
AB			150MG	A090514 003	Jun 02, 2009	Sep	CAHN
AB			300MG	A090514 004	Jun 02, 2009	Sep	CAHN

TRETINOIN

CAPSULE; ORAL

TRETINOIN

>A>	AB		ANCHEN PHARMS	10MG	A201687 001	Oct 24, 2012	Oct	NEWA
>D>		+	BARR	10MG	A077684 001	Jun 22, 2007	Oct	CTEC
>A>	AB	+	BARR LABS INC	10MG	A077684 001	Jun 22, 2007	Oct	CTEC

CREAM; TOPICAL

AVITA

AB		MYLAN PHARMS INC	0.025%	N020404 003	Jan 14, 1997	Jun	CAHN
----	--	------------------	--------	-------------	--------------	-----	------

RENOVA

	+	VALEANT INTL	0.02%	N021108 001	Aug 31, 2000	Jan	CAHN
AB2	+		0.05%	N019963 001	Dec 29, 1995	Jan	CAHN

RETIN-A

AB	+	VALEANT INTL	0.025%	N019049 001	Sep 16, 1988	Jan	CAHN
AB1	+		0.05%	N017522 001		Jan	CAHN
AB	+		0.1%	N017340 001		Jan	CAHN

TRETINOIN

AB		PRECISION DERMAT	0.025%	A075264 001	Dec 24, 1998	May	CAHN
	+		0.0375%	A090098 001	Mar 22, 2010	May	CAHN
AB1			0.05%	A075265 001	Dec 24, 1998	May	CAHN
			0.075%	A202209 001	Oct 11, 2012	Sep	NEWA
AB			0.1%	A075213 001	Dec 24, 1998	May	CAHN
AB2		SUNEVA MEDCL	0.05%	A076498 001	Sep 15, 2005	May	CAHN

GEL; TOPICAL

RETIN-A

AB	+	VALEANT INTL	0.01%	N017955 001		Jan	CAHN
AB	+		0.025%	N017579 002		Jan	CAHN

TRETINOIN

AB		PRECISION DERMAT	0.01%	A075589 001	Jun 11, 2002	May	CAHN
AB			0.025%	A075529 001	Feb 22, 2000	May	CAHN

SOLUTION; TOPICAL

RETIN-A

AT	+	VALEANT INTL	0.05%	N016921 001		Jan	CAHN
----	---	--------------	-------	-------------	--	-----	------

SWAB; TOPICAL

RETIN-A

	@	VALEANT INTL	0.05%	N016921 002		Jan	CAHN
--	---	--------------	-------	-------------	--	-----	------

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

AZMACORT

	@	ABBOTT	0.1MG/INH	N018117 001	Apr 23, 1982	May	DISC
--	---	--------	-----------	-------------	--------------	-----	------

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	FOUGERA PHARMS	0.025%	A085692 001		Jan	CAHN
AT		0.1%	A085692 003		Jan	CAHN
AT	+	0.5%	A085692 002		Jan	CAHN

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	FOUGERA PHARMS	0.025%	A040467 001	Apr 21, 2003	Jan	CAHN
AT		0.1%	A040467 002	Apr 21, 2003	Jan	CAHN
>D> AT	MORTON GROVE	0.025%	A088450 001	Apr 01, 1985	Oct	CRLD
>A> AT	+	0.025%	A088450 001	Apr 01, 1985	Oct	CRLD

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	FOUGERA PHARMS	0.025%	A085691 001		Jan	CAHN
AT		0.1%	A085691 003		Jan	CAHN
AT		0.5%	A085691 002		Jan	CAHN

SPRAY, METERED; NASAL

TRIAMCINOLONE ACETONIDE

AB	TEVA PHARMS	0.055MG/SPRAY	A078104 001	Jul 30, 2009	Mar	CAHN
----	-------------	---------------	-------------	--------------	-----	------

TRIAZOLAM

TABLET; ORAL

TRIAZOLAM

AB	MYLAN PHARMS INC	0.125MG	A074031 001	Mar 25, 1994	Sep	CAHN
AB		0.25MG	A074031 002	Mar 25, 1994	Sep	CAHN

TRIFLURIDINE

SOLUTION/DROPS; OPHTHALMIC

TRIFLURIDINE

AT	ALCON PHARMS LTD	1%	A074311 001	Oct 06, 1995	Sep	CAHN
----	------------------	----	-------------	--------------	-----	------

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

TRIMETHOBENZAMIDE HYDROCHLORIDE

@ HOSPIRA	100MG/ML	A088804 001	Apr 03, 1987	Jun	DISC
-----------	----------	-------------	--------------	-----	------

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

SANCTURA XR

AB	+	ALLERGAN	60MG	N022103 001	Aug 03, 2007	Sep	CFTG
----	---	----------	------	-------------	--------------	-----	------

TROSPIUM CHLORIDE

AB		WATSON LABS INC FL	60MG	A091289 001	Oct 12, 2012	Sep	NEWA
----	--	--------------------	------	-------------	--------------	-----	------

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	JUBILANT ORGANOSYS	EQ 500MG BASE	A201506 001	Apr 03, 2012	Mar	NEWA
AB		EQ 1GM BASE	A201506 002	Apr 03, 2012	Mar	NEWA
AB	MYLAN PHARMS INC	EQ 500MG BASE	A078518 001	May 24, 2010	Sep	CAHN
AB		EQ 1GM BASE	A078518 002	May 24, 2010	Sep	CAHN

VALGANCICLOVIR HYDROCHLORIDE

FOR SOLUTION; ORAL

VALCYTE

+	HOFFMANN LA ROCHE	50MG/ML	N022257 001	Aug 28, 2009	May	CAHN
---	-------------------	---------	-------------	--------------	-----	------

TABLET; ORAL

VALCYTE

+	HOFFMANN LA ROCHE	EQ 450MG BASE	N021304 001	Mar 29, 2001	May	CAHN
---	-------------------	---------------	-------------	--------------	-----	------

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOCIN HYDROCHLORIDE

AB	VIROPHARMA	EQ 125MG BASE	N050606 001	Apr 15, 1986	Mar	CFTG
AB	+	EQ 250MG BASE	N050606 002	Apr 15, 1986	Mar	CFTG

VANCOMYCIN HYDROCHLORIDE

AB	AKORN	EQ 125MG BASE	A065478 001	Apr 09, 2012	Mar	NEWA
AB		EQ 250MG BASE	A065478 002	Apr 09, 2012	Mar	NEWA
AB	APP PHARMS LLC	EQ 125MG BASE	A065453 001	Jun 18, 2012	Jun	NEWA
AB		EQ 250MG BASE	A065453 002	Jun 18, 2012	Jun	NEWA
AB	STRIDES ARCOLAB LTD	EQ 125MG BASE	A065490 001	Apr 09, 2012	Mar	NEWA
AB		EQ 250MG BASE	A065490 002	Apr 09, 2012	Mar	NEWA
AB	WATSON LABS	EQ 125MG BASE	A065510 001	Apr 09, 2012	Mar	NEWA
AB		EQ 250MG BASE	A065510 002	Apr 09, 2012	Mar	NEWA

INJECTABLE; INJECTION

VANCOLED

>D>	@ BAXTER HLTHCARE	EQ 500MG BASE/VIAL	A062682 001	Jul 22, 1986	Oct	CAHN
>D>	@	EQ 1GM BASE/VIAL	A062682 002	Mar 30, 1988	Oct	CAHN
>D>	@	EQ 2GM BASE/VIAL	A062682 003	May 11, 1988	Oct	CAHN
>D>	@	EQ 5GM BASE/VIAL	A062682 004	May 11, 1988	Oct	CAHN
>D>	@	EQ 10GM BASE/VIAL	A062682 005	May 11, 1988	Oct	CAHN
>A>	@ HIKMA MAPLE	EQ 500MG BASE/VIAL	A062682 001	Jul 22, 1986	Oct	CAHN
>A>	@	EQ 1GM BASE/VIAL	A062682 002	Mar 30, 1988	Oct	CAHN
>A>	@	EQ 2GM BASE/VIAL	A062682 003	May 11, 1988	Oct	CAHN
>A>	@	EQ 5GM BASE/VIAL	A062682 004	May 11, 1988	Oct	CAHN
>A>	@	EQ 10GM BASE/VIAL	A062682 005	May 11, 1988	Oct	CAHN

VANCOMYCIN HYDROCHLORIDE

>D>	@ BAXTER HLTHCARE	EQ 500MG BASE/VIAL	A062879 001	Aug 02, 1988	Oct	CAHN
>D>	@	EQ 1GM BASE/VIAL	A062879 002	Aug 02, 1988	Oct	CAHN
>A>	@ HIKMA MAPLE	EQ 500MG BASE/VIAL	A062879 001	Aug 02, 1988	Oct	CAHN
>A>	@	EQ 1GM BASE/VIAL	A062879 002	Aug 02, 1988	Oct	CAHN
AP	SAGENT PHARMS	EQ 5GM BASE/VIAL	A200837 001	Aug 10, 2012	Jul	NEWA
AP	SANDOZ INC	EQ 5GM BASE/VIAL	A201048 001	Aug 10, 2012	Jul	NEWA
AP		EQ 10GM BASE/VIAL	A201048 002	Aug 10, 2012	Jul	NEWA

VANDETANIB

TABLET; ORAL

CAPRELSA

	IPR PHARMS INC	100MG	N022405 001	Apr 06, 2011	Feb	CTNA
+		300MG	N022405 002	Apr 06, 2011	Feb	CTNA

VARDENAFIL HYDROCHLORIDE

TABLET; ORAL

LEVITRA

AB	BAYER HLTHCARE	2.5MG	N021400 003	Aug 19, 2003	Apr	CFTG
AB		5MG	N021400 001	Aug 19, 2003	Apr	CFTG
AB		10MG	N021400 002	Aug 19, 2003	Apr	CFTG
AB	+	20MG	N021400 004	Aug 19, 2003	Apr	CFTG

VARDENAFIL HYDROCHLORIDE

AB	TEVA PHARMS	2.5MG	A091347 001	May 03, 2012	Apr	NEWA
AB		5MG	A091347 002	May 03, 2012	Apr	NEWA
AB		10MG	A091347 003	May 03, 2012	Apr	NEWA

TABLET; ORAL

VARDENAFIL HYDROCHLORIDE

AB	TEVA PHARMS	20MG	A091347 004	May 03, 2012	Apr	NEWA
----	-------------	------	-------------	--------------	-----	------

VECURONIUM BROMIDE

INJECTABLE; INJECTION

VECURONIUM BROMIDE

>D>	@ BAXTER HLTHCARE	10MG/VIAL	A075218 001	Aug 23, 1999	Oct	CAHN
>D>	@	20MG/VIAL	A075218 002	Aug 23, 1999	Oct	CAHN
AP	BEDFORD	10MG/VIAL	A075549 001	Jun 13, 2000	Jun	CRLD
		20MG/VIAL	A075549 002	Jun 13, 2000	Jun	CRLD
>A>	@ HIKMA MAPLE	10MG/VIAL	A075218 001	Aug 23, 1999	Oct	CAHN
>A>	@	20MG/VIAL	A075218 002	Aug 23, 1999	Oct	CAHN
AP +	SUN PHARMA GLOBAL	10MG/VIAL	A079001 001	Jun 17, 2009	Jun	CRLD
AP +		20MG/VIAL	A079001 002	Jun 17, 2009	Jun	CRLD

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	ANCHEN PHARMS	EQ 37.5MG BASE	A078087 001	Mar 16, 2012	Mar	NEWA
AB		EQ 75MG BASE	A078087 002	Mar 16, 2012	Mar	NEWA
AB		EQ 150MG BASE	A078087 003	Mar 16, 2012	Mar	NEWA

TABLET; ORAL

VENLAFAXINE HYDROCHLORIDE

AB	HERITAGE PHARMS INC	EQ 25MG BASE	A078554 001	Jan 09, 2009	Aug	CAHN
AB		EQ 37.5MG BASE	A078554 002	Jan 09, 2009	Aug	CAHN
AB		EQ 50MG BASE	A078554 003	Jan 09, 2009	Aug	CAHN
AB		EQ 75MG BASE	A078554 004	Jan 09, 2009	Aug	CAHN
AB		EQ 100MG BASE	A078554 005	Jan 09, 2009	Aug	CAHN

VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CALAN SR

AB +	PFIZER	120MG	N019152 003	Mar 06, 1991	Feb	CTNA
AB +		180MG	N019152 002	Dec 15, 1989	Feb	CTNA
AB +		240MG	N019152 001	Dec 16, 1986	Feb	CTNA

VERAPAMIL HYDROCHLORIDE

AB	APOTEX CORP	120MG	A200878 001	Apr 20, 2012	Apr	NEWA
AB		180MG	A200878 002	Apr 20, 2012	Apr	NEWA
AB		240MG	A200878 003	Apr 20, 2012	Apr	NEWA

VIGABATRIN

FOR SOLUTION; ORAL

SABRIL

+	LUNDBECK LLC	500MG/PACKET	N022006 001	Aug 21, 2009	Apr	CAHN
---	--------------	--------------	-------------	--------------	-----	------

TABLET; ORAL

SABRIL

+	LUNDBECK LLC	500MG	N020427 001	Aug 21, 2009	Apr	CAHN
---	--------------	-------	-------------	--------------	-----	------

VILAZODONE HYDROCHLORIDE

TABLET; ORAL

VIIBRYD

+	FOREST LABS INC	10MG	N022567 001	Jan 21, 2011	Apr	CRLD
		40MG	N022567 003	Jan 21, 2011	Apr	CRLD

VINCRIStINE SULFATE

INJECTABLE, LIPOSOMAL; INTRAVENOUS

MARQIBO KIT

+	TALON THERAP	5MG/5ML (1MG/ML)	N202497	001	Aug 09, 2012	Aug	NEWA
---	--------------	------------------	---------	-----	--------------	-----	------

VINORELBINE

INJECTABLE; INJECTION

VINORELBINE

AP	ONCO THERAPIES LTD	EQ 10MG BASE/ML	A200148	001	Aug 31, 2012	Aug	NEWA
----	--------------------	-----------------	---------	-----	--------------	-----	------

VINORELBINE TARTRATE

INJECTABLE; INJECTION

VINORELBINE TARTRATE

>D>	AP	BAXTER HLTHCARE	EQ 10MG BASE/ML	A075992	001	Jun 10, 2003	Oct	CAHN
>A>	AP	HIKMA MAPLE	EQ 10MG BASE/ML	A075992	001	Jun 10, 2003	Oct	CAHN
	AP	JIANGSU HANSON PHARM	EQ 10MG BASE/ML	A091106	001	Sep 26, 2012	Sep	NEWA

VISMODEGIB

CAPSULE; ORAL

ERIVEDGE

+	GENENTECH	150MG	N203388	001	Jan 30, 2012	Jan	NEWA
---	-----------	-------	---------	-----	--------------	-----	------

VORICONAZOLE

INJECTABLE; IV (INFUSION)

VFEND

AP	+	PFIZER	200MG/VIAL	N021267	001	May 24, 2002	May	CFTG
----	---	--------	------------	---------	-----	--------------	-----	------

VORICONAZOLE

AP		SANDOZ INC	200MG/VIAL	A090862	001	May 30, 2012	May	NEWA
----	--	------------	------------	---------	-----	--------------	-----	------

TABLET; ORAL

VORICONAZOLE

>D>	AB	MATRIX LABS LTD	50MG	A090547	001	Apr 22, 2010	Oct	CAHN
>D>	AB		200MG	A090547	002	Apr 22, 2010	Oct	CAHN
>A>	AB	MYLAN PHARMS INC	50MG	A090547	001	Apr 22, 2010	Oct	CAHN
>A>	AB		200MG	A090547	002	Apr 22, 2010	Oct	CAHN
	AB	TEVA PHARMS	50MG	A091658	001	Apr 06, 2012	Mar	NEWA
	AB		200MG	A091658	002	Apr 06, 2012	Mar	NEWA

ZICONOTIDE

INJECTABLE; INTRATHECAL

PRIALT

@ JAZZ PHARMS COMMERCL 200MCG/2ML (100MCG/ML)

N021060	003	Dec 28, 2004	Mar	CAHN
---------	-----	--------------	-----	------

@ JAZZ PHARMS INTL 200MCG/2ML (100MCG/ML)

N021060	003	Dec 28, 2004	Jun	CAHN
---------	-----	--------------	-----	------

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL

PRIALT

+	JAZZ PHARMS COMMERCL	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004	Mar	CAHN
+		500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004	Mar	CAHN
+		500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004	Mar	CAHN
+	JAZZ PHARMS INTL	100MCG/1ML (100MCG/ML)	N021060	002	Dec 28, 2004	Jun	CAHN
+		500MCG/5ML (100MCG/ML)	N021060	004	Dec 28, 2004	Jun	CAHN
+		500MCG/20ML (25MCG/ML)	N021060	001	Dec 28, 2004	Jun	CAHN

ZIDOVUDINE

TABLET; ORAL

ZIDOVUDINE

>D>	AB	HEC PHARM INC	300MG	A202058 001	Oct 07, 2011	Oct	CAHN
>A>	AB	HEC PHARM USA INC	300MG	A202058 001	Oct 07, 2011	Oct	CAHN
	AB	MYLAN PHARMS INC	300MG	A078922 001	Feb 14, 2008	Sep	CAHN
		@ RANBAXY LABS LTD	300MG	A077327 001	Sep 19, 2005	Apr	DISC

ZIPRASIDONE HYDROCHLORIDE

CAPSULE; ORAL

GEODON

AB	+	PFIZER	EQ 20MG BASE	N020825 001	Feb 05, 2001	Feb	CFTG
AB			EQ 40MG BASE	N020825 002	Feb 05, 2001	Feb	CFTG
AB			EQ 60MG BASE	N020825 003	Feb 05, 2001	Feb	CFTG
AB			EQ 80MG BASE	N020825 004	Feb 05, 2001	Feb	CFTG

ZIPRASIDONE HYDROCHLORIDE

AB		APOTEX CORP	EQ 20MG BASE	A077561 001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077561 002	Mar 02, 2012	Feb	NEWA
AB			EQ 60MG BASE	A077561 003	Mar 02, 2012	Feb	NEWA
AB			EQ 80MG BASE	A077561 004	Mar 02, 2012	Feb	NEWA
AB		DR REDDYS LABS INC	EQ 20MG BASE	A077565 001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077565 002	Mar 02, 2012	Feb	NEWA
AB			EQ 60MG BASE	A077565 003	Mar 02, 2012	Feb	NEWA
AB			EQ 80MG BASE	A077565 004	Mar 02, 2012	Feb	NEWA
AB		LUPIN PHARMS	EQ 20MG BASE	A077560 001	Mar 02, 2012	Feb	NEWA
AB			EQ 40MG BASE	A077560 002	Mar 02, 2012	Feb	NEWA
AB			EQ 60MG BASE	A077560 003	Mar 02, 2012	Feb	NEWA
AB			EQ 80MG BASE	A077560 004	Mar 02, 2012	Feb	NEWA
AB		SANDOZ INC	EQ 20MG BASE	A077562 001	Jun 01, 2012	May	NEWA
AB			EQ 40MG BASE	A077562 002	Jun 01, 2012	May	NEWA
AB			EQ 60MG BASE	A077562 003	Jun 01, 2012	May	NEWA
AB			EQ 80MG BASE	A077562 004	Jun 01, 2012	May	NEWA
AB		WOCKHARDT LTD	EQ 20MG BASE	A090348 001	Sep 05, 2012	Aug	NEWA
AB			EQ 40MG BASE	A090348 002	Sep 05, 2012	Aug	NEWA
AB			EQ 60MG BASE	A090348 003	Sep 05, 2012	Aug	NEWA
AB			EQ 80MG BASE	A090348 004	Sep 05, 2012	Aug	NEWA

ZOLPIDEM TARTRATE

TABLET; ORAL

ZOLPIDEM TARTRATE

AB		CIPLA LTD	5MG	A077388 001	Jul 30, 2012	Jul	NEWA
AB			10MG	A077388 002	Jul 30, 2012	Jul	NEWA
>D>	AB	MYLAN	5MG	A078016 001	Apr 23, 2007	Oct	DISC
>D>	AB		10MG	A078016 002	Apr 23, 2007	Oct	DISC
>A>		@ MYLAN PHARMS INC	5MG	A078016 001	Apr 23, 2007	Oct	DISC
>A>		@	10MG	A078016 002	Apr 23, 2007	Oct	DISC

ZONISAMIDE

CAPSULE; ORAL

ZONISAMIDE

AB		MYLAN PHARMS INC	25MG	A077647 001	Dec 22, 2005	Sep	CAHN
AB			50MG	A077647 002	Dec 22, 2005	Sep	CAHN
AB			100MG	A077647 003	Dec 22, 2005	Sep	CAHN

OTC DRUG PRODUCT LIST - 32ND EDITION

OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

2-1

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE; ORAL

PEPCID COMPLETE

+	MCNEIL CONS	800MG;10MG;165MG	N020958	001	Oct 16, 2000	Mar	CAHN
---	-------------	------------------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE

SYRUP; ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

@	RANBAXY LABS LTD	5MG/5ML	A090183	002	Apr 24, 2008	Jul	DISC
---	------------------	---------	---------	-----	--------------	-----	------

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@	RANBAXY LABS LTD	5MG/5ML	A090183	001	Apr 24, 2008	Jul	DISC
---	------------------	---------	---------	-----	--------------	-----	------

TABLET, CHEWABLE; ORAL

CHILDREN'S ZYRTEC ALLERGY

>A>		MCNEIL CONS	5MG	N021621	003	Nov 16, 2007	Oct	CAHN
-----	--	-------------	-----	---------	-----	--------------	-----	------

>A>	+		10MG	N021621	004	Nov 16, 2007	Oct	CAHN
-----	---	--	------	---------	-----	--------------	-----	------

>D>		PFIZER	5MG	N021621	003	Nov 16, 2007	Oct	CAHN
-----	--	--------	-----	---------	-----	--------------	-----	------

>D>	+		10MG	N021621	004	Nov 16, 2007	Oct	CAHN
-----	---	--	------	---------	-----	--------------	-----	------

CHILDREN'S ZYRTEC HIVES RELIEF

>A>		MCNEIL CONS	5MG	N021621	005	Nov 16, 2007	Oct	CAHN
-----	--	-------------	-----	---------	-----	--------------	-----	------

>A>	+		10MG	N021621	006	Nov 16, 2007	Oct	CAHN
-----	---	--	------	---------	-----	--------------	-----	------

>D>		PFIZER	5MG	N021621	005	Nov 16, 2007	Oct	CAHN
-----	--	--------	-----	---------	-----	--------------	-----	------

>D>	+		10MG	N021621	006	Nov 16, 2007	Oct	CAHN
-----	---	--	------	---------	-----	--------------	-----	------

TABLET; ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

>D>		ACTAVIS ELIZABETH	5MG	A078615	003	Dec 28, 2007	Oct	DISC
-----	--	-------------------	-----	---------	-----	--------------	-----	------

>A>	@		5MG	A078615	003	Dec 28, 2007	Oct	DISC
-----	---	--	-----	---------	-----	--------------	-----	------

>D>			10MG	A078615	004	Dec 28, 2007	Oct	DISC
-----	--	--	------	---------	-----	--------------	-----	------

>A>	@		10MG	A078615	004	Dec 28, 2007	Oct	DISC
-----	---	--	------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CETIRIZINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

	SUN PHARM INDS LTD	5MG;120MG	A090922	001	Sep 28, 2012	Sep	NEWA
--	--------------------	-----------	---------	-----	--------------	-----	------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SWAB; TOPICAL

CHLORAPREP ONE-STEP SEPP

+	CAREFUSION	2%;70% (0.67ML)	N021555	001	Oct 07, 2002	Aug	CAHN
---	------------	-----------------	---------	-----	--------------	-----	------

CHLORAPREP SINGLE SWABSTICK

+	CAREFUSION	2%;70% (1.75ML)	N021555	002	May 10, 2005	Aug	CAHN
---	------------	-----------------	---------	-----	--------------	-----	------

CHLORAPREP TRIPLE SWABSTICK

+	CAREFUSION	2%;70% (5.25ML)	N021555	003	Jun 10, 2009	Aug	CAHN
---	------------	-----------------	---------	-----	--------------	-----	------

CHLORASCUB MAXI SWABSTICK

+	PROF DSPLS	3.15%;70% (5.1ML)	N021524	003	Jun 03, 2005	Mar	CAHN
---	------------	-------------------	---------	-----	--------------	-----	------

CHLORASCUB SWAB

+	PROF DSPLS	3.15%;70% (1ML)	N021524	001	Jun 03, 2005	Mar	CAHN
---	------------	-----------------	---------	-----	--------------	-----	------

CHLORASCUB SWABSTICK

+	PROF DSPLS	3.15%;70% (1.6ML)	N021524	002	Jun 03, 2005	Mar	CAHN
---	------------	-------------------	---------	-----	--------------	-----	------

DEXTROMETHORPHAN POLISTIREX

SUSPENSION, EXTENDED RELEASE; ORAL

DEXTROMETHORPHAN POLISTIREX

	TRIS PHARMA INC	EQ 30MG HBR/5ML	A091135	001	May 25, 2012	May	NEWA
--	-----------------	-----------------	---------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE; ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

STRIDES ARCOLAB LTD	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A200888 001	Mar 05, 2012	Feb	NEWA
---------------------	--	-------------	--------------	-----	------

FAMOTIDINE

TABLET, CHEWABLE; ORAL

PEPCID AC

@ MCNEIL CONS

10MG

N020801 001 Sep 24, 1998 Mar CAHN

+

20MG

N020801 002 Dec 17, 2007 Mar CAHN

TABLET; ORAL

FAMOTIDINE

SANDOZ

10MG

A076101 001 Oct 21, 2002 Oct DISC

>D>

@

10MG

A076101 001 Oct 21, 2002 Oct DISC

>A>

PEPCID AC

MCNEIL CONS

10MG

N020325 001 Apr 28, 1995 Mar CAHN

+

20MG

N020325 002 Sep 23, 2003 Mar CAHN

PEPCID AC (GELTAB)

MCNEIL CONS

10MG

N020902 001 Aug 05, 1999 Mar CAHN

FEXOFENADINE HYDROCHLORIDE

TABLET; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS

30MG

A091567 002 Feb 06, 2012 Jan NEWA

WOCKHARDT LTD

30MG

A079112 002 Feb 08, 2012 Jan NEWA

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

SUN PHARM INDS

30MG

A091567 001 Feb 06, 2012 Jan NEWA

WOCKHARDT LTD

30MG

A079112 001 Feb 08, 2012 Jan NEWA

FEXOFENADINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS

60MG

A091567 004 Feb 06, 2012 Jan NEWA

SUN PHARM INDS

180MG

A091567 006 Feb 06, 2012 Jan NEWA

WOCKHARDT LTD

60MG

A079112 004 Feb 08, 2012 Jan NEWA

WOCKHARDT LTD

180MG

A079112 006 Feb 08, 2012 Jan NEWA

FEXOFENADINE HYDROCHLORIDE HIVES

SUN PHARM INDS

60MG

A091567 003 Feb 06, 2012 Jan NEWA

SUN PHARM INDS

180MG

A091567 005 Feb 06, 2012 Jan NEWA

WOCKHARDT LTD

60MG

A079112 003 Feb 08, 2012 Jan NEWA

WOCKHARDT LTD

180MG

A079112 005 Feb 08, 2012 Jan NEWA

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

ACCUCAPS INDS

EQ 200MG FREE ACID AND POTASSIUM SALT

A077338 001 Jul 10, 2009 Oct CAHN

>D>

EQ 200MG FREE ACID AND POTASSIUM SALT

A077338 001 Jul 10, 2009 Jan CAHN

PLD ACQUISITIONS

EQ 200MG FREE ACID AND POTASSIUM SALT

A077338 001 Jul 10, 2009 Oct CAHN

>A>

TABLET; ORAL

IBUPROFEN

CONTRACT PHARMACAL

200MG

A073691 001 Feb 25, 1994 Oct DISC

>D>

@

200MG

A073691 001 Feb 25, 1994 Oct DISC

>A>

IBUPROFEN SODIUM

TABLET; ORAL

ADVIL

+ PFIZER CONS HLTHCARE EQ 200MG BASE

N201803 001 Jun 12, 2012 Jun NEWA

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

DR REDDYS LABS LTD 15MG

A202194 001 May 18, 2012 Apr NEWA

PERRIGO R AND D 15MG

A202319 001 May 18, 2012 Apr NEWA

WOCKHARDT LTD 15MG

A202727 001 May 18, 2012 Apr NEWA

PREVACID 24 HR

+ NOVARTIS 15MG

N022327 001 May 18, 2009 Apr CFTG

LEVONORGESTREL

TABLET; ORAL

LEVONORGESTREL

WATSON LABS INC 1.5MG

A200670 001 Jul 12, 2012 Jun NEWA

PLAN B

+ TEVA BRANDED PHARM 0.75MG

N021045 002 Aug 24, 2006 May CAHN

PLAN B ONE-STEP

+ DURAMED 1.5MG

N021998 001 Jul 10, 2009 Jun CFTG

LORATADINE

SYRUP; ORAL

LORATADINE

@ RANBAXY LABS LTD 1MG/ML

A076529 001 Aug 20, 2004 Jul DISC

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

>D> SANDOZ EQ 200MG BASE

A074646 001 Jan 13, 1997 Oct DISC

>A> @ EQ 200MG BASE

A074646 001 Jan 13, 1997 Oct DISC

NICOTINE

FILM, EXTENDED RELEASE; TRANSDERMAL

NICOTINE

AVEVA 7MG/24HR

A074612 002 Jul 28, 2003 Apr NEWA

14MG/24HR

A074612 003 Oct 20, 1997 Apr NEWA

NICOTINE POLACRILEX

TROCHE/LOZENGE; ORAL

NICOTINE POLACRILEX

PERRIGO R AND D EQ 2MG BASE

A203690 001 Oct 09, 2012 Sep NEWA

EQ 4MG BASE

A203690 002 Oct 09, 2012 Sep NEWA

POLYETHYLENE GLYCOL 3350

FOR SOLUTION; ORAL

POLYETHYLENE GLYCOL 3350

@ PADDOCK LLC 17GM/SC00PFUL

A090567 001 Oct 15, 2009 Sep DISC

POTASSIUM IODIDESOLUTION; ORAL
THYROSHIELD

>A>	+	ARCO PHARMS LLC	65MG/ML	A077218 001	Jan 12, 2005	Oct	CAHN
>D>	+	FLEMING	65MG/ML	A077218 001	Jan 12, 2005	Oct	CAHN

RANITIDINE HYDROCHLORIDE

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

APOTEX INC	EQ 150MG BASE	A200172 001	May 31, 2012	May	NEWA
SHASUN CHEMS	EQ 75MG BASE	A201745 001	Feb 29, 2012	Feb	NEWA

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

CUMULATIVE SUPPLEMENT NUMBER 10 OCTOBER 2012

NO OCTOBER 2012 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO OCTOBER 2012 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST - 32ND EDITION

A - 1

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE - ABACAVIR SULFATE</u>						
A091294 001					PC	Dec 16, 2012
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N021539 001	8148356	May 21, 2026	DP			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N202450 001	5840279	Jun 21, 2016	DP		NCE	Jul 23, 2017
	6071498	Jun 21, 2016	DP			
	6681768	Aug 07, 2022	DP			
	6750226	Sep 05, 2020	DS DP U-1264			
	7078412	Jul 16, 2020	DS DP U-1263			
	8051851	Apr 22, 2027	DP			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N022320 001	8105618	Dec 23, 2022	U-1078			
	8129362	Jul 18, 2027	U-1078			
	8241649	Dec 23, 2022	DP			
<u>ALBUMIN HUMAN - OPTISON</u>						
N020899 001					M-120	Aug 17, 2015
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N021457 001	6446627	Dec 18, 2017	DP			
	8132712	Sep 07, 2028	DP			
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N020983 001	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>ALCAFTADINE - LASTACFT</u>						
N022134 001	>A> 5468743	Nov 21, 2013	DS DP			
<u>ALENDRONATE SODIUM - BINOSTO</u>						
N202344 001	7488496	Aug 11, 2023	DS DP			
	7964212	Mar 06, 2023	DS DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N022217 001	8168616	Jul 05, 2025	DP			
<u>ALISKIREN HEMIFUMARATE; VALSARTAN - VALTURNA</u>						
N022217 002	8168616	Jul 05, 2025	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N021775 001	8112290	Jul 31, 2030	U-1225			
<u>AMBRISENTAN - LETAIRIS</u>						
N022081 001	RE42462	Jul 29, 2018	DS			
<u>AMBRISENTAN - LETAIRIS</u>						
N022081 002	RE42462	Jul 29, 2018	DS			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N020965 001	8216289	May 01, 2018	U-289			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 001	8101599	May 16, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 002	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 003	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 004	8101599	May 16, 2023	DP			
<u>AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN - EXFORGE HCT</u>						
N022314 005	8101599	May 16, 2023	DP			
<u>APREPITANT - EMEND</u>						
N021549 001	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1282			
<u>APREPITANT - EMEND</u>						
N021549 002	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1282			
<u>APREPITANT - EMEND</u>						
N021549 003	8258132	Sep 26, 2027	DP U-901			
	8258132	Sep 26, 2027	DP U-1282			
<u>ARFORMOTEROL TARTRATE - BROVANA</u>						
N021912 001	6589508	Apr 03, 2013	U-793			
	6667344	Jun 22, 2021	DP			
	6814953	Jun 22, 2021	U-793			
	8110706	Nov 09, 2021	DP			
<u>ARSENIC TRIOXIDE - TRISENOX</u>						
N021248 001	>A> 8273379	Nov 10, 2018	U-1291			
<u>ATOVAQUONE; PROGUANIL HYDROCHLORIDE - ATOVAQUONE AND PROGUANIL HYDROCHLORIDE</u>						
A091211 001					PC	Mar 13, 2012
<u>AVANAFIL - STENDRA</u>						
N202276 001	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
	>A> 7501409	May 05, 2023	DP			
<u>AVANAFIL - STENDRA</u>						
N202276 002	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
	>A> 7501409	May 05, 2023	DP			
<u>AVANAFIL - STENDRA</u>						
N202276 003	6656935	Sep 13, 2020	DS DP U-155		NCE	Apr 27, 2017
	>A> 7501409	May 05, 2023	DP			
<u>AXITINIB - INLYTA</u>						
N202324 001	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			
<u>AXITINIB - INLYTA</u>						
N202324 002	6534524	Jun 30, 2020	DS DP		NCE	Jan 27, 2017
	7141581	Jun 30, 2020	U-1220			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>AZELASTINE HYDROCHLORIDE; FLUTICASON PROPIONATE - DYMISTA</u>						
N202236 001	8163723	Aug 29, 2023	U-81		NC	May 01, 2015
	8163723	Aug 29, 2023	U-77			
	8163723	Aug 29, 2023	U-707			
	8163723	Aug 29, 2023	U-644			
	8168620	Feb 24, 2026	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N202331 001	5583141	Dec 10, 2013	DS DP U-3			
	5736555	Jun 25, 2012	DS DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N202331 002	5583141	Dec 10, 2013	DS DP U-3			
	5736555	Jun 25, 2012	DS DP U-3			
	7157584	May 22, 2025	DS			
	7572920	Jan 07, 2025	DP U-3			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N022205 001	6197341	Mar 13, 2018	DP U-1229		NDF	Feb 03, 2015
	7452872	Aug 24, 2026	U-1229			
	7625884	Aug 24, 2026	U-1229			
<u>BECLOMETHASONE DIPROPIONATE - QNASL</u>						
N202813 001	5605674	Feb 25, 2014	DP		NP	Mar 23, 2015
	5683677	Nov 04, 2014	DP			
	5776432	Jul 07, 2015	DP			
	7780038	Jan 24, 2027	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N022249 001					NCE ODE PED PED	Mar 20, 2013 Mar 20, 2015 Sep 20, 2015 Sep 20, 2013
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N022249 002					NCE ODE PED PED	Mar 20, 2013 Mar 20, 2015 Sep 20, 2015 Sep 20, 2013
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N050819 001	>A> 8288434	Aug 05, 2029	DP U-124			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N022185 001					>A> I-659	Oct 17, 2015
<u>BIMATOPROST - LATISSE</u>						
N022369 001	8101161	May 25, 2024	U-1218			
	8101161	May 25, 2024	U-1217			
	8263054	Aug 25, 2023	U-1277			
<u>BIMATOPROST - LUMIGAN</u>						
N022184 001	8278353	Mar 16, 2025	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>BIVALIRUDIN - ANGIOMAX</u>						
N020873 001	5196404	Dec 15, 2014	DS DP U-1232			
	5196404	Dec 15, 2014	DS DP U-1040			
	5196404*PED	Jun 15, 2015				
<u>BOCEPREVIR - VICTRELIS</u>						
N202258 001	8119602	Mar 17, 2027	U-1233			
	RE43298	Feb 22, 2022	DS DP U-1128			
<u>BORTEZOMIB - VELCADE</u>						
N021602 001					NR	Jan 23, 2015
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N203341 001	6002008	Mar 27, 2018	DS DP U-1284		NCE	Sep 04, 2017
	7417148	Jan 23, 2026	U-1283		ODE	Sep 04, 2019
	7767678	Nov 23, 2026	DS DP			
	7919625	Dec 11, 2025	DP			
	RE42376	Sep 24, 2019	DS			
<u>BOSUTINIB MONOHYDRATE - BOSULIF</u>						
N203341 002	6002008	Mar 27, 2018	DS DP U-1284		NCE	Sep 04, 2017
	7417148	Jan 23, 2026	U-1283		ODE	Sep 04, 2019
	7767678	Nov 23, 2026	DS DP			
	7919625	Dec 11, 2025	DP			
	RE42376	Sep 24, 2019	DS			
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N021398 001	8133890	Apr 19, 2022	U-1235			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 001	8143239	Jan 29, 2023	DP U-1073			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N021929 002	8143239	Jan 29, 2023	DP U-1073			
<u>BUPIVACAINE - EXPAREL</u>						
N022496 001	6132766	Nov 16, 2013	DP			
	8182835	Sep 18, 2018	DP U-1246			
<u>BUPIVACAINE - EXPAREL</u>						
N022496 002	6132766	Nov 16, 2013	DP			
	8182835	Sep 18, 2018	DP U-1246			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N022410 003					NDF	Aug 30, 2013
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE</u>						
N022410 004					NDF	Aug 30, 2013
<u>CALCIPOTRIENE - SORILUX</u>						
N022563 001	8263580	May 26, 2026	DP U-1280		I-657	Sep 27, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CARFILZOMIB - KYPROLIS</u>						
N202714 001	7232818	Apr 14, 2025	DS DP		NCE	Jul 20, 2017
	7417042	Jun 07, 2026	DS DP		ODE	Jul 20, 2019
	7491704	Apr 14, 2025	U-1260			
	7737112	Dec 07, 2027	DP			
	8129346	Dec 25, 2026	U-1260			
	8207125	Apr 14, 2025	DS DP			
	8207126	Apr 14, 2025	DP			
	8207127	Apr 14, 2025	U-1260			
	8207297	Apr 14, 2025	DS DP			
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 001	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 002	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 003	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CARVEDILOL PHOSPHATE - COREG CR</u>						
N022012 004	6022562	Oct 17, 2015	DP	Y		
	8101209	Sep 11, 2025	DP			
	8101209*PED	Mar 11, 2026				
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N200327 001	8247400	Feb 10, 2031	DP U-282			
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N200327 002	8247400	Feb 10, 2031	DP U-282			
<u>CEVIMELINE HYDROCHLORIDE - CEVIMELINE</u>						
A091260 001					PC	Apr 06, 2013
<u>CHLORHEXIDINE GLUCONATE - CHLORHEXIDINE GLUCONATE</u>						
N021669 001	7717889	Feb 27, 2025	DP U-1022			
<u>CHOLINE C-11 - CHOLINE C-11</u>						
N203155 001					NCE W	Sep 12, 2017 Sep 12, 2017
<u>CICLESONIDE - ZETONNA</u>						
N202129 001	5482934	Oct 24, 2017	DS DP U-1002		NP	Jan 20, 2015
	5605674	Feb 25, 2014	DP			
	5683677	Nov 04, 2014	DP			
	5775321	Jul 07, 2015	DP			
	6006745	Dec 28, 2016	DP			
	6036942	Apr 30, 2013	DP			
	6120752	May 13, 2018	DP			
	6264923	May 13, 2018	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>CICLOPIROX - LOPROX</u>						
N021159 001	8227490	Sep 16, 2017	U-1256			
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - PREPOPIK</u>						
N202535 001					NP	Jul 16, 2015
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156 001	5856346	Jan 05, 2021	DS DP U-893			
<u>CLEVIDIPINE BUTYRATE - CLEVIPREX</u>						
N022156 002	5856346	Jan 05, 2021	DS DP U-893			
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A078223 001					PC	Jun 30, 2012
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
A078854 001					PC	Jun 30, 2012
<u>CLOPIDOGREL BISULFATE - CLOPIDOGREL BISULFATE</u>						
A077665 002					PC	Nov 13, 2012
<u>CLOPIDOGREL BISULFATE - CLOPIDOGREL BISULFATE</u>						
A091023 001					PC	Nov 13, 2012
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N203100 001	5814639	Sep 29, 2015	DS DP			
	5914331	Jul 02, 2017	DS			
	5922695	Jul 25, 2017	DS U-257			
	5935946	Jul 25, 2017	DS DP U-257			
	5977089	Jul 25, 2017	DS DP U-257			
	6043230	Jul 25, 2017	U-257			
	6642245	Nov 04, 2020	U-257			
	6703396	Mar 09, 2021	DS DP			
	7176220	Nov 20, 2023	DS DP U-257			
	7635704	Jan 12, 2026	DS DP U-257			
	8148374	Sep 03, 2029	DS DP U-1279			
<u>COLCHICINE - COLCRYS</u>						
N022352 001	7964648	Oct 06, 2028	U-1161			
	8097655	Oct 06, 2028	U-1020			
<u>CRIZOTINIB - XALKORI</u>						
N202570 001	8217057	Nov 06, 2029	DS DP			
<u>CRIZOTINIB - XALKORI</u>						
N202570 002	8217057	Nov 06, 2029	DS DP			
<u>CYSTEAMINE HYDROCHLORIDE - CYSTARAN</u>						
N200740 001					>A> NP	Oct 02, 2015
					>A> ODE	Oct 02, 2019
<u>DAPTOMYCIN - CUBICIN</u>						
N021572 002	8129342	Nov 28, 2020	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 001	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 002	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 003	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 004	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N021976 005	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157	Jun 26, 2016	U-935			
	6037157*PED	Dec 26, 2016				
	6335460	Aug 25, 2012	DS DP U-935			
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460	Aug 25, 2012	DS DP U-744			
	6335460	Aug 25, 2012	DS DP U-903			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-935			
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506	Jun 23, 2019	U-935			
	7470506*PED	Dec 23, 2019				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N202895 001	5843946	Dec 01, 2015	DP U-1209			
	5843946*PED	Jun 01, 2016				
	6037157	Jun 26, 2016	U-1209			
	6037157*PED	Dec 26, 2016				
	6248775	Aug 13, 2014	DS			
	6248775*PED	Feb 13, 2015				
	6335460	Aug 25, 2012	DS DP U-1209			
	6335460*PED	Feb 25, 2013				
	6703403	Jun 26, 2016	U-1209			
	6703403*PED	Dec 26, 2016				
	7470506	Jun 23, 2019	U-1209			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 001	5925730	May 18, 2021	DS DP U-943			
<u>DEGARELIX ACETATE - FIRMAGON</u>						
N022201 002	5925730	May 18, 2021	DS DP U-943			
<u>DESLOMATADINE; PSEUDOEPHEDRINE SULFATE - CLARINEX-D 12 HOUR</u>						
N021313 001	8187630	Dec 19, 2020	DP U-1017			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N021992 001	8269040	Jul 05, 2027	DS			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N021992 002	8269040	Jul 05, 2027	DS			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXAMETHASONE - OZURDEX</u>						
N022315 001	8088407	Oct 20, 2020	DP U-1205			
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
N050818 001	8101582	Dec 19, 2027	DP U-1082			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N022287 001	8105626	Sep 27, 2026	DP			
	8105626*PED	Mar 27, 2027				
	8173158	Mar 17, 2030	U-951			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-949			
	8173158*PED	Sep 17, 2030				
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N022287 002	8105626	Sep 27, 2026	DP			
	8105626*PED	Mar 27, 2027				
	8173158	Mar 17, 2030	U-951			
	8173158	Mar 17, 2030	U-950			
	8173158	Mar 17, 2030	U-949			
	8173158*PED	Sep 17, 2030				
<u>DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA</u>						
N021879 001	8227484	Jul 17, 2023	U-1093			
<u>DICLOFENAC POTASSIUM - CAMBIA</u>						
N022165 001	8097651	Jun 16, 2026	DS DP U-436			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N022202 001	8110606	Feb 24, 2029	U-980			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N020947 001	8217078	Jul 10, 2029	U-1248			
<u>DIENOGEST; ESTRADIOL VALERATE - NATAZIA</u>						
N022252 001	8153616	Jan 30, 2028	U-1240		I-648	Mar 14, 2015
<u>DIFLUPREDNATE - DUREZOL</u>						
N022212 001					I-653 ODE	Jun 13, 2015 Jun 13, 2019
<u>DIPHENHYDRAMINE CITRATE; IBUPROFEN - ADVIL PM</u>						
N021394 001	8263647	May 30, 2022	DP			
<u>DORIPENEM - DORIBAX</u>						
N022106 001	8247402	Mar 30, 2021	DS DP			
<u>DORIPENEM - DORIBAX</u>						
N022106 002	8247402	Mar 30, 2021	DS DP			
<u>DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE - COSOPT PF</u>						
N202667 001					NP	Feb 01, 2015
<u>DOXYCYCLINE - ORACEA</u>						
N050805 001	8206740	Dec 24, 2025	DP U-925			
<u>DRONEDARONE HYDROCHLORIDE - MULTAQ</u>						
N022425 001	5223510	Jul 26, 2013	DS DP U-992			
	5223510	Jul 26, 2013	DS DP U-1261			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>DROSPIRENONE; ESTRADIOL - ANGELIQ</u>						
N021355 001					NS	Mar 01, 2015
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 001	5023269	Jun 11, 2013	DS DP U-882		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-839		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-799		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-797		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-398			
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019	U-882			
	6596756*PED	Mar 10, 2020				
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 002	5023269	Jun 11, 2013	DS DP U-882		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-839		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-799		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-797		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-398			
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019	U-882			
	6596756*PED	Mar 10, 2020				
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N021427 004	5023269	Jun 11, 2013	DS DP U-882		I-632	Nov 04, 2013
	5023269	Jun 11, 2013	DS DP U-839		I-617	Nov 19, 2012
	5023269	Jun 11, 2013	DS DP U-799		PED	May 04, 2014
	5023269	Jun 11, 2013	DS DP U-797		PED	May 19, 2013
	5023269	Jun 11, 2013	DS DP U-796			
	5023269	Jun 11, 2013	DS DP U-795			
	5023269	Jun 11, 2013	DS DP U-605			
	5023269	Jun 11, 2013	DS DP U-398			
	5023269	Jun 11, 2013	DS DP U-1094			
	5023269*PED	Dec 11, 2013				
	5508276	Jul 18, 2014	DP			
	5508276*PED	Jan 18, 2015				
	6596756	Sep 10, 2019	U-882			
	6596756*PED	Mar 10, 2020				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N021937 001	5663169	Sep 02, 2014	U-750			
	5663169	Sep 02, 2014	U-1170			
	5811423	Aug 07, 2012	U-750			
	5811423	Aug 07, 2012	U-1170			
	5922695	Jul 25, 2017	DS U-750			
	5922695	Jul 25, 2017	DS U-1170			
	5935946	Jul 25, 2017	DS DP U-750			
	5935946	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-750			
	5977089	Jul 25, 2017	DS DP U-1170			
	6043230	Jul 25, 2017	U-750			
	6043230	Jul 25, 2017	U-1170			
	6642245	Nov 04, 2020	U-750			
	6642245	Nov 04, 2020	U-1170			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 001	7160870	Nov 20, 2022	DS DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 002	7160870	Nov 20, 2022	DS DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 003	7160870	Nov 20, 2022	DS DP U-930			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N022291 004	7160870	Nov 20, 2022	DS DP U-930			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N202123 001	8080551	Apr 11, 2023	DS DP		NCE	May 20, 2016
	8101629	Aug 09, 2022	DP			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N021752 001	5922695	Jul 25, 2017	DS U-1259			
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	6043230	Jul 25, 2017	DP U-541			
	6043230	Jul 25, 2017	DP U-1170			
	6043230	Jul 25, 2017	DP U-1259			
	6043230	Jul 25, 2017	DP U-248			
<u>ENTECAVIR - BARACLUDE</u>						
N021797 001					>A> NPP	Oct 12, 2015
<u>ENTECAVIR - BARACLUDE</u>						
N021797 002					>A> NPP	Oct 12, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ENTECAVIR - BARACLUDE</u>						
N021798 001					>A> NPP	Oct 12, 2015
<u>ENZALUTAMIDE - XTANDI</u>						
N203415 001	7709517	Aug 13, 2027	DS DP		NCE	Aug 31, 2017
	8183274	May 15, 2026	U-1281			
<u>EPINEPHRINE - AUVI-Q</u>						
N201739 001	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
<u>EPROSARTAN MESYLATE - EPROSARTAN MESYLATE</u>						
A202012 001					PC	Jun 17, 2012
<u>EPROSARTAN MESYLATE - EPROSARTAN MESYLATE</u>						
A202012 002					PC	Jun 17, 2012
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N201532 001	8097648	Jan 22, 2021	U-1096			
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 001					PC	Sep 10, 2012
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 002					PC	Sep 10, 2012
<u>ESCITALOPRAM OXALATE - ESCITALOPRAM OXALATE</u>						
A076765 003					PC	Sep 10, 2012
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 001	5877192	May 27, 2014	U-773			
	5877192	May 27, 2014	U-729			
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 002	5877192	May 27, 2014	U-773			
	5877192	May 27, 2014	U-729			
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 003	5690960	Nov 25, 2014	DP U-1207			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-1207			
	5714504*PED	Aug 03, 2015				
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-1207			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1207			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1207			
	6428810*PED	May 03, 2020				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM</u>						
N021957 004	5690960	Nov 25, 2014	DP U-1207			
	5690960*PED	May 25, 2015				
	5714504	Feb 03, 2015	DP U-1207			
	5714504*PED	Aug 03, 2015				
	5877192	May 27, 2014	U-1207			
	5877192*PED	Nov 27, 2014				
	5900424	May 04, 2016	DS U-1207			
	5900424*PED	Nov 04, 2016				
	6369085	May 25, 2018	DS DP U-1207			
	6369085*PED	Nov 25, 2018				
	6428810	Nov 03, 2019	DP U-1207			
	6428810*PED	May 03, 2020				
	6875872	May 27, 2014	DS			
	6875872*PED	Nov 27, 2014				
	7411070	May 25, 2018	DS			
	7411070*PED	Nov 25, 2018				
<u>ESZOPICLONE - LUNESTA</u>						
N021476 001	6319926	Jan 16, 2012	U-620			
	6319926*PED	Jul 16, 2012				
	6444673	Feb 14, 2014	DS DP			
	6444673*PED	Aug 14, 2014				
	6864257	Aug 30, 2012	U-629			
	6864257*PED	Mar 02, 2013				
	7381724	Jan 16, 2012	DS DP U-629			
	7381724*PED	Jul 16, 2012				
<u>ESZOPICLONE - LUNESTA</u>						
N021476 002	6319926	Jan 16, 2012	U-620			
	6319926*PED	Jul 16, 2012				
	6444673	Feb 14, 2014	DS DP			
	6444673*PED	Aug 14, 2014				
	6864257	Aug 30, 2012	U-629			
	6864257*PED	Mar 02, 2013				
	7381724	Jan 16, 2012	DS DP U-629			
	7381724*PED	Jul 16, 2012				
<u>ESZOPICLONE - LUNESTA</u>						
N021476 003	6319926	Jan 16, 2012	U-620			
	6319926*PED	Jul 16, 2012				
	6444673	Feb 14, 2014	DS DP			
	6444673*PED	Aug 14, 2014				
	6864257	Aug 30, 2012	U-629			
	6864257*PED	Mar 02, 2013				
	7381724	Jan 16, 2012	DS DP U-629			
	7381724*PED	Jul 16, 2012				
<u>ETONOGESTREL - NEXPLANON</u>						
N021529 002				NP		May 31, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE	
ETRAVIRINE - INTELENCE									
N022187 001	6878717	Nov	05, 2019	U-256			NPP	Mar	26, 2015
	6878717	Nov	05, 2019	U-1237					
	6878717	Nov	05, 2019	U-1016					
	7037917	Dec	13, 2020	DS DP	U-256				
	7037917	Dec	13, 2020	DS DP	U-1237				
	7037917	Dec	13, 2020	DS DP	U-1016				
ETRAVIRINE - INTELENCE									
N022187 002	6878717	Nov	05, 2019	U-256			NPP	Mar	26, 2015
	6878717	Nov	05, 2019	U-1237					
	6878717	Nov	05, 2019	U-1016					
	7037917	Dec	13, 2020	DS DP	U-256				
	7037917	Dec	13, 2020	DS DP	U-1237				
	7037917	Dec	13, 2020	DS DP	U-1016				
ETRAVIRINE - INTELENCE									
N022187 003	6878717	Nov	05, 2019	U-256			NPP NCE	Mar	26, 2015
	6878717	Nov	05, 2019	U-1237					
	6878717	Nov	05, 2019	U-1016					
	7037917	Dec	13, 2020	DS DP	U-1237				
	7887845	Mar	25, 2019	DP					
	8003789	Nov	01, 2019	DS DP					
EVEROLIMUS - AFINITOR									
N022334 001	5665772	Sep	09, 2019	DS DP			I-655	Jul	20, 2015
	5665772*PED	Mar	09, 2020				I-650	Apr	26, 2015
	6004973	Jul	12, 2016	DP			I-638	May	05, 2014
	6004973*PED	Jan	12, 2017				I-630	Oct	29, 2013
	7297703	Dec	06, 2019	DP			NCE	Mar	30, 2014
	7297703*PED	Jun	06, 2020				ODE	Apr	26, 2019
							ODE	May	05, 2018
							ODE	Oct	29, 2017
							PED	Oct	26, 2019
							PED	Nov	05, 2018
							PED	Apr	29, 2018
							PED	Oct	26, 2015
EVEROLIMUS - AFINITOR							PED	Nov	05, 2014
							PED	Sep	30, 2014
							PED	Apr	29, 2014
N022334 002	5665772	Sep	09, 2019	DS DP			I-655	Jul	20, 2015
	5665772*PED	Mar	09, 2020				I-650	Apr	26, 2015
	6004973	Jul	12, 2016	DP			I-638	May	05, 2014
	6004973*PED	Jan	12, 2017				I-630	Oct	29, 2013
	7297703	Dec	06, 2019	DP			NCE	Mar	30, 2014
	7297703*PED	Jun	06, 2020				ODE	Apr	26, 2019
							ODE	May	05, 2018
							ODE	Oct	29, 2017
							PED	Oct	26, 2019
							PED	Nov	05, 2018
							PED	Apr	29, 2018
							PED	Oct	26, 2015
							PED	Nov	05, 2014
							PED	Sep	30, 2014
							PED	Apr	29, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - AFINITOR</u>						
N022334 003	5665772	Sep 09, 2019	DS DP		I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018
					PED	Apr 29, 2018
					PED	Oct 26, 2015
					PED	Nov 05, 2014
					PED	Sep 30, 2014
					PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR</u>						
N022334 004	5665772	Sep 09, 2019	DS DP		I-655	Jul 20, 2015
	5665772*PED	Mar 09, 2020			I-650	Apr 26, 2015
	6004973	Jul 12, 2016	DP		I-638	May 05, 2014
	6004973*PED	Jan 12, 2017			I-630	Oct 29, 2013
	7297703	Dec 06, 2019	DP		NCE	Mar 30, 2014
	7297703*PED	Jun 06, 2020			ODE	Apr 26, 2019
					ODE	May 05, 2018
					ODE	Oct 29, 2017
					PED	Oct 26, 2019
					PED	Nov 05, 2018
					PED	Apr 29, 2018
					PED	Oct 26, 2015
					PED	Nov 05, 2014
					PED	Sep 30, 2014
					PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N203985 001	5665772	Sep 09, 2019	DS DP		I-630	Oct 29, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP		ODE	Oct 29, 2017
	6004973*PED	Jan 12, 2017			PED	Apr 29, 2018
	7297703	Dec 06, 2019	DP		PED	Sep 30, 2014
	7297703*PED	Jun 06, 2020			PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N203985 002	5665772	Sep 09, 2019	DS DP		I-630	Oct 29, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP		ODE	Oct 29, 2017
	6004973*PED	Jan 12, 2017			PED	Apr 29, 2018
	7297703	Dec 06, 2019	DP		PED	Sep 30, 2014
	7297703*PED	Jun 06, 2020			PED	Apr 29, 2014
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N203985 003	5665772	Sep 09, 2019	DS DP		I-630	Oct 29, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP		ODE	Oct 29, 2017
	6004973*PED	Jan 12, 2017			PED	Apr 29, 2018
	7297703	Dec 06, 2019	DP		PED	Sep 30, 2014
	7297703*PED	Jun 06, 2020			PED	Apr 29, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 001	5665772	Sep 09, 2019	DS DP U-1049		NP	Apr 20, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP U-1049		PED	Sep 30, 2014
	6004973*PED	Jan 12, 2017			PED	Oct 20, 2013
	6239124	Aug 11, 2017	U-1049			
	6239124*PED	Feb 11, 2018				
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 002	5665772	Sep 09, 2019	DS DP U-1049		NP	Apr 20, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP U-1049		PED	Sep 30, 2014
	6004973*PED	Jan 12, 2017			PED	Oct 20, 2013
	6239124	Aug 11, 2017	U-1049			
	6239124*PED	Feb 11, 2018				
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				
<u>EVEROLIMUS - ZORTRESS</u>						
N021560 003	5665772	Sep 09, 2019	DS DP U-1049		NP	Apr 20, 2013
	5665772*PED	Mar 09, 2020			NCE	Mar 30, 2014
	6004973	Jul 12, 2016	DP U-1049		PED	Sep 30, 2014
	6004973*PED	Jan 12, 2017			PED	Oct 20, 2013
	6239124	Aug 11, 2017	U-1049			
	6239124*PED	Feb 11, 2018				
	6440990	Sep 24, 2013	DP U-1049			
	6440990*PED	Mar 24, 2014				
	6455518	Jul 29, 2017	U-1049			
	6455518*PED	Jan 29, 2018				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N022200 001	5424286	Dec 01, 2016	U-1108		NP	Jan 27, 2015
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017	U-656			
	6872700	Jan 14, 2020	U-654			
	6956026	Jan 07, 2018	U-687			
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP U-1223			
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP U-1223			
	7741269	Jan 07, 2018	U-1224			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773 001					M-113	Oct 19, 2014
					M-111	Oct 19, 2014

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N021773	002				M-113 M-111	Oct 19, 2014 Oct 19, 2014
<u>EZETIMIBE - ZETIA</u>						
N021445	001				M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687	001				M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687	002				M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687	003				M-109	Jan 24, 2015
<u>EZETIMIBE; SIMVASTATIN - VYTORIN</u>						
N021687	004				M-109	Jan 24, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363	001				M-112	Feb 09, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363	002				M-112	Feb 09, 2015
<u>FAMCICLOVIR - FAMVIR</u>						
N020363	003				M-112	Feb 09, 2015
<u>FAMOTIDINE; IBUPROFEN - DUEXIS</u>						
N022519	001 >A> 8309127	Jul 18, 2026	DP			
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118	001 8124125	Oct 01, 2024	DP U-1234			
<u>FENOFIBRATE - FENOGLIDE</u>						
N022118	002 8124125	Oct 01, 2024	DP U-1234			
<u>FENTANYL - SUBSYS</u>						
N202788	001				NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788	002				NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788	003				NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788	004				NP	Jan 04, 2015
<u>FENTANYL - SUBSYS</u>						
N202788	005				NP	Jan 04, 2015
<u>FENTANYL CITRATE - FENTORA</u>						
N021947	001 8092832	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947	002 8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947	003 8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 004	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N021947 005	8092832	Dec 30, 2024	DP			
	8119158	Dec 30, 2024	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N022569 001	8216604	Oct 03, 2024	U-767			
<u>FENTANYL CITRATE - LAZANDA</u>						
N022569 002	8216604	Oct 03, 2024	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 001	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 002	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 003	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 004	7579019	Jan 22, 2020	U-767			
<u>FENTANYL CITRATE - ONSOLIS</u>						
N022266 005	7579019	Jan 22, 2020	U-767			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 001	6858650	Jul 03, 2022	DS U-913			
	8088398	Jun 07, 2027	DP U-913			
<u>FESOTERODINE FUMARATE - TOVIAZ</u>						
N022030 002	6858650	Jul 03, 2022	DS U-913			
	8088398	Jun 07, 2027	DP U-913			
<u>FINGOLIMOD - GILENYA</u>						
N022527 001	6004565	Sep 23, 2017	U-1086			
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 001	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 002	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLORBETAPIR F-18 - AMYVID</u>						
N202008 003	7687052	Apr 30, 2027	DS DP		NCE	Apr 06, 2017
<u>FLUNISOLIDE - AEROSPAN HFA</u>						
N021247 001	5776433	Jul 07, 2015	DP			
	5980867	Jul 06, 2018	DP			
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N021112 001	8247395	Oct 22, 2022	DP			
<u>FLUOCINONIDE - VANOS</u>						
N021758 001	8232264	Mar 09, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N022051 001	8062264	Apr 05, 2026	DP			
	8147461	Mar 10, 2025	DP			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N021433 001	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N021433 002	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N021433 003	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N021254 001	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N021254 002	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N021254 003	7832351	Jun 19, 2023	DP			
	7832351*PED	Dec 19, 2023				
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N021548 001					NPP PED	Apr 27, 2015 Oct 27, 2015
<u>FOSAMPRENAVIR CALCIUM - LEXIVA</u>						
N022116 001					NPP PED	Apr 27, 2015 Oct 27, 2015
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N022023 002	5512570	Mar 04, 2014	U-850			
	5538982	Jul 23, 2013	U-850			
	5716942	Feb 10, 2015	U-850			
	7214692	Sep 18, 2012	U-850			
<u>FOSPROPOFOL DISODIUM - LUSEDRA</u>						
N022244 001	6204257	Jul 01, 2022	DS DP U-945			
<u>GABAPENTIN - GRALISE</u>						
N022544 001	8192756	Oct 25, 2022	DP U-1114			
	8252332	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN - GRALISE</u>						
N022544 002	8192756	Oct 25, 2022	DP U-1114			
	8252332	Oct 25, 2022	DP U-1114			
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 001	8048917	Nov 06, 2022	DS DP U-1247		I-652	Jun 06, 2015
	8114909	Apr 11, 2026	U-1231			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N022399 002	8048917	Nov 06, 2022	DS DP U-1247		I-652	Jun 06, 2015
	8114909	Apr 11, 2026	U-1231			
<u>GADOBENATE DIMEGLUMINE - MULTIANCE</u>						
N021357 001					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIANCE</u>						
N021357 002					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIANCE</u>						
N021357 003					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIANCE</u>						
N021357 004					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIANCE MULTIPACK</u>						
N021358 001					I-654	Jul 06, 2015
<u>GADOBENATE DIMEGLUMINE - MULTIANCE MULTIPACK</u>						
N021358 002					I-654	Jul 06, 2015
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 001	6676929	May 04, 2020	DP			
<u>GADOFOSVESET TRISODIUM - ABLAVAR</u>						
N021711 002	6676929	May 04, 2020	DP			
<u>GADOXETATE DISODIUM - EOVI</u>						
N022090 001	5798092	Aug 25, 2015	DS DP			
	6039931	Nov 13, 2021	U-1239			
<u>GLYCOPYRROLATE - CUVPOSA</u>						
N022571 001					ODE	Jul 28, 2017
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE</u>						
A077369 001					PC	Sep 26, 2012
<u>HYDROCHLOROTHIAZIDE; IRBESARTAN - IRBESARTAN AND HYDROCHLOROTHIAZIDE</u>						
A077369 002					PC	Sep 26, 2012
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020 001					PC	Mar 20, 2013
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020 002					PC	Mar 20, 2013
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020 003					PC	Mar 20, 2013
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020 004					PC	Mar 20, 2013
<u>HYDROCHLOROTHIAZIDE; VALSARTAN - VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A078020 005					PC	Mar 20, 2013
<u>HYDROMORPHONE HYDROCHLORIDE - EXALGO</u>						
N021217 004	5702725	Jul 07, 2014	DP U-1043		NDF	Mar 01, 2013
	5914131	Jul 07, 2014	DP U-1043			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N202057 001	8188146	Jan 27, 2020	DS DP			
	>A> 8293727	Feb 09, 2030	U-1287			
	>A> 8293728	Feb 09, 2030	U-1287			
	>A> 8298554	Apr 29, 2030	DP			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 001					ODE	Dec 19, 2015
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N021588 002					ODE	Dec 19, 2015
<u>IMIQUIMOD - ZYCLARA</u>						
N022483 001	8236816	Dec 11, 2029	U-68			
	>A> 8299109	Dec 11, 2029	U-68			
<u>IMIQUIMOD - ZYCLARA</u>						
N022483 002	8222270	Dec 11, 2029	U-68			
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 001	6432452	Aug 19, 2018	DS U-68		NCE	Jan 23, 2017
	6844013	Aug 19, 2018	DS DP U-1221			
	7410656	Aug 19, 2018	DS U-1222			
	>A> 8278292	Feb 20, 2027	DS DP			
<u>INGENOL MEBUTATE - PICATO</u>						
N202833 002	6432452	Aug 19, 2018	DS U-68		NCE	Jan 23, 2017
	6844013	Aug 19, 2018	DS DP U-1221			
	7410656	Aug 19, 2018	DS U-1222			
	>A> 8278292	Feb 20, 2027	DS DP			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30</u>						
N021172 001	5866538	Jun 19, 2017	DP			
	5866538*PED	Dec 19, 2017				
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR</u>						
N021536 001	5750497	Jun 16, 2019	DS DP U-668		M-117 M-115	May 18, 2015 Apr 06, 2015
<u>INSULIN LISPRO RECOMBINANT - HUMALOG</u>						
N020563 001					>A> NR	Oct 12, 2015
<u>INSULIN LISPRO RECOMBINANT - HUMALOG PEN</u>						
N020563 002					>A> NR	Oct 12, 2015
<u>IOFLUPANE I-123 - DATSCAN</u>						
N022454 001	5310912	Feb 25, 2013	DS			
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 001					PC	Sep 26, 2012
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 002					PC	Sep 26, 2012
<u>IRBESARTAN - IRBESARTAN</u>						
A077159 003					PC	Sep 26, 2012
<u>IRON SUCROSE - VENOFER</u>						
N021135 001					NPP	Sep 21, 2015
<u>IRON SUCROSE - VENOFER</u>						
N021135 002					NPP	Sep 21, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>IRON SUCROSE - VENOFER</u>						
N021135 004					NPP	Sep 21, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 001	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 002	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 003	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>ISOTRETINOIN - ABSORICA</u>						
N021951 004	7435427	Sep 21, 2021	DP		NP	May 25, 2015
<u>IVACAFTOR - KALYDECO</u>						
N203188 001	7495103	May 20, 2027	DS DP		NCE ODE	Jan 31, 2017 Jan 31, 2019
<u>IVERMECTIN - SKLICE</u>						
N202736 001	6103248	May 22, 2018	DP		NP	Feb 07, 2015
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 001	RE41911	Sep 28, 2020	DS DP U-961			
	RE41911*PED	Mar 28, 2021				
<u>IXABEPILONE - IXEMPRA KIT</u>						
N022065 002	RE41911	Sep 28, 2020	DS DP U-961			
	RE41911*PED	Mar 28, 2021				
<u>KETOCONAZOLE - EXTINA</u>						
N021738 001	8026238	Oct 19, 2018	DP U-1213			
<u>KETOCONAZOLE - XOLEGEL</u>						
N021946 001	8232276	Nov 24, 2020	DP			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N021528 001	8008338*PED	Nov 24, 2027				
	8207215	May 28, 2024	U-1251			
	8207215*PED	Nov 28, 2024				
<u>LACOSAMIDE - VIMPAT</u>						
N022253 001	>A> RE38551	Mar 17, 2022	DS DP U-914			
<u>LACOSAMIDE - VIMPAT</u>						
N022253 002	>A> RE38551	Mar 17, 2022	DS DP U-914			
<u>LACOSAMIDE - VIMPAT</u>						
N022253 003	>A> RE38551	Mar 17, 2022	DS DP U-914			
<u>LACOSAMIDE - VIMPAT</u>						
N022253 004	>A> RE38551	Mar 17, 2022	DS DP U-914			
<u>LACOSAMIDE - VIMPAT</u>						
N022254 001	>A> RE38551	Mar 17, 2022	DS DP U-911			
<u>LACOSAMIDE - VIMPAT</u>						
N022255 001	>A> RE38551	Mar 17, 2022	DS DP U-914			
<u>LAMIVUDINE; ZIDOVUDINE - LAMIVUDINE AND ZIDOVUDINE</u>						
A079081 001					PC	May 15, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 001	5635517	Oct 04, 2019	DS		U-1211	
	6045501	Aug 28, 2018			U-1210	
	6281230	Jul 24, 2016			U-1212	
	6315720	Oct 23, 2020			U-1210	
	6555554	Jul 24, 2016	DP		U-1211	
	6561976	Aug 28, 2018			U-1210	
	6561977	Oct 23, 2020			U-1210	
	6755784	Oct 23, 2020			U-1210	
	6908432	Aug 28, 2018			U-1210	
	7189740	Apr 11, 2023			U-1215	
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023			U-1216	
	8204763	Aug 28, 2018			U-1249	
	>A> 8288415	Jul 24, 2016	DS DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 002	5635517	Oct 04, 2019	DS		U-1211	
	6045501	Aug 28, 2018			U-1210	
	6281230	Jul 24, 2016			U-1212	
	6315720	Oct 23, 2020			U-1210	
	6555554	Jul 24, 2016	DP		U-1211	
	6561976	Aug 28, 2018			U-1210	
	6561977	Oct 23, 2020			U-1210	
	6755784	Oct 23, 2020			U-1210	
	6908432	Aug 28, 2018			U-1210	
	7189740	Apr 11, 2023			U-1215	
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023			U-1216	
	8204763	Aug 28, 2018			U-1249	
	>A> 8288415	Jul 24, 2016	DS DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 003	5635517	Oct 04, 2019	DS		U-1211	
	6045501	Aug 28, 2018			U-1210	
	6281230	Jul 24, 2016			U-1212	
	6315720	Oct 23, 2020			U-1210	
	6555554	Jul 24, 2016	DP		U-1211	
	6561976	Aug 28, 2018			U-1210	
	6561977	Oct 23, 2020			U-1210	
	6755784	Oct 23, 2020			U-1210	
	6908432	Aug 28, 2018			U-1210	
	7189740	Apr 11, 2023			U-1215	
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023			U-1216	
	8204763	Aug 28, 2018			U-1249	
	>A> 8288415	Jul 24, 2016	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 004	5635517	Oct 04, 2019	DS		U-1211	
	6045501	Aug 28, 2018			U-1210	
	6281230	Jul 24, 2016			U-1212	
	6315720	Oct 23, 2020			U-1210	
	6555554	Jul 24, 2016	DP		U-1211	
	6561976	Aug 28, 2018			U-1210	
	6561977	Oct 23, 2020			U-1210	
	6755784	Oct 23, 2020			U-1210	
	6908432	Aug 28, 2018			U-1210	
	7189740	Apr 11, 2023			U-1215	
	7465800	Apr 27, 2027	DS DP			
	7968569	Oct 07, 2023			U-1216	
	8204763	Aug 28, 2018			U-1249	
	>A> 8288415	Jul 24, 2016	DS DP			
<u>LENALIDOMIDE - REVLIMID</u>						
N021880 005	5635517	Oct 04, 2019	DS		U-1211	
	6045501	Aug 28, 2018			U-1210	
	6281230	Jul 24, 2016			U-1212	
	6315720	Oct 23, 2020			U-1210	
	6555554	Jul 24, 2016	DP		U-1211	
	6561976	Aug 28, 2018			U-1210	
	6561977	Oct 23, 2020			U-1210	
	6755784	Oct 23, 2020			U-1210	
	6908432	Aug 28, 2018			U-1210	
	7119106	Jul 24, 2016	DP			
	7189740	Apr 11, 2023			U-1215	
	7465800	Apr 27, 2027	DS DP			
	7855217	Nov 24, 2024	DS DP			
	7968569	Oct 07, 2023			U-1216	
	8204763	Aug 28, 2018			U-1249	
	>A> 8288415	Jul 24, 2016	DS DP			
<u>LEVETIRACETAM - KEPRA</u>						
N021035 001					NPP	Dec 16, 2014
					PED	Jun 16, 2015
<u>LEVETIRACETAM - KEPRA</u>						
N021035 002					NPP	Dec 16, 2014
					PED	Jun 16, 2015
<u>LEVETIRACETAM - KEPRA</u>						
N021035 003					NPP	Dec 16, 2014
					PED	Jun 16, 2015
<u>LEVETIRACETAM - KEPRA</u>						
N021035 004					NPP	Dec 16, 2014
					PED	Jun 16, 2015
<u>LEVETIRACETAM - KEPRA</u>						
N021505 001					NPP	Dec 16, 2014
					PED	Jun 16, 2015
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL</u>						
N022064 001	5698558	Jul 26, 2013			U-812	
	5698558*PED	Jan 26, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVOCETIRIZINE DIHYDROCHLORIDE - XYZAL</u>						
N022157 001	5698558	Jul 26, 2013	U-852			
	5698558*PED	Jan 26, 2014				
<u>LIDOCAINE; TETRACAINE - SYNERA</u>						
N021623 001	6465709	Jul 07, 2020	DP			
<u>LINACLOTIDE - LINZESS</u>						
N202811 001	7304036	Jan 28, 2024	DS DP U-1278		NCE	Aug 30, 2017
	7371727	Jan 28, 2024	DS			
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024	U-1278			
<u>LINACLOTIDE - LINZESS</u>						
N202811 002	7304036	Jan 28, 2024	DS DP U-1278		NCE	Aug 30, 2017
	7371727	Jan 28, 2024	DS			
	7704947	Jan 28, 2024	DS DP			
	7745409	Jan 28, 2024	DS DP			
	8080526	Jan 28, 2024	DS DP			
	8110553	Jan 28, 2024	U-1278			
<u>LINAGLIPTIN - TRADJENTA</u>						
N201280 001	6303661	Apr 24, 2017	U-774		M-121	Aug 13, 2015
	6303661	Apr 24, 2017	U-1270		M-118	Aug 13, 2015
	6890898	Feb 02, 2019	U-493			
	6890898	Feb 02, 2019	U-1270			
	7078381	Feb 02, 2019	U-493			
	7078381	Feb 02, 2019	U-1270			
	7459428	Feb 02, 2019	U-493			
	7459428	Feb 02, 2019	U-1270			
	8119648	Aug 12, 2023	U-774			
	8119648	Aug 12, 2023	U-1270			
	8178541	Aug 12, 2023	U-775			
	8178541	Aug 12, 2023	U-1270			
	8178541	Aug 12, 2023	U-1245			
	8178541	Aug 12, 2023	U-1244			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 001	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 002	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N201281 003	6303661	Apr 24, 2017	U-802		NCE	May 02, 2016
	6890898	Feb 02, 2019	U-1039		NC	Jan 30, 2015
	7078381	Feb 02, 2019	U-1039			
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1039			
	8119648	Aug 12, 2023	U-802			
	8178541	Aug 12, 2023	DP U-775			
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N022341 001	8114833	Aug 13, 2025	DP		M-115	Apr 06, 2015
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 001	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 002	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 003	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 004	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7671030	Feb 24, 2023	DP U-727			
	7674774	Mar 18, 2023	DP U-842			
	7678771	Mar 25, 2023	DP U-842			
	7687467	Apr 08, 2023	DP U-842			
	7713936	Feb 24, 2023	U-727			
	7718619	Feb 24, 2023	DP U-842			
	7723305	Feb 24, 2023	DP U-842			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 005	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N021977 006	7662788	Feb 24, 2023	U-727		I-645	Jan 31, 2015
	7713936	Feb 24, 2023	U-727			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906 001	8268349	Aug 25, 2024	DP			
	8268349*PED	Feb 25, 2025				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N021906 002	8268349	Aug 25, 2024	DP			
	8268349*PED	Feb 25, 2025				
<u>LORCASERIN HYDROCHLORIDE - BELVIQ</u>						
N022529 001	6953787	Apr 10, 2023	DS DP U-1253		NCE	Jun 27, 2017
	6953787	Apr 10, 2023	DS DP U-1254			
	6953787	Apr 10, 2023	DS DP U-1255			
	6953787	Apr 10, 2023	DS DP U-1252			
	7514422	Apr 10, 2023	U-1252			
	7514422	Apr 10, 2023	U-1253			
	7514422	Apr 10, 2023	U-1254			
	7514422	Apr 10, 2023	U-1255			
	7977329	Apr 10, 2023	DS DP U-1254			
	7977329	Apr 10, 2023	DS DP U-1253			
	7977329	Apr 10, 2023	DS DP U-1255			
	7977329	Apr 10, 2023	DS DP U-1252			
	8168624	Apr 18, 2029	DS DP			
	8207158	Apr 10, 2023	U-1252			
	8207158	Apr 10, 2023	U-1253			
	8207158	Apr 10, 2023	U-1254			
	8207158	Apr 10, 2023	U-1255			
	>A> 8273734	Apr 10, 2023	U-1255			
	>A> 8273734	Apr 10, 2023	U-1254			
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 001	8097649	Oct 16, 2020	DP			
	8097653	Nov 14, 2022	U-1214			
	8114890	Sep 05, 2020	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N021908 002	8097649	Oct 16, 2020	DP			
	8114890	Sep 05, 2020	DP			
<u>LUCINACTANT - SURFAXIN</u>						
N021746 001	5407914	Nov 17, 2012	DS DP U-1242			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 001					D-134	Apr 26, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 002					D-134	Apr 26, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 003	>A> 5532372	Jul 02, 2013	DS		D-134 NCE	Apr 26, 2015 Oct 28, 2015
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N200603 004	>A> 5532372	Jul 02, 2013	DS		D-134 NCE	Apr 26, 2015 Oct 28, 2015
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N021842 001					M-116	May 17, 2015
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N021842 002					M-116	May 17, 2015
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE</u>						
A090406 001					PC	Feb 13, 2013

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE						
A090406 002					PC	Feb 13, 2013
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET						
N021410 001	8236345	Oct 07, 2022	DP			
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET						
N021410 002	8236345	Oct 07, 2022	DP			
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET						
N021410 003	8236345	Oct 07, 2022	DP			
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET						
N021410 004	8236345	Oct 07, 2022	DP			
METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE - AVANDAMET						
N021410 005	8236345	Oct 07, 2022	DP			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR						
N202270 001	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR						
N202270 002	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR						
N202270 003	6303661	Apr 24, 2017	U-1227			
	6340475	Sep 19, 2016	DP			
	6635280	Sep 19, 2016	DP			
	6699871	Jul 26, 2022	DS DP U-1227			
	6890898	Feb 02, 2019	U-1228			
	7078381	Feb 02, 2019	U-1227			
	7125873	Jul 26, 2022	DP U-1227			
	7326708	Apr 11, 2026	DS DP U-1227			
	7459428	Feb 02, 2019	U-1227			
METHYLNALTREXONE BROMIDE - RELISTOR						
N021964 001	8247425	Dec 31, 2030	U-1185			
METHYLNALTREXONE BROMIDE - RELISTOR						
N021964 002	8247425	Dec 31, 2030	U-1185			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N021964 003	8247425	Dec 31, 2030	U-1185			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 001	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 002	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 003	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N021121 004	8163798	Jul 31, 2017	DP			
	8163798*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 001					PC	Jul 01, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 002					PC	Jul 01, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - METHYLPHENIDATE HYDROCHLORIDE</u>						
A078458 003					PC	Jul 01, 2012
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N202100 001					>A> NDF	Aug 27, 2015
<u>MICONAZOLE - ORAVIG</u>						
N022404 001	7651698	Sep 11, 2022	U-1051			
<u>MIFEPRISTONE - KORLYM</u>						
N202107 001					NP	Feb 17, 2015
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 001	6602911	Jan 14, 2023	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 002	6602911	Jan 14, 2023	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 003	6602911	Jan 14, 2023	U-882			
<u>MILNACIPRAN HYDROCHLORIDE - SAVELLA</u>						
N022256 004	6602911	Jan 14, 2023	U-882			
<u>MINOCYCLINE HYDROCHLORIDE - ARESTIN</u>						
N050781 001	6682348	Mar 29, 2022	DP			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 001	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 002	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 003	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 004	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 005	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 006	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 007	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N050808 008	8252776	Jun 24, 2025	U-124			
	8268804	Jun 24, 2025	U-1078			
<u>MIRABEGRON - MYRBETRIQ</u>						
N202611 001	6346532	Oct 15, 2018	DS DP		NCE	Jun 28, 2017
	6562375	Aug 01, 2020	DP			
	6699503	Sep 10, 2013	DP			
	7342117	Nov 04, 2023	DS			
	7750029	Dec 18, 2023	U-913			
	7982049	Nov 04, 2023	DP			
<u>MIRABEGRON - MYRBETRIQ</u>						
N202611 002	6346532	Oct 15, 2018	DS DP		NCE	Jun 28, 2017
	6562375	Aug 01, 2020	DP			
	6699503	Sep 10, 2013	DP			
	7342117	Nov 04, 2023	DS			
	7750029	Dec 18, 2023	U-913			
	7982049	Nov 04, 2023	DP			
<u>MITOMYCIN - MITOSOL</u>						
N022572 001	7806265	Feb 01, 2029	DP		ODE	Feb 07, 2019
	8186511	Jul 19, 2026	DP			
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N021067 001	8173172	Mar 17, 2018	DP			
	8173172*PED	Sep 17, 2018				
<u>MOMETASONE FUROATE - ASMANEX TWISTHALER</u>						
N021067 002	8173172	Mar 17, 2018	DP			
	8173172*PED	Sep 17, 2018				
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020829 002					NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830 001					NPP	Mar 26, 2015

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N020830	002				NPP	Mar 26, 2015
<u>MONTELUKAST SODIUM - SINGULAIR</u>						
N021409	001				NPP	Mar 26, 2015
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321	001	7682633	Jun 19, 2027	U-1241		
		8158156	Jun 19, 2027	U-1241		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321	002	7682633	Jun 19, 2027	U-1241		
		8158156	Jun 19, 2027	U-1241		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321	003	7682633	Jun 19, 2027	U-1241		
		8158156	Jun 19, 2027	U-1241		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321	004	7682633	Jun 19, 2027	U-1241		
		8158156	Jun 19, 2027	U-1241		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321	005	7682633	Jun 19, 2027	U-1241		
		8158156	Jun 19, 2027	U-1241		
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N022321	006	7682633	Jun 19, 2027	U-1241		
		8158156	Jun 19, 2027	U-1241		
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N019599	002				NS	Jan 13, 2015
<u>NEPAFENAC - NEPAFENAC</u>						
N203491	001				>A> NP	Oct 16, 2015
<u>NICOTINE - NICODERM CQ</u>						
N020165	004	8075911	May 22, 2021	DP		
<u>NICOTINE - NICODERM CQ</u>						
N020165	005	8075911	May 22, 2021	DP		
<u>NICOTINE - NICODERM CQ</u>						
N020165	006	8075911	May 22, 2021	DP		
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068	001	8163904	Aug 23, 2028	DS DP		
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N022068	002	8163904	Aug 23, 2028	DS DP		

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>NITRIC OXIDE - INOMAX</u>						
N020845 002	5558083	Nov 22, 2013	DP U-1226			
	5558083*PED	May 22, 2014				
	5732693	Dec 13, 2016	DP U-1230			
	5732693*PED	Jun 13, 2017				
	5752504	Dec 13, 2016	DP U-1230			
	5752504*PED	Jun 13, 2017				
	8282966	Jun 30, 2029	U-1286			
	8282966*PED	Dec 30, 2029				
	>A> 8291904	Jan 06, 2031	DP U-1226			
	>A> 8291904*PED	Jul 06, 2031				
	>A> 8293284	Jun 30, 2029	U-1286			
	>A> 8293284*PED	Dec 30, 2029				
<u>NITRIC OXIDE - INOMAX</u>						
N020845 003	5558083	Nov 22, 2013	DP U-1226			
	5558083*PED	May 22, 2014				
	5732693	Dec 13, 2016	DP U-1230			
	5732693*PED	Jun 13, 2017				
	5752504	Dec 13, 2016	DP U-1230			
	5752504*PED	Jun 13, 2017				
	8282966	Jun 30, 2029	U-1286			
	8282966*PED	Dec 30, 2029				
	>A> 8291904	Jan 06, 2031	DP U-1226			
	>A> 8291904*PED	Jul 06, 2031				
	>A> 8293284	Jun 30, 2029	U-1286			
	>A> 8293284*PED	Dec 30, 2029				
<u>NITROGLYCERIN - NITROLINGUAL PUMPSPRAY</u>						
N018705 002	7872049	Mar 14, 2028	DP U-39			
<u>OMACETAXINE MEPE SUCCINATE - SYNRI BO</u>						
N203585 001					>A> NCE	Oct 26, 2017
<u>OXCARBAZEPINE - TRILEPTAL</u>						
N021285 001	8119148	Dec 19, 2020	DP U-724			
	8119148*PED	Jun 19, 2021				
<u>OXYBUTYNIN - ANTUROL</u>						
N202513 001	7029694	Apr 26, 2020	DP U-318			
	7179483	Apr 26, 2020	U-318			
	7198801	Jun 25, 2022	DP			
	8241662	Apr 26, 2020	U-318			
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N022204 001	8241662	Apr 26, 2020	U-318			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 001	8114383	Oct 10, 2024	DP			
	>A> 8309060	Nov 20, 2023	DP U-443			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 002	8114383	Oct 10, 2024	DP			
	>A> 8309060	Nov 20, 2023	DP U-443			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 003	8114383	Oct 10, 2024	DP			
	>A> 8309060	Nov 20, 2023	DP U-443			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 004	8114383	Oct 10, 2024	DP			
	>A> 8309060	Nov 20, 2023	DP U-443			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 005	8114383	Oct 10, 2024	DP			
	>A> 8309060	Nov 20, 2023	DP U-443			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 006	8114383	Oct 10, 2024	DP			
	>A> 8309060	Nov 20, 2023	DP U-443			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N022272 007	8114383	Oct 10, 2024	DP			
	>A> 8309060	Nov 20, 2023	DP U-443			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 001	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	>A> 8309060	Nov 20, 2023	DP			
	>A> 8309122	Feb 04, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 002	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	>A> 8309060	Nov 20, 2023	DP			
	>A> 8309122	Feb 04, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 003	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	>A> 8309060	Nov 20, 2023	DP			
	>A> 8309122	Feb 04, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 004	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	>A> 8309060	Nov 20, 2023	DP			
	>A> 8309122	Feb 04, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 005	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	>A> 8309060	Nov 20, 2023	DP			
	>A> 8309122	Feb 04, 2023	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 006	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	>A> 8309060	Nov 20, 2023	DP			
	>A> 8309122	Feb 04, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N201655 007	7851482	Jul 10, 2029	DS			
	8114383	Aug 08, 2024	DP			
	8192722	Sep 15, 2025	DP			
	>A> 8309060	Nov 20, 2023	DP			
	>A> 8309112	Feb 04, 2023	DP			
<u>PACLITAXEL - ABRAXANE</u>						
N021660 001	>A> 5439686	Feb 22, 2013	DP U-1290		>A> I-658	Oct 11, 2015
	>A> 5439686	Feb 22, 2013	DP U-1092			
	>A> 5498421	Mar 12, 2013	DP U-1092			
	>A> 5498421	Mar 12, 2013	DP U-1290			
	>A> 5498421	Mar 12, 2013	DP U-634			
	>A> 6096331	Feb 22, 2013	DP U-1092			
	>A> 6096331	Feb 22, 2013	DP U-1290			
	>A> 6096331	Feb 22, 2013	DP U-633			
	>A> 6506405	Feb 22, 2013	DP U-633			
	>A> 6506405	Feb 22, 2013	DP U-1092			
	>A> 6506405	Feb 22, 2013	DP U-1290			
	>A> 6537579	Feb 22, 2013	U-1290			
	>A> 6537579	Feb 22, 2013	U-632			
	>A> 6537579	Feb 22, 2013	U-1092			
	>A> 7820788	Mar 03, 2024	DP U-1092			
	>A> 7820788	Mar 03, 2024	DP U-1290			
	>A> 7923536	Dec 09, 2023	U-1117			
	>A> 7923536	Dec 09, 2023	U-1290			
	>A> 8034375	Aug 13, 2026	U-1290			
	>A> 8138229	Dec 09, 2023	DP U-1092			
	>A> 8138229	Dec 09, 2023	DP U-1290			
	>A> 8268348	Feb 21, 2026	U-1290			
	>A> RE41884	Aug 14, 2016	U-1290			
	>A> RE41884	Aug 14, 2016	U-1117			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 001	>A> 5254556	Oct 15, 2013	DS DP U-543		M-119	Aug 29, 2015
	>A> 5254556*PED	Apr 15, 2014				
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 002	>A> 5254556	Oct 15, 2013	DS DP U-543		M-119	Aug 29, 2015
	>A> 5254556*PED	Apr 15, 2014				
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 003	>A> 5254556	Oct 15, 2013	DS DP U-543		M-119	Aug 29, 2015
	>A> 5254556*PED	Apr 15, 2014				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 004	>A> 5254556	Oct 15, 2013	DS DP U-543		M-119	Aug 29, 2015
	>A> 5254556*PED	Apr 15, 2014				
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N022264 005	>A> 5254556	Oct 15, 2013	DS DP U-543		M-119	Aug 29, 2015
	>A> 5254556*PED	Apr 15, 2014				
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - CREON</u>						
N020725 004					I-625 M-93 NCE	Apr 30, 2013 Jul 29, 2019 Apr 30, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N022175 001					NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - PERTZYE</u>						
N022175 002					NCE	May 17, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 001					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 002					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ULTRESA</u>						
N022222 003					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N022542 001					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - VIOKACE</u>						
N022542 002					NCE	Mar 01, 2017
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 001	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 002	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 003	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 004	8221747	Feb 20, 2028	DP			
	8246950	Feb 20, 2028		U-1274		
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 005	8221747	Feb 20, 2028	DP		NCE	Aug 27, 2014
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N022210 006	8221747	Feb 20, 2028	DP		NCE	Aug 27, 2014
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465 001	8114885	Dec 19, 2021	DS DP		I-649 ODE	Apr 26, 2015 Apr 26, 2019
<u>PAZOPANIB HYDROCHLORIDE - VOTRIENT</u>						
N022465 002	8114885	Dec 19, 2021	DS DP		I-649 ODE	Apr 26, 2015 Apr 26, 2019

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N202799 007	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS</u>						
N202799 008	7084245	May 12, 2024	DS DP U-1238			
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 001	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 002	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 003	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 004	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 005	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEGINESATIDE ACETATE - OMONTYS PRESERVATIVE FREE</u>						
N202799 006	7084245	May 12, 2024	DS DP U-1238		NCE	Mar 27, 2017
	7414105	May 12, 2024	DS DP U-1238			
	7528104	May 12, 2024	DS DP			
	7550433	Jun 02, 2026	U-1238			
	7919118	May 12, 2024	DS DP			
	7919461	Jun 02, 2026	U-1238			
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N021462 001					>A> M-122	Oct 17, 2015
<u>PEMETREXED DISODIUM - ALIMTA</u>						
N021462 002					>A> M-122	Oct 17, 2015
<u>PERAMPANEL - FYCOMPA</u>						
N202834 001					>A> NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N202834 002					>A> NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N202834 003					>A> NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N202834 004					>A> NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N202834 005					>A> NCE	Oct 22, 2017
<u>PERAMPANEL - FYCOMPA</u>						
N202834 006					>A> NCE	Oct 22, 2017
<u>PHENTERMINE HYDROCHLORIDE - SUPRENZA</u>						
N202088 003	6149938	Jul 23, 2018	DP U-1243			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 001	7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 002	7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 003	7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N022580 004	7056890	Jun 14, 2020	DP U-1262		NC	Jul 17, 2015
	7553818	Jun 14, 2020	U-1262			
	7659256	Jun 14, 2020	DP U-1262			
	7674776	Jun 14, 2020	DP U-1262			
<u>PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE</u>						
A076801 001					PC	Feb 13, 2013
<u>PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE</u>						
A076801 002					PC	Feb 13, 2013
<u>PIOGLITAZONE HYDROCHLORIDE - PIOGLITAZONE HYDROCHLORIDE</u>						
A076801 003					PC	Feb 13, 2013
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 001	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 002	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 003	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN</u>						
N050684 004	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 001	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 002	8133883	Apr 14, 2023	DP U-282			
<u>PIPERACILLIN SODIUM; TAZOBACTAM SODIUM - ZOSYN IN PLASTIC CONTAINER</u>						
N050750 003	8133883	Apr 14, 2023	DP U-282			
<u>POSACONAZOLE - NOXAFIL</u>						
N022003 001	8263600	Apr 01, 2022	DP			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N022067 001	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			
<u>PREDNISOLONE ACETATE - FLO-PRED</u>						
N022067 002	7799331	Oct 11, 2028	DP U-139			
	7799331	Oct 11, 2028	DP U-1068			
<u>PREDNISONE - RAYOS</u>						
N202020 001	6488960	Mar 14, 2020	DP U-1267			
	6677326	Mar 14, 2020	DP U-1268			
	>A> 8309124	Apr 23, 2024	U-1292			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PREDNISONE - RAYOS</u>						
N202020 002	6488960	Mar 14, 2020	DP U-1267			
	6677326	Mar 14, 2020	DP U-1268			
	>A> 8309124	Apr 23, 2024				
<u>PREDNISONE - RAYOS</u>						
N202020 003	8168218	Jan 07, 2028	DP U-1269			
	>A> 8309124	Apr 23, 2024	U-1292			
<u>PREGABALIN - LYRICA</u>						
N021446 001	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 002	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 003	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 004	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 005	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 006	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 007	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N021446 008	6001876	Dec 30, 2018	U-819	Y	I-651	Jun 20, 2015
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PREGABALIN - LYRICA</u>						
N022488 001	6001876	Dec 30, 2018	U-819	Y		
	6001876	Dec 30, 2018	U-55	Y		
	RE41920	Dec 30, 2018	U-1250			
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N021438 001	6500454	Oct 04, 2021	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>PROPRANOLOL HYDROCHLORIDE - INNOPRAN XL</u>						
N021438 002	6500454	Oct 04, 2021	DP			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N022145 001					M-114	Mar 28, 2015
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N203045 001	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N203045 002	7169780	Oct 03, 2023	DS DP		M-114	Mar 28, 2015
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
<u>REGADENOSON - LEXISCAN</u>						
N022161 001	8106029	Jun 22, 2019	U-1042			
	8106183	Feb 02, 2027	DS			
	8133879	Jun 22, 2019	DP			
	8183226	Jun 22, 2019	U-116			
<u>REGORAFENIB - STIVARGA</u>						
N203085 001	>A> 7351834	Jan 12, 2020	DS		NCE	Sep 27, 2017
<u>REPAGLINIDE - PRANDIN</u>						
N020741 001	6677358	Jun 12, 2018	DS DP U-1265			
<u>REPAGLINIDE - PRANDIN</u>						
N020741 002	6677358	Jun 12, 2018	DS DP U-1265			
<u>REPAGLINIDE - PRANDIN</u>						
N020741 003	6677358	Jun 12, 2018	DS DP U-1265			
<u>RETAPAMULIN - ALTABAX</u>						
N022055 001	RE43390	Apr 12, 2021	DS DP U-805			
<u>RIFAXIMIN - XIFAXAN</u>						
N021361 001	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N022554 001	8158644	Jun 19, 2024	DP			
	8158781	Jun 19, 2024	DS			
	8193196	Sep 02, 2027	DS DP			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N202022 001	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
<u>RISEDRONATE SODIUM - ATELVIA</u>						
N022560 001	8246989	Jan 16, 2026	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>RITONAVIR - NORVIR</u>						
N022417 001	8268349	Aug 25, 2024	DP			
	8268349*PED	Feb 25, 2925				
<u>RIVASTIGMINE - EXELON</u>						
N022083 005	5602176	Feb 11, 2014	DS DP U-322		NS	Aug 31, 2015
	6316023	Jan 08, 2019	DP			
	6335031	Jan 08, 2019	DP			
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 001	5602162	Jan 28, 2012		Y		
	5602162*PED	Jul 28, 2012				
<u>RIZATRIPTAN BENZOATE - MAXALT</u>						
N020864 002	5602162	Jan 28, 2012		Y		
	5602162*PED	Jul 28, 2012				
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 001	5602162	Jan 28, 2012	U-240	Y		
	5602162*PED	Jul 28, 2012				
<u>RIZATRIPTAN BENZOATE - MAXALT-MLT</u>						
N020865 002	5602162	Jan 28, 2012	U-240	Y		
	5602162*PED	Jul 28, 2012				
<u>ROMIDEPSIN - ISTODAX</u>						
N022393 001	4977138	Aug 22, 2013	DS DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 001	8246979	Sep 01, 2027	DP U-1273		I-647	Apr 02, 2015
	8246979	Sep 01, 2027	DP U-1272		I-646	Apr 02, 2015
	8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 002	8246979	Sep 01, 2027	DP U-1273		I-647	Apr 02, 2015
	8246979	Sep 01, 2027	DP U-1272		I-646	Apr 02, 2015
	8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 003	8246979	Sep 01, 2027	DP U-1273		I-647	Apr 02, 2015
	8246979	Sep 01, 2027	DP U-1272		I-646	Apr 02, 2015
	8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 004	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1273			
	8246979	Sep 01, 2027	DP U-1272			
	8246980	Nov 27, 2025	DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ROTIGOTINE - NEUPRO</u>						
N021829 005	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1273			
	8246979	Sep 01, 2027	DP U-1272			
	8246980	Nov 27, 2025	DP			
<u>ROTIGOTINE - NEUPRO</u>						
N021829 006	6699498	Nov 27, 2020	DP		I-647	Apr 02, 2015
	6884434	Mar 30, 2021	DP		I-646	Apr 02, 2015
	7413747	Mar 18, 2019	DP			
	8246979	Sep 01, 2027	DP U-1273			
	8246979	Sep 01, 2027	DP U-1272			
	8246980	Nov 27, 2025	DP			
<u>RUFINAMIDE - BANZEL</u>						
N021911 001	>A> 7750028	Oct 19, 2018	U-106			
<u>RUFINAMIDE - BANZEL</u>						
N021911 002	>A> 7750028	Oct 19, 2018	U-106			
<u>RUFINAMIDE - BANZEL</u>						
N021911 003	>A> 7750028	Oct 19, 2018	U-106			
<u>RUFINAMIDE - BANZEL</u>						
N201367 001	6740669	Nov 14, 2022	DS DP			
	>A> 7750028	Oct 19, 2018	U-106			
<u>SILDENAFIL CITRATE - REVATIO</u>						
N021845 001	5250534	Mar 27, 2012	DS DP		I-598	May 07, 2012
	5250534*PED	Sep 27, 2012			M-61	Aug 30, 2015
					PED	Mar 01, 2016
					PED	Nov 07, 2012
<u>SILDENAFIL CITRATE - REVATIO</u>						
N022473 001	5250534	Mar 27, 2012	DS DP		M-61	Aug 30, 2015
	5250534*PED	Sep 27, 2012			NDF	Nov 20, 2012
					PED	Mar 01, 2016
					PED	May 20, 2013
<u>SILDENAFIL CITRATE - REVATIO</u>						
N203109 001					NDF	Aug 30, 2015
					PED	Mar 01, 2016
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 001	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019	U-155			
	6469012*PED	Apr 22, 2020				
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 002	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019	U-155			
	6469012*PED	Apr 22, 2020				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SILDENAFIL CITRATE - VIAGRA</u>						
N020895 003	5250534	Mar 27, 2012				
	5250534*PED	Sep 27, 2012				
	6469012	Oct 22, 2019	U-155			
	6469012*PED	Apr 22, 2020				
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 001	>A> 6699871	Jul 26, 2022	DS DP U-1188			
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 002	>A> 6699871	Jul 26, 2022	DS DP U-1188			
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 003	>A> 6699871	Jul 26, 2022	DS DP U-1188			
	8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 004	>A> 6303661	Apr 24, 2017	U-1188			
	>A> 6699871	Jul 26, 2022	DS DP U-1188			
	>A> 6890898	Feb 02, 2019	U-1191			
	>A> 6890898	Feb 02, 2019	U-1190			
	>A> 6890898	Feb 02, 2019	U-1189			
	>A> 7078381	Feb 02, 2019	U-1188			
	>A> 7125873	Jul 26, 2022	DP U-1193			
	>A> 7125873	Jul 26, 2022	DP U-1192			
	>A> 7125873	Jul 26, 2022	DP U-1190			
	>A> 7125873	Jul 26, 2022	DP U-1189			
	>A> 7326708	Apr 11, 2026	DS DP U-1188			
	>A> 7459428	Feb 02, 2019	U-1189			
	>A> 8168637	Jun 26, 2022	DP U-1188			
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 005	>A> 6303661	Apr 24, 2017	U-1188			
	>A> 6699871	Jul 26, 2022	DS DP U-1188			
	>A> 6890898	Feb 02, 2019	U-1191			
	>A> 6890898	Feb 02, 2019	U-1190			
	>A> 6890898	Feb 02, 2019	U-1189			
	>A> 7078381	Feb 02, 2019	U-1188			
	>A> 7125873	Jul 26, 2022	DP U-1193			
	>A> 7125873	Jul 26, 2022	DP U-1192			
	>A> 7125873	Jul 26, 2022	DP U-1190			
	>A> 7125873	Jul 26, 2022	DP U-1189			
	>A> 7326708	Apr 11, 2026	DS DP U-1188			
	>A> 7459428	Feb 02, 2019	U-1189			
	>A> 8168637	Jun 26, 2022	DP U-1188			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>SIMVASTATIN; SITAGLIPTIN PHOSPHATE - JUVISYNC</u>						
N202343 006	>A> 6303661	Apr 24, 2017	U-1188			
	>A> 6699871	Jul 26, 2022	DS DP U-1188			
	>A> 6890898	Feb 02, 2019	U-1191			
	>A> 6890898	Feb 02, 2019	U-1190			
	>A> 6890898	Feb 02, 2019	U-1189			
	>A> 7078381	Feb 02, 2019	U-1188			
	>A> 7125873	Jul 26, 2022	DP U-1193			
	>A> 7125873	Jul 26, 2022	DP U-1192			
	>A> 7125873	Jul 26, 2022	DP U-1190			
	>A> 7125873	Jul 26, 2022	DP U-1189			
	>A> 7326708	Apr 11, 2026	DS DP U-1188			
	>A> 7459428	Feb 02, 2019	U-1189			
	>A> 8168637	Jun 26, 2022	DP U-1188			
<u>SODIUM NITRITE - SODIUM NITRITE</u>						
N203922 001					ODE	Jan 14, 2018
<u>SODIUM OXYBATE - XYREM</u>						
N021196 001	8263650	Dec 22, 2019	DP U-1102			
	8263650	Dec 22, 2019	DP U-1101			
<u>SODIUM THIOSULFATE - SODIUM THIOSULFATE</u>						
N203923 001					ODE	Jan 14, 2018
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N022239 001	7776007	Nov 22, 2026	DP			
	8118771	Aug 10, 2023	DP			
	8241243	Dec 25, 2025	DP			
	8241244	Nov 21, 2022	DP			
	8267903	Mar 18, 2023	DP			
<u>TAFLUPROST - ZIOPTAN</u>						
N202514 001	5886035	Dec 18, 2017	DS DP U-778		NCE	Feb 10, 2017
<u>TALIGLUCERASE ALFA - ELELYSO</u>						
N022458 001	8227230	Feb 24, 2024	DS DP		NCE	May 01, 2017
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA</u>						
N203794 001	>A> 6071970	Jun 06, 2017	U-1289		>A> NCE	Nov 20, 2013
	>A> 7994364	Jun 27, 2025	DS DP U-1289			
	>A> RE39593	Aug 05, 2022	DS DP U-1289			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 001	6071970	Jun 06, 2017	U-1276		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	7994364	Jun 27, 2025	DS DP U-1178			
	8114383	Oct 10, 2024	DP			
	RE39593	Aug 05, 2022	DS DP U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 002	6071970	Jun 06, 2017	U-1276		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	7994364	Jun 27, 2025	DS DP U-1178			
	8114383	Oct 10, 2024	DP			
	RE39593	Aug 05, 2022	DS DP U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 003	6071970	Jun 06, 2017	U-1276		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	7994364	Jun 27, 2025	DS DP U-1178			
	8114383	Oct 10, 2024	DP			
	RE39593	Aug 05, 2022	DS DP U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 004	6071970	Jun 06, 2017	U-1276		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	7994364	Jun 27, 2025	DS DP U-1178			
	8114383	Oct 10, 2024	DP			
	RE39593	Aug 05, 2022	DS DP U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u>						
N200533 005	6071970	Jun 06, 2017	U-1276		I-656	Aug 28, 2015
	6071970	Jun 06, 2017	U-1178			
	7994364	Jun 27, 2025	DS DP U-1276			
	7994364	Jun 27, 2025	DS DP U-1178			
	8114383	Oct 10, 2024	DP			
	RE39593	Aug 05, 2022	DS DP U-1276			
	RE39593	Aug 05, 2022	DS DP U-1178			
<u>TAZAROTENE - FABIOR</u>						
N202428 001					NDF	May 11, 2015
<u>TECHNETIUM TC-99M SULFUR COLLOID KIT - AN-SULFUR COLLOID</u>						
N017858 001					ODE	Aug 13, 2019
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 001	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
<u>TELAVANCIN HYDROCHLORIDE - VIBATIV</u>						
N022110 002	8101575	May 01, 2021	DP			
	8158580	May 01, 2021	DP			
<u>TELBIVUDINE - TYZEKA</u>						
N022154 001	7858594	Sep 11, 2023	DS DP U-999			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TEMSIROLIMUS - TORISEL</u>						
N022088 001	5362718	Apr 18, 2014	DS DP		M-92	Jul 09, 2013
	5362718*PED	Oct 18, 2014			M-91	Apr 26, 2013
	8026276	Jan 20, 2026	DP		M-61	May 30, 2015
	8026276*PED	Jul 20, 2026			ODE	May 30, 2014
					PED	Nov 30, 2015
					PED	Nov 30, 2014
					PED	Jan 09, 2014
					PED	Oct 26, 2013
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 001	5922695	Jul 25, 2017	DS U-999		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-250		PED	Jul 18, 2015
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-1275			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-1275			
	6043230	Jul 25, 2017	U-999			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-1275			
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N021356 002	5922695	Jul 25, 2017	DS U-248		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-250		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017
	5922695	Jul 25, 2017	DS U-1275		PED	Sep 24, 2017
	5922695*PED	Jan 25, 2018			PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-248		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-250		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-256			
	5935946	Jul 25, 2017	DS DP U-999			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TENOFVIR DISOPROXIL FUMARATE - VIREAD						
N021356 003	5922695	Jul 25, 2017	DS U-248		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-250		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-248		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-250		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-256		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-999			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				
TENOFVIR DISOPROXIL FUMARATE - VIREAD						
N021356 004	5922695	Jul 25, 2017	DS U-248		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-250		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-999		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-248		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-250		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-256		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-999			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TENOFOVIR DISOPROXIL FUMARATE - VIREAD</u>						
N022577 001	5922695	Jul 25, 2017	DS U-248		M-95	Oct 01, 2013
	5922695	Jul 25, 2017	DS U-250		NPP	Aug 16, 2015
	5922695	Jul 25, 2017	DS U-256		NPP	Mar 24, 2013
	5922695	Jul 25, 2017	DS U-999		NDF	Jan 18, 2015
	5922695	Jul 25, 2017	DS U-1275		ODE	Mar 24, 2017
	5922695*PED	Jan 25, 2018			PED	Sep 24, 2017
	5935946	Jul 25, 2017	DS DP U-999		PED	Jul 18, 2015
	5935946	Jul 25, 2017	DS DP U-1275		PED	Apr 01, 2014
	5935946	Jul 25, 2017	DS DP U-248		PED	Sep 24, 2013
	5935946	Jul 25, 2017	DS DP U-250			
	5935946	Jul 25, 2017	DS DP U-256			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-250			
	5977089	Jul 25, 2017	DS DP U-256			
	5977089	Jul 25, 2017	DS DP U-999			
	5977089	Jul 25, 2017	DS DP U-1275			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-1275			
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-250			
	6043230	Jul 25, 2017	U-256			
	6043230	Jul 25, 2017	U-999			
	6043230*PED	Jan 25, 2018				
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N202992 001	5459163	Oct 17, 2012	DP		NCE	Sep 12, 2017
	5679709	Oct 21, 2014	DP U-1285			
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N202992 002	5459163	Oct 17, 2012	DP		NCE	Sep 12, 2017
	5679709	Oct 21, 2014	DP U-1285			
<u>TESAMORELIN ACETATE - EGRIFTA</u>						
N022505 002	5861379	May 26, 2015	DS DP U-1100		NCE	Nov 10, 2015
	6020311	May 26, 2015	DS DP U-1100			
	7144577	Jul 14, 2020	U-1100			
	7316997	Aug 14, 2023	U-1100			
<u>TESTOSTERONE - ANDROGEL</u>						
N022309 002					NP	Apr 29, 2014
<u>TESTOSTERONE - ANDROGEL</u>						
N022309 003					NP	Apr 29, 2014
<u>TESTOSTERONE - TESTIM</u>						
N021454 001	8178518	Apr 21, 2023	DP			
<u>TESTOSTERONE - TESTOSTERONE</u>						
N202763 001					NP	Feb 14, 2015
<u>THALIDOMIDE - THALOMID</u>						
N020785 001	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>THALIDOMIDE - THALOMID</u>						
N020785 002	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
<u>THALIDOMIDE - THALOMID</u>						
N020785 003	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
<u>THALIDOMIDE - THALOMID</u>						
N020785 004	8143283	Mar 01, 2013	U-1236			
	8204763	Aug 28, 2018	U-1249			
<u>TOLVAPTAN - SAMSCA</u>						
N022275 001	>A> 5258510	Nov 02, 2012	DS DP			
<u>TOLVAPTAN - SAMSCA</u>						
N022275 002	>A> 5258510	Nov 02, 2012	DS DP			
<u>TOLVAPTAN - SAMSCA</u>						
N022275 003	>A> 5258510	Nov 02, 2012	DS DP			
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 001					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 002					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 004					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020505 005					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 001					NPP	Jul 15, 2014
<u>TOPIRAMATE - TOPAMAX</u>						
N020844 002					NPP	Jul 15, 2014
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N020981 001	8158645	Dec 10, 2024	DP			
<u>TOPOTECAN HYDROCHLORIDE - HYCAMTIN</u>						
N020981 002	8158645	Dec 10, 2024	DP			
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 001					PC	Jun 27, 2012
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 002					PC	Jun 27, 2012
<u>TRAMADOL HYDROCHLORIDE - TRAMADOL HYDROCHLORIDE</u>						
A091607 003					PC	Jun 27, 2012
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N022430 001	>A> 8273795	Mar 04, 2025	U-1182			
<u>TRAVOPROST - TRAVATAN Z</u>						
N021994 001	8268299	Oct 13, 2029	DP			
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 001	8133893	Mar 13, 2029	DS DP			

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>TRAZODONE HYDROCHLORIDE - OLEPTRO</u>						
N022411 002	8133893	Mar 13, 2029	DS DP			
<u>TRIAMCINOLONE ACETONIDE - TRIESENCE</u>						
N022048 001	8128960	Dec 17, 2029	DP			
	8211880	Mar 10, 2029	U-1258			
	8211880	Mar 10, 2029	U-1257			
<u>TRYPAN BLUE - MEMBRANEBLUE</u>						
N022278 001					ODE	Feb 20, 2016
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N021400 001	>A> 8273876	Jul 23, 2027	U-1288			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N021400 002	>A> 8273876	Jul 23, 2027	U-1288			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N021400 003	>A> 8273876	Jul 23, 2027	U-1288			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N021400 004	>A> 8273876	Jul 23, 2027	U-1288			
<u>VEMURAFENIB - ZELBORAF</u>						
N020429 001	8143271	Jun 21, 2026	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 001	8193195	Jun 05, 2022	U-839			
	8236804	Jun 05, 2022	U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 002	8193195	Jun 05, 2022	U-839			
	8236804	Jun 05, 2022	U-839			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N022567 003	8193195	Jun 05, 2022	U-839			
	8236804	Jun 05, 2022	U-839			
<u>VINCRIStINE SULFATE - MARQIBO KIT</u>						
N020497 001	5543152	Jun 20, 2014	DP		NP	Aug 09, 2015
	5741516	Jun 20, 2014	DP		ODE	Aug 09, 2019
	5814335	Jun 20, 2014	DP			
	6723338	Mar 31, 2020	U-1271			
	7247316	Sep 25, 2020	DP			
	7887836	Mar 31, 2020	U-1271			
<u>VISMODEGIB - ERIVEDGE</u>						
N03388 001	7888364	Nov 11, 2028	DS DP		NCE	Jan 30, 2017
<u>VORINOSTAT - ZOLINZA</u>						
N021991 001	>A> 7456219	Mar 11, 2027	DS			
	8093295	May 16, 2026	DP			
	8101663	Mar 04, 2023	U-892			
	>A> RE38506	Nov 29, 2013	DS DP			
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 001					PC	Aug 29, 2012

PATENT & EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2012

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 002					PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 003					PC	Aug 29, 2012
<u>ZIPRASIDONE HYDROCHLORIDE - ZIPRASIDONE HYDROCHLORIDE</u>						
A077560 004					PC	Aug 29, 2012
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N022328 001	8242131	Aug 20, 2029	U-1266			
	8252809	Feb 16, 2025	DP			
<u>ZOLPIDEM TARTRATE - INTERMEZZO</u>						
N022328 002	8242131	Aug 20, 2029	U-1266			
	8252809	Feb 16, 2025	DP			

Footnote:

1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 31st Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of patent terms is available at
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>